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Abstract 
	  
The	  worldwide	   incidence	   of	   atopic	   disease,	   including	   asthma,	   has	   increased	   dramatically	  
over	  the	  last	  few	  decades.	  In	  New	  Zealand,	  asthma	  affects	  at	  least	  one	  in	  four	  children	  and	  
one	  in	  six	  adults,	  a	  prevalence	  among	  the	  highest	  reported	  in	  the	  world.	  Up	  to	  half	  of	  these	  
individuals	   suffer	   from	   exacerbations	   of	   disease	   that	   are	   driven	   by	   allergic	   airway	  
inflammation.	   Key	   instigators	   of	   allergic	   airway	   inflammation	   are	   CD4+	   Th2	   cells	   that	  
respond	   to	   normally	   harmless	   inhaled	   antigens	   presented	   by	   airway-­‐surveying	   antigen	  
presenting	   cells	   (APC).	   Th2	   production	   of	   chemical	   mediators	   subsequently	   induces	  
eosinophilia,	  mucus	  hypersecretion	   and	   airway	   remodeling;	   the	   characteristic	   features	   of	  
allergic	  airway	  pathology.	  Allergen-­‐specific	   cytotoxic	  T	   lymphocytes	   (CTL)	  can	  ameliorate	  
airway	   inflammation	   in	   a	   model	   of	   acute	   allergic	   airway	   inflammation,	   however,	   the	  
mechanism	  of	  their	  inhibitory	  activity	  is	  not	  fully	  defined.	  Furthermore,	  the	  effects	  of	  CTLs	  
on	   established	   airway	   inflammation,	   like	   that	   which	   presents	   clinically,	   have	   not	   been	  
elucidated.	  	  
	  
In	   this	   thesis,	   a	   mouse	   model	   of	   allergic	   airway	   inflammation	   was	   established	   and	  
characterised,	  where	  multiple	  allergen	  exposures	  stimulated	  significant	  airway	  pathology.	  
Additionally,	   a	  model	   involving	   the	   adoptive	   transfer	   of	   in	   vitro-­‐generated	   Th2	   cells	   into	  
naive	  hosts	  was	  developed	  to	  investigate	  the	  cellular	  interactions,	  phenotype,	  and	  disease-­‐
mediating	  functions	  of	  these	  cells	  during	  active	  inflammation.	  Pathology	  was	  examined	  by	  
enumeration	  of	  lung-­‐	  and	  airway-­‐infiltrating	  inflammatory	  cells,	  assessment	  of	  the	  extent	  of	  
mucus	  production,	  as	  well	  as	  the	  measurement	  of	  inflammatory	  mediators.	  Lung	  tissue	  was	  
also	   examined	   microscopically	   to	   investigate	   the	   interaction	   of	   CTLs	   with	   key	   disease-­‐
mediating	  cells:	  Th2	  cells	  and	  APCs	  –	  specifically,	  lung	  CD103+	  and	  CD11b+	  dendritic	  cells	  
(DCs).	   	   The	   cellular	   targets	   of	   cytolytic	   CTLs	   were	   additionally	   investigated	   by	   use	   of	  
fluorescent	   probes	   to	   detect	   the	   expression	   of	   active	   cell-­‐apoptosis-­‐associated	   caspases	  
within	  dying	  cells.	  
	  
Treatment	  with	  allergen-­‐specific	  CTLs	  was	   found	   to	   suppress	   inflammation	  over	  multiple	  
allergen	  challenges,	  and	  was	  additionally	  effective	  in	  the	  amelioration	  of	  established	  allergic	  
airway	   inflammation.	   Therapeutic	   success	   was	   associated	   with	   reduced	   early	   cytokine	  
   iv 
production	  by	  Th2	  cells	  in	  lung,	  as	  well	  as	  diminishing	  their	  subsequent	  accumulation	  and	  
production	  of	  IL-­‐4	  and	  IL-­‐13.	  In	  addition,	  treatment	  with	  CTLs	  increased	  the	  proportion	  of	  
caspase+	  DCs	   in	  the	   lung-­‐draining	  mediastinal	   lymph	  node	  and	  decreased	  the	  numbers	  of	  
CD103+	  and	  CD11b+	  DC	  in	  the	  lung.	  The	  targeting	  of	  DCs	  was	  dependent	  on	  their	  ability	  to	  
directly	  interact	  with	  CTLs	  through	  the	  presentation	  of	  antigen	  on	  MHC-­‐I,	  with	  lung	  imaging	  
revealing	  interactions	  not	  only	  with	  the	  CD103+	  classical	  cross-­‐presenting	  DCs,	  but	  also	  in	  
the	  critical	  allergy-­‐driving	  CD11b+	  DCs.	  Therefore,	  allergen-­‐specific	  CTLs	  deplete	  CD103+	  
and	   CD11b+	   DC	   populations	   in	   the	   lung,	   which	   in	   turn	   reduces	   allergen	   presentation	   to	  
disease-­‐mediating	   Th2	   cells,	   resulting	   in	   amelioration	   of	   allergic	   airway	   inflammation.	  
Immunotherapy	  with	  allergen-­‐specific	  CTLs	  thus	  represents	  a	  targeted	  treatment	  that	  may	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   Distilled	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   Forkhead	  box	  P3	  
   xix 
FSC	  	   	   Forward	  scatter	  
GATA3	   	   GATA-­‐binding	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  33	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  and	  Eosin	  stain	  
i.n.	   	   Intranasal	  
i.p.	  	   	   Intraperitoneal	  
i.v.	  	   	   Intravenous	  
Id2	   	   Inhibitor	  of	  DNA	  protein	  2	  
IDO	  	   	   Indoleamine	  2,3-­‐dioxygenase	  
IFN	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Ig	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IL	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  lymphoid	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  colony-­‐stimulating	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   Median	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  intensity	  
MHC	  	   	   Major	  histocompatibility	  complex	  
MLN	   	   Mediastinal	  lymph	  node	  
MMP	   	   Matrix	  metalloproteinase	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   Monocyte-­‐derived	  dendritic	  cell	  
mRNA	  	   	   Messenger	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  acid	  
MyD88	  	   	   Myeloid	  differentiation	  primary	  response	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NFκB	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  activated	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   Ovalbumin	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OVA	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  MHC	  class	  I	  peptide	  (SIINFEKL)	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  MHC	  class	  II	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  (ISQAVHAAHAEINEAGR)	  
PAMP	  	   	   Pathogen-­‐associated	  molecular	  pattern	  
PBS	  	   	   Phosphate	  buffered	  saline	  
PCR	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  chain	  reaction	  
PD-­‐1	  	   	   Programmed	  death	  receptor	  1	  
PE	  	   	   Phycoerythrin	  
PerCP	  	   	   Peridinin	  chlorophyll	  protein	  
PKO	   	   Perforin	  deficient	  
pDC	  	   	   Plasmacytoid	  dendritic	  cell	  
PI	  	   	   Propidium	  iodide	  
PRR	  	   	   Pattern	  recognition	  receptor	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RAG	  	   	   Recombination	  activating	  gene	  
SA	  	   	   Streptavidin	  
SD	  	   	   Standard	  deviation	  
SE	  	   	   Standard	  error	  
SEM	  	   	   Standard	  error	  of	  mean	  
SPI-­‐6	  	   	   Serine	  protease	  inhibitor-­‐6	  
SSC	  	   	   Side	  scatter	  
STAT	  	   	   Signal	  Transducers	  and	  Activator	  of	  Transcription	  
TAP	  	   	   Transporter	  associated	  with	  antigen	  processing	  
TCR	  	   	   T	  cell	  receptor	  
Tfh	   	   Follicular	  helper	  T	  cell	  
TGF	  	   	   Transforming	  growth	  factor	  
Th	  	   	   T	  helper	  
TLR	  	   	   Toll-­‐like	  receptor	  
TNF	  	   	   Tumour	  necrosis	  factor	  
Treg	  	   	   Regulatory	  T	  cell	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An	  epidemic	   is	  occurring	  and	  we	  do	  not	  understand	  why.	  Atopic	  diseases	  such	  as	  asthma	  
and	  atopic	  dermatitis	  now	  affect	  at	  least	  one	  in	  four	  children	  and	  one	  in	  six	  adults	  in	  New	  
Zealand	  (1),	  with	  many	  more	  suffering	  from	  allergic	  rhinitis;	  a	  prevalence	  that	  is	  among	  the	  
highest	   reported	   in	   the	   world.	   Furthermore,	   worldwide	   incidence	   of	   atopic	   disease	   has	  
increased	  dramatically	  in	  the	  past	  30	  years.	  	  	  
	  
Asthma	   is	   characterised	   by	   chronic	   airway	   inflammation	   with	   a	   history	   of	   respiratory	  
symptoms	  such	  as	  wheeze,	  shortness	  of	  breath,	  chest	  tightness	  and	  cough.	  A	  diagnosis	  may	  
be	   confirmed	   when	   these	   symptoms	   are	   accompanied	   by	   a	   variable	   and	   reversible	  
limitation	  in	  expiratory	  airflow,	  measured	  as	  a	  reduction	  in	  the	  forced	  expiratory	  volume	  in	  
1	  second,	  compared	  to	  the	  normal	  range	  for	  children	  or	  adults	  (2).	  These	  symptoms	  result	  
from	  multiple	   episodes	   of	   contraction	   of	   the	   airways	   and	   over-­‐production	   of	  mucus	   that	  
restrict	  an	  individual’s	  ability	  to	  breathe.	  Even	  in	  the	  absence	  of	  recent	  symptoms,	  and	  with	  
lung	   function	   in	   the	   normal	   range,	   episodic	   exacerbations	   may	   occur	   due	   to	   airway	  
hyperresponsiveness	  to	  direct	  or	  indirect	  stimuli	  and	  underlying	  chronic	  inflammation.	  It	  is	  
not	   understood	   why	   asthma	   resolves	   spontaneously	   in	   some	   individuals,	   while	   others	  
experience	  long-­‐term	  persisting	  disease.	  
	  	  
A	   heterogeneous	   disorder,	   multiple	   factors	   may	   drive	   asthma,	   and	   many	   disease	  
phenotypes	   have	   been	   identified(3-­‐5).	   The	   most	   common	   phenotypes	   may	   be	   broadly	  
divided	   into	   atopic	   and	  non-­‐atopic	   asthma.	  Atopic	   asthma	   (also	   referred	   to	   as	   allergic	   or	  
extrinsic	   asthma)	   is	   that	   which	   develops	   as	   a	   result	   of	   repeated	   allergic	   responses	   to	  
environmental	   stimuli	   in	   the	   airway.	   Often	   commencing	   in	   childhood,	   allergic	   asthma	   is	  
most	  often	  associated	  with	  a	  personal	  or	  family	  history	  of	  atopic	  diseases	  such	  as	  eczema,	  
allergic	  rhinitis,	  or	  food	  or	  drug	  allergy.	  These	  patients	  commonly	  present	  with	  eosinophilic	  
airway	  inflammation,	  evident	  by	  sputum	  analysis	  (3-­‐5).	  Non-­‐atopic	  asthma	  (also	  referred	  to	  
as	  non-­‐allergic	  or	  intrinsic	  asthma),	  conversely,	  is	  not	  associated	  with	  allergy,	  and	  in	  most	  
cases	  the	  causative	  agent	   is	  unknown.	  Multiple	   factors	  may	  cause	  exacerbations	   including	  
physical	  exertion,	  respiratory	  infection,	  work-­‐place	  triggers,	  or	  exposure	  to	  chemicals	  and	  
cigarette	   smoke.	   Airway	   inflammatory	   infiltrates	   in	   these	   patients	   may	   be	   primarily	  
neutrophils	  or	  eosinophils,	  while	  in	  some	  cases	  few	  cells	  are	  present	  in	  sputum	  (3-­‐5).	  Up	  to	  
half	  of	   the	   individuals	  who	  suffer	   from	  asthma	  are	  of	   the	  atopic,	  allergic	  subtype.	  Further	  
   4 
work	  is	  required	  to	  understand	  the	  critical	  factors	  underlying	  the	  interaction	  of	  the	  immune	  
system	  with	  the	  external	  environment	  that	  consequently	  result	  in	  allergy,	  which	  may	  lead	  
to	   breakthroughs	   in	   the	   treatment	   of	   allergic	   asthma.	   This	   thesis	   is	   concerned	   with	   the	  
pursuit	  of	  such	  studies,	  specifically	  related	  to	  the	  allergic	  asthmatic	  subtype.	  
	  
The	   critical	   causative	   factors	   contributing	   to	   the	   development	   of	   allergy,	   including	   that	  
which	  manifests	  in	  the	  lung,	  are	  not	  yet	  fully	  understood;	  it	  is	  not	  known	  why	  one	  particular	  
individual	   may	   become	   allergic	   to	   the	   same	   stimulus	   that	   another	   will	   respond	   to	   with	  
tolerance.	  However,	  multiple	  contributing	   factors	  have	  been	  recognised.	  While	  no	  specific	  
gene	   has	   been	   identified	   that	   solely	   confers	   susceptibility	   to	   allergic	   asthmatic	   disease,	   a	  
strong	   correlation	   exists	  with	   those	  who	   suffer	   from	  atopy:	   the	   genetic	   predisposition	   to	  
mount	   mucosal	   immunoglobulin	   type	   E	   responses	   (6).	   It	   is	   unlikely	   that	   genetic	   factors	  
alone,	  however,	  are	  sufficient	  to	  mediate	  increasing	  incidence	  with	  the	  striking	  rapidity	  that	  
has	  been	  recently	  described.	  It	  has	  been	  hypothesised	  that	  our	  behaviour	  in	  relation	  to	  our	  
environment	   is	   largely	   to	   blame.	   The	   “hygiene	   hypothesis”	   proposed	   that	   the	   decreased	  
exposure	  of	  children	  to	  immune	  stimulating	  factors,	  such	  as	  infectious	  disease,	  has	  led	  to	  an	  
increase	   in	   allergy	   (7-­‐10).	   However,	   evidence	   has	   also	   emerged	   that	   the	   incidence	   of	  
respiratory	   viral	   infection	   during	   early	   life,	   such	   as	   that	   caused	   by	   respiratory	   syncytial	  
virus,	   predisposes	   to	   the	   development	   of	   chronic	   airway	   inflammation	   and	   asthmatic	  
disease	  (11-­‐14).	   In	  either	  case,	   these	  and	  many	  other	  studies	  have	  not	  yet	   fully	  answered	  
the	   question:	   how	   is	   allergic	   disease	   to	   harmless	   inhaled	   constituents	   initiated	   and	  
maintained?	  	  Further	  studies	  are	  needed	  to	  elucidate	  these	  factors.	  	  
	  
For	   the	   rapidly	   growing	   number	   of	   individuals	  who	   suffer	   from	   allergy,	   another	   issue	   is	  
paramount:	   the	   need	   for	   safe,	   effective	   therapies	   or,	   ideally,	   a	   cure.	   Currently	  
corticosteroids	   are	   commonly	   prescribed	   for	   the	   treatment	   of	   allergic	   asthma	   and	   have	  
been	  reported	  effective	   in	  alleviating	  asthma	  attacks	   in	  both	  children	  and	  adults	   (15,	  16),	  
showing	  reasonable	  safety	  when	  used	  as	  a	  short-­‐term	  treatment	  during	  exacerbations	  only	  
(17).	   However,	   many	   patients	   are	   prescribed	   long-­‐term	   courses	   of	   corticosteroids	   for	  
maintaining	  the	  control	  of	  asthma	  symptoms,	  and	  experience	  side	  effects:	  weakened	  anti-­‐
viral	  immune	  responses	  in	  the	  lung,	  suppression	  of	  adrenal	  function	  and	  decreases	  in	  bone	  
density(18,	   19).	   Therefore,	   the	   non-­‐specific	   nature	   of	   this	   treatment	   regime	   results	   in	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additional	   undesired	   pathology.	   Corticosteroid-­‐resistant	   disease	   has	   also	   emerged,	  
prompting	  the	  requirement	  for	  new,	  and	  more	  targeted,	  therapies.	  	  
	  
An	  alternative	  approach	  to	  broad	  suppression	  of	   immune	  responses	   is	   to	  redirect	  allergic	  
responses	   towards	   tolerance.	   Subcutaneous	   and	   sublingual	   immunotherapies	   have	   been	  
developed	   where	   small	   but	   incremental	   amounts	   of	   the	   allergen	   that	   an	   individual	   is	  
allergic	  to	  are	  administered	  by	  subcutaneous	  injection	  or	  as	  a	  tablet	  under	  the	  tongue.	  As	  
the	   skin	   and	   mouth	   are	   home	   to	   immune	   cells	   that	   preferentially	   drive	   tolerogenic	  
responses,	   the	   aim	   of	   treatment	   is	   to	   stimulate	   these	   cells	   in	   the	   hopes	   that,	   gradually,	  
tolerance	  will	   override	  allergy.	  This	   is	   successful	   for	  many	   individuals,	   and	  prevention	  of	  
recurrent	   disease	   such	   as	   allergic	   rhinitis	   may	   persist	   for	   a	   number	   of	   years	   after	   the	  
cessation	   of	   treatment	   (20-­‐24).	   However,	   responses	   vary	   and	   some	   people	   do	   not	  
experience	  an	  improvement	  in	  asthmatic	  symptoms,	  or	  a	  plateau	  of	  efficacy	  may	  be	  reached	  
at	  certain	  concentrations,	  although	  this	  has	  not	  been	  widely	  assessed	  in	  asthma	  patients.	  In	  
addition,	  the	  specific	  allergen	  that	  is	  driving	  the	  allergic	  response	  must	  be	  known	  to	  enable	  
attempted	  desensitisation,	  which	  may	  be	  complicated	  to	  treat	  in	  the	  many	  patients	  that	  are	  
sensitised	  to	  multiple	  allergens	  (discussed	  in	  Chapter	  5).	  Symptoms	  may	  also	  return	  upon	  
cessation	   of	   regular	   immunotherapy	   treatments.	   Furthermore,	   some	   individuals	  who	   are	  
very	  highly	  allergic	  to	  particular	  allergens	  and	  prone	  to	  anaphylaxis	  cannot	  be	  exposed	  to	  
this	  regime,	  and	  the	  majority	  of	  individuals	  who	  are	  undergoing	  sublingual	  or	  subcutaneous	  
immunotherapy	   are	   still	   recommended	   to	   receive	   adjunct	   corticosteroid	   treatment	   (2).	  





1.1 Key players in the induction of immune responses 
	  
The	  immune	  system	  involves	  an	  array	  of	  mediators,	  receptors,	  cells,	  tissues,	  and	  organs	  that	  
work	   in	   concert	   to	   differentiate	   self	   from	   foreign,	   and	   harmless	   from	   injurious,	   and	   is	  
commissioned	  with	   the	   task	   of	   responding	   appropriately	   to	   evade	   damage	   and	  maintain	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homeostasis.	  Classically	  divided	  into	  innate	  and	  adaptive,	  the	  immune	  response	  can	  target	  
foreign	  pathogens	  in	  a	  variety	  of	  ways.	  	  
	  
A	  comprehensive	  and	  immediate	  response	  begins	  upon	  the	  sensing	  of	  pathogen-­‐associated	  
or	  danger-­‐associated	  molecular	  patterns	  (PAMPs	  and	  DAMPs,	  respectively)	  by	  cells	  of	   the	  
innate	   immune	   system	   including	   dendritic	   cells,	   macrophages	   and	   neutrophils;	   a	   rapid	  
reaction	  ensues	  whereby	  the	  activation	  of	  signalling	  pathways	  and	  production	  of	  cytokines	  
and	   chemokines	   function	   to	   eradicate	   the	   invader,	   or	   direct	   inflammation	   to	   the	   site	   of	  
DAMPs	  of	  host	  origin.	  Innate	  immunity	  is	  broadly	  active	  against	  foreign	  antigens	  and,	  while	  
enhanced	   innate	   immune	   responses	   may	   occur	   upon	   successive	   exposures,	   no	   specific	  
immunological	  memory	   is	  generated.	   In	  contrast,	   adaptive	   immunity	   involves	   the	  specific	  
recognition	  of	  antigens.	  Throughout	  the	  course	  of	  this	  response,	  effector	  cells	  are	  generated	  
that	  carry	  out	  short-­‐lived	   functions	  to	  eliminate	   the	   incident	   threat;	  additionally,	  memory	  
cells	   are	   produced	   that	   remain	   after	   the	   contraction	   of	   the	   primary	   immune	   response.	  
While	   adaptive	   immune	   cells	   are	  not	  mobilised	   as	   rapidly	   as	   innate	   responders,	  memory	  
cells	  respond	  quickly	  upon	  secondary	  and	  subsequent	  encounters	  of	  the	  same	  antigen.	  	  	  
	  	  
Exposed	  to	  the	  surrounding	  environment	  every	  time	  a	  breath	  is	  taken,	  the	  lung	  is	  accosted	  
with	   a	   massive	   variety	   of	   inhaled	   aeroantigens.	   As	   such,	   maintaining	   health	   and	  
homeostasis	   in	   the	   lung	   requires	   a	   competent	   surveillance	   system	   with	   the	   ability	   to	  
discriminate	  harmless	  constituents	  as	  well	  as	  potential	  threats.	  To	  fulfil	  this	  role,	  innate	  and	  
adaptive	   immune	  cells	  and	  chemical	  mediators	  collaborate	   to	   target	   invaders	  and	  protect	  
the	  body	  from	  insult.	  This	  arsenal	  is	  arguably	  led	  and	  co-­‐ordinated	  through	  the	  directorship	  
of	  lung	  dendritic	  cells,	  possessing	  important	  roles	  in	  the	  realms	  of	  both	  innate	  and	  adaptive	  
immunity.	  	  	  	  	  
	  
In	   this	  chapter,	   the	  characteristics	  and	   functions	  of	  dendritic	  cells	  will	  be	   introduced.	  The	  
focus	  will	   then	  be	  turned	  to	  key	  players	   in	   lung	  pathogenesis;	  CD4+	  T	  cells.	  Their	  specific	  
roles	   as	  well	   as	   the	   contribution	  of	   collaborating	   cells	   and	   factors	   in	   the	  orchestration	  of	  
allergy	   in	   the	   lung	  will	  be	  examined.	  Finally,	  CD8+	  T	  cells	  will	  be	  described,	  a	  population	  
that	  may	  present	  hope	  for	  a	  novel	  immunotherapy	  for	  allergic	  asthma.	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1.1.1 Dendritic cells drive T cell responses 
Dendritic	  cells,	   liaising	  with	  innate	  factors,	  are	  central	  to	  the	  initiation	  and	  propagation	  of	  
adaptive	   immune	   responses.	   Present	   in	   most	   lymphoid	   and	   non-­‐lymphoid	   tissues,	  
immature	  DCs	   carry	  out	   constant	   surveillance	  of	   their	   surroundings	  and	  display	  effective	  
phagocytic	   function.	  Upon	  detection	  of	  PAMPs	   (or	  DAMPs)	   through	  pathogen	   recognition	  
receptors	   (PRRs),	   maturation	   of	   DCs	   occurs;	   upregulation	   of	   co-­‐stimulatory	   molecules	  
occurs	   and	   cytokine	   production	   commences,	   with	   DCs	   migrating	   to	   the	   draining	   lymph	  
nodes	  where	  interaction	  with	  adaptive	  immune	  cells	  can	  occur,	  and	  T	  cell	  responses	  may	  be	  
initiated.	  	  
	  
1.1.1.1 DC subpopulations 
Under	   steady	   state	   conditions,	   two	   main	   subpopulations	   of	   DCs	   have	   been	   described	   in	  
humans	   and	  mice:	   conventional	   (cDC)	   and	   plasmacytoid	   DCs	   (pDC).	   In	   the	   mouse,	   cDCs	  
include	   lymphoid	   resident	   and	   peripheral	   migratory	   populations,	   within	   which	   further	  
subsets	  may	  be	  derived	  on	  the	  basis	  of	  cell	  surface	  marker	  expression.	  During	  inflammation,	  
monocyte	  precursors	  give	  rise	  to	   inflammatory	  DCs,	  also	  referred	  to	  as	  monocyte-­‐derived	  
DC	   (moDC).	  Different	  PRRs	  are	  expressed	  by	  each	  DC	  subset,	   and	  different	   cytokines	  and	  
chemokines	  are	  secreted	  upon	  activation;	  as	  such,	  specialised	  DC	  subsets	  have	  distinct	  roles	  
in	  antigen	  presentation	  and	  the	  initiation	  and	  regulation	  of	  T	  cell	  responses.	  These	  DC	  are	  
introduced	  herein,	  while	  specific	  lung	  DC	  populations	  will	  be	  expanded	  on	  in	  section	  1.2.	  
	  
Lymphoid resident cDC 
DCs	   resident	   in	   the	   thymus,	   lymph	  nodes	   and	   spleen	   include	  CD8α+CD11b-­‐	   and	  CD8α-­‐
CD11b+	   DCs	   (25).	   The	   development	   of	   these	   DC	   relies	   on	   the	   presence	   of	   FMS-­‐related	  
tyrosine	   kinase	   3	   ligand	   (Flt3-­‐ligand),	   as	   demonstrated	   by	   their	   low	   frequency	   in	   Flt3-­‐
ligand	   null	   mice	   and	   exaggerated	   presence	   in	   normal	   mice	   upon	   administration	   of	   Flt3-­‐
ligand	  (26,	  27).	  Additionally,	  inhibitor	  of	  DNA	  protein	  2	  (Id2)	  and	  IFN	  regulatory	  protein	  8	  
(IRF8)	   drive	   the	   differentiation	   of	   the	   CD11b-­‐	   subset.	   The	   CD8α+CD11b-­‐	   DC	   are	   derived	  
from	  bone	  marrow	  precursors	  that	  continuously	  seed	  the	  lymphoid	  organs;	  making	  up	  20%	  
of	  spleen	  DC	  and	  70%	  of	  thymus	  DC	  (28-­‐30).	  The	  CD8α+	  and	  CD8α-­‐	  subsets	  express	  several	  
differentiating	  markers:	  while	  CD8α-­‐	  DC	  express	  CD11b	  (28,	  29),	  CD172a/Sirpα	   (31)	  and	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TLR7	  (32),	  CD8α+	  DC	  express	  Clec9A	  (33-­‐35),	  CD205/DEC205	  (28,	  30,	  36),	  CD36	  (37)	  and	  
CD24	  (30,	  38)	  as	  well	  as	  TLR3	  and	  TLR12	  (32,	  39).	  Some	  of	  these	  distinguishing	  markers,	  
such	  as	  CD36	  and	  Clec9A,	  are	  receptors	  that	  afford	  specialisations	  for	  antigen	  handling	  to	  
CD8α+	  DCs,	  which	   the	   CD8α-­‐	   subset	   do	   not	   possess;	   CD8α+	  DC	   are	  more	   efficient	   in	   the	  
uptake	  and	  presentation	  of	  antigens	  obtained	  from	  dead	  cells	  (40-­‐43),	  and	  are	  also	  better	  at	  
cross-­‐presenting	  cell-­‐bound	  and	  soluble	  antigens	  on	  MHC-­‐I	  (44,	  45),	  especially	  during	  the	  
steady	   state.	   Both	   subsets,	   however,	   may	   efficiently	   present	   antigens	   after	   receptor-­‐
mediated	  endocytosis	  (46,	  47).	  	  
	  
Under	  steady-­‐state	  conditions,	  immune	  regulatory	  properties	  have	  been	  ascribed	  to	  CD8α+	  
DCs;	   they	   are	  more	   efficient	   than	   spleen	  CD8-­‐	  DCs	   at	   inducing	   FoxP3+	   regulatory	  T	   cells	  
both	   in	  vitro	  and	   in	  vivo	  (48),	   largely	  due	  to	  their	  production	  of	  TGF-­‐β.	  However,	  this	  is	   in	  
contrast	   to	   the	   thymus	   where	   blood-­‐derived	   CD8-­‐	   DCs	   are	   more	   efficient	   at	   generating	  
regulatory	  T	  cells	  than	  the	  CD8+	  DC	  (49).	  	  An	  additional	  important	  role	  is	  served	  by	  CD8α+	  
DCs,	  in	  the	  maintenance	  of	  peripheral	  tolerance;	  antigen	  targeted	  to	  DEC205+	  DC	  has	  been	  
shown	   to	   induce	   deletional	   tolerance	   and	   generate	   regulatory	   T	   cell	   responses	   (50-­‐52).	  
Once	   activated,	   CD8α+	   DC	   are	   major	   producers	   of	   IL-­‐12p70	   (53,	   54)	   and	   stimulate	  
inflammatory	   responses,	   importantly	   the	   development	   of	   Th1	   cell	   responses	   is	   primarily	  
directed	   by	   the	   CD8α+,	   but	   not	   CD8α-­‐,	   DCs	   (55,	   56).	   	   Their	   ability	   to	   produce	   IL-­‐12	   and	  
cross-­‐present	   antigens	   also	   provides	   the	   stimuli	   for	   driving	   CTL	   responses.	   This	   is	  
associated	  with	  their	  particularly	  important	  role	  in	  the	  development	  of	  anti-­‐viral	  immunity	  
during	  infection	  by	  influenza	  virus,	  respiratory	  syncytial	  virus,	  herpes	  simplex	  virus	  type	  1,	  
vaccinia	  virus	  and	  lymphocytic	  choriomeningitis	  virus	  (57-­‐63)	  as	  well	  as	  contributing	  to	  T	  
cell	   priming	   for	   intracellular	   pathogens	   including	   Listeria	   monocytogenes,	   Salmonella	  
typhimurium,	  Toxoplasma	  gondii	  and	  Plasmodium	  spp	  (39,	  61,	  64-­‐66).	  These	  studies	  reveal	  
that	  different	  lymphoid	  DC	  subsets	  are	  specialised	  to	  stimulate	  different	  immune	  responses,	  
driving	  both	  tolerogenic	  and	  inflammatory	  responses	  according	  to	  the	  type	  of	  stimuli.	  	  
	  
Migratory cDC 
Migratory	   DCs,	   present	   in	   most	   peripheral	   tissues,	   include	   CD103+CD11b-­‐	   and	   CD103-­‐
CD11b+	  subsets.	  In	  the	  intestinal	  lamina	  propria,	  CD103+CD11b+	  DC	  also	  exist,	  and	  the	  skin	  
epidermal	   layer	   is	   populated	  by	   langerin+	  Langerhans	   cells	   (67-­‐70).	   CD103+	  DC,	   derived	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from	   the	   same	  precursor	   cells	   as	  CD8+	   lymphoid	  DC,	   are	   specialised	   for	   cross-­‐presenting	  
cell-­‐associated	  antigens.	  Similarly,	  their	  development	  depends	  on	  Flt3-­‐ligand,	  Id2	  and	  IRF8,	  
although	  the	  intestinal	  lamina	  propria	  CD103+CD11b+	  DC	  do	  not	  require	  Id2	  or	  IRF8.	  The	  
CD103-­‐CD11b+	   subset,	   on	   the	   other	   hand,	   depends	   on	   Flt3-­‐ligand	   and	   the	   M-­‐CSF	  
(macrophage	   colony-­‐stimulating	   factor)	   receptor	   (70).	   Additionally,	   lamina	   propria	   and	  
dermal	  DC	  require	  GM-­‐CSF	  (granulocyte	  macrophage	  colony-­‐stimulating	  factor)	  	  (71,	  72).	  	  
	  
Migratory	  DCs	  primarily	  function	  as	  tissue	  surveillance	  cells,	  sampling	  foreign	  antigens	  and	  
transporting	   them	   to	   the	   draining	   lymph	   nodes	   where	   immune	   responses	   may	   be	  
stimulated.	   Interestingly,	  while	   these	  DC	   are	   highly	   specialised	   for	   the	   uptake	   of	   antigen,	  
they	  are	  not	  always	  efficient	  at	  antigen	  presentation	  under	  particular	  conditions,	  especially	  
compared	   to	   lymphoid	   resident	   DC.	   It	   has	   been	   found	   that	   during	   lung	   infection	   with	  
influenza	  virus,	  infected	  migratory	  CD11b+	  DC	  trafficked	  to	  the	  MLN	  but	  were	  incapable	  of	  
presenting	   antigen	   to	   CD8+	   T	   cells	   (73);	   rather	   antigen	   was	   transferred	   to	   lymphoid	  
resident	   cross-­‐presenting	  CD8+	  DC	   that	   effectively	   stimulate	  CD8+	  T	   cells	   (58).	  A	   similar	  
phenomenon	   has	   been	   implicated	   for	   skin-­‐derived	   dermal	   DCs	   (74).	   Inter-­‐DC	   antigen	  
transfer	  has	  been	  reported	  both	  in	  vitro	  and	  in	  vivo,	  and	  has	  been	  suggested	  to	  be	  important	  
for	  stimulating	  both	  regulatory	  and	  inflammatory	  immune	  responses	  (60,	  74-­‐76).	  Therefore,	  
migratory	  DC	  are	  important	  for	  the	  uptake	  and	  delivery	  of	  antigens	  from	  peripheral	  tissues	  
to	   lymph	   nodes	   where	   they	   can	   directly	   and	   indirectly	   stimulate	   T	   cell	   responses.	  
Additionally,	   the	   inter-­‐DC	   antigen	   transfer	   suggests	   that	  DCs	  with	  different	   specialisation	  
and	  roles	  may	  co-­‐operate	  to	  stimulate	  different	  immune	  response	  according	  to	  the	  nature	  
of	  the	  antigen.	  	  	  	  	  
	  
	  
Plasmacytoid DC  
Plasmacytoid	  DCs	  (pDC),	  unlike	  conventional	  DC,	  are	  CD11clo	  ,	  and	  may	  be	  identified	  further	  
as	  B220+CD11b-­‐GR-­‐1+.	  Developing	  under	   the	  control	  of	   the	   transcription	   factor	  E2-­‐2,	  pDC	  
are	  present	  in	  low	  numbers	  in	  the	  tissue	  during	  steady	  state	  conditions	  and	  accumulate	  in	  
both	   lymphoid	   and	   non-­‐lymphoid	   tissues	   under	   pathological	   conditions	   (77).	   These	   DC	  
function	   to	  drive	  protective	   immunity	  as	  well	  as	   tolerance	  (78-­‐81).	  During	  viral	   infection,	  
pDC	  are	  activated	  in	  response	  to	  ssRNA	  and	  ssDNA	  through	  TLR7	  and	  TLR9,	  respectively,	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and	  produce	  significant	  amounts	  of	  type-­‐I	  interferon	  (82),	  promoting	  anti-­‐viral	  innate	  and	  
adaptive	  immune	  responses.	  However,	  they	  are	  poor	  immunostimulatory	  DC	  (83,	  84),	  and	  
interaction	  with	  T	  cells	  most	  often	  results	  in	  the	  generation	  of	  T	  regulatory	  cells	  (85-­‐87).	  
	  
Monocyte-derived DC 
Under	  inflammatory	  conditions,	  monocyte-­‐derived	  DC	  (moDC)	  are	  generated	  and	  recruited	  
into	  tissues	  by	  microbial	  or	  inflammatory	  stimuli	  (88);	  highly	  plastic	  and	  versatile	  cells	  that	  
are	   influenced	   by,	   and	   co-­‐operate	   with,	   local	   DC.	   Unlike	   conventional	   DC,	   moDC	   arise	  
independently	  of	  Flt3-­‐ligand	  and	  GM-­‐CSFR,	  rather	  they	  are	  dependent	  on	  CSF-­‐1R	  (89),	  and	  
have	  thus	  recently	  been	  suggested	  to	  represent	  a	  distinct	  cellular	  population,	  rather	  than	  a	  
true	   DC	   subset	   (90);	   nevertheless	   multiple	   functional	   capabilities	   are	   shared	   with	   cDC.	  
Characterised	   as	   MHC-­‐II+CD11c+CD11b+CD64+FCεR1α+Ly6C+,	   moDC	   are	   crucial	   to	   the	  
induction	  of	  protective	  Th1	  immunity	  during	  infection	  with	  various	  pathogens	  and	  protect	  
the	  gut	  from	  invading	  bacteria	  (91,	  92).	  In	  a	  pathogenic	  model	  that	  is	  potentially	  the	  most	  
well-­‐described,	  L.	  monocytogenes	  infection	  induces	  rapid	  recruitment	  of	  moDC	  to	  the	  spleen	  
in	  a	  CSF-­‐1R	  dependent	  manner	  (89),	  followed	  by	  their	  secretion	  of	  high	  levels	  of	  TNF-­‐α	  and	  
iNOS	  (93).	  Interestingly,	  while	  this	  cytokine	  production	  was	  required	  for	  bacterial	  clearance,	  
the	  absence	  of	  moDC	  did	  not	  affect	   the	  priming	  of	  CD4+	  and	  CD8+	  T	  cell	   responses	   (93).	  
This	  finding	  suggests	  that	  direct	  effector	  function	  is	  the	  predominant	  role	  of	  moDC	  in	  this	  
context,	   rather	   than	   T	   cell	   priming.	   Other	   studies,	   however,	   have	   demonstrated	   an	  
important	   role	   for	   moDC	   as	   inducers	   of	   Th1	   immunity	   during	   Leishmania	   infection,	  
producing	   IL-­‐12	   and	   inducing	   antigen-­‐specific	   CD4+	   T	   cell	   priming	   (88).	   Their	   antigen-­‐
presenting	   and	   Th1-­‐inducing	   functions	   during	   non-­‐infections	   disease	   has	   also	   been	  
demonstrated	  (91).	  The	  role	  of	  moDC	  in	  Th2	  immunity	  will	  be	  discussed	  in	  section	  1.2.	  	  	  	  
	  
1.1.1.2 Antigen processing and presentation to T cells 
Most	  nucleated	   cells	   present	   endogenous	   antigens	   on	  MHC-­‐I	   as	   a	  way	  of	   displaying	   their	  
cellular	  contents;	  these	  antigens	  are	  recognised	  by	  CD8+	  T	  cells	  that	  can	  detect	  aberrant	  self	  
or	   foreign	   infectious	   protein.	   Although	   many	   cells	   have	   also	   been	   ascribed	   specialised	  
antigen	  presenting	  capability	  by	  various	  authors,	  few	  of	  these	  cells	  can	  take	  up	  exogenous	  
antigens	  and	  effectively	  process	  and	  present	   them	  on	  both	  MHC-­‐I	  and	  MHC-­‐II	   to	   facilitate	  
interaction	  with	  CD8+	  T	  cells	  and	  CD4+	  T	  cells.	  Macrophages	  are	  efficient	  in	  the	  uptake	  and	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processing	   of	   antigens	   but	  weakly	   express	  MHC-­‐II	   and	   costimulatory	  molecules,	   as	   such,	  
they	   are	   predominantly	   ineffective	   in	   the	   activation	   of	   CD4+	   T	   cells,	   although	   in	   the	  
presence	   of	   IFN-­‐γ,	   MHC-­‐II	   upregulation	   can	   occur.	   Additionally,	   while	   macrophages	   can	  
cross-­‐present	  apoptotic	  cellular	  debris,	  they	  are	  unable	  to	  cross-­‐prime	  naïve	  CTLs	  (94,	  95).	  
B	  cells	  are	  not	  as	  successful	  in	  antigen	  uptake	  and	  primarily	  activate	  memory	  CD4+	  T	  cells;	  
they	  are	  unable	  to	  stimulate	  naïve	  CD4+	  T	  cells	  (96,	  97).	  Conversely,	  DCs	  are	  highly	  effective	  
at	   antigen	  uptake	  and	  processing,	   and	   can	  present	   exogenous	  antigens	   to	  both	  CD4+	  and	  




Antigen uptake by immature DC 
Immature	  DCs	   use	   phagocytosis,	  macropinocytosis	   and	   receptor-­‐mediated	   endocytosis	   to	  
take	  up	  particulate	  and	  soluble	  antigens	  (98-­‐100).	  In	  the	  absence	  of	  PRR	  stimulation,	  these	  
antigens	  are	  processed	  gradually	  in	  lysosomes	  and	  loaded	  onto	  few	  MHC-­‐II	  molecules	  (101-­‐
103),	   with	   weak	   expression	   of	   the	   co-­‐stimulatory	   molecules	   CD80,	   CD86	   and	   CD40	   (36,	  
104).	   No	   associated	   pro-­‐inflammatory	   cytokine	   production	   occurs	   (105,	   106).	   As	   such,	  
limited	  presentation	  of	  antigen	  to	  T	  cells	  occurs	  in	  the	  immature	  state,	  and	  in	  the	  absence	  of	  
significant	  co-­‐stimulation	  engaging	  T	  cell	  CD28	  and	  CD40L,	  these	  interactions	  do	  not	  result	  
in	  effector	  T	  cell	  differentiation,	  although	  some	  T	  cell	  proliferation	  may	  occur	  (50,	  51,	  107).	  
This	  is	  not,	  however,	  a	  meaningless	  interaction.	  Rather,	  it	  has	  been	  shown	  that	  this	  process	  
is	  important	  for	  the	  maintenance	  of	  T	  cell	  tolerance.	  Indeed,	  the	  depletion	  of	  immature	  DCs	  
under	  steady-­‐state	  conditions	  results	  in	  the	  development	  of	  autoimmune	  disease	  (108).	  
	  
Upon	  encounter	  of	  antigens	  such	  as	  PAMPs,	  immature	  DCs	  become	  activated.	  DCs	  recognise	  
a	   vast	   array	   of	   PAMPs	   through	   Toll-­‐like	   receptors	   (TLRs)	   that	   activate	   intracellular	  
signalling.	   This	   results	   in	   the	   increased	   synthesis	   and	   expression	   of	   MHC-­‐II	   and	  
upregulation	   of	   co-­‐stimulatory	   molecules	   CD80,	   CD86	   and	   CD40,	   as	   well	   as	   cytokine	  
production	  (109,	  110).	  DC	  may	  also	  indirectly	  sense	  pathogens	  through	  the	  presence	  of	  pro-­‐
inflammatory	   cytokines,	   such	   as	   TNF-­‐α	   and	   IL-­‐1β,	   which	   are	   additionally	   capable	   of	  
inducing	  the	  upregulation	  of	  adhesion	  and	  co-­‐stimulatory	  molecules	  (99,	  111,	  112).	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Antigen processing and presentation 
DCs,	  upon	  activation	  in	  peripheral	  tissues,	  migrate	  to	  draining	  lymph	  nodes.	  This	  migration	  
occurs	   through	   upregulated	  DC	   expression	   of	   CCR7	  which	   allows	   their	   homing	   to	   lymph	  
nodes	  along	  a	  CCL19	  and	  CCL21	  chemokine	  gradient	  (113).	  Here,	  DCs	  enter	  the	  naïve	  T	  cell-­‐
rich	   paracortex	   region	   where	   antigen-­‐specific	   T	   cells	   are	   normally	   found,	   facilitating	  
effective	   antigen	   presentation.	   The	   presentation	   of	   antigens	   to	   naïve	   T	   cells	   by	   activated	  
DCs	  then	  results	  in	  the	  activation	  and	  differentiation	  of	  fully	  functional	  effector	  T	  cells.	  It	  is	  
possible	   for	   DC	   to	   restrict	   antigen	   presentation	   to	   the	   antigens	   internalised	   during	  
maturation,	  which	  favours	  the	  stimulation	  of	  T	  cells	  that	  are	  specific	  for	  pathogen-­‐derived	  
antigens	  (112).	  Different	  DC	  subsets	  also	  express	  distinct	  cell	  surface	  molecules	  and	  secrete	  
different	   cytokines,	  which	  also	   influence	   the	   type	  of	   immune	  response	   that	   is	   induced,	   as	  
discussed	   in	   section	  1.1.1.1.	   Therefore,	   depending	   on	   the	   stimuli,	   activated	  DCs	  drive	   the	  
expansion	   of	   specific	   T	   cells,	   facilitating	   the	   required	   response.	   Evidence	   also	   exists	   to	  
suggest	  that	  activated	  DCs	  may	  remain	  in	  peripheral	  tissues	  such	  as	  the	  lung,	  gut	  and	  skin,	  
and	  present	  antigen	  locally,	  allowing	  for	  the	  induction	  of	  local	  T	  cell	  responses	  (114-­‐117).	  
	  
Classic antigen presentation 
In	   classical	   antigen	  presentation	  pathways,	   exogenously-­‐derived	  antigens	  may	  be	  directly	  
presented	  on	  MHC-­‐II	  to	  CD4+	  T	  cells,	  while	  endogenous	  antigens	  are	  presented	  on	  MHC-­‐I	  to	  
CD8+	  T	  cells.	  Additionally,	  NKT	  cells	  are	  stimulated	  through	  loading	  of	  lipid	  antigens	  onto	  
CD1	  molecules	   (118,	   119).	   Alternatively,	   exogenous	   antigens	  may	   be	   cross-­‐presented	   on	  
MHC-­‐I	   for	   interaction	   with	   CD8+	   T	   cells.	   The	   mechanism	   by	   which	   cross-­‐presentation	  
occurs	   is	   not	   fully	   understood.	   Captured	   antigen	   may	   be	   degraded	   in	   cytoplasmic	  
proteasomes	  and	  loaded	  onto	  MHC-­‐I	  in	  a	  manner	  dependent	  on	  transport	  associated	  with	  
antigen	   processing	   (TAP)	   molecules	   (120),	   or,	   endosomal	   degradation	   may	   occur,	   with	  
antigen	  loading	  onto	  MHC-­‐I	  in	  a	  TAP-­‐independent	  manner	  (121).	  	  	  
	  
Cross-presentation of antigen 
Various	   antigen	   presenting	   cells	   (APCs)	   have	   been	   reported	   to	   cross-­‐present	   antigens	   in	  
vitro,	  however	  it	  appears	  that	  DCs	  are	  the	  primary	  cross-­‐presenting	  APCs	  in	  vivo	  (122).	  The	  
reason	  for	  this	  discrepancy	  is	  unclear,	  however	  it	  may	  be	  that	  high	  antigen	  concentration	  in	  
some	  in	  vitro	  systems	  allows	  for	  the	  direct	  loading	  of	  antigen	  onto	  surface	  MHC-­‐I	  molecules.	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Particular	  DC	  subsets	  appear	  to	  be	  specialised	  in	  the	  efficient	  cross-­‐presentation	  of	  antigens,	  
although	   it	   is	  unclear	  whether	  the	  ability	   to	  cross-­‐present	   is	   intrinsic,	  or	  rather	  conferred	  
according	  to	  the	  nature	  of	  the	  antigen	  or	  cytokine	  environment	  encountered.	  The	  subsets	  of	  
DCs	   widely	   recognised	   as	   proficient	   cross-­‐presenting	   cells	   include	   CD8α+	   lymphoid-­‐
resident	  DCs	  as	  well	  as	  CD103+	  migratory	  DCs	  that	  have	  transported	  antigen	  to	  the	  lymph	  
nodes	   from	  the	   lungs	  and	  skin	   (57,	  73,	  123-­‐126).	  Cytokines	   such	  as	  GM-­‐CSF	  promote	   the	  
ability	  of	  DCs	  to	  cross-­‐present	  antigens	  (127).	  	  	  	  
	  
A	   recently	   discovered	   phenomenon	   describes	   a	   mechanism	   by	   which	   DCs	   may	   acquire	  
intact	   antigen-­‐MHC-­‐I	   complexes	   from	   other	   nearby	  DC	   that	   are	   cross-­‐presenting	   antigen.	  
This	   process,	   termed	   cross-­‐dressing,	   facilitates	   the	   expansion	   of	   the	   cross-­‐presenting	   DC	  
pool,	   and	   may	   also	   allow	   poor	   cross-­‐presenting	   APCs	   to	   stimulate	   effective	   naïve	   and	  
memory	  CD8+	  T	  cell	  responses	  (76,	  128-­‐132).	  	  
	  
Cross-­‐presentation	  has	  multiple	  functionally	  important	  roles.	  Under	  steady	  state	  conditions,	  
cross-­‐presentation	  facilitates	  the	  generation	  of	  central	  and	  peripheral	  tolerance	  of	  CD8+	  T	  
cells	   to	   self	   and	   foreign	   antigens	   (133-­‐137).	   A	   major	   role	   for	   cross-­‐presenting	   DCs	   also	  
exists	   in	   anti-­‐tumour	   immune	   responses	   (138).	   Defective	   CD8α+	   and	   CD103+	   DCs	   are	  
ineffective	  at	  generating	  CD8+	  T	  cells	  to	  target	  tumours.	  In	  models	  of	  infection,	  DCs	  that	  are	  
uninfected	  may	   acquire	   pathogen-­‐derived	   antigens	   from	   infected	   cells	   and	   cross-­‐present	  
these	   to	   CD8+	   T	   cells(139).	   This	   is	   critically	   important	   in	   the	   stimulation	   of	   particular	  
antiviral	  immune	  responses;	  indeed,	  in	  basic	  leucine	  zipper	  transcriptional	  factor	  ATF-­‐like	  
3	  (BATF3)-­‐deficient	  mice,	  which	  lack	  CD8α+	  and	  CD103+	  cross-­‐presenting	  DCs,	  the	  CD8+	  T	  
cell	  response	  to	  Sendai	  virus	  and	  West	  Nile	  virus	  was	  diminished	  (138,	  140).	  Additionally,	  
Gamma-­‐interferon-­‐inducible	  lysosomal	  thiol	  reductase	  (GILT)-­‐deficient	  mice,	  within	  which	  
antigens	  may	  not	  be	  cross	  presented,	  display	  impaired	  CD8+	  T	  cell	  responses	  to	  HSV-­‐1	  and	  
influenza	   viruses	   (141).	   These	   evidences	   together	   highlight	   the	   significant	   roles	   of	   cross-­‐
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1.1.2 CD4+ T cell subsets	  
The	  roles	  of	  CD4+	  T	  cells	  are	  incredibly	  diverse;	  from	  immune	  activation,	  to	  resolution	  and	  
tissue	  repair.	  At	  least	  five	  subsets	  of	  T-­‐helper	  cells	  have	  been	  well	  characterised:	  Th1,	  Th2,	  
Th17,	  T-­‐regulatory	  cells	  (Treg)	  and	  T	  follicular	  helper	  cells	  (Tfh).	  Additional	  subsets,	  such	  
as	  Th9	  cells,	  have	  also	  recently	  been	  described.	  	  As	  depicted	  in	  Figure	  1.1,	  these	  subsets	  are	  
characterised	  by	  their	  distinct	  transcription	  factors	  and	  specific	  cytokine	  production.	  T	  cell	  
subsets	  are	  thus	  purposed	  with	  different	  functions	  in	  the	  regulation	  of	  immune	  responses.	  
Major	  factors	  contributing	  to	  the	  determination	  of	  the	  effector	  subset	  fate	  of	  naïve	  Th	  cells	  




Figure	  1.1:	  CD4+	  T	  cell	  subsets	   	  
Upon	  recognition	  of	  antigen	  presented	  on	  MHC-­‐II	  by	  APC,	  naive	  CD4+	  T	  cells	  differentiate	  
into	   distinct	   subsets	   according	   to	   co-­‐stimulatory	   factors	   and	   the	   cytokine	  
microenvironment.	  A	  unique	   set	   of	   transcription	   factors	   is	   expressed	  by	   each	   subset	   and	  
characteristic	   cytokine	   production	   enables	   them	   to	   carry	   out	   diverse	   roles	   in	   immune	  
responses.	  The	  differentiation	  of	  four	  subsets,	  Th1,	  Th2,	  Th17	  and	  Tregs,	  from	  naive	  CD4+	  T	  
cells	   has	   been	  demonstrated;	   conversely	   it	   is	   less	   clear	  whether	  Tfh	   derive	   directly	   from	  
naive	  CD4+	  T	  cells	  or	  from	  previously	  differentiated	  Th	  subsets,	  while	  Th9	  may	  arise	  as	  a	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Upon	   recognition	   of	   their	   cognate	   antigen,	   naïve	  CD4+	  T	   cells	   in	  vivo	   rapidly	   engage	   in	   a	  
stable	   interaction	   with	   antigen-­‐presenting	   DCs	   (142).	   The	   activation	   markers	   CD69	   and	  
CD44	   are	   subsequently	   upregulated,	   and	   CD62L	   downregulated.	   In	   the	   fate	   decision	  
between	   Th1	   and	   Th2,	   the	   strength	   of	   TCR	   signalling	   has	   been	   implicated.	  While	   strong	  
signals	  reportedly	  stimulate	  Th1	  cells	   in	  vitro,	   through	  the	   inhibition	  of	  STAT5,	  weak	  TCR	  
signalling	  has	  been	  reported	  to	   induce	  Th2	  (143).	  The	  presence	  of	   IL-­‐12	  and	  IFN-­‐γ	   in	   the	  
cytokine	  microenvironment	   polarise	   naïve	   CD4+	   T	   cells	   to	   a	   Th1	   phenotype	   through	   the	  
induction	  of	  STAT1	  and	  STAT4	  signalling	  that	  induces	  the	  master	  Th1	  transcription	  factor,	  
T-­‐bet	  (144,	  145).	  Production	  of	   IFN-­‐γ	  characteristically	  ensues.	  Th2	  differentiation	  occurs	  
through	  the	  induction	  of	  the	  Th2	  master	  regulatory	  transcription	  factor	  GATA-­‐3.	  This	  may	  
require	   IL-­‐2-­‐mediated	   activation	   of	   STAT5	   and	   IL-­‐4-­‐driven	   STAT6	   activation	   (146).	   The	  
resulting	  Th2	  cells	  produce	  IL-­‐4,	   IL-­‐5	  and	  IL-­‐13.	  The	  detailed	  development	  and	  functional	  
characteristics	  of	  Th2	  cells	  are	  further	  discussed	  in	  section	  1.2.	  	  
	  
Th17	  cells	  have	  been	  proposed	  to	  differentiate	  as	  a	  result	  of	  TGF-­‐β	  and	  IL-­‐6	  stimulation,	  in	  
association	  with	  IL-­‐23	  (147,	  148).	  TGF-­‐β	  and	  IL-­‐6	  act	  in	  combination	  with	  TCR	  stimulation	  
to	  induce	  the	  expression	  of	  the	  IL-­‐23R	  and	  the	  Th17	  master	  regulatory	  transcription	  factor	  
RORγt	  through	  activation	  of	  SMADs	  and	  STAT3.	  The	  production	  of	  IL-­‐17A,	  IL-­‐17F	  and	  IL-­‐22	  
then	   characterise	   the	   Th17	   response	   (149,	   150).	   The	   presence	   of	   IL-­‐2	   antagonises	   the	  
generation	   of	   Th17	   cells,	   overriding	   the	   effects	   of	   IL-­‐6	   and	   TGF-­‐β	   if	   also	   present	   (151);	  
instead,	  the	  differentiation	  of	  Treg	  cells	  is	  promoted	  by	  IL-­‐2	  and	  critically	  mediated	  through	  
TGF-­‐β-­‐driven	   induction	   of	   the	   master	   Treg	   regulatory	   transcription	   factor,	   Foxp3	   (152,	  
153).	   Tregs	   then	   produce	   TGF-­‐β	   and	   IL-­‐10	   to	   regulate	   immune	   responses.	   Interestingly,	  
TCR	  signal	  strength	  also	  plays	  a	  contributing	  role	  in	  the	  fate	  determination	  between	  Th17	  
and	  Treg	  differentiation.	  Upon	  weak	  TCR	  signalling,	  Th17-­‐inducing	  cytokines	   fail	   to	  drive	  
Th17	  differentiation;	  instead,	  this	  TCR	  stimulation	  results	  in	  the	  expression	  of	  Foxp3	  (154-­‐
156).	   Strong	   TCR	   signalling	   however,	   capable	   of	   blocking	   STAT5	   activation	   and	   Th2	  
development	   as	   previously	   mentioned,	   may	   similarly	   result	   in	   the	   inhibition	   of	   STAT5-­‐
mediated	  Foxp3	  activation	  and	  thus	  allow	  for	  the	  induction	  of	  Th17	  cells	  (157,	  158)	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It	  is	  not	  clear	  whether	  Tfh	  cells	  differentiate	  from	  previously	  committed	  Th1,	  Th2	  or	  Th17	  
cells,	   or	   whether	   they	   originate	   directly	   from	   naïve	   CD4+	   T	   cells.	   As	   such,	   the	   cytokine	  
signals	  involved	  in	  the	  differentiation	  of	  Tfh	  cells	  are	  not	  fully	  understood.	  However,	  their	  
roles	   in	   the	   facilitation	   of	   T	   cell-­‐dependent	   humoral	   immune	   responses	   have	   been	  
recognised.	   Tfh	   cells	   promote	   the	   formation	   of	   germinal	   centres,	   immunoglobulin	   class	  
switching,	   affinity	   maturation	   of	   B	   cells	   and	   maintain	   antibody	   responses	   (159).	   Their	  
master	  regulator,	  B-­‐cell	  lymphoma	  6	  (Bcl-­‐6)	  is	  induced	  via	  STAT3	  activation	  (160,	  161).	  
	  	  
Th9	  cells,	  named	  due	  to	  their	  characteristic	  production	  of	  IL-­‐9,	  were	  recently	  identified,	  and	  
share	  a	   similar	  developmental	  pathway	   to	  Th2	  cells	   (162,	  163).	  Classic	  Th2-­‐signalling	   IL-­‐
4/STAT6/GATA3,	   alongside	  TGF-­‐β	   stimulation	  of	  PU.1,	   leads	   to	   the	  development	  of	   IL-­‐9	  
producing	  cells	  (164).	   Identified	  more	  than	  20	  years	  after	  the	  delineation	  of	  Th1	  and	  Th2	  
cells,	  the	  role	  of	  the	  Th9	  subset	  was	  previously	  unappreciated,	  with	  IL-­‐9	  production	  being	  
attributed	  to	  Th2	  cells	  and	  Tregs	  (165).	  Indeed,	  cells	  previously	  committed	  to	  a	  Th2	  profile	  
were	   found	   to	   develop	   into	  Th9	   cells	   upon	  TGF-­‐β	   stimulation	   (162,	   163).	  However,	   this	  
subset	  can	  also	  develop	  directly	   from	  naïve	  CD4+	  T	  cells	   in	  the	  presence	  of	  both	  IL-­‐4	  and	  
TGF-­‐β.	  	  
	  
While	   specific	   CD4+	   T	   cell	   subsets	   have	   been	   described,	   the	   delineation	   between	   these	  
subsets	  is	  not	  completely	  black	  and	  white.	  It	  was	  originally	  thought	  that	  Th1	  and	  Th2	  cells	  
became	   irreversibly	   committed	   to	   a	   terminal	   differentiation,	   insomuch	   as	   the	   cell	   would	  
become	   incapable	   of	   reverting	   into	   a	   different	   subset.	   However,	   CD4+	   T	   cells	   have	   been	  
described	   that	   display	   features	   of	  more	   than	   one	   specific	   subset.	   Studies	   have	   identified	  
cells	  that	  co-­‐express	  Th1	  and	  Th2	  markers:	  GATA3+	  IL-­‐4+	  and	  T-­‐bet+	  IFN-­‐γ+	  cells	  (166).	  
Th2/Th17	  markers	  may	  also	  be	  co-­‐expressed:	  GATA3+	  IL-­‐4+	  and	  RoRγt+	  IL-­‐17A+	  (167).	  
IL-­‐9,	   characteristic	   of	   Th9	   cells,	   may	   also	   be	   secreted	   by	   Th2	   cells	   (163).	   Additionally,	  
diminished	  expression	  of	  FoxP3	  causes	  Tregs	  to	  revert	  back	  to	  effector	  T	  cells	  producing	  IL-­‐
2	  and	  IL-­‐4	  (168,	  169),	  while	  IL-­‐12	  can	  revert	  Th2	  polarised	  cells	  to	  Th0/Th1	  (170).	  These	  
evidences	   reveal	   that	   fully	   differentiated	   CD4+	   T	   cells	   are,	   to	   some	   extent,	   plastic	   and	  
capable	  of	  adapting	  to	  their	  microenvironment	  as	  required.	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It	  is	  my	  opinion	  that	  the	  described	  componentry	  of	  the	  immune	  system	  as	  we	  know	  it	  will	  
likely	  not	  be	  entirely	  similar	  to	  that	  in	  time	  to	  come.	  The	  pathogenic	  threats	  that	  are	  ever-­‐
evolving	  under	  numerous	  natural	  and	  man-­‐made	  pressures	  calls	  also	  for	  the	  diversification	  
of	  immune	  responses.	  This	  could	  lead	  to	  the	  development	  of	  immune	  cell	  subsets	  that	  may	  
not	   in	   fact	   have	   been	   historically	  misidentified,	   but	   rather	   represent	   a	   novel	   facet	   of	   the	  
immune	  repertoire	  to	  counteract	  novel	  threats	  accordingly.	  	  
	  
	  
1.1.2.1 The role of CD4+ T cells 
The	   roles	   of	   these	   functionally	   and	   phenotypically	   diverse	   CD4+	   T	   cells	   in	   health	   and	  
disease	   are	  many.	   These	   responses	  must	   be	   fine-­‐tuned	   and	   tightly	   regulated	   such	   that	   a	  
particular	  cell	  population	  does	  not	  overreact	  or	   insufficiently	  respond	  to	  stimuli,	  which	  in	  
either	  case	  may	  lead	  to	  disease.	  	  
	  	  
Type	  1	  immune	  responses	  (defined	  herein	  as	  those	  driven	  by	  cytokines	  classically,	  but	  not	  
exclusively,	   attributed	   to	   Th1	   cells,	   rather	   than	   referring	   to	   type	   1	   hypersensitivity	  
reactions)	  and	  Th17	  immune	  responses	  are	  initiated	  in	  response	  to	  bacteria,	  viruses,	  fungi	  
and	  protozoa,	  for	  which	  Th1	  and	  Th17	  cells	  are	  key	  mediators.	  Th1	  cells	  are	  important	  in	  
cell-­‐mediated	  immunity	  that	  drives	  delayed	  type	  hypersensitivity	  through	  the	  production	  of	  
IFN-­‐γ	   (171,	   172),	   defending	   against	   intracellular	   parasites	   (173).	   Exaggerated	   effects,	  
however,	   can	   lead	   to	   the	   development	   of	   autoimmune	   disease	   (174)	   such	   as	   Type	   1	  
diabetes	  	  (175),	  and	  additionally	  has	  a	  pathogenic	  role	  in	  inflammatory	  bowel	  disease	  (176,	  
177).	   Th17	   cells,	   through	   their	   production	   of	   IL-­‐17,	   promote	   the	   maturation	   and	  
chemotaxis	   of	   neutrophils	   that	   mediate	   defence	   against	   bacteria	   and	   fungi	   (178,	   179).	  
Additionally,	  Th17	  cells	  are	  a	  source	  of	  IL-­‐22,	  which	  has	  been	  shown	  to	  be	  indispensible	  in	  
the	   stimulation	   of	   epithelial	   induced	   antimicrobial	   defence	   genes	   that	   protect	   against	  
bacterial	   infection	   (180,	   181).	   However,	   a	   role	   for	   Th17	   cells	   has	   also	   been	   described	   in	  
allergy;	   they	   are	   strongly	   associated	   with	   the	   development	   and	   maintenance	   of	   atopic	  
dermatitis	   (182),	   and	   nickel	   allergy	   (183).	   IL-­‐17	   may	   also	   drive	   autoimmunity	   such	   as	  
rheumatoid	   arthritis	   (184),	   systemic	   lupus	   erythematosus	   (185)	   and	   psoriasis	   (186),	   as	  
well	  as	  transplant	  rejection	  (187).	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The	  type	  2	  adaptive	  immune	  response,	   largely	  driven	  by	  Th2	  cells,	  (and	  defined	  herein	  as	  
those	  driven	  by	  cytokines	  classically,	  but	  not	  exclusively,	  attributed	  to	  Th2	  cells,	  rather	  than	  
referring	  to	  type	  2	  hypersensitivity	  reactions)	  mediates	  extracellular	  immunity	  in	  response	  
to	   the	   invasion	   of	   specific	   pathogens;	   particularly	   important	   for	   protection	   against	  
intestinal	   helminths.	   Th2	   responses	   enhance	   mucosal	   barrier	   defences	   and	   mediate	   the	  
expulsion	  or	  killing	  of	  parasites	  in	  a	  manner	  that	  is	  dependent	  on	  CD4+	  T	  cells,	  IL-­‐4/IL-­‐13,	  
IL-­‐4R	   and	   STAT6	   signalling	   (188).	  While	   IL-­‐13	   is	   critical	   for	  worm	   expulsion,	   exogenous	  
administration	  of	  IL-­‐4	  is	  also	  sufficient	  to	  do	  so	  (189).	  The	  archetypal	  Th2	  cytokines	  drive	  
the	   activation	   of	   eosinophils,	   mast	   cells,	   and	   goblet	   cells,	   which	   stimulate	   inflammatory	  
responses	   and	   the	   production	   of	   mucus	   at	   epithelial	   surfaces;	   while	   this	   response	   is	  
necessary	  for	  protection	  against	  parasites,	  it	  can	  also	  be	  directed	  against	  harmless	  inhaled	  
antigens	   (that	   is,	   those	   that	   are	   not	   normally	   disease-­‐causing	   in	   healthy	   individuals)	   and	  
consequently	  cause	  disease	  in	  the	  lung.	  These	  pathogenic	  Th2	  responses	  are	  central	  to	  the	  
development	   and	   maintenance	   of	   atopic	   dermatitis,	   allergic	   rhinitis	   and	   allergic	   asthma	  
(discussed	  in	  section	  1.2).	  	  
	  
Foxp3+	  T	  regulatory	  cells	  have	  many	  roles	  in	  the	  maintenance	  of	  immune	  homeostasis	  and	  
are	  key	   in	   the	   regulation	  of	   effector	  T	   cell	   function	   in	   the	  periphery.	  Tregs,	   constitutively	  
expressing	  CD25	  and	   secreting	   IL-­‐10	   and	  TGF-­‐β,	   are	   key	   in	   the	   tolerance	  of	   self-­‐antigens	  
and	   limiting	  overactive	  T	  cell	   responses	   (190,	  191).	   In	   the	  realm	  of	  Th2	  responses,	  Tregs	  
are	  especially	  important	  for	  curbing	  the	  generation	  of	  disease.	  Tregs	  help	  restrict	  the	  onset	  
and	   strength	   of	   Th2	   responses	   during	   active	   helminth	   infection	   and	   limit	   the	   severity	   of	  
intestinal	  disease	  (192,	  193).	  The	  adoptive	  transfer	  of	  allergen-­‐specific	  Tregs	  has	  also	  been	  
shown	   to	   suppress	   allergic	   inflammation	   in	   sensitised	   mice	   (194).	   Foxp3+	   Treg-­‐derived	  
cytokines	   suppress	   airway	   inflammation	   either	   through	   an	   IL-­‐10-­‐independent,	   TGF-­‐β-­‐
mediated	   mechanism	   (195),	   or	   through	   IL-­‐10-­‐dependent	   mechanisms	   (194,	   196).	   These	  
cytokines	  may	  act	  on	  DCs	   to	   reduce	  DC	  number	  and	  activation	   (197),	   thereby	  reducing	  T	  
cell	   stimuli,	  or	  directly	  suppress	  Th2	  responses	  by	  decreasing	   IL-­‐4	  production,	  serum	  IgE	  
and	   lung	   eosinophilia	   (198).	   Again,	   not	   all	   responses	   mediated	   by	   these	   T	   cells	   are	  
beneficial;	  Tregs	  are	  also	   implicated	   in	  autoimmune	  diseases	   (199)	  and	   the	  generation	  of	  
tolerance	   to	   tumours,	   preventing	   the	   induction	   of	   anti-­‐tumour	   immune	   responses	   (200-­‐
202).	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1.1.3 CD8+ T cells 
In	   contrast	   to	   CD4+	   T	   cells,	   naïve	   CD8+	   T	   cells	   do	   not	   immediately	   engage	   in	   prolonged	  
interactions	  with	  DC,	  but	  rather	  associate	  with	  multiple	  antigen-­‐presenting	  DCs	  transiently,	  
over	  a	  number	  of	  hours,	  before	  a	  stable	  interaction	  is	  formed	  (203).	  DCs	  then	  stimulate	  the	  
differentiation	  of	  naïve	  CD8+	  T	  cells	  into	  effector	  T	  cells	  with	  cytolytic	  function:	  cytotoxic	  T	  
lymphocytes	  (CTL).	  DCs	  play	  a	  critical	  role	  in	  the	  development	  of	  fully	  activated	  CTLs	  (122,	  
204,	  205)	  and	  this	  process	   is	  critically	  dependent	  on	  sufficient	  co-­‐stimulation	  through	  DC	  
CD80/CD86	  and	  CD8+	  T	  cell	  CD28	  (206-­‐208).	  To	  successfully	  prime	  naïve	  CD8+	  T	  cells	  that	  
differentiate	  into	  effective	  killer	  cells	  as	  well	  as	  long-­‐lived	  memory	  cells,	  DCs	  must	  enlist	  the	  
help	  of	  CD4+	  T	  cells	  to	  provide	  the	  signals	  required	  to	  licence	  DCs	  (209,	  210).	  This	  occurs	  
through	   the	  engagement	  of	  DC	  CD40	  by	  CD4+	  T	   cell	  CD40L	   (211,	  212).	  Licenced	  DCs	  are	  
then	  capable	  of	  priming	  CTLs	  even	  after	  CD4+	  T	  cell	  interaction	  has	  ceased	  (209,	  213).	  DC-­‐
derived	  IL-­‐12	  also	  acts	  to	  promote	  the	  proliferation	  and	  survival	  of	  CTLs	  (214,	  215).	  	  
	  
1.1.3.1 CTL subsets 
CTLs	  may	  be	  characterised	  as	  type	  1	  or	  type	  2,	  termed	  Tc1	  and	  Tc2.	  These	  subsets,	  similarly	  
to	  Th1	  and	  Th2	  cells,	  produce	  distinctive	  cytokine	  repertoires	  resulting	  in	  different,	  or	  even	  
opposing,	  functions.	  Tc1	  cells	  secrete	  IFN-­‐γ,	  while	  Tc2	  cells	  produce	  IL-­‐4,	  IL-­‐5,	  IL-­‐6	  and	  IL-­‐
10	  (216,	  217).	  Cytokine	  signalling	  is	  important	  in	  the	  fate	  decision	  between	  Tc1	  and	  Tc2;	  in	  
vitro	   experiments	   have	   revealed	   that	   if	   IL-­‐4	   is	   present	   during	   CD8+	   T	   cell	   priming,	   IL-­‐4-­‐
producing	  CTLs	  are	  generated	  (216,	  218,	  219),	  conversely,	  IL-­‐12	  stimulation	  results	  in	  CTLs	  
that	  produce	  IFN-­‐γ	  (Curtsinger,	  J	  Exp	  Med,	  2003).	  Similarly	  to	  the	  Th1/Th2	  paradigm,	  the	  
cytokine	  profile	  of	  Tc1	  and	  Tc2	  cells	   results	   in	   their	  differing	  effects	  on	  disease.	  Tc1	  cells	  
ameliorate	  allergic	  airway	   inflammation	  (220-­‐226)	  whereas	  Tc2	  exaggerate	  disease	  (227-­‐
229).	  Tumour-­‐specific	  Tc1	  cells	  provide	  protection	  against	  tumour	  challenge,	  while	  Tc2	  do	  
not	   do	   so	   efficiently	   (230,	   231).	   The	   generation	   of	   a	   graft-­‐versus-­‐leukaemia	   response	   is	  
promoted	  by	  Tc1	  and	  abrogated	  by	  Tc2,	  conversely,	  higher	  numbers	  of	  Tc2	  cells	  correlates	  
with	  better	  humoral	   responses	   to	   influenza	  vaccination	   (232,	  233),	  potentially	  due	   to	   the	  
Tc2-­‐derived	  IL-­‐4	  that	  can	  provide	  B	  cell	  help	  (234)	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The	   CTLs	   generated	   undergo	   clonal	   expansion	   and	   migrate	   to	   peripheral	   tissues	   where	  
pathogenic	  stimuli	  are	  present	  (235,	  236).	  Here,	  CTLs	  mediate	   the	  elimination	  of	   infected	  
cells.	  	  
	  
1.1.3.2 CTL-mediated killing of target cells 
Antigen-­‐specific	  CTLs,	  upon	  recognition	  of	  their	  cognate	  antigen	  loaded	  on	  cellular	  MHC-­‐I,	  
mediate	   the	   killing	   of	   target	   cells.	   This	   is	   achieved	   either	   through	   direct	   CTL	   granule-­‐
mediated	  cytolysis,	  or	  through	  the	  engagement	  of	  target	  cell	  receptors	  that	  signal	  apoptosis.	  
CTLs	   synthesise	   and	   store	   granules	   that	   contain	   proteins	   that	   induce	   rapid	   cytolysis,	  
including	  perforin	   and	   granzymes.	  Upon	  CTL	   engagement	  with	   target	   cell	   antigen-­‐MHC-­‐I,	  
the	  CTL	  releases	  the	  granules	  into	  a	  tight	  intercellular	  junction	  between	  the	  two	  cells,	  and	  
signals	  apoptosis	  of	  the	  target	  cell.	  These	  phenomena	  are	  described	  in	  this	  section.	  
	  
Granule-mediated cytolysis 
It	   is	   not	   fully	   understood	  how	  perforin	  mediates	   cytotoxicity.	   The	  prevailing	   view	   is	   that	  
perforin	   forms	   pores	   in	   target	   cell	   membranes,	   through	   which	   pro-­‐apoptotic	   granzymes	  
may	  be	  directed	  into	  the	  cytosol	  of	  the	  target	  cell,	   inducing	  cell	  death	  (237-­‐242).	  Law	  and	  
colleagues	  used	  X-­‐ray	  crystallography	   to	   reveal	   the	   structure	  of	  perforin	  and	  generated	  a	  
reconstruction	   of	   the	   perforin	   pore	   by	   cryo-­‐electron	   microscopy	   to	   elucidate	   the	  
mechanism	  of	  perforin	  pore	  formation	  (243).	  In	  brief,	  this	  is	  mediated	  by	  the	  binding	  of	  a	  C-­‐
terminal	   C2	   domain	   on	   the	   perforin	   molecule	   with	   the	   target	   cell	   membrane,	   in	   a	   Ca2+	  
dependent	  manner.	  The	  perforin	  assembles	  into	  oligomers	  on	  the	  target	  cell	  surface,	  which	  
then	  undergoes	  a	  conformational	  change	  that	  allows	  membrane	  insertion	  and	  formation	  of	  
a	  transmembrane	  pore,	  through	  which	  granzymes	  are	  directed.	  The	  cylindrical	  pore	  model	  
has	  been	  accordingly	  implicated	  in	  other	  studies	  (244,	  245),	  with	  some	  demonstrating	  15-­‐
20nm	  pores	  being	  formed,	  sufficient	  to	  allow	  the	  passage	  of	  a	  granzyme	  molecule,	  such	  as	  
Granzyme	   B	   –	   4.3nm	   (243,	   246,	   247).	   However,	   being	   a	   historically	   controversial	   topic,	  
most	   recently	   this	   view	   has	   been	   again	   challenged;	   using	   concentrations	   of	   perforin	   that	  
coincide	   with	   granzyme	   translocation	   and	   apoptotic	   cell	   death	   (246,	   248),	   Metkar	   and	  
colleagues	  report	  that	  pores	  of	  similar	  size	  to	  that	  described	  by	  others	  were	  not	  identified.	  
Rather,	   protein	   “arcs”	   formed	   toroidal	   pores	   under	   these	   conditions	   (249).	   This	   finding	  
suggested	  that	  cylindrical	  pores,	  still	  formed	  under	  higher	  perforin	  concentrations,	  may	  be	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dispensable	  for	  granzyme	  delivery.	  The	  toroidal	  pores	  consist	  of	  inserted	  peptides	  and	  lipid	  
that	   together	   form	   a	   water	   channel,	   in	   contrast	   to	   the	   cylindrical	   pores	   that	   are	   lined	  
exclusively	  by	  protein	  and	  prevent	  the	  movement	  of	  phospholipids	  across	  the	  bilayer	  (250,	  
251);	  this	  water	  channel	  may	  provide	  more	  favourable	  conditions	  for	  the	  passage	  of	  highly	  
cationic	  granzymes.	  Metkar	  and	  colleagues	  thus	  propose	  that	  cylindrical	  pores	  may	  serve	  a	  
function	  distinct	  from	  the	  delivery	  of	  granzymes,	  which	  are	  likely	  to	  be	  transferred	  through	  
the	  toroidal	  pores.	  Although	  controversy	  still	  exists	  in	  the	  mechanistic	  detail	  of	  this	  form	  of	  
cytolysis,	   together,	   these	   studies	   are	  driving	   the	   refinement	  of	   our	  understanding	  of	  how	  
perforin	  and	  granzymes	  mediate	  target	  cell	  death.	  	  	  
	  
In	  any	  case,	  it	  has	  been	  established	  that	  perforin	  is	  critical	  for	  cytolysis,	  as	  revealed	  in	  the	  
study	  of	  disease.	  CTLs	  from	  perforin	  knock	  out	  (PKO)	  mice	  show	  reduced	  cytotoxicity	  and	  a	  
defective	   ability	   to	   induce	   membrane	   damage	   and	   apoptosis,	   compared	   to	   perforin	  
sufficient	  mice	  (252).	  As	  such,	  perforin	  deficiency	  causes	  delayed	  clearance	  of	  viruses	  (253)	  
as	  well	  as	  attenuated	  primary	  and	  drastically	  deficient	  secondary	  response	  to	  viral	  infection	  
(254).	  The	  effects	  of	  perforin	  deficiency	  are	  more	  striking	   in	  humans:	  patients	  who	  suffer	  
from	  familial	  haemophagocytic	  lymphohistiocytosis,	  where	  perforin	  is	  defective,	  experience	  
uncontrolled	  activation	  of	  T	  cells	  and	  macrophages	  and	  the	  overproduction	  of	  inflammatory	  
cytokines	   (255-­‐258).	   This	   condition	   rapidly	   results	   in	   death.	   Together,	   these	   studies	  
highlight	   the	   importance	   of	   perforin	   in	   the	   elimination	   of	   infected	   cells,	   as	   well	   as	   the	  
critical	   requirement	   for	   perforin	   in	   the	   maintenance	   of	   human	   immune	   regulation	   and	  
homeostasis.	  	  
	  
Numerous	  serine	  proteases	  are	  delivered	   to	   target	  cells,	  of	  which	  granzymes	  A	  and	  B	  are	  
the	   most	   well	   characterised.	   While	   granzyme	   A	   drives	   target	   cell	   death	   in	   a	   caspase-­‐
independent	   manner,	   granzyme	   B	   activates	   intracellular	   caspases	   to	   initiate	   apoptosis	  
(259-­‐261).	  Whether	   these	   granzymes	   are	   required	   for	   cytotoxic	   control	   of	   disease	   is	   not	  
clear;	  their	  role	  varies	  according	  to	  the	  pathogenic	  stimulus.	  A	  requirement	  for	  granzyme	  A	  
and	   B	   has	   been	   demonstrated	   in	   the	   suppression	   of	   poxvirus	   infection	   (262),	   however	  
cytomegalovirus-­‐infected	   or	   influenza-­‐infected	  mice	   exhibit	   sufficient	   anti-­‐viral	   immunity	  
in	  the	  absence	  of	  granzymes	  A	  and	  B	  (263,	  264).	  Some	  studies	  have	  questioned	  the	  role	  of	  
granzymes	  in	  the	  CTL-­‐mediated	  suppression	  of	  disease	  altogether;	  granzyme	  A	  and	  B	  may	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not	  be	  required	  for	  anti-­‐tumour	  immunity	  (265).	  Interestingly,	  it	  appears	  that	  the	  ability	  of	  
granzymes	   to	  mediate	   apoptosis	   is	   critically	   dependent	   on	   perforin	   (266).	   These	   studies	  
suggest	   specialised	   roles	   exist	   for	   granzymes	   in	   the	   control	  of	  disease,	  which	  may	  not	  be	  
directly	   mediated	   by	   perforin,	   however,	   may	   remain	   under	   the	   control	   of	   perforin	  
expression.	  	  
	  
Receptor-mediated cytolysis  
Receptor-­‐mediated	  cytolysis	   is	  primarily	  driven	  by	  ligands	  and	  receptors	  belonging	  to	  the	  
TNF-­‐α	   superfamily:	   Fas	   ligand	   (FasL),	   which	   binds	   Fas,	   TNF-­‐α	   that	   binds	   to	   the	   TNF-­‐α	  
receptor	   1	   and	   2	   and	   death	   receptor	   3,	   while	   TNF-­‐related	   apoptosis-­‐inducing	   ligand	  
(TRAIL)	  binds	  death	  receptor	  5	  and	  other	  receptors.	  Binding	  of	  CTL	  Fas	  ligand	  (FasL)	  to	  a	  
target	   cell	   Fas	   receptor	   (241)	   results	   in	   the	   recruitment	   of	   Fas-­‐associated	   death	   domain	  
(FADD)	  protein	  and	  caspase-­‐8	  that	  bind	  to	  Fas	  and	  interact	  with	  the	  death	  domain	  (DD)	  and	  
death	   effector	  domain	   (DED)	   to	   form	  a	  death-­‐inducing	   signal	   complex	   (DISC)	   (267,	   268).	  
Similarly,	   signalling	   through	   the	   TNF-­‐α	   receptors	   and	   TRAIL	   receptors	   results	   in	   the	  
recruitment	   of	   FADD,	   or	   TNF-­‐receptor	   1-­‐associated	   via	   death	   domain	   (TRADD),	   and	  
subsequent	   formation	   of	   DISC	   (269,	   270).	   The	   formation	   of	   DISC	   drives	   activation	   of	  
caspase-­‐8	  molecules	  that	  further	  recruit	  and	  activate	  caspase	  3	  and	  caspase	  7	  which	  cleave	  
cellular	  proteins	  and	  drive	  target	  cell	  apoptosis.	  Similarly	  to	  the	  requirement	  for	  perforin,	  
Fas-­‐FasL	  signalling	  appears	  to	  be	  crucial	  to	  immune	  homeostasis;	  deficiency	  or	  mutation	  in	  
Fas	  or	  FasL	  can	  lead	  to	  lymphadenopathy	  or	  autoimmune	  disease	  (271).	  	  	  
	  
	  
1.1.4 The generation of immunological memory	  
The	  stimulation	  of	  effector	  T	  cell	   responses	  also	  results	   in	   the	  development	  of	  memory	  T	  
cells.	  While	   the	  majority	  of	   activated	  effector	   cells	   apoptose	  upon	  withdrawal	  of	   antigen-­‐
stimulated	  cytokines	  and	  survival	  factors,	  a	  fraction	  of	  cells	  survive	  to	  become	  memory	  cells	  
(272,	  273).	  These	   cells	  may	   reside	   in	   tissues	  and	  are	   capable	  of	   rapidly	   responding	  upon	  
secondary	   exposure	   to	   antigens.	   Populations	   of	   central	   and	   effector	   memory	   T	   cells	   are	  
generated,	   distinguished	   by	   their	   expression	   of	   CD62L	   and	   CCR7.	   Cells	   that	   are	  
CD62LhiCCR7hi	  preferentially	  home	  to	  lymph	  nodes	  and	  are	  labelled	  central	  memory	  T	  cells,	  
conversely,	  CD62LloCCR7lo	  cells	  home	  to	  nonlymphoid	  tissues	  and	  acquire	  effector	  function	  
   23 
more	  rapidly,	  termed	  effector	  memory	  cells	  (274-­‐276).	  It	  has	  also	  recently	  been	  determined	  
that	  a	  population	  of	  memory	  stem	  cells	  exists	  that	  may	  directly	  give	  rise	  to	  central	  memory,	  
effector	  memory	  and	  effector	  T	   cells	   (277).	  These	   cells	   are	   specific	   for	  multiple	   antigens,	  
foreign	   and	   self,	   and	   are	   capable	   of	   enhanced	   proliferation	   and	   reconstitution	   of	  
immunodeficient	  hosts	  in	  comparison	  to	  traditionally	  recognised	  memory	  cell	  populations.	  	  	  
	  
Interestingly,	   of	   the	   memory	   cell	   subsets,	   CD4+	   and	   CD8+	   memory	   T	   cells	   are	   retained	  
differently.	   The	   memory	   phenotype	   and	   function	   of	   CD8+	   memory	   T	   cells	   may	   be	  
maintained	   for	   life	   (278),	   even	   in	   the	   absence	   of	   antigen	   stimulation	   (279-­‐281).	   These	  
memory	  cells	  may	  instead	  be	  maintained	  by	  nonspecific	  stimuli	  (224,	  282,	  283).	  Conversely,	  
the	  persistence	  of	  CD4+	  T	  cell	  memory	  has	  been	  debated.	  It	  has	  been	  shown	  that	   in	  vitro-­‐
differentiated	   Th1	   and	   Th2	   cells	   may	   be	   transferred	   into	   naïve	   hosts	   and	   retain	   their	  
cytokine	   profile	   for	   a	   number	   of	   months	   (284,	   285).	   On	   the	   other	   hand,	   it	   was	   also	  
demonstrated	  that	  antigen-­‐experienced	  cells	  may	  lose	  their	  enhanced	  helper	  function	  over	  
time	   (286-­‐288),	   thus	   suggesting	   that	   CD4+	   T	   cell	   memory	   wanes	   without	   continuous	  
antigenic	  exposure	  (289).	  These	  differences	  are	  likely	  a	  reflection	  of	  the	  immune	  system’s	  
requirements	  for	  maintaining	  homeostasis.	  It	  is	  not,	  perhaps,	  that	  the	  development	  of	  CD4+	  
T	   cell	   memory	   is	   simply	   inferior	   to	   that	   of	   CD8+	   T	   cell	   memory,	   per	   se,	   but	   rather	   the	  
waning	  of	  CD4+	  T	  cell	  memory	  may	  serve	  a	  protective	  purpose,	  so	  as	  not	  to	  allow	  sustained	  
CD4+	  T	   cell	   responses	   after	   the	   ‘threat’	   of	   antigenic	   stimuli	   has	   been	   removed.	   This	  may	  
also	   be	   important	   in	   maintaining	   Th1/Th2	   balance	   such	   that	   tolerogenic,	   rather	   than	  




1.1.5 Immune cells in the lung under steady state conditions	  
The	   lung	   is	   a	   site	   of	   constant	   antigen	   exposure,	   and	   as	   such,	   multiple	   immune	   cell	  
populations	   reside	  within	   the	  compartments	  of	   the	   lung	  where	   they	   interact	  with	  barrier	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Lung macrophages 
Under	   steady-­‐state	   conditions,	   up	   to	   95%	   of	   cells	   recovered	   from	   the	   lung	   by	   broncho-­‐
alveolar	  lavage	  are	  alveolar	  macrophages	  (AMs)	  (290).	  The	  role	  of	  AMs	  in	  the	  pathogenesis	  
of	   allergic	   asthma,	   however,	   is	   not	   fully	   understood.	   Characteristically	  
F4/80+MerTK+CD11c+Siglec-­‐F+CD11bloMHCIIlo	  and	  displaying	  significant	  autofluorescence,	  
studies	  have	  revealed	  both	  protective	  (291-­‐293)	  and	  pro-­‐inflammatory	  (294,	  295)	  roles	  for	  
these	  abundant	  cells,	  making	  it	  difficult	  to	  reconcile	  their	  involvement	  in	  asthmatic	  disease.	  
AMs,	   through	   their	   production	   of	   IL-­‐10,	   IL-­‐12	   and	   nitric	   oxide,	   decrease	   pulmonary	   DC	  
antigen	  presentation	  (296,	  297)	  and	  subsequent	  T	  cell	  proliferation	  (298,	  299),	  as	  well	  as	  
prevent	  the	  development	  of	  airway	  hyperreactivity	  (AHR)	  (291).	  Conversely,	  in	  response	  to	  
IgE,	  AMs	  have	  been	  shown	  to	  drive	  pulmonary	  inflammation	  by	  facilitating	  the	  infiltration	  
and	   activation	   of	   eosinophils	   and	   neutrophils	   through	   the	   up-­‐regulation	   of	   adhesion	  
molecules	   such	   as	   E-­‐selectin,	   vascular	   adhesion	   molecule-­‐1	   and	   intercellular	   adhesion	  
molecule-­‐1	  (300-­‐304).	  A	  recent	  publication	  by	  Zaslona	  and	  colleagues	  aimed	  to	  shed	  some	  
light	   on	   these	   apparently	   disparate	   roles	   	   (305);	   by	   selectively	   depleting	   either	   resident	  
AMs	   or	   circulating	   monocytes-­‐	   the	   latter	   of	   which	   the	   authors	   highlight	   as	   putative	  
precursors	  to	  AMs-­‐	  it	  was	  reported	  that	  resident	  AMs	  were	  in	  fact	  protective	  in	  asthma.	  In	  
contrast,	   infiltrating	   monocytic	   cells	   recruited	   during	   lung	   inflammation	   promoted	  
pathogenesis.	   The	   work	   of	   these	   authors	   addressed	   an	   important	   point:	   that	   the	  
incongruent	  reports	  of	  AM	  roles	  may	  in	  fact	  be	  due	  to	  the	  differing	  activity	  of	  lung	  resident	  
and	   recruited	   AMs	   under	   inflammatory	   conditions;	   though	   it	   was	   found	   that	   local	  
proliferation,	  rather	  than	  recruitment,	  was	   important	   for	   the	  maintenance	  of	   the	  AM	  pool	  
during	  the	  early	  phase	  allergic	  response.	   	  It	  must	  be	  noted,	  however,	  that	  the	  depletion	  of	  
circulating	   monocytes	   would	   also	   prevent	   the	   infiltration	   of	   monocyte-­‐derived	  
inflammatory	   DCs.	   As	   critical	   mediators	   of	   allergic	   airway	   inflammation	   (306),	   moDC-­‐
derived	   proinflammatory	   chemokines	   promote	   the	   elicitation	   of	   allergic	   airway	  
inflammation,	   and	   thus	   potentially	   effects	   the	   effective	   recruitment	   and	   development	   of	  
AMs	  also.	  As	  such,	  the	  role	  of	  AMs	  in	  the	  asthmatic	  response	  is	  still	  yet	  to	  be	  conclusively	  
elucidated.	  	  
	  
Two	   other	   macrophage	   populations	   reside	   in	   the	   lung	   under	   steady	   state	   conditions:	  
bronchial	  macrophages	  (BM)	  and	  interstitial	  macrophages	  (IM).	  While	  little	  is	  known	  about	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the	   role	   of	   BMs,	   these	   cells	   possess	   substantial	   IL-­‐10	   receptors,	   but	   not	   IL-­‐4	   or	   IL-­‐7	  
receptors,	   indicating	   a	   role	   in	   tolerance	  may	   exist	   (307).	   	   These	   cells	   display	   an	   altered	  
phenotype	  in	  asthma	  patients;	  CD16	  and	  CD64	  are	  downregulated,	  compared	  to	  BMs	  from	  
healthy	  subjects,	  and	  this	  results	  in	  poor	  phagocytic	  activity	  (307,	  308).	  In	  contrast	  to	  AMs,	  
IMs	   are	   generally	   considered	   antigen-­‐presenting	   macrophages	   (309);	   they	   display	  
enhanced	   MHC-­‐II	   expression	   as	   compared	   to	   AMs	   (310,	   311)	   and	   present	   antigens	   to	  
interstitial	  T	  cells.	   IMs	  have,	  however,	  been	  shown	  to	  promote	  tolerance	  and	  prevent	  Th2	  
inflammation	  in	  the	  airway	  through	  production	  of	  IL-­‐10	  (311).	  It	  has	  been	  shown	  that	  AMs	  
in	  fact	  originate	  from	  IMs;	  IMs	  are	  a	  necessary	  intermediate	  between	  blood	  monocytes	  and	  
AMs	  (312).	  	  
	  
Macrophages	  may	  be	  characterised	  into	  M1	  and	  M2	  subsets	  (313).	  Similarly	  to	  Th1	  and	  Th2,	  
M1	   drive	   inflammation	   in	   response	   to	   intracellular	   pathogens	   while	   M2	   phagocytose	  
foreign	  pathogens	  and	  apoptotic	  cells	  (314-­‐317).	  The	  presence	  of	  IFN-­‐y	  and	  LPS	  polarises	  
M1	  cells	  and	  IL-­‐4/IL-­‐13	  drive	  M2	  polarisation.	  This	  is	  not	  always	  the	  case,	  however;	  innate	  
cytokines	  such	  as	  IL-­‐33	  can	  induce	  both	  M1	  and	  M2	  (295,	  318,	  319),	  and	  IL-­‐4	  has	  also	  been	  
shown	  to	  induce	  pro-­‐inflammatory	  cytokine	  production	  by	  M1	  macrophages	  (319).	  As	  such,	  
the	  overlapping	   induction	  patterns	  and	  subsequent	   functions	  of	  M1	  and	  M2	  have	  made	   it	  
difficult	  to	  assign	  strictly	  specific	  roles	  for	  these	  subsets.	  In	  asthma,	  M2	  cells	  are	  primarily	  
implicated	  through	  their	  production	  of	  FIZZ1	  and	  Ym-­‐1	  in	  response	  to	  Th2	  cytokines;	  these	  
mediators	  normally	  function	  to	  maintain	  pulmonary	  homeostasis,	  however	  their	  excessive	  
production	  during	  asthma	  drives	  lung	  injury	  (312).	  	  
	  
Lung DCs 
Although	   making	   up	   a	   lesser	   proportion	   of	   the	   bronchoalveolar	   lavage	   (BAL)-­‐recovered	  
cells,	  multiple	   DC	   populations	   reside	   in	   the	   airway	   and	   lung	   parenchyma.	   This	   primarily	  
includes	  CD11c+CD11b+	  and	  CD11c+CD103+	  cDC,	  as	  well	  as	  pDCs.	  The	  CD11b+	  subset	  are	  
mainly	  located	  in	  the	  submucosa	  and	  perivascular	  regions	  (320,	  321)	  and	  are	  functionally	  
specialised	   for	   the	   presentation	   of	   antigens	   to	   CD4+	   T	   cells	   to	   prime	   and	   restimulate	  
effector	  responses	  (123,	  322).	  In	  the	  steady	  state,	  CD11b+	  DC	  have	  been	  shown	  to	  secrete	  
chemokines	   that	   promote	   homeostasis,	   whereas	   CD103+	   DC	   usually	   only	   secrete	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chemokines	   under	   inflammatory	   conditions	   (322).	   CD11b+	   DC	   perform	   critical	   roles	   in	  
driving	  allergic	  inflammation	  in	  the	  airway	  (306,	  323),	  as	  discussed	  in	  section	  1.2.	  	  
	  
The	  trachea	  and	  large	  airways	  are	  associated	  with	  CD103+	  DC,	  specialised	  in	  the	  uptake	  of	  
antigens	   for	  migration	   to	   the	  mediastinal	   lymph	   node	   and	   cross-­‐presentation	   to	   CD8+	   T	  
cells	  (73,	  123,	  126,	  324).	  The	  expression	  of	  tight	  junction	  proteins	  enables	  their	  traverse	  of	  
the	  epithelium	   to	  acquire	  antigen	   (320).	  The	   localisation	  and	   function	  of	   these	   important	  
CD8+	  T	  cell-­‐stimulating	  DCs	  have	  not	  been	  well	  characterised	   in	   the	   lung.	  One	  report	  has	  
shown	   their	   steady	   state	   localisation	   to	   be	   primarily	   within	   the	   airway	   mucosa	   and	  
arteriole	  walls	  (320),	  however	  this	  is	  yet	  to	  be	  demonstrated	  by	  other	  groups.	  Additionally,	  
their	  redistribution	  and	  behaviour	  during	  inflammatory	  conditions	  is	  not	  known.	  	  
	  
In	   terms	  of	   cell	   number	  CD11cmidCD11b-­‐	  pDC,	   also	   expressing	  Siglec-­‐H	  and	  bone	  marrow	  
stromal	  antigen-­‐1,	  are	  a	  minor	  population	  in	  the	  lung.	  However,	  an	  important	  role	  has	  been	  
demonstrated	   for	   the	   tolerance	   of	   inhaled	   antigens	   (325).	   This	  may	   occur	   through	   their	  
ability	   to	   suppress	   cDC-­‐mediated	   stimulation	   of	   effector	   T	   cells	   (325,	   326).	   Additionally,	  
pDC	  can	  directly	  induce	  Tregs,	  which	  also	  promote	  tolerance	  (86,	  327,	  328).	  	  
	  
Additional immune cells in the lung 
Although	   few	   in	   number	   relative	   to	   macrophages	   and	   DCs,	   the	   steady	   state	   lung	   is	   also	  
populated	  by	  innate	  lymphoid	  cells	  and	  tissue-­‐resident	  mast	  cells.	  Of	  particular	  significance	  
in	   the	   lung,	   a	   population	   of	   Type	   2	   ILCs	   has	   been	   described	   in	   both	  mice	   (329-­‐336)	   and	  
humans	  (330,	  337);	  upon	  stimulation	  with	  IL-­‐33,	  IL-­‐2	  and	  IL-­‐7,	  these	  ILCs	  produce	  IL-­‐5	  and	  
IL-­‐13	  but	  not	  IL-­‐22,	  IL-­‐17A	  or	  IFN-­‐γ	  (329,	  330).	  Similarly	  to	  CD4+	  Th2	  cells,	  ILC2	  in	  the	  lung	  
have	  been	  ascribed	  roles	  in	  protection	  against	  helminth	  infection,	  accumulating	  in	  response	  
to	   IL-­‐33,	   and	   producing	   IL-­‐5	   that	   is	   hypothesised	   to	   aid	   worm	   expulsion	   (333,	   338).	  
Conversely,	   pathological	   contributions	   to	   the	   development	   of	   allergy	   has	   also	   been	  
described,	   with	   ILC2	   implicated	   in	   the	   development	   of	   airway	   eosinophilia	   and	   mucus	  
production	   in	   response	   to	   allergen	   challenge,	   and	   ILC-­‐derived	   IL-­‐13	   reportedly	   crucial	   to	  
the	  generation	  of	  AHR	  (331,	  332,	  336).	  It	  has,	  however,	  recently	  been	  shown	  that	  lung	  ILCs	  
promote	  beneficial	  tissue	  repair	  in	  response	  to	  acute	  epithelial	  damage,	  such	  as	  that	  caused	  
by	   viral	   infection	   with	   Influenza	   A	   (339).	   The	   healing	   response	   may	   be	   driven	   by	   ILC-­‐
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derived	   amphiregulin,	   a	  mediator	   produced	   in	   large	   amounts	   by	   ILC2	   in	   the	   lung	   during	  
viral	   infection	   (339),	   shown	   to	  be	   linked	   to	   tissue	   repair	  during	   acute	   epithelial	   insult	   as	  
well	  as	  asthma	  (340,	  341).	  	  
	  
Mast	  cells	  may	  be	  classified,	  according	  to	  their	  localisation	  in	  the	  lung,	  into	  mucosal	  (MMC)	  
and	   connective	   tissue	   (CTMC)	   subsets,	   although	   phenotypic	   differences	   in	   the	   protease	  
expression	  profile	  of	  mast	  cells	  also	  exist.	  In	  the	  steady	  state,	  the	  MMC	  population	  reside	  in	  
the	  respiratory	  mucosa	  (342-­‐344),	  predominantly	  expressing	  chymases	  MCPT1	  and	  MCPT2	  
and	  low	  levels	  of	  histamine	  and	  serotonin	  (345,	  346).	  MMC	  may	  be	  dependent,	  at	   least	   in	  
part,	   on	   T	   cells	   for	   population	   maintenance	   as	   well	   as	   expansion	   during	   inflammatory	  
conditions	   (347,	  348).	  Conversely,	  CTMC	  are	   found	  around	   large	  airways	   (344,	  349),	   and	  
express	  a	  range	  of	  mediators	  including	  chymase	  MCPT4,	  elastase	  MCPT5,	  tryptases	  MCPT6	  
and	  7	  and	  carboxypeptidase	  A3	  as	  well	  as	  high	  levels	  of	  histamine	  and	  serotonin	  (345,	  346).	  
The	  maintenance	  and	  expansion	  of	  the	  CTMC	  subset	  is	  not	  dependent	  on	  T	  cells	  (347,	  348).	  
Although	   few	   in	  number	   in	   the	  steady	  state,	   the	   localisation	  of	  mast	   cells	  within	   the	   lung	  
positions	   them	   for	   rapid	   response	   to	   invading	   pathogens.	   As	   such,	   mast	   cells	   have	   been	  
shown	   to	   be	   important	   for	   the	   defence	   against	   bacteria,	   viruses	   and	   parasites(350-­‐353).	  
However,	  mast	  cells	  also	  play	  a	  role	  in	  pathological	  responses	  under	  particular	  conditions.	  
Importantly,	   the	   damaging	   effects	   of	   mast	   cells	   have	   been	   implicated	   in	   Th2	   disease,	  
contributing	  to	  allergic	  airway	  inflammation	  as	  discussed	  in	  section	  1.2.2.2.	  
	  
The	   frequency	   and	   role	   of	   immune	   cells	   in	   the	   lung	   changes	   in	   response	   to	   various	  
inflammatory	   stimuli.	   The	   generation	   of	   allergic	   airway	   inflammation	   results	   in	   the	  
infiltration	  of	  multiple	  additional	  immune	  cell	  subsets	  that	  mediate	  disease	  as	  described	  in	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1.2 Orchestration of Th2-mediated disease 
	  
The	  requirement	  for	  APCs	  in	  the	  initiation	  of	  T	  cell	  immunity	  is	  clear,	  however,	  for	  reasons	  
that	   have	   not	   been	   fully	   elucidated,	   APCs	   may	   sometimes	   direct	   aberrant,	   insufficient,	  
excessive	   or	   inappropriate	   immune	   responses	   that	   can	   lead	   to	   disease.	   The	   activity	   of	  
multiple	   cell	   populations,	   costimulatory	   molecules,	   as	   well	   as	   the	   cytokine	  
microenvironment	   may	   influence	   the	   development	   and	   progression	   of	   disease.	   Allergic	  
responses,	  driven	  by	  the	  development	  of	  Th2	  cells	  and	  associated	  cytokines,	  may	  develop	  at	  
sites	  where	   antigens	   are	   encountered;	   commonly,	   the	   skin,	   gastrointestinal	   tract	   and	   the	  
lung.	   In	   the	   airway,	   activation	   of	   antigen-­‐specific	   Th2	   immunity	   can	   lead	   to	   chronic	  
inflammation	  characteristic	  of	  asthmatic	  disease.	  	  
	  
1.2.1 Characteristics of allergens 
It	   is	  well	  established	  that	  certain	  proteins	  commonly	   induce	  allergy.	  Recent	  decades	  have	  
seen	   a	   striking	   rise	   in	   allergy,	   often	   associated	  with	   factors	   that	  may	   be	   encountered	   in	  
everyday	   life;	   house	   dust	   mites,	   pollens,	   animal	   dander	   and	   various	   foods.	   What	   is	   less	  
understood	   is	   how	   the	   interplay	   between	   these	   factors	   and	   the	   immune	   system	   drives	  
allergy,	  as	  opposed	  to	  tolerance.	  	  
	  
While	  varying	  in	  size,	  conformation,	  and	  allergenicity,	  common	  characteristics	  of	  allergens	  
exist.	   Both	   B-­‐cell	   and	   T-­‐cell	   epitopes	   are	   required,	   allowing	   the	   binding	   of	   IgE	   and	   the	  
initiation	   of	   a	   Th2	   cellular	   response,	   respectively.	   Protease	   activity	   (commonly	   cysteine,	  
serine	  or	  aspartic	  proteases)	  is	  frequently	  associated	  with	  allergens	  from	  HDM,	  cockroach,	  
fungi	   and	   pollens	   (354-­‐360).	   This	   property	   may	   facilitate	   allergen	   sensitisation	   through	  
damaging	   epithelia,	   breaching	   primary	   defensive	   barriers	   and	   stimulating	   immune	  
responsiveness	   (361).	   In	   a	   similar	   manner,	   respiratory	   viruses	   and	   air	   pollutants	   also	  
impair	  barrier	  function	  by	  disrupting	  tight	  junctions	  (362,	  363).	  	  
	  
Glycosylation	  is	  also	  a	  predominant	  feature;	  major	  allergens	  from	  dust	  mites	  (Der	  p	  -­‐1	  and	  -­‐
2),	   cats	   (Fel	   d	   1),	   dogs	   (Can	   f	   1),	   cockroaches	   (Bla	   g	   2),	   and	   peanuts	   (Ara	   h	   1)	   are	  
glycosylated,	  with	   1-­‐2,	   1-­‐3	   and	   1-­‐6	  mannose	   representing	   the	   dominant	   sugars	   on	   these	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allergens	   (364-­‐366).	   Cedar	   (Cry	   j	   1)	   and	   cypress	   (Cha	  o	  1)	  pollens	   and	  ovalbumin	   (OVA)	  
allergens	  also	  possess	  mannans	  (367-­‐369).	  Indeed,	  mannose	  receptors	  have	  been	  reported	  
to	  facilitate	  the	  recognition	  and	  uptake	  of	  allergens	  by	  DCs	  (370,	  371).	  
	  
Allergens	  may	  engage	  TLRs	  (372,	  373)	  or	  induce	  DAMPs	  by	  protease	  activity	  within	  tissues,	  
providing	  stimulatory	  signals	  to	  initiate	  immune	  responses	  (374).	  Other	  biologically	  active	  
constituents	  of	  allergens	  may	  include	  chitins	  and	  endotoxin,	  however	  the	  presence	  of	  these	  
molecules	   does	   not	   necessarily	   drive	   Th2	   immunity.	   The	   involvement	   of	   chitin	   in	   the	  
pathology	  of	  allergy	  is	  a	  point	  of	  contention.	  When	  administered	  to	  the	  lungs	  of	  mice,	  chitin	  
induces	  the	  accumulation	  of	  Th2-­‐associated,	  IL-­‐4	  expressing	  cells	  (375).	  In	  response,	  acidic	  
mammalian	   chitinase	   (AMCase)	   is	   produced	   by	   epithelial	   cells	   and	   macrophages	   in	  
substantial	   amounts	   via	   a	   Th2	   specific,	   IL-­‐13	   mediated	   pathway	   (376).	   However,	   when	  
AMCase	  is	  inhibited,	  or	  transgenic	  or	  AMCase-­‐deficient	  mice	  are	  used,	  allergen	  sensitisation	  
and	   challenge	   leads	   to	   the	   development	   of	   similar	   features	   of	   allergic	   airway	   disease	   as	  
control	   mice	   (377).	   As	   such,	   it	   appears	   that	   the	   activity	   of	   chitins	   and	   AMCase	   are	   not	  
critical	  to	  the	  development	  of	  allergy,	  but	  may	  nevertheless	  aid	  allergenic	  simulation	  of	  Th2	  
responses.	  	  
	  	  
Endotoxin,	   recognised	   by	   TLR4,	   has	   been	   detected	   in	   association	   with	   many	   common	  
allergens.	  Eisenbarth	  and	  colleagues	  reported	  that	  low	  level	  LPS	  inhaled	  with	  antigens	  was	  
necessary	  for	  the	  induction	  of	  Th2	  responses	  through	  TLR4	  signalling	  (372).	  Additionally,	  
in	   vivo	   experiments	   using	   bone	   marrow	   chimeric	   mice	   that	   lacked	   TLR4	   specifically	   on	  
epithelial	   cells	   demonstrated	   that	   the	   allergic	   response	   to	   HDM	   was	   substantially	  
ameliorated	  when	  endotoxin	  was	  not	  sensed	  (373,	  378).	  The	  administration	  of	  high	  doses	  
of	   LPS	   with	   antigen,	   on	   the	   other	   hand,	   results	   in	   Th1	   polarised	   responses(372).	   The	  
contribution	  of	  LPS	  to	  the	  allergenicity	  of	  protein	  antigens,	  then,	  depends,	  at	   least	   in	  part,	  
on	  the	  concentration	  of	  endotoxin	  associated	  with	  the	  inhaled	  antigen.	  	  	  	  	  
	  
While	   numerous	   factors	   appear	   to	   confer	   allergenic	   potential,	   many	   allergens	   are	   not	  
intrinsically	  immunogenic	  and	  the	  mechanism	  of	  their	  allergenicity	  is	  unclear.	  Furthermore,	  
it	  is	  still	  not	  understood	  why	  allergic	  sensitisation	  and	  Th2	  immunity	  develop	  in	  particular	  
individuals	  to	  particular	  allergens	  while	  others	  remain	  tolerant	  to	  the	  same	  proteins.	  These	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findings	   suggest	   that	   “allergens”	   themselves	   are	   not	   the	   primary	   determinant	   of	   the	  
development	  of	  allergy,	  but	  rather	  the	  individual’s	  predisposition	  to	  allergy	  is	  responsible	  
for	  the	  initiation	  of	  Th2	  disease.	  	  
	  
	  
1.2.2 Priming Th2 immunity 
During	   the	   course	   of	   tissue	   surveillance,	   phagocytic	   and	   specialised	   APCs,	   upon	   allergen	  
uptake,	  migrate	   to	   regional	   lymph	  nodes	   or	   local	  mucosal	   sites	  where	   interaction	  with	  T	  
cells	  occurs	  (described	  in	  detail	  in	  1.1.1	  DC	  section	  and	  Figure	  1.2	  Allergic	  response).	  Upon	  
encountering	   cognate	   antigen	   through	   their	   TCR,	   in	   association	   with	   appropriate	  
costimulatory	  signals	  and	  cytokine	  stimulation,	  CD4+	  T	  cells	  are	  signalled	  to	  differentiate.	  	  
	  
Priming of Th2 responses to inhaled antigens 
Epithelial	  cells	  of	   the	  skin,	   intestine	  and	  lung	  provide	  a	  physical	  barrier	  to	  pathogens,	  but	  
are	  also	  capable	  of	  cytokine	  production	  upon	  encounter	  of	  allergens	  and	  helminth	  products	  
(372,	   379).	   In	   the	   lung,	   inhaled	   aero-­‐constituents	   barrage	   the	   lung	   barrier	   epithelium	  
frequently.	   It	   is	  becoming	   increasingly	  evident	  that	  the	  pulmonary	   innate	   immune	  system	  
has	  a	  significant	  role	  in	  the	  generation	  of	  Th2	  immunity	  in	  the	  lung,	  as	  well	  as	  contributing	  
to	  associated	  asthmatic	  disease.	  Many	  allergens	  can	  directly	  or	   indirectly	  act	  on	  epithelial	  
cells	   to	   stimulate	   the	   production	   of	   Th2-­‐polarising	   cytokines	   including	   Thymic	   Stromal	  
Lymphopoietin	  (TSLP)	  (380),	  IL-­‐33	  (381,	  382)	  and	  IL-­‐25	  (383),	  as	  well	  as	  the	  production	  of	  
GM-­‐CSF	  (373)	  and	  stimulation	  of	  barrier	  permeability	  (384,	  385).	  The	  Der	  p	  2	  component	  
of	   one	   such	   allergen,	   house	   dust	   mite	   (HDM),	   directly	   binds	   epithelial	   cell	   TLR4,	   the	  
expression	  and	  allergen-­‐binding	  of	  which	  is	  necessary	  and	  sufficient	  for	  DC	  activation	  (373).	  	  
Additionally,	  and	  in	  a	  manner	  not	  dependent	  on	  TLR4,	   in	  vitro	  studies	  have	  demonstrated	  
the	   HDM-­‐induced	   airway	   epithelial	   cell	   production	   of	   CCL20,	   chemokines	   attracting	  
immature	  DCs	  (386-­‐388).	  
	  
Allergens	  may	  also	  gain	  access	   to	  DCs	   through	   the	  disruption	  of	   epithelial	   tight	   junctions	  
(384,	   385,	   389)	   The	   stimulation	   of	   the	   innate	   immune	   system	   and	   targeting	   of	   lung	  
epithelia	   are	   thus	   implicated	   as	   important	   initiating	   factors	   in	   the	   facilitation	   of	   Th2	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priming.	  DCs	   then	  play	   a	   crucial	   role	   in	  bridging	   innate	   and	   adaptive	   immune	   responses,	  
acting	  in	  concert	  with	  local	  cytokines	  to	  prime	  CD4+	  T	  cells.	  	  
	  
It	   has	  been	  demonstrated	   that	  CD11c+	  DC	  are	   absolutely	   required	   for	  Th2	   induction	  and	  
development	  (390).	  Importantly,	  of	  the	  lung	  DC	  populations,	  it	  is	  CD11b+	  DCs	  that	  are	  the	  
key	  players	  in	  the	  priming	  of	  Th2	  cells,	  conversely,	  CD103+	  DC	  are	  not	  required	  (306).	  As	  
such,	  the	  characterisation	  of	  a	  Th2-­‐driving	  DC	  phenotype	  has	  been	  the	  subject	  of	  intensive	  
investigation.	  Various	  costimulatory	  molecules	  on	  DCs	  have	  been	  proposed	  as	  key	  factors	  in	  
providing	   the	   accessory	   stimulation	   required	   for	   priming	   Th2	   cells.	   Essential	   for	   the	  
activation	   and	   effector	   function	   of	   T	   cells,	   early	   interactions	   between	   B7-­‐1/B7-­‐2	  
(CD80/CD86)	  on	  DC	  and	  CD28	  on	  T	  cells,	  as	  well	  as	  the	  interactions	  of	  CD40	  on	  DC	  with	  T	  
cell	  CD40L,	  have	  been	  targeted	  in	  attempt	  to	  elucidate	  their	   importance	   in	  mediating	  Th2	  
responses.	  Blockade	  of	  B7/CD28	  was	  shown	  to	  reduce	  allergic	  inflammation	  by	  decreasing	  
lung	  eosinophilia,	  type	  2	  cytokines,	  IgE	  and	  airway	  hyperreactivity	  (391-­‐393).	  Conversely,	  
targeting	  of	  CD40/CD40L	   in	  models	  of	   allergic	   airway	   inflammation	  produced	  discordant	  
results	  between	  studies;	  in	  an	  acute	  model	  where	  OVA	  was	  administered	  twice	  on	  a	  single	  
day,	  it	  was	  reported	  that	  CD40L-­‐-­‐/-­‐	  deficient	  mice	  display	  reduced	  airway	  eosinophilia	  and	  
IL-­‐4,	  though	  IL-­‐5	  was	  unaffected	  (394).	  In	  contrast,	  a	  study	  utilising	  CD40-­‐/-­‐	  mice	  exposed	  
to	  multiple	  OVA	  challenges	  over	  8	  days	  revealed	  comparable	  inflammation	  to	  WT	  controls,	  
despite	  a	  lack	  of	  IgE	  production	  (395).	  Therefore,	  these	  costimulatory	  molecules	  appear	  to	  
play	  a	  role,	  albeit	  not	  fully	  understood,	  in	  the	  pathogenesis	  of	  Th2	  responses	  in	  the	  airway.	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Figure	  1.2:	  The	  allergic	  response	  
(A)	  Sensitisation	  to	  allergens	  may	  occur	  upon	   initial	  exposure.	  Professional	  APCs,	  such	  as	  
DCs,	   take	   up	   allergens	   from	   the	   airway,	   or	   through	   disrupted	   epithelial	   tight	   junctions.	  
Innate	  cytokines	  produced	  by	  activated	  lung	  epithelial	  cells,	  such	  as	  IL-­‐25,	  TSLP,	  IL-­‐33	  and	  
GM-­‐CSF,	   collaborate	   in	   the	   activation	  of	   local	  DC	   and	   ILC2;	   the	   latter	   being	   stimulated	   to	  
produce	   Th2	   cytokines	   IL-­‐5	   and	   IL-­‐13.	   Activated	   APCs	  migrate	   to	   regional	   lymph	   nodes	  
where	   interaction	  with	   T	   cells	   occurs.	   Upon	   encountering	   cognate	   antigen	   through	   their	  
TCR,	  CD4+	  T	  cells	  are	  signalled	  to	  differentiate	  into	  effector	  cells,	  migrating	  back	  to	  the	  site	  
of	  allergen	  exposure.	  Activated	  CD4+	  T	  cells	  also	  interact	  with	  antigen-­‐specific	  B	  cells,	  with	  
CD40/CD40L	   interactions	   and	   T	   cell-­‐derived	   IL-­‐4	   driving	   the	   switching	   of	   B	   cells	   to	   IgE	  
production.	  The	  IgE	  produced	  recirculates	  in	  the	  blood,	  preferentially	  binding	  high	  affinity	  
FcεR-­‐I	   antibody	   receptors,	   present	   on	   tissue-­‐resident	   mast	   cells	   as	   well	   as	   circulating	  
basophils.	   	   In	   the	   lung,	  sensitisation	  culminates	  with	  allergen-­‐specific	   IgE	  binding	  to	  mast	  
cells	  of	  the	  airway	  epithelium	  and	  mucosa,	  rendering	  them	  capable	  of	  directly	  responding	  
to	  allergens	  upon	  secondary	  exposure.	  Upon	  contraction	  of	   the	  primary	  response,	  a	  small	  
proportion	   of	   T	   cells	   remain	   in	   the	   tissue	   as	   resident	  memory	   T	   cells	   (TRM),	  while	   cells	  
expressing	   lymph-­‐node-­‐homing	   CCR7	   and	   CD62L	   traffic	   to	   the	   lymph	   nodes	   as	   central	  
memory	  T	  cells	  (TCM),	  capable	  of	  rapidly	  reacting	  to	  recurrent	  allergen-­‐specific	  insults.	  
(B)	   In	   previously	   sensitised	   individuals,	   re-­‐exposure	   to	   allergens	   drives	   an	   inflammatory	  
response	   in	   the	  airway.	  During	   the	  early	  phase	  asthmatic	   reaction,	   inhaled	  allergens	  bind	  
allergen-­‐specific	  IgE	  on	  mast	  cells	  in	  the	  lung,	  leading	  to	  degranulation	  and	  release	  of	  stored	  
and	   synthesised	   inflammatory	   mediators.	   The	   combination	   of	   these	   mediators	   drives	  
mucus	   secretion,	   vasodilation	   and	   airway	   hyperreactivity,	   characterising	   immediate	  
hypersensitivity.	   The	   late	   phase	   asthmatic	   reaction	   then	   predominates,	   with	   the	  
recruitment	   of	   allergen-­‐specific	   Th2	   cells	   driven	   by	   DC	   production	   of	   chemoattractants	  
including	  CCL17	  and	  CCL22.	  Activated	  Th2	  cells	  are	  then	  central	  to	  the	  induction	  of	  allergic	  
airway	   inflammation,	   producing	   key	   cytokines	   IL-­‐4,	   IL-­‐5,	   and	   IL-­‐13	   that	   facilitate	   the	  
activation	   and	   influx	   of	   multiple	   inflammatory	   cells,	   as	   well	   as	   stimulating	   airway	  
hyperreactivity,	   goblet	   cell	   mucus	   production,	   and	   the	   activation	   and	   maturation	   of	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More	   recently,	   DC	   expression	   of	   the	   costimulatory	   molecule	   OX40	   ligand	   (OX40L)	   has	  
emerged	  as	  significant	  in	  the	  generation	  of	  Th2	  immunity	  (396-­‐398);	  although	  it	  has	  been	  
demonstrated	   that	  OX40L	  does	  not	  polarise	  Th2	  responses,	  but	  rather	  stimulates	  optimal	  
Th2	  priming	  and	  memory	  (399).	  While	  Th1	  cell	   responses	  may	  also	  require	  OX40-­‐OX40L	  
interactions,	  a	  unique	  role	  for	  OX40L-­‐mediated	  promotion	  of	  Th2	  cell	  differentiation	  exists	  
in	   the	   absence	   of	   IL-­‐12	   (400)	   (discussed	   further	   in	   the	   following	   section,	   The	   cytokine	  
micro-­‐environment	   in	   Th2	   differentiation).	   The	   inducible	   nature	   of	   OX40L	   renders	   this	  
costimulatory	  molecule	  of	  particular	  interest	  in	  the	  development	  of	  Th2	  immune	  responses,	  
as	   specific	   targeting	   may	   be	   possible.	   The	   upregulation	   of	   OX40L	   is	   induced	   by	   innate	  
cytokines	   TSLP,	   IL-­‐25	   and	   IL-­‐33	   (400,	   401),	   and	   contributes	   to	   the	   induction	   of	   T	   cell	  
cytokine	  production	  as	  well	  as	  clonal	  expansion	  and	   the	  development	  of	  memory	  CD4+	  T	  
cells	  (402-­‐405).	  Additionally,	  abrogation	  of	  allergic	  airway	   inflammation	  may	  be	  achieved	  
through	  OX40L	  blockade	  (397).	  The	  role	  of	  OX40L	  co-­‐stimulation	  is	  not	  critical	  in	  all	  models	  
of	   Th2	   induction,	   however;	   rather	   OX40L	   is	   primarily	   important	   in	   TSLP-­‐driven	   Th2	  
differentiation.	  The	  priming	  of	  Th2	  cells	  under	  TSLP-­‐independent	  conditions,	  such	  as	  DCs	  
stimulated	   by	   certain	   helminths,	   does	   not	   require	   OX40L	   (406).	   Therefore,	   OX40L	  




The importance of IL-4 for Th2 differentiation 
The	   effective	   priming	   and	   differentiation	   of	   Th2	   cells	   is	   primarily	   dependent	   on	   the	  
presence	  of	   IL-­‐4	   in	   the	   local	  microenvironment	   (143,	   146,	   407).	   In	  vitro	   studies	   revealed	  
that	   engagement	   of	   the	   IL-­‐4	   receptor	   on	   CD4+	   T	   cells	   activates	   a	   number	   of	  
phosphotyrosine	   binding	   domain-­‐containing	   proteins,	   of	   which	   signal	   transducer	   and	  
activator	  of	  transcription	  6	  (STAT6)	  is	  necessary	  and	  sufficient	  to	  mediate	  both	  IL-­‐4-­‐driven	  
Th2	   differentiation	   and	   cell	   expansion	   (408-­‐411).	   Subsequent	   upregulation	   of	   GATA-­‐
binding	   protein	   3	   (GATA3)	   expression	   ensues,	   which	   is	   the	  master	   regulator	   of	   Th2	   cell	  
differentiation	   and	   cytokine	   production	   (412-­‐414).	   It	   has	   recently	   been	   shown	   that,	   in	  
contrast	   to	   the	   critical	   requirement	   for	   STAT6	   in	   vitro,	   some	   forms	   of	   Th2	   cell	  
differentiation	  can	  occur	  in	  vivo	  independently	  of	  the	  IL-­‐4-­‐IL-­‐4R-­‐STAT6	  pathway;	  however,	  
GATA3	  activation	  remains	  essential	  (147,	  148,	  415,	  416).	  The	  expression	  of	  GATA3	  may	  be	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induced	  by	  Notch	  activation	  (417),	  and	  activation	  of	  Wnt	  signalling	  by	  β-­‐catenin	  and	  T	  cell	  
factor	   1	   (418);	   as	   such,	   these	   factors	   have	   also	   been	   reported	   to	   be	   necessary	   for	   Th2	  
responses	  in	  vivo,	  however,	  it	  is	  not	  fully	  known	  whether	  this	  is	  through	  direct	  or	  indirect	  
influence	  on	  GATA3	  transcription.	  Suppression	  of	  Th1	  and	  Th17	  responses	  is	  also	  achieved	  
through	   GATA3	   expression,	   partly	   through	   upregulation	   of	   growth	   factor	   independent	   1	  
that	  mediates	   transcriptional	   repression	   of	   IFN-­‐γ	   and	   IL-­‐17	   (419).	   An	   additional	   protein	  
kinase,	  mechanistic	  target	  of	  rapamycin	  (mTOR),	  plays	  a	  critical	  role	  in	  the	  regulation	  of	  T	  
cell	  differentiation,	  and	  the	  deletion	  of	  it’s	  associated	  protein	  complex	  mTORC2	  results	  in	  an	  
inability	  to	  produce	  IL-­‐4	  leading	  to	  defective	  Th2	  differentiation	  (420,	  421).	  
	  
Cellular sources of IL-4 
The	   essential	   cellular	   source	   of	   IL-­‐4	   has	   been	   a	   point	   of	   some	   contention.	   Numerous	  
potential	  candidates	  have	  been	  proposed	  including	  both	  adaptive	  and	  innate	  immune	  cells.	  
CD4+	  T	  cells	  can	  themselves	  produce	  IL-­‐4,	  independently	  of	  IL-­‐4	  signalling,	  upon	  activation;	  
peptide-­‐stimulated,	  naïve	  CD4+	  T	  cells	  from	  IL-­‐4Rα-­‐deficient	  mice	  have	  been	  demonstrated	  
to	  secrete	  sufficient	  IL-­‐4	  for	  the	  induction	  of	  Th2	  cell	  differentiation	  in	  an	  autocrine	  and/or	  
paracrine	  manner	  (158,	  422,	  423).	  However,	  this	  has	  not	  been	  demonstrated	  in	  vivo.	  	  
	  
An	   additional	   producer	   of	   significant	   amounts	   of	   IL-­‐4	   is	   the	   Natural	   Killer	   T	   (NKT)	   cell,	  
capable	   of	   an	   immediate	   response	   upon	   TCR	   engagement(149).	   NKT	   cells	   have	   been	  
identified	  in	  the	  BAL	  of	  asthma	  patients,	  implicating	  a	  role	  for	  NKT	  cell-­‐derived	  cytokines	  in	  
human	   asthma	   (424);	   it	   has	   also	   been	   reported	   that	  NKT	   cells	   are	   essential	   for	   allergen-­‐
induced	   airway	   hyperreactivity	   during	   effector	   Th2	   responses	   (425).	   However,	   IL-­‐4	  
production	  by	  NKT	  cells	  appears	  to	  be	  not	  critical	  for	  the	  priming	  of	  Th2	  cells,	  as	  CD1d-­‐	  and	  
β2-­‐microglobulin-­‐deficient	   mice	   that	   lack	   NKT	   cells	   remain	   capable	   of	   Th2	   cell	  
differentiation	   and	   responses	   (425-­‐427).	   Additionally,	   no	   significant	   recruitment	   of	   IL-­‐4-­‐
producing	  NKT	  cells	  was	  observed	  in	  the	  lungs	  of	  Nippostrongylus	  	  brasiliensis	  infected	  mice,	  
precluding	  their	  role	   in	  the	   local	  primary	  Th2	  response;	   instead,	  CD4+	  Th2	  cells	  were	  the	  
only	  IL-­‐4	  producing	  T	  cells	  identified	  in	  the	  lung	  in	  this	  study	  (147).	  	  
	  
Cells	   of	   the	   innate	   immune	   system	   may	   also	   rapidly	   produce	   IL-­‐4	   upon	   antigenic	  
stimulation.	  The	  newly	  identified	  ILC2s	  display	  similar	  functional	  characteristics	  to	  that	  of	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CD4+	  Th2	  cells,	  including	  the	  production	  of	  IL-­‐5	  and	  IL-­‐13.	  ILC2s	  have	  also	  been	  reported	  to	  
produce	  IL-­‐4	   in	  humans	  (428),	  however,	  minimal	  IL-­‐4	  production	  has	  been	  demonstrated	  
in	  experimental	  in	  vivo	  murine	  models	  (429);	  as	  such,	  the	  importance	  of	  ILC2-­‐derived	  IL-­‐4	  
is	  yet	  to	  be	  established.	  
	  
Basophils	  have	  recently	  emerged	  as	  a	  potentially	   important	   IL-­‐4	  producing	  component	  of	  
Th2	   immunity.	   Although	   making	   up	   only	   0.5%	   of	   steady	   state	   circulating	   blood	   cells,	  
basophils	   readily	   secrete	   IL-­‐4,	   as	   well	   as	   TSLP,	   in	   response	   to	   activation	   by	   protease	  
allergens	  such	  as	  papain	  or	  HDM	  (430,	  431)	  as	  well	  as	  Th2-­‐inducing	  parasites	  (147,	  148).	  
Additionally,	   they	   have	   been	   proposed	   as	   possible	   professional	   antigen-­‐presenting	   cells	  
(432-­‐434)	  supporting	  the	  notion	  that	  basophils	  may	  be	  critically	  important	  in	  Th2	  immune	  
responses.	   However,	   other	   authors	   have	   suggested	   their	   role	   in	   IL-­‐4	   production	   to	   be	  
redundant	   and	   questioned	   the	   importance,	   even	   the	   existence,	   of	   basophil-­‐mediated	  
antigen	  presentation	   (390,	  431,	  435).	   Intranasal	  HDM	  exposure	  was	  shown	   to	   induce	   the	  
recruitment	   of	   basophils	   to	   lung-­‐draining	   lymph	  nodes,	   but	   they	   did	   not	   take	   up	   inhaled	  
allergen,	   nor	   upregulate	   antigen	   presentation	   molecules;	   indeed	   basophil-­‐mediated	  
activation	   of	   T	   cells	   was	   not	   observed	   (431).	   The	   investigation	   of	   the	   importance	   of	  
basophils	   has	   been	   complicated	   somewhat	   by	   particular	   experimental	   approaches.	   In	  
support	   of	   a	   critical	   role	   for	   basophils	   in	   Th2	   immunity,	   particularly	   in	   the	   lung,	   initial	  
evidence	  was	  provided	  by	  use	  of	  a	  basophil-­‐depleting	  antibody	  that	  targets	  the	  FcεRI	  (434),	  
however,	   it	  was	   later	  discovered	   that	   inflammatory	  moDCs,	  also	  expressing	   this	   receptor,	  
were	  depleted	  by	  the	  antibody	  (431).	  Indeed,	  it	  was	  determined	  by	  Hammad	  and	  colleagues	  
that	  moDC,	  and	  not	  basophils,	  were	  crucial	  for	  the	  induction	  of	  Th2	  immunity.	  	  	  
	  
During	  primary	  Th2	  responses,	  additional	  sources	  of	  IL-­‐4	  have	  been	  identified.	  Eosinophils	  
may	  be	  recruited	   in	  massive	  number	  and	  are	  capable	  of	  producing	   IL-­‐4	  abundantly	   (147,	  
436,	  437),	  also	  reportedly	  having	  antigen-­‐presenting	  functions	  (438,	  439).	  However,	  while	  
a	  CD4+	  T	  cell	   response	  may	  be	   inducible	  by	  eosinophils,	  anti-­‐CCR3-­‐mediated	  depletion	  of	  
eosinophils	  does	  not	  affect	  Th2	  cytokine	  production	  (437),	  neither	  do	  eosinophil-­‐deficient	  
mice	   have	   impaired	   Th2	   responses(440),	   suggesting	   that	   the	   role	   of	   eosinophils	   is	   not	  
critical.	  The	  contribution	  of	  γδ-­‐T	  cell-­‐derived	   IL-­‐4	  has	  also	  been	  reported	  (441)	  and	  mast	  
cells	   participate	   significantly	   after	   chronic	   antigen	   exposure(442,	   443).	   However,	   while	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rapid	  activation	  may	  occur,	  these	  cells	  are	  not	  thought	  to	  provide	  the	  critical	  initial	  source	  
of	  IL-­‐4	  required	  for	  the	  priming	  of	  Th2	  cells(147,	  444).	  
	  
The	  crucial	  early	  source	  of	  IL-­‐4	  has	  to	  date	  not	  been	  identified;	  this	  may	  be	  brought	  to	  light	  
in	  coming	  years.	  However,	  an	  alternative	  hypothesis	  may	  also	  be	  proposed:	  Th2	  immunity,	  
having	  diverse	   stimulating	   factors	   and	  purposes,	  may	  be	   inducible	  by	   the	   contribution	  of	  
multiple	   redundant	   sources	   of	   IL-­‐4,	   the	   involvement	   of	   each	   depending	   on	   micro-­‐
environmental	   factors,	   and	   of	   which	   none	   may	   be	   uniquely,	   universally,	   critical.	  
Alternatively,	  IL-­‐4	  may	  indeed	  be	  unnecessary.	  	  
	  
The cytokine micro-environment in Th2 differentiation 
In	  addition	   to	   IL-­‐4,	   the	  priming	  of	  Th2	   responses	  also	   involves	   the	   interplay	  of	   cytokines	  
such	   as	   IL-­‐2,	   TSLP,	   IL-­‐25	   and	   IL-­‐33;	   the	   involvement	   and	   relative	   importance	   of	   each	  
cytokine	  varying	  depending	  on	  the	  Th2	  model	  under	  investigation.	  Some	  authors	  attribute	  a	  
critical	   role	   to	   IL-­‐2,	  a	  growth	   factor	  produced	  rapidly	  by	  activated	  T	  cells	  and	  DCs,	   in	   the	  
development	   of	   Th2	   differentiation	   -­‐	   primarily	   due	   to	   the	   importance	   of	   IL-­‐2-­‐mediated	  
induction	   of	   STAT5	   expression	   (445,	   446);	   however,	   STAT5	   is	   also	   promoted	   by	   the	  
presence	  of	  IL-­‐7	  and/or	  TSLP	  (447).	  Importantly,	  the	  activation	  of	  STAT5	  is	  crucial	  for	  the	  
in	  vitro	  differentiation	  of	  IL-­‐4-­‐producing	  Th2	  cells;	  in	  vivo	  neutralisation	  of	  IL-­‐2	  also	  inhibits	  
IL-­‐4	  production(158,	  445,	  446).	  Somewhat	  surprisingly,	  however,	  in	  vivo	  TCR-­‐driven	  clonal	  
expansion	   of	   CD4+	   T	   cells	   is	   not	   affected	   in	   the	   absence	   of	   IL-­‐2	   or	   functional	   IL-­‐2	  
receptors(448-­‐450),	   indicating	   that	   the	   critical	   effects	   of	   IL-­‐2	   on	   Th2	   cell	   differentiation	  
might	  be	  more	  related	  to	  preparing	  CD4+	  T	  cells	  for	  Th2	  cytokine	  production.	  Interestingly,	  
where	  strong	  STAT5	  activation	  is	  induced,	  a	  lower	  concentration	  of	  GATA3	  is	  required	  for	  
the	   induction	   of	   Th2	   responses.	   However,	   in	   the	   absence	   of	   Gata3,	   constitutively	   active	  
STAT5A	   is	  not	  sufficient	   to	   induce	  Th2	  differentiation,	  again	   implicating	  a	  critical	   role	   for	  
GATA3	  (414).	  	  
	  
TSLP,	  produced	  by	  epithelial	  cells,	  mast	  cells	  and	  basophils	  (430,	  451-­‐453),	  can	  act	  on	  DCs	  
to	   preferentially	   prime	   the	   differentiation	   of	   naïve	   CD4+	  T	   cells	   into	  Th2	   cells	   as	  well	   as	  
playing	  a	  significant	  role	  during	  effector	  Th2	  responses	  (451,	  454).	  This	  was	  proposed	  by	  
some	  groups	  to	  be	  induced	  by	  TSLP-­‐mediated	  upregulation	  of	  OX40L	  and	  suppression	  of	  DC	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IL-­‐12	   production.	   Under	   physiologically	   non-­‐allergic	   conditions,	   DCs	   activated	   in	   the	  
presence	  of	  IL-­‐4	  or	  IL-­‐13	  would	  subsequently	  produce	  IL-­‐12,	  purportedly	  as	  a	  mechanism	  
of	  negative	  regulation	  of	  Th2	  responses	  by	  redirecting	  the	  response	  to	  favour	  Th1	  activity	  
(455,	  456).	  Defective	  IL-­‐12	  production,	  or	  TSLP-­‐mediated	  suppression	  of	  IL-­‐12,	  could	  thus	  
allow	   the	   development	   of	   Th2	   responses	   such	   as	   those	   resulting	   in	   allergy	   (457-­‐460).	  	  
However,	  when	  DCs	  are	  activated	  with	  human	  TSLP	  as	  well	  as	  CD40L	  stimulation,	  blocking	  
of	   IL-­‐12	   production	   does	   not	   occur;	   nevertheless,	   Th2	   differentiation	   may	   still	   proceed	  
(461).	   Additionally,	   it	   was	   shown	   that	   IL-­‐12-­‐deficient	   mice,	   which	   are	   still	   capable	   of	  
developing	  substantial	  numbers	  of	  CD4+	  T	  cells	   in	  response	   to	  pathogenic	  stimuli,	  do	  not	  
develop	  Th2	  responses	  by	  default(462).	  Thus,	  it	  appeared	  likely	  that	  there	  were	  additional	  
roles	  for	  TSLP	  in	  affecting	  DC	  functions	  that	  drive	  Th2.	  Indeed,	   it	  was	  recently	  discovered	  
that	   STAT5	   is	   required	   for	   TSLP-­‐dependent	   DC	   activation.	   Bell	   and	   colleagues	  
demonstrated	  that	  DC-­‐specific	  deletion	  of	  STAT5	  resulted	  in	  their	  inability	  to	  drive	  type	  2	  
allergic	  responses	  in	  the	  lung	  as	  well	  as	  the	  skin	  (454);	  no	  effect	  on	  type	  1	  immunity	  was	  
observed.	   The	   STAT5-­‐deficient	   DC	   did	   not	   respond	   to	   TSLP,	   which	   prevented	   their	  
activation,	  chemokine	  production	  and	  upregulation	  of	  costimulatory	  moleculesCD80,	  CD86,	  
and	   OX40L.	   Therefore,	   the	   ability	   of	   TSLP	   to	   drive	   Th2	   immunity	   in	   the	   lungs	   and	   skin	  
critically	  relies	  on	  STAT5	  in	  DCs.	  	  
	  
Upon	   PRR	   activation,	   epithelial	   cell	   production	   of	   IL-­‐25	   and	   IL-­‐33	   also	   promotes	   Th2	  
responses.	  Additionally	  produced	  by	  Th2	  cells,	   IL-­‐25,	  of	   the	  IL-­‐17	  family,	  and	  IL-­‐33	  of	   the	  
IL-­‐1	  and	  IL-­‐18	  family,	  have	  been	  demonstrated	  to	  induce	  IL-­‐4,	  IL-­‐5	  and	  IL-­‐13,	  as	  well	  as	  IL-­‐
4-­‐mediated	  IgE	  production,	  that	  may	  result	  in	  Th2	  disease	  in	  the	  lungs	  and	  gastrointestinal	  
tract	   (463,	   464).	   Stimulated	   by	   IL-­‐25	   and	   IL-­‐33,	   as	   well	   as	   TSLP,	   ILC2	   represent	   an	  
important	  component	  of	  this	  early	  Th2-­‐polarising	  cytokine	  production	  (332,	  334,	  336,	  465,	  
466).	   Interestingly,	   the	   requirement	   for	   ILC2	   in	   the	   priming	   of	   some	   Th2	   responses	   has	  
been	   reported,	   but	   only	   in	   the	   context	   of	   local	   antigen	   exposure;	   experimental	   models	  
involving	  systemic	  priming	  do	  not	  require	  ILC2	  (467).	  Rather,	  a	  critical	  role	  for	  T	  and	  B	  cells	  
in	  the	  development	  of	  the	  primary	  CD4+	  Th2-­‐cell	  mediated	  immune	  response	  is	  implicated	  
(463).	  Indeed,	  epithelial	  cell-­‐derived	  IL-­‐25	  (383)	  and	  IL-­‐33	  (464)	  can	  directly	  act	  on	  CD4+	  T	  
cells,	   resulting	   in	   IL-­‐4-­‐dependent	   Th2	   cell	   differentiation.	   IL-­‐33,	   additionally,	   stimulates	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basophils	   to	   induce	   the	   production	   of	   IL-­‐4	   (468,	   469),	   as	  well	   as	   basophil	   and	  mast	   cell	  
release	  of	  histamine	  (464,	  470,	  471)	  potentiating	  the	  development	  of	  Th2	  immunity.	  	  
	  
	  
1.2.2.1 Sensitisation to aeroallergens 	  
Exposure	   to	   inhaled	   aeroallergens	   results	   in	   the	   sensitisation	   of	   an	   individual	   and	  
consequential	   allergic	   airway	   inflammation	   upon	   subsequent	   exposure	   to	   the	   specific	  
allergen(s)	  (See	  Figure	  1.2	  A	  –	  The	  allergic	  response).	  Central	  to	  the	  development	  of	  allergy	  
is	  the	  priming	  of	  a	  Th2	  response,	  as	  discussed	  in	  Section	  1.2.2.	  Priming	  induces	  maturation,	  
expansion	  and	  migration	  of	  Th2	  cells	  to	  the	  site	  of	  allergen	  exposure	  (472,	  473).	  Th2	  cells	  
then	  produce	  large	  amounts	  of	  IL-­‐4	  and	  IL-­‐13;	  this	  cytokine	  microenvironment,	  as	  well	  as	  
CD40/CD40L	  signalling,	  leads	  to	  B	  cell	  class	  switching	  of	  immunoglobulin	  production	  to	  IgE	  
(474-­‐476).	   It	   was	   initially	   thought	   that	   B	   cell	   immunoglobulin	   class	   switching	   occurred	  
exclusively	   in	  germinal	  centres	  of	   the	   lymph	  nodes,	  however	   it	  has	  since	  been	  discovered	  
that	  clonal	  selection	  and	  affinity	  maturation	  of	  IgE-­‐producing	  B	  cells	  can	  also	  be	  induced	  in	  
the	   respiratory	  mucosa	   (477)	   and	   gastrointestinal	   tract	   (478)	   of	   allergic	   individuals.	   IgE	  
antibodies	  then	  circulate	  in	  the	  blood,	  or	  are	  trafficked	  locally,	  and	  preferentially	  bind	  the	  
high	  affinity	  Fcε	  antibody	  receptor,	  FcεR-­‐I,	  present	  on	  tissue-­‐resident	  mast	  cells	  as	  well	  as	  
circulating	   basophils.	   	   In	   the	   lung,	   sensitisation	   culminates	   with	   allergen-­‐specific	   IgE	  
binding	   to	   mast	   cells	   of	   the	   airway	   epithelium	   and	   mucosa,	   rendering	   them	   capable	   of	  
directly	   responding	   to	   allergens	   upon	   secondary	   exposure	   (479,	   480).	   The	   effector	   Th2	  
response	  is	  also	  accompanied	  by	  the	  development	  of	  long-­‐lived	  memory	  CD4+	  T	  cells	  and	  B	  
cells	   that	  migrate	   to	   lymphoid	   or	   inflamed	   tissue,	   such	   as	   the	   lungs,	   and	   rapidly	   react	   to	  
recurrent	  allergen-­‐specific	  insults	  in	  the	  airway	  (discussed	  in	  section	  1.1.4).	  
	  
	  
1.2.2.2 Aeroallergen challenge: Th2 effector functions and cytokine production 
mediate the pathology of atopic allergic asthma	  
In	   sensitised	   individuals,	   the	   inhalation	   of	   aeroallergens	   leads	   to	   the	   orchestration	   of	   a	  
rapid	  secondary	  immune	  response	  that	  mediates	  allergic	  airway	  disease	  (See	  Figure	  1.2	  B).	  
This	  response	  comprises	  early,	  IgE-­‐mediated,	  and	  late,	  T	  cell-­‐mediated	  components.	  	  
   40 
	  
Initially,	  inhaled	  allergens	  bind	  allergen-­‐specific	  IgE	  on	  mast	  cells	  in	  the	  lung,	  cross-­‐linking	  
IgE	  and	  activating	  complex	  intracellular	  signalling	  pathways	  (480).	  Mast	  cells	  then	  rapidly	  
degranulate	   and	   release	   stored	   histamines	   and	   proteases;	   eicosanoids,	   leukotrienes	   and	  
prostaglandins	   are	   rapidly	   synthesised,	   and	   the	   production	   of	   cytokines	   commences;	  
notably,	   IL-­‐4,	   IL-­‐5	  and	   IL-­‐13	  as	  well	  as	  TNF	  contribute	   to	  allergic	  disease	  (481,	  482).	  The	  
combination	   of	   these	   mediators	   drives	   mucus	   secretion,	   vasodilation	   and	   airway	  
hyperreactivity,	   characterising	   the	   early	   phase	   asthmatic	   reaction	   –	   or	   ‘immediate	  
hypersensitivity’	   (483).	   Four	   to	   six	   hours	   later,	   the	   late	   phase	   asthmatic	   reaction	  
predominates,	  with	  allergen-­‐specific	  Th2	  cells	  driving	  allergic	  airway	  inflammation.	  	  
	  
The	  recruitment	  of	  Th2	  cells	  to	  the	  airways	  is	  crucial	  to	  the	  pathogenesis	  of	  allergic	  asthma	  
(484,	   485).	   After	   proliferation	   in	   the	  MLN	   (486),	   the	   homing	   of	   Th2	   cells	   to	   the	   lungs	   is	  
dependent	   on	   chemoattractant	   receptor	   signalling.	   STAT6	   expression	   performs	   a	   critical	  
master	  regulatory	  role	  in	  orchestrating	  the	  expression	  of	  Th2-­‐attracting	  chemokines	  CCL11,	  
CCL17,	  CCL22,	  and	  CCL24	  and	  the	  subsequent	  recruitment	  of	  Th2	  cells	  to	  the	  allergic	  lung	  
(487,	   488).	   Interestingly,	   the	   STAT6	   required	   for	   chemokine	   expression	   and	   Th2	  
recruitment	   is	   critically	   sourced	   from	   bone	   marrow-­‐derived	   myeloid	   cells,	   while	   airway	  
lining	  cells	  are	  not	  necessary;	  specifically,	  CD11b+	  cDC	  in	  the	  lung	  are	  a	  crucially	  important	  
source	   of	   CCL17	   and	   CCL22(488).	   Chemokines	   act	   to	   recruit	   Th2	   cells	   through	  
chemoattractant	   receptors	   CCR3,	   CCR4,	   CCR8	   and	   the	   PGD2	   receptor	   CRTH2	   (489).	  
Attempts	  to	  determine	  which	  of	  these	  receptors	  plays	  a	  crucial	  role	  in	  the	  trafficking	  of	  Th2	  
cells	  in	  vivo,	  however,	  revealed	  that	  targeted	  deletion	  of	  any	  of	  these	  receptors	  individually	  
did	  not	  prevent	  Th2	  homing	  (490-­‐492).	  These	  findings	  suggest	  that	  multiple	  receptors	  are	  
commonly	  stimulated	  to	  induce	  Th2	  cell	  homing.	  	  
	  
After	  trafficking	  to	  the	  lung,	  Th2	  lymphocytes	  recognise	  and	  respond	  to	  allergens	  presented	  
by	   lung-­‐surveying	   APCs.	   Importantly,	   it	   has	   been	   shown	   that	   the	   induction	   of	   secondary	  
Th2	  responses	  to	  aeroallergens,	  as	  well	  as	  maintenance	  of	  chronic	   inflammation,	   is	  under	  
the	   essential	   influence	   of	   DC	   (493).	   	   CD11c+	   DCs	   are	   necessary	   and	   sufficient	   for	   the	  
induction	  of	  the	  effector	  Th2	  immune	  response	  that	  leads	  to	  allergic	  asthma;	  their	  depletion	  
during	   airway	   challenge	   abrogates	   the	   characteristic	   features	   of	   disease	   in	   previously	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sensitised	  mice	  (321).	  Following	  allergen	  challenge	  of	  sensitised	  mice,	  CD11b+	  DCs	  increase	  
in	  number	  and	   localise	  within	   the	  vicinity	  of	   allergic	   airways	   (494).	   It	   has	  been	   reported	  
that	   CD11b+	   DC	   may	   be	   found	   presenting	   allergens	   in	   the	   airways	   up	   to	   8	   weeks	   after	  
allergen	  exposure	  (114);	   	  perhaps	  indicating	  that	  inter-­‐DC	  antigen	  transfer	  is	  occurring	  to	  
prolong	  the	  duration	  of	  antigen	  presentation	  (60,	  74-­‐76).	  Specialised	  in	  presenting	  soluble	  
antigens	   to	   CD4+	   T	   cells	   (123,	   322),	   CD11b+	   DCs	   were	   recently	   reliably	   separated	   into	  
CD64-­‐	   conventional	   and	   CD64+	  monocyte-­‐derived	   DCs	   (306).	   The	   CD11b+CD64+	  moDC,	  
recruited	   to	   the	   lung	   under	   inflammatory	   conditions,	   were	   subsequently	   found	   to	  
contribute	  significantly	  to	  the	  progression	  of	  Th2	  immunity	  through	  the	  production	  of	  pro-­‐
inflammatory	  chemokines	  (306).	  Conversely,	   lung	  CD103+	  DC	  and	  plasmacytoid	  DCs	  have	  
not	   been	   implicated	   in	   the	   CD4+	   Th2	   cell-­‐mediated	   allergic	   response;	   CD103+	   DC	   are	  
specialised	   in	   cross-­‐presentation	   to	   CD8+	   T	   cells	   (73,	   126),	   while	   allergen-­‐loaded	  
plasmacytoid	  DCs	  have	  been	  demonstrated	  to	  suppress	  airway	  inflammation	  in	  sensitised	  
mice	  (325).	  	  
	  
Th2 cytokines mediate allergic disease 
Activated	  Th2	  cells	  produce	  key	  cytokines	  IL-­‐4,	  IL-­‐5,	  and	  IL-­‐13	  that	  facilitate	  the	  activation	  
and	   influx	   of	   multiple	   inflammatory	   cells	   that	   mediate	   pathogenic	   effects	   on	   the	   airway	  
(Figure	  1.2	  B).	  IL-­‐10	  may	  also	  be	  produced,	  however	  an	  inhibitory	  role	  has	  been	  described	  
for	  IL-­‐10	  production	  in	  allergic	  disease	  (495-­‐498).	  It	  is	  worth	  noting	  that	  after	  the	  priming	  
of	  Th2	  cells,	  IL-­‐4	  is	  not	  required	  for	  allergic	  airway	  inflammation	  to	  proceed;	  blocking	  of	  IL-­‐
4	   during	   allergen	   inhalation	   challenge	   results	   in	   intact	   airway	   inflammatory	   responses,	  
however,	  STAT6	  signalling	  is	  still	  required	  for	  the	  recruitment	  of	  eosinophils	  and	  Th2	  cells	  
to	  the	  lung	  (499,	  500).	  IL-­‐4,	  however,	  works	  in	  concert	  with	  IL-­‐5	  and	  IL-­‐13	  to	  induce	  airway	  
eosinophilia.	  In	  atopic	  allergic	  asthma,	  eosinophils	  are	  the	  major	  infiltrating	  cell	  population	  
found	  in	  the	  lung	  tissue	  and	  bronchoalveolar	  lavage	  (BAL)	  fluid	  of	  asthmatic	  patients	  (501);	  
the	  extent	  of	  eosinophilia	  correlates	  with	  disease	  severity	  (502).	  Th2	  cell-­‐derived	  IL-­‐5,	  IL-­‐
13	   and	   IL-­‐4	   act	   on	   lung	   epithelial	   and	   endothelial	   cells	   to	   produce	   eotaxin-­‐1	   (CCL11),	   -­‐2	  
(CCL24)	  and	  -­‐3	  (CCL26)	  that	  act	  as	  chemoattractants	  to	  recruit	  eosinophils	  by	   interaction	  
with	   eosinophil	   chemokine	   receptor	   CCR3	   (503-­‐506).	   IL-­‐5	   itself	   is	   also	   important	   for	  
mediating	   the	   release	   of	   eosinophils	   from	   the	   bone	   marrow,	   as	   well	   as	   driving	   their	  
differentiation,	   proliferation	   and	  maturation	   (507-­‐509).	   Additionally,	   IL-­‐4	   plays	   a	   role	   in	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enabling	   eosinophil	  migration	   across	   the	   endothelium	   (510,	   511),	   	   and	   IL-­‐3	   and	   GM-­‐CSF	  
have	  been	   reported	   to	  play	  a	   role	   in	   facilitating	  eosinophil	  maturation	   (512).	   In	   the	   lung,	  
primed	  eosinophils	  release	  a	  massive	  arsenal	  of	  proteins,	  lipids,	  chemokines	  and	  cytokines	  
that	  generate	  characteristic	  asthmatic	  lung	  pathology.	  Of	  note,	  IL-­‐4,	  IL-­‐13,	  TGF-­‐α,	  eosinophil	  
peroxidase,	  cysteinyl	  leukotrienes	  and	  major	  basic	  protein	  contribute	  to	  the	  development	  of	  
airway	   hyperreactivity	   through	   epithelial	   cell	   damage,	   smooth	  muscle	   contractility	   (513,	  
514),	   vascular	   permeability	   (515)	   and	   mast	   cell	   activation	   and	   survival	   (516,	   517).	   The	  
same	  mediators	  and	  additional	  fibroblast	  growth	  factors	  and	  TGF-­‐β	  play	  a	  role	  in	  ongoing	  
airway	  remodelling	  and	  chronic	  inflammation	  (518-­‐523).	  	  
	  
The	  primary	  effects	  of	   IL-­‐13	  on	  the	  allergic	  airway,	  additional	   to	   those	  already	  described,	  
are	   the	   induction	   of	   the	   Mucin	   5AC	   protein	   (Muc5AC)	   and	   goblet	   cell	   hyperplasia,	   that	  
together	   lead	   to	   increased	   mucus	   production,	   as	   well	   as	   airway	   remodelling	   that	   drives	  
smooth	  muscle	  hyperreactivity	   (524,	  525).	  However,	   investigations	  by	  numerous	  authors	  
have	  revealed	  differences	  in	  the	  requirement	  for	  IL-­‐13	  during	  the	  acute	  and	  chronic	  phase	  
of	  disease.	  Transgenic	  overexpression	  of	  IL-­‐13,	  or	  the	  direct	  administration	  of	  IL-­‐13	  to	  the	  
airways	   has	   been	   shown	   to	   induce	   mucus	   secretion,	   IgE	   production,	   eosinophilia,	   and	  
subepithelial	  fibrosis	  (526-­‐528).	  IL-­‐13	  blockade	  or	  deletion	  of	  the	  IL-­‐13	  gene	  was	  reported	  
to	   prevent	   or	   reverse	   these	   features	   of	   disease	   (529-­‐531).	   However,	   in	   chronic	   airway	  
inflammation	   IL-­‐13,	  while	  capable	  of	  potentiating	  disease,	  may	  not	  have	  a	  necessary	  role.	  
IL-­‐13	  blockade	  after	  allergen	  challenge	  has	  been	  shown	  ineffective;	  specifically,	  structural	  
changes	   to	   the	   airway	   and	   associated	   AHR	   are	   not	   reversed	   once	   established	   (529,	   532,	  
533).	  As	   it	   can	  be	  difficult	   to	  block	  cytokine	  production	  completely,	   it	   is	  possible	   that	   the	  
studies	   utilising	   antibody	   blockade	   of	   IL-­‐13	   may	   not	   have	   observed	   fully	   effective	  
suppression	   of	   IL-­‐13;	   indeed	   this	   data	   was	   not	   clearly	   shown	   in	   these	   publications.	  
However,	  it	  was	  clear	  that	  although	  the	  AHR	  and	  structural	  changes	  were	  not	  reversible	  in	  
these	  chronic	  models	  of	  disease,	  the	  acute	  phase	  components	  of	  the	  allergic	  response,	  such	  
as	   eosinophilia	   and	   cell	   infiltrates	   into	   the	   airway	  were	   in	   fact	   suppressed	   by	   anti-­‐IL-­‐13	  
treatment.	  Therefore,	  these	  results	  appear	  consistent	  with	  IL-­‐13	  having	  a	  redundant	  role	  in	  
perpetuating	  the	  features	  of	  chronic	  airway	  inflammation.	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Mast cells in allergic airway inflammation 
Th2	  cells	  are	  also	  responsible	  for	  the	  activation	  of	  mast	  cells	  through	  the	  production	  of	  IL-­‐3,	  
IL-­‐4,	  IL-­‐13	  and	  IL-­‐9	  (481,	  534-­‐536);	  however,	  the	  IL-­‐9	  production	  classically	  attributed	  to	  
Th2	  cells	  may	  in	  fact	  be	  most	  significantly	  produced	  by	  recently	  described	  Th9	  cells	  (162,	  
163).	   The	   role	   of	   mast	   cells	   in	   active	   allergic	   airway	   inflammation	   is	   not	   fully	   resolved.	  
Hallmark	  features	  of	  chronic	  asthma	  such	  as	  AHR	  and	  eosinophilia	  may	  be	  generated	  in	  the	  
absence	  of	  mast	  cells	  (444)	  or	  IgE	  (537,	  538).	  However,	  mast	  cell-­‐dependent	  (539)	  and	  IgE-­‐
induced	   (539,	   540)	   pathways	   also	   exist	   for	   the	   development	   of	   AHR	   in	   mice.	   This	  
discrepancy	   may	   have	   evolved	   from	   differences	   in	   experimental	   models	   in	   terms	   of	   the	  
concentration	  of	  allergenic	   stimuli	   and	  method	  of	  exposure.	  Although	  participating	   in	   the	  
early	   asthmatic	   response,	   it	   appears	   that	   mast	   cells	   are	   not	   critical	   for	   the	   induction	   of	  
allergic	   asthma	   in	   models	   that	   induce	   strong	   eosinophilia	   (444).	   Chronic	   exposure	   to	  
allergens,	  however,	  leads	  to	  an	  increase	  in	  mast	  cell	  numbers	  in	  the	  lung	  tissue	  (443)	  that	  
then	   amplify	   antigen-­‐dependent	   inflammation	   (541).	  Mast	   cells	  may	   be	   found	   associated	  
with	   airway	   smooth	   muscle	   in	   human	   asthmatics	   whereby	   muscle	   cell	   contractility	   is	  
increased,	   facilitating	   the	   development	   of	   airway	   resistance	   and	   AHR	   (542,	   543).	   Upon	  
activation,	  mast	  cells	  secrete	  a	  wide	  range	  of	  mediators	  including	  histamine,	  prostaglandin	  
D2,	   TNF-­‐α,	   mast	   cell	   proteases	   and	   leukotriene	   C4	   (LTC4)	   that	   generate	  
bronchoconstriction,	   mucus	   secretion	   and	   vascular	   permeability;	   additionally	   producing	  
the	  key	  Th2	  cytokines	   IL-­‐4,	   IL-­‐5	  and	   IL-­‐13	  as	  well	  as	  pro-­‐inflammatory	  TGF-­‐β	   (544-­‐546).	  
These	  mediators	  promote	  the	  recruitment	  of	  Th2	  cells,	  eosinophils,	  basophils,	  neutrophils	  
and	  monocytes,	  as	  well	  as	  aiding	  their	   infiltration	  of	   the	   lung	  tissue	  during	  the	   late	  phase	  
asthmatic	  response	  (547-­‐549).	  	  
 
Basophils in allergic airway inflammation 
Basophils	   share	   many	   common	   phenotypic	   and	   functional	   features	   with	   mast	   cells,	  
importantly	  including	  FcεR-­‐I	  expression	  and	  the	  production	  of	  mediators	  such	  as	  histamine	  
and	  LTC4.	  As	  such,	  some	  overlapping	  roles	  exist	   for	   these	  cells.	  However,	  numerous	  non-­‐
redundant	   activities	   are	   carried	   out	   by	   basophils	   to	   amplify	   allergic	   airway	   responses.	  
While	   mast	   cells	   are	   long-­‐lived,	   tissue-­‐resident	   and	   primarily	   required	   for	   immediate	  
hypersensitivity	   reactions,	   basophils	   are	   predominantly	   a	   short-­‐lived	   circulatory	  
population,	  homing	  to	  sites	  of	  allergic	  inflammation	  as	  part	  of	  the	  late	  phase	  response	  (550).	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The	  recruitment	  of	  basophils	  to	  the	  allergic	  lung	  is	  not	  fully	  understood	  as	  reliable	  unique	  
basophil-­‐specific	  markers	  have	  not	  yet	  been	  described,	  however,	  it	  is	  known	  that	  T	  cells	  are	  
critically	   involved	   in	   this	   process	   (431,	   551),	   whereas	   STAT6,	   IL-­‐4	   and	   IL-­‐13	   are	   not	  
required	  (147).	  IL-­‐3,	  IL-­‐5,	  nerve	  growth	  factor	  and	  GM-­‐CSF	  as	  well	  as	  innate	  cytokines	  IL-­‐25	  
and	   IL-­‐33	   may	   promote	   basophil	   influx	   and	   release	   of	   chemical	   mediators	   including	  
histamine	   and	  LTC4	   (468,	   469,	   552,	   553).	   Importantly,	   basophils	   –	   primed	  by	   IL-­‐3	   (554-­‐
557)	  –	  are	  major	  producers	  of	  IL-­‐4,	  which	  is	  secreted	  minimally	  by	  mast	  cells	  (558,	  559),	  as	  
well	  as	  TSLP	  (430),	  thus	  driving	  the	  amplification	  of	  Th2	  immunity.	  	  
	  
	  
1.2.2.3 Airway remodelling and chronic allergic airway disease	  
Individuals	  that	  suffer	  from	  allergic	  asthma	  are	  often	  recurrently	  or	  persistently	  exposed	  to	  
the	  allergens	   that	  elicit	   their	  allergic	  reactions.	  While	  multiple	  early	  phase	  and	   late	  phase	  
reactions	   are	   induced	   and	   subsequently	   resolve,	   structural	   damage	   to	   the	   airway	  
accumulates	   and	   persists	   long	   term;	   characteristic	   asthmatic	   airway	   remodelling	   thus	  
becomes	   evident	   over	   time,	   and	   chronic	   disease	   develops.	   Distinguishing	   features	   of	  
remodelling	   include	   increased	   numbers	   of	   mucus-­‐producing	   goblet	   cells	   in	   the	   airway	  
epithelium,	   subepithelial	   fibrosis,	   increased	   airway	   smooth	  muscle	  mass,	   proliferation	   of	  
blood	   vessels,	   airway	   oedema	   and	   tissue	   destruction	   (560-­‐562).	   Together,	   these	   changes	  
result	  in	  thickening	  of	  the	  airway	  wall.	  	  	  
	  
Markers	  of	  epithelial	  repair	  are	  characteristically	  present	  alongside	  inflammatory	  features	  
in	  chronic	  disease.	  	  Tenascin-­‐c,	  normally	  absent	  or	  weakly	  expressed	  in	  the	  lung,	  increases	  
under	   pathological	   conditions	   such	   as	   inflammation,	   infection,	   biomechanical	   stress	   and	  
wound	  healing,	  and	  is	  an	  early	  initiator	  of	  airway	  wall	  remodelling	  (563,	  564).	  Expression	  is	  
enhanced	   in	   the	   subepithelial	   extracellular	   matrix	   and	   correlates	   with	   the	   extent	   of	  
bronchial	  mast	  cell	  and	  eosinophil	  infiltration	  (565).	  Tenascin-­‐c	  stimulates	  IL-­‐5,	  IL-­‐13	  and	  
IgE	  secretion	  from	  lymphocytes	  (566),	  potentially	  through	  an	  indirect	  mechanism	  whereby	  
tenascin-­‐c	  stimulates	  the	  rolling	  and	  tethering	  of	  cells,	  provoking	  lymphocyte	  trafficking	  to	  
inflamed	   mucosa	   where	   cells	   may	   be	   stimulated	   (567-­‐569).	   These	   mediators	   are	  
significantly	  reduced	  in	  the	  BAL	  of	  allergen	  sensitised/challenged	  tenascin-­‐c-­‐deficient	  mice	  
(566);	  as	  such,	  an	  important	  role	  exists	  in	  the	  pathogenesis	  of	  asthma.	  	  
   45 
	  
Matrix	  metalloproteinases	  (MMPs)	  are	  also	  involved	  in	  lung	  diseases	  that	  are	  characterised	  
by	  airway	  remodelling.	  MMP-­‐9,	  the	  predominant	  family	  member	  in	  asthma	  (570),	  actively	  
degrades	   type	   IV	   collagen	   to	   allow	   inflammatory	   cell	   trafficking	   throughout	   the	   lung.	  
Importantly,	  MMP-­‐9	  is	  required	  for	  the	  successful	  migration	  of	  DCs	  into	  the	  airway	  to	  take	  
up	  antigens	  (571,	  572),	  as	  well	  as	  playing	  an	  important	  role	  in	  the	  activation	  of	  TGF-­‐β1	  that	  
drives	  subepithelial	  fibrosis	  (573).	  	  
	  
Repeated	  allergen	  exposure	  can	  also	  result	  in	  the	  production	  of	  IgE	  to	  multiple	  epitopes	  of	  
the	   same	   allergen,	   or	   to	   unrelated	   allergens.	   A	  mechanism	   through	  which	   this	   can	   arise	  
involves	  facilitated	  antigen	  presentation	  (FAP)	  mediated	  by	  CD23,	  an	  IgE	  binding	  receptor	  
of	   the	   C-­‐type	   lectin	   superfamily,	   that	   can	   be	   expressed	   by	   cells	   such	   as	   epithelial	   cells,	  
myeloid	   cells	   and	   B	   cells	   (574).	   Airway	   epithelial	   cell	   CD23	   binds,	   and	   mediates	   the	  
transcytosis	  of,	  IgE	  and	  antigen-­‐IgE	  complexes	  across	  the	  epithelium,	  enabling	  the	  binding	  
of	   this	   IgE	   to	   mast	   cells,	   basophils,	   macrophages	   and	   DC	   in	   the	   lung	   tissue	   (575).	   This	  
process	  may	  also	  occur	  in	  the	  gastrointestinal	  tract	  (576).	  Antigen-­‐IgE	  complexes	  can	  bind	  
CD23	   molecules	   on	   non-­‐specific	   myeloid	   cells	   and	   B	   cells,	   which	   may	   then	   present	   the	  
antigens	  to	  cognate	  T	  cells	  (577).	  This	  FAP-­‐driven	  presentation	  of	  new	  epitopes	  or	  allergens	  
to	  T	  cells	  in	  the	  presence	  of	  Th2	  cytokines	  may	  promote	  their	  differentiation	  into	  Th2	  cells,	  
subsequently	  inducing	  the	  B	  cell	  production	  of	  IgE	  specific	  for	  the	  new	  allergens.	  IL-­‐4	  and	  
IL-­‐13	  have	  also	  been	  demonstrated	  to	  increase	  the	  expression	  of	  CD23	  on	  myeloid	  cells	  and	  
B	   cells,	   enhancing	   the	  potential	   for	   this	   phenomenon	   to	   occur	   (476).	   Thus,	  when	   allergic	  
individuals	  are	  exposed	  to	  multiple	  potential	  allergens	  simultaneously,	  FAP	  in	  a	  Th2	  micro-­‐
environment	   can	  mediate	   sensitisation	   to	   the	  additional	   allergen	   specificities.	   Indeed,	   the	  
majority	  of	  individuals	  who	  suffer	  from	  allergic	  airway	  inflammation	  are	  polysensitised	  (22,	  




Respiratory viral infection drives exacerbation of asthma 
Common	  respiratory	  viruses	  such	  as	  rhinovirus,	   influenza,	  and	  respiratory	  syncytial	  virus	  
can	  markedly	  exacerbate	  the	  symptoms	  of	  asthma	  (580-­‐582).	  Rhinovirus	  infection	  has	  been	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shown	   to	   enhance	   histamine	   release,	   eosinophil	   recruitment	   and	   AHR	   during	   allergen	  
exposure	  (581,	  582).	  While	  it	  is	  not	  fully	  understood	  how	  this	  occurs,	  exacerbations	  may	  be	  
driven	   by	   the	   effects	   of	   viruses	   and	   viral	   replication	   on	   the	   airway	   epithelium	   and	  
associated	   cells.	   Viral	   products	   have	   been	   demonstrated	   to	   act	   directly	   on	  mast	   cells,	   in	  
humans	   and	  murine	  models,	   by	   inducing	   TLR	   signalling,	   especially	   through	   TLR-­‐7	   (583,	  
584).	   In	   chronic	   asthmatic	   disease,	   the	   elevated	   number	   of	  mast	   cells	   within	   the	   airway	  
epithelium	   and	   smooth	   muscle	   layers	   positions	   them	   for	   rapid	   inflammatory	   responses	  
(542,	   543).	   These	   combined	   effects	   of	   viruses	   on	   key	   allergy-­‐driving	   cells	   represent	   a	  





1.3 CTLs in the treatment of allergic airway disease  
	  
The	  role	  of	  the	  CD8+	  T	  cell	   in	  allergic	  asthma	  is	  not	  fully	  defined,	  and	  has	  been	  a	  point	  of	  
some	  controversy.	  Multiple	  studies	  have	  revealed	  contexts	  in	  which	  CD8+	  T	  cells	  exaggerate	  
or	  abrogate	  allergic	  airway	  inflammation.	  CD8+	  T	  cells	  may	  be	  of	  a	  Tc1	  or	  Tc2	  phenotype	  
(as	  discussed	  in	  Section	  1.1.3.1).	  Tc1	  cells,	  characterised	  by	  their	  production	  of	  IFN-­‐γ,	  and	  
clearance	  of	  virus-­‐infected	  cells,	  promote	  Th1	  responses.	  Conversely,	  Tc2	  cells	  produce	  IL-­‐5	  
and	  IL-­‐13,	  amplifying	  Th2	  disease.	  As	  such,	  in	  models	  of	  allergic	  airway	  inflammation,	  CD8+	  
T	  cells	  have	  been	  shown	  to	  have	  either	  pro-­‐inflammatory	  (227-­‐229)	  or	  suppressive	  activity	  
(220-­‐226)	   on	   asthmatic	   disease.	   The	   pathway	   through	  which	   suppression	   is	   achieved	   by	  
Tc1	   has	   not	   been	   fully	   elucidated,	   although	   numerous	   potential	   mechanisms	   have	   been	  
proposed.	  	  
	  
A	  number	  of	  studies	  have	  highlighted	  the	  role	  of	  the	  key	  CTL	  effector	  cytokine	  IFN-­‐γ	  in	  the	  
suppression	  of	   allergic	  disease	   (221,	  585);	  CD8+	  T	   cells	   from	   IFN-­‐γ	  knock	  out	  mice	  were	  
unable	  to	  suppress	  inflammation	  like	  their	  WT	  counterparts.	  IFN-­‐γ	  is	  known	  to	  inhibit	  IgE	  
production	  (586,	  587),	  presenting	  a	  mechanism	  through	  which	  allergic	  responses	  may	  be	  
prevented.	   However,	   evidence	   surfaced	   that	   questioned	   the	   importance	   of	   CD8+	   T	   cell-­‐
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derived	  IFN-­‐γ	  in	  the	  suppression	  of	  IgE	  production.	  The	  adoptive	  transfer	  of	  IFN-­‐γ-­‐/-­‐	  CD8+	  
T	  cells	  was	  shown	  to	  suppress	  IgE	  production	  similarly	  to	  WT	  cells	  (588).	  Additionally,	  both	  
Tc1	   and	   Tc2	   cells	   are	   capable	   of	   suppressing	   IgE	   production,	   despite	   the	   limited	   IFN-­‐γ	  
production	  of	  Tc2	   cells	   (589).	   The	   importance	   of	   suppressing	   IgE	   is	   particularly	   relevant	  
during	   antigen	   exposure	   that	   may	   lead	   to	   sensitisation.	   Once	   adaptive	   immunity	   is	  
generated	  in	  the	  form	  of	  an	  antigen-­‐specific	  Th2	  response,	  IgE-­‐independent	  stimulation	  of	  
allergic	   airway	   inflammation	   may	   occur.	   The	   effective	   suppression	   of	   established	   Th2	  
responses	   by	   CTLs	  must	   then	   require	   an	   alternative	  mechanism	   of	   action.	   Indeed,	   it	   has	  
been	  demonstrated	  that	  CD8+	  T	  cells	  can	  mediate	  suppression	  of	  the	  late	  allergic	  response	  
including	  reduced	  eosinophilia	  and	  Th2-­‐cytokines,	  without	  affecting	   the	   levels	  of	  antigen-­‐
specific	  serum	  IgE	  (220).	  
	  
It	   has	   been	   suggested,	   alternatively,	   that	   CTL-­‐derived	   IFN-­‐γ	   alleviates	   allergic	   disease	  
through	   the	   skewing	  of	  Th2	   immunity	   towards	   a	  Th1	  bias	   that	   subsequently	   antagonises	  
Th2	  responses.	  This	  may	  occur	  through	  the	  IFN-­‐γ-­‐mediated	  stimulation	  of	  DCs	  to	  produce	  
IL-­‐12.	   Indeed,	   adoptive	   transfer	   of	   antigen-­‐specific	   CD8+	   T	   cells	   in	   a	   model	   of	   allergic	  
airway	   inflammation	  has	  been	   reported	   to	   result	   in	   a	   reduction	   in	  BAL	  eosinophilia,	   IL-­‐4	  
and	   IL-­‐5,	   with	   an	   associated	   increase	   in	   IL-­‐12p70	   (223).	   It	   was	   further	   demonstrated	   in	  
vitro	  that	  CD8+	  T	  cells	  primed	  CD8-­‐α+DC	  for	  IL-­‐12	  production	  in	  a	  cell	  contact-­‐dependent	  
manner	  (590).	  In	  contrast,	  other	  authors	  have	  shown	  that	  while	  enhanced	  DC	  production	  of	  
IL-­‐12p70	  antagonised	   IL-­‐13-­‐driven	  gene	   induction	  and	  STAT6	  phosphorylation,	   it	  had	  no	  
effect	   on	   Th2	   cytokine	   production,	   BAL	   inflammatory	   infiltrates	   or	   IgE	   synthesis	   (591).	  
Furthermore,	   additional	   studies	   reported	   successful	   amelioration	   of	   allergic	   airway	  
inflammation	   by	   CD8+	   T	   cells	   that	   did	   not	   involve	   detectable	   production	   of	   IL-­‐12	   (226).	  
These	   conflicting	   results	   suggest	   that	  while	   IL-­‐12	  may	  be	   suppressive	   in	   some	  models	   of	  
allergic	   inflammation,	   it	   is	   not	   a	   critical	   factor	   in	   CD8+	   T	   cell-­‐mediated	   amelioration	   of	  
disease.	  Of	  note,	  the	  work	  of	  Wong	  and	  Wells	  involved	  the	  co-­‐administration	  of	  endotoxin	  
with	  antigen	  which	  may	  promote	  IL-­‐12	  production	  and	  Th1	  skewing	  via	  DC	  TLR	  stimulation,	  
independently	  of	   their	   interaction	  with	  CD8+	  T	  cells	  (372).	   	  Lewkowich	  and	  Enomoto,	  on	  
the	  other	  hand,	  used	  low-­‐endotoxin	  allergen	  preparations	  (226,	  591).	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While	  IFN-­‐γ	  may	  be	  the	  archetypal	  Th1-­‐associated	  cytokine,	  classic	  Th1-­‐polarising	  signals	  
may	  not	   always	   counterbalance	  Th2	   immunity.	   IFN-­‐γ	   has	   also	   been	   shown	   to	   exacerbate	  
allergic	  disease	  (592,	  593)	  and	  Th1	  cells	  adoptively	  transferred	  with	  Th2	  cells	  contribute	  to,	  
rather	  than	  suppress,	  airway	  inflammation	  (594).	  
	  
While	   CTL-­‐derived	   IFN-­‐γ	   may	   have	   the	   capability	   to	   modulate	   Th2	   inflammation	   as	  
discussed	   herein,	   Enomoto	   et	   al	   demonstrated	   that	   adoptively	   transferred	   CTLs	   did	   not	  
require	  IFN-­‐γ	  to	  suppress	  inflammation	  in	  previously	  sensitised	  mice;	  neutralisation	  of	  IFN-­‐
γ	  still	  resulted	  in	  prevention	  of	  disease	  in	  an	  acute	  setting	  (226).	  The	  authors	  propose	  that	  
this	  discrepancy	  in	  the	  requirement	  for	  IFN-­‐γ,	  which	  is	  in	  contrast	  to	  the	  results	  generated	  
using	  IFN-­‐γ	  -­‐/-­‐	  CTLs,	  may	  stem	  from	  the	  fact	  that	  IFN-­‐γ	  -­‐/-­‐	  CTLs	  have	  an	  impaired	  ability	  to	  
kill	  target	  cells.	  This	  observation	  is	  in	  accordance	  with	  the	  findings	  of	  Tang	  and	  colleagues,	  
who	  reported	  that	  IFN-­‐γ	  -­‐/-­‐	  CTLs	  were	  poorly	  cytotoxic	  and	  in	  fact	  displayed	  a	  Tc2/Tc17-­‐
biased	  phenotype,	   rendering	   them	  capable	  of	   inducing	  and	  exacerbating	  eosinophilia	  and	  
neutrophilia	   (595).	  This	   factor	  was	  deemed	   important	  by	   the	  work	  of	  Enomoto	  et	  al	   that	  
highlighted	  the	  critical	  requirement	  for	  perforin	  in	  successful	  CTL-­‐mediated	  amelioration	  of	  
acute	  asthmatic	  disease,	  which	  suggested	  that	  cell(s)	  were	  targeted	  and	  killed	  as	  a	  means	  of	  
suppressing	  the	  Th2	  response.	  The	  identity	  of	  the	  critical	  target	  cells,	  however,	  has	  not	  yet	  
been	  revealed.	  	  
	  
The	   ability	   of	   CTLs	   to	   kill	   target	   cells	   relies	   on	   the	   recognition	   of	   their	   cognate	   antigen	  
through	  TCR	  stimulation.	  Whether	  CD8+	  T	  cells	  need	  to	  be	  allergen-­‐specific	  to	  successfully	  
suppress	  allergic	  airway	  inflammation,	  however,	  has	  been	  questioned.	  Some	  allergens,	  such	  
as	  the	  Der	  p	  2	  component	  of	  HDM,	  may	  directly	  activate	  CTLs	  through	  TLR	  signalling	  in	  the	  
absence	  of	  their	  cognate	  antigen	  (596-­‐598),	  and	  large	  pools	  of	  activated	  CTLs	  may	  carry	  out	  
effective	  immune	  responses	  to	  alternative	  antigen	  specificities	  during	  viral	   infection	  (224,	  
599-­‐601).	   It	   has	   also	   been	   reported	   that	   resting	  memory	   CD8+	   T	   cells	  may	   be	   activated	  
during	  viral	  infection	  in	  a	  non	  antigen-­‐specific	  manner.	  These	  cells	  respond	  to	  the	  cytokine	  
environment	   in	   lymphoid	   tissue	   as	   well	   as	   the	   lung	   and	   liver,	   particularly	   through	  
stimulation	   by	   IL-­‐12	   and	   IL-­‐18	   (224).	   The	   resulting	   CTL	   activation,	   however,	   primarily	  
drives	   the	   production	   of	   IFN-­‐γ	   that	   modulates	   immune	   responses	   somewhat	   non-­‐
specifically.	  Indeed,	  studies	  that	  have	  investigated	  the	  effects	  of	  non	  allergen-­‐specific	  CTLs	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on	  allergic	  airway	  disease	  revealed	  that	   IFN-­‐γ	  was	  central	   to	  suppressive	  responses	  (221,	  
585).	   Interestingly,	   Enomoto	   and	   Ronchese	   discovered	   that	   CTLs	   of	   different	   allergen	  
specificity	   could	   suppress	   airway	   inflammation	   only	   when	   endotoxin	   was	   present,	   in	   a	  
presumably	   IFN-­‐γ	  dependent	   fashion	  (unpublished	  observations).	  CTL-­‐mediated	  killing	  of	  
target	  cells,	  however,	  occurs	  secondary	  to	  TCR	  ligation;	  as	  such,	  only	  allergen-­‐specific	  CTLs	  
can	  suppress	  allergic	  airway	  inflammation	  in	  the	  absence	  of	  endotoxin.	  While	  conventional	  
vaccines	   do	   not	   induce	   CTL	   responses,	   antigen-­‐specific	   CTL-­‐mediated	   immune	   responses	  
may	  be	  elicited	  in	  vivo	  through	  the	  use	  of	  dendritic	  cell	  vaccines,	  as	  has	  been	  widely	  used	  in	  
the	   stimulation	   of	   anti-­‐tumour	   responses	   (602-­‐605);	   in	   a	   model	   of	   allergic	   airway	  
inflammation,	   this	  can	  achieve	  protection	  similarly	   to	  adoptive	  transfer	  of	  CTLs	  (226).	  An	  
alternative	  method	  for	  the	  induction	  of	  CTL	  responses	  is	  to	  vaccinate	  using	  viral	  vectors	  to	  
target	   delivery	   of	   antigenic	   epitopes	   into	   DCs.	   This	   has	   been	   carried	   out	   experimentally,	  
commonly	  using	  adenovirus	  or	  vaccinia	  virus	  vectors,	  resulting	  in	  effective	  CTL	  responses	  
including	  anti-­‐tumour	   immunity	   (606-­‐609).	  However,	   this	  method	  may	  not	  gain	  approval	  
for	   use	   in	   patients	   due	   to	   infection	   risk.	   Recently,	   a	   novel	   vaccine	   that	   stimulates	   an	  
allergen-­‐specific	   endogenous	   CTL-­‐mediated	   response	   was	   developed;	   this	   vaccine	   is	  
described,	   and	   its	   effects	   on	   allergic	   airway	   inflammation	   investigated,	   in	   this	   thesis	  
(Chapter	  5).	  	  
	  
A	  general	  trend	  may	  be	  observed	  in	  the	  findings	  of	  the	  studies	  presented	  herein,	  whereby	  
two	   major	   mechanisms	   are	   described	   for	   the	   CTL-­‐mediated	   suppression	   of	   airway	  
inflammation.	   Firstly,	   IFN-­‐γ	   from	   activated	   CTLs	   may	   counteract	   allergen-­‐induced	   Th2	  
immune	  responses,	  occurring	  in	  a	  non-­‐antigen	  specific	  manner	  in	  the	  presence	  of	  endotoxin.	  
However,	  the	  requirement	  for	  IFN-­‐γ	  is	  debatable,	  and	  it	  appears	  that	  it	  is	  not	  sufficient	  for	  
the	  suppression	  of	  disease	  on	  its	  own.	  Secondly,	  antigen-­‐specific	  killing	  of	  target	  cells	  may	  
occur	  in	  a	  perforin-­‐dependent	  manner,	  independently	  of	  endotoxin	  effects,	  and	  without	  the	  
requirement	   for	   IFN-­‐γ.	   The	   work	   involving	   IFN-­‐γ	   has	   been	   useful	   to	   further	   the	  
understanding	  of	  CTL-­‐mediated	   immune	  responses	  and	  how	  Th1-­‐skewing	  may	  be	  able	   to	  
divert	   or	   re-­‐program	   pathogenic	   Th2	   immune	   responses,	   however,	   in	   terms	   of	   the	  
treatment	   of	   allergic	   lung	   disease,	   the	   need	   for	   a	   targeted	   therapy	   that	   dampens	   only	  
specific	   inappropriate	   responses	   is	   of	   utmost	   importance	   in	   preserving	   lung	   health	   and	  
immune	  defence	  against	  infectious	  disease.	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From	   these	   studies	   it	   is	   evident	   that	   CTLs	   are	   capable	   of	   suppressing	   allergic	   airway	  
inflammation	   and,	   although	   this	   is	   yet	   to	   be	   tested	   in	   clinical	   studies,	   the	   potential	   for	  
treatment	   of	   allergic	   asthma	   exists.	   However,	   investigations	   into	   the	   mechanism	   of	  
suppression	   have	   produced	   conflicting,	   inconclusive	   results.	   Additionally,	   while	   many	  
studies	  have	  shown	  the	  capability	  of	  CTLs	   to	  prevent	   inflammation	  during	   initial	  allergen	  
challenge,	   it	   is	   not	   known	  whether	   suppression	  may	   be	   achieved	   in	   chronic	   disease,	   and	  
how	   long	   this	  protection	  persists.	   Further	  work	   is	   also	   required	   to	   identify	   the	   targets	  of	  
CTL-­‐mediated	   killing	   and	   the	   localisation	   of	   CTL-­‐target	   cell	   interactions.	   These	   insights	  




1.4 Modelling allergic asthma 
	  
Key	  to	  furthering	  understanding	  of	  the	  basic	  science	  of	  health	  and	  disease,	  animal	  models	  of	  
disease	  provide	  a	  tool	  with	  which	  we	  may	  also	  investigate	  the	  effects	  of	  novel	  therapies.	  For	  
animal	  experimental	  results	  to	  be	  potentially	  applicable	  and	  translatable	  to	  human	  health	  a	  
model	  system	  must	  be	  developed	  where	  the	  pathology	  closely	  resembles	  that	  of	  the	  human	  
disease.	   The	   characteristic	   features	   of	   allergic	   asthma	  may	  be	   generated	   in	  mice	  using	   in	  
vivo	   sensitisation	   techniques	   or	   the	   adoptive	   transfer	   of	   in	   vitro	   activated	   Th2	   cells.	  
Different	   strains	   of	   wild	   type	   mice	   may	   be	   used	   and	   the	   type	   and	   amount	   of	   allergen	  
exposure	   varies	   between	   studies.	   As	   such,	   the	   pathology	   developed	   in	   these	  models	  may	  
differ	   and	   findings	  may	   not	   be	   fully	   comparable	   throughout	   the	   literature.	   Regardless	   of	  
these	   disparities,	   well-­‐characterised	   models	   of	   allergic	   airway	   inflammation	   allow	   for	  
understanding	  of	  the	  limitations	  as	  well	  as	  the	  conclusions	  that	  may	  be	  deduced	  from	  each	  
study	  and	  provide	  important	  insights	  that	  may	  be	  related	  to	  human	  health.	  	  
	  
1.4.1 Methods of inducing allergic airway inflammation	  
To	  generate	  allergic	  airway	  inflammation	  in	  mice,	  allergen-­‐specific	  Th2	  responses	  may	  be	  
primed	   through	   a	   number	   of	   routes.	   Commonly,	   intranasal	   (in.)	   or	   intraperitoneal	   (i.p.)	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exposure	  to	  allergen	   is	  used	  to	   facilitate	  sensitisation.	  Model	  allergens	  may	  be	  mixed	   into	  
aqueous	   solutions	   and	   delivered	   to	   the	   lung	   either	   through	   nebuliser-­‐generated	   aerosols	  
that	  are	  inhaled,	  or	  instillation	  of	  the	  solution	  directly	  into	  the	  nares	  or	  trachea	  of	  mice.	  The	  
airway	  epithelium	  and	  associated	  cells	  then	  respond	  to	  allergens	  through	  the	  recognition	  of	  
PAMPs	  by	  TLRs;	  as	  discussed	   in	  section	  1.2,	   this	   leads	  to	  the	  activation	  of	  DCs	  that	  prime	  
Th2	   responses.	   While	   i.n.	   sensitisation	   to	   protease	   allergens	   can	   be	   successful,	   weaker	  
allergens	  usually	   require	   additional	  Th2-­‐polarising	   stimuli	   for	   the	   generation	  of	   allergen-­‐
specific	  IgE.	  This	  may	  be	  achieved	  intranasally	  through	  the	  co-­‐administration	  of	  low	  doses	  
of	  LPS	  (610),	  or	  by	  systemic	  sensitisation	  through	  i.p.	  injection	  of	  allergen	  co-­‐administered	  
with	   a	   Th2-­‐promoting	   adjuvant	   such	   as	   aluminium	   hydroxide	   (Alum).	   Sensitisation	   via	  
these	   different	   routes	   may	   elicit	   allergic	   airway	   inflammation	   that	   is	   initiated	   through	  
differing	  pathways.	  Direct	   intranasal	   exposure	   results	   in	   the	   activation	  of	   innate	   immune	  
cells	  such	  as	  APCs,	   ILCs,	  mast	  cells,	  and	  the	  airway	  epithelium	  (611,	  612).	   In	  contrast,	   i.p.	  
sensitisation	  subverts	   the	   involvement	  of	   the	  airway	  cells,	  activating	  peritoneal	  APCs	  that	  
stimulate	   the	   differentiation	   of	   Th2	   cells	   in	   draining	   lymph	   nodes.	   Nevertheless,	   both	  
models	   reliably	  generate	  robust	  Th2	   immune	  responses	   in	   the	   lung	  upon	  airway	  allergen	  
challenge.	  As	  such,	   the	  model	  of	   sensitisation	   is	   largely	  developed	   in	  accordance	  with	   the	  
protocol	   appropriate	   for	   the	   allergen	   of	   choice,	   to	   fulfil	   the	   purposes	   of	   different	  
experimental	  questions.	  	  
	  
1.4.2 Model allergens in the induction of experimental allergic asthma 
Common	   experimental	   allergens	   used	   to	   induce	   Th2	   immunity	   in	   the	   airways	   of	   mice	  
include	   OVA,	   HDM,	   and	   cockroach	   extracts,	   Aspergillus	   fumigatus,	   Alternaria	   alternata,	  
ragweed,	  cedar	  and	  cypress	  pollens.	  Predominantly,	  studies	  of	  allergic	  airway	  inflammation	  
have	   utilised	  OVA	   or	  HDM;	   distinct	   differences	   exist	   in	   these	   allergens	   that	   can	   alter	   the	  
phenotype	  of	  allergic	  disease.	  	  
	  
The	  widespread	   use	   of	   OVA	   as	   a	  model	   allergen	   has	   led	   to	   extensive	   characterisation	   of	  
OVA-­‐induced	   asthmatic	   pathology.	   The	  OVA	   protein	   contains	   two	  main	   epitopes	   that	   are	  
immunogenic	  in	  C57BL/6	  mice,	  OVA257-­‐264	  which	  may	  be	  presented	  on	  MHC-­‐I	  to	  stimulate	  
CD8+	  T	  cell	   responses	  and	  OVA323-­‐339,	  presented	  on	  MHC-­‐II	   for	   the	  stimulation	  of	  CD4+	  T	  
cells	   (613-­‐616).	   Many	   different	   experimental	   protocols	   exist	   for	   the	   sensitisation	   and	  
   52 
challenge	  phases	  that	  lead	  to	  allergic	  disease,	  however	  the	  basic	  outline	  of	  these	  models	  is	  
similar.	  Airway	  exposure	  to	  OVA,	  in	  the	  absence	  of	  prior	  sensitisation,	  leads	  to	  a	  tolerogenic	  
response	   (586,	   617)	   and	   as	   such,	   mice	   are	   usually	   sensitised	   systemically	   by	   i.p.	  
administration	   of	   OVA	   protein	   along	   with	   a	   Th2-­‐promoting	   adjuvant	   such	   as	   Alum.	  
Commonly,	   two	   i.p.	   doses	   of	   OVA/Alum	   are	   administered	   some	   time	   apart	   to	   boost	   IgE	  
production	   (618);	   this	   also	   lessens	   the	   chance	   of	   failed	   i.p	   vaccination	   as	   a	   result	   of	  
technical	   error.	   Airway	   exposure	   to	   OVA	   is	   then	   performed	   either	   intranasally,	  
intratracheally,	   or	   by	   inhalation	   of	   aerosolised	   OVA	   which	   drives	   a	   local	   Th2-­‐mediated	  
allergic	  response	  in	  the	  lung.	  
	  
More	  recently,	  HDM	  is	  becoming	  a	  popular	  model	  allergen	  in	  the	  study	  of	  allergic	  asthma,	  as	  
it	   commonly	   presents	   as	   an	   airway	   allergen	   in	   human	   disease	   (619).	   Different	   research	  
groups	   have	   used	   preparations	   of	   either	   crushed	   whole	   dust	   mites,	   or	   select	   extracted	  
components	   such	   as	   the	  major	  Dermatophagoides	  pteronyssinus	  group	   1	   or	   2	   epitopes	   to	  
which	   80-­‐90%	   of	   mite	   allergic	   patients	   react:	   Der	   p	   1	   and	   Der	   p	   2	   (620,	   621).	   These	  
epitopes	  have	  different	  roles	  in	  the	  promotion	  of	  allergic	  sensitisation	  in	  the	  lung.	  Der	  p	  1,	  a	  
cysteine	   protease,	   acts	   on	   respiratory	   epithelial	   cells	   to	   induce	   the	   release	   of	   pro-­‐
inflammatory	   mediators	   (622).	   This	   is	   thought	   to	   be	   achieved	   by	   protease-­‐mediated	  
disruption	  of	  epithelial	  barriers	  and	  subsequent	  access	  to	  APCs	  (389,	  623,	  624).	  Der	  p	  2,	  on	  
the	  other	  hand,	  does	  not	  possess	  enzymatic	  activity,	  however	  it	  has	  been	  shown	  that	  Der	  p	  
2	  sensitisation	  also	   leads	   to	   the	  generation	  of	  specific	   IgE	  as	  well	  as	  airway	   inflammation	  
(596,	  625).	  While	  it	  is	  not	  clear	  how	  this	  occurs	  in	  the	  absence	  of	  protease	  function,	  it	  has	  
been	   shown	   that	   Der	   p	   2,	   in	   concert	   with	   LPS,	   can	   activate	   bronchial	   epithelial	   cells	   via	  
inducing	   TLR	   4	   signalling	   (598).	   Inflammation	   may	   be	   driven	   by	   the	   activation	   of	  
intracellular	  MAPK	  and	  NF-­‐κB	  signalling	  pathways	  which	  stimulate	  the	  production	  of	  pro-­‐
inflammatory	  cytokines	  as	  well	  as	  factors	  that	  facilitate	  the	  infiltration	  of	  immune	  cells	  into	  
the	  lung	  (388).	  	  
	  
Standardisation	   of	   models	   of	   HDM-­‐induced	   allergic	   airway	   inflammation	   has	   been	  
complicated	   by	   the	   fact	   that	   numerous	   immunogenic	   factors	   differ	   in	   the	   HDM-­‐derived	  
preparations	  utilised.	  The	  relative	  amount	  of	  Der	  p	  1	  to	  Der	  p	  2	  in	  crushed	  whole	  mites	  may	  
vary	  and	  differing	  amounts	  of	  LPS	  are	  also	  naturally	  associated	  with	  the	  mites,	  and	  as	  such,	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each	  particular	  HDM	  preparation	  may	  differ	  in	  the	  amount	  of	  endotoxin	  present.	  Due	  to	  the	  
auto-­‐adjuvanting	   properties	   of	   LPS,	   HDM-­‐mediated	   allergic	   airway	   inflammation	  may	   be	  
induced	   solely	   through	   airway	   exposure	   to	   the	   allergen	   (373).	   Multiple	   doses	   are	  
administered	   intranasally	   or	   intratracheally	   to	   progressively	   stimulate	   allergic	   airway	  
inflammation.	   The	   endotoxin	   component	   of	  HDM	   stimulates	   a	   neutrophilic	   component	   to	  
airway	  infiltrates	  that	  is	  not	  present	  after	  endotoxin-­‐free	  OVA	  allergen	  exposure	  (373,	  626,	  
627).	  However,	   the	  eosinophilic	   inflammation	   induced	  by	  HDM	  exposure	   is	  much	  weaker	  
than	   that	   elicited	   by	   OVA/Alum	   immunisation	   and	   thus	   may	   be	   more	   difficult	   to	   draw	  
conclusions	  between	  treatment	  groups	  (experimental	  observation).	  	  
	  
A	  criticism	  that	  has	  gained	  some	  momentum	  is	  the	  fact	  that	  models	  that	  utilise	  OVA,	  which	  
is	   normally	   tolerated,	   rely	   on	   co-­‐administration	   of	   adjuvant	   and	   systemic	   sensitisation	  
which	   is	   not	   considered	   to	  mimic	   natural	   sensitisation	   as	   closely	   as	   the	   HDM	   protocols.	  
However,	  this	  may	  not	  be	  an	  entirely	  flawless	  argument.	  In	  humans,	  the	  majority	  of	  inhaled	  
antigens	   do	   not	   drive	   allergic	   responses,	   but	   rather	   are	   tolerated;	   and	   in	   non-­‐allergic	  
individuals,	  common	  allergens	  such	  as	  HDM	  are	  also	  tolerated	  upon	  exposure.	  As	  such,	  even	  
“human	  relevant”	  allergens	  require	  adjuvanting	  cofactors,	  such	  as	  LPS,	  PAMPs	  and	  DAMPs,	  
as	  well	  as	  host	  susceptibility,	  to	  produce	  allergic	  disease.	  Therefore,	  the	  use	  of	  adjuvants	  in	  
OVA-­‐induced	   allergic	   airway	   inflammation	   does	   not	   preclude	   these	   models	   from	  
representing	   valid,	   physiologically	   relevant	   asthmatic	   disease.	   Importantly,	   as	   OVA	   has	  
been	  well	  characterised,	  distinct	  CD4+	  and	  CD8+	  T	  cell	  epitopes	  defined,	  and	  endotoxin-­‐free	  
preparations	  generated,	  our	  understanding	  of	  the	  pathology	  generated	  by	  OVA	  is	  grounded	  
in	  extensive	  literary	  reports	  of	  experimentation	  in	  this	  model.	  As	  such,	  the	  efficacy	  of	  novel	  
therapies	  on	  specific	  parameters	  of	  allergic	  airway	  inflammation	  may	  be	  examined.	  	  
	  
1.4.3 Murine models of experimental allergic asthma 
Evidence	  is	  emerging	  in	  the	  literature	  that	  describes	  how	  genotypic	  differences	  in	  wild	  type	  
mice	  may	  affect	  their	  responses	  to	  allergen	  sensitisation	  and	  challenge	  protocols.	  The	  most	  
commonly	  used	  strains	  of	  mice	  in	  the	  modelling	  of	  allergic	  airway	  inflammation,	  C57BL/6	  
and	  BALB/c,	  differ	  in	  their	  tendency	  to	  drive	  Th2	  responses.	  While	  allergic	  disease	  may	  be	  
provoked	   in	  both	  C57BL/6	  and	  BALB/c	  mice,	   it	   has	  been	   reported	   that	  BALB/c	  mice	   are	  
more	  prone	   to	  Th2	  bias,	   due	   to	   their	   intrinsically	  higher	   susceptibility	   to	  develop	  allergy	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than	   C57BL/6	   (628).	   Indeed,	   when	   exposed	   to	   the	   same	   experimental	   protocol,	   BALB/c	  
mice	  experience	  enhanced	  AHR,	  eosinophilia	  and	  mast	  cell	  numbers	   in	   the	   lung	   tissue,	  as	  
well	  as	  elevated	  levels	  of	   IL-­‐4,	   IL-­‐5	  and	  IL-­‐13	  compared	  to	  C57BL/6	  mice	  (500,	  629-­‐631).	  
Other	  authors,	  however,	  have	  reported	  that	  C57BL/6	  mice	  display	  higher	  BAL	  eosinophilia	  
and	  neutrophilia,	  peribronchial	  eosinophilia,	  as	  well	  as	  increased	  expression	  of	  chemokines	  
CCL11	  and	  CCL5	   in	  BAL	   (630,	  632).	  As	   such,	   that	  BALB/c	  mice	  are	   “Th2	  prone”	  does	  not	  
necessarily	  reflect	   the	  complete	  picture;	  rather,	   they	  may	  display	  a	  greater	  propensity	   for	  
the	   development	   of	   allergic	   disease	   that	   both	   BALB/c	   and	   C57BL/6	   mice	   do	   in	   fact	  
experience,	  with	  some	  variation	  in	  phenotype.	  	  
	  
Differences	   in	   the	  ability	   to	  generate	  Th2	   responses	  may	   stem	   from	  genetic	  variance	  and	  
the	   different	   pathways	   through	   which	   allergic	   responses	   are	   initiated,	   however	   little	  
information	  is	  available	  on	  what	  these	  specific	  factors	  are.	  It	  has	  been	  shown	  that	  CD4+	  T	  
cells	  derived	   from	  BALB/c	  mice	  show	  a	  bias	   towards	   IL-­‐4	  production	   in	   response	   to	  TCR	  
stimulation	   (633).	   Additionally,	   decreased	   IL-­‐12	   receptor	   expression	   may	   reduce	   the	  
promotion	  of	  Th1	  and	  suppression	  of	  Th2	  responses	  (634).	  The	  airway	  epithelium	  has	  been	  
found	  to	  respond	  to	  antigen	  challenge	  differently	   in	   the	   two	  strains,	  with	  resulting	  NF-­‐κB	  
activation	  being	  more	  prominent	  in	  BALB/c	  mice	  (635).	  C57BL/6	  mice,	  on	  the	  other	  hand,	  
have	   elevated	   production	   of	   innate	   immunosuppressive	   molecules	   such	   as	   surfactant	  
protein-­‐D,	  which	  may	  confer	  some	  resistance	  to	  the	  generation	  of	  AHR	  (629).	  	  
	  
As	   a	   result	   of	   these	   differences,	   studies	   attempting	   to	   understand	   the	   critical	   factors	  
involved	  in	  asthma	  pathogenesis	  have	  revealed	  contrasting	  results.	  Experiments	  conducted	  
on	  C57BL/6	  mice	  report	  a	  critical	  requirement	  for	  eosinophils	  in	  the	  generation	  of	  AHR	  and	  
goblet	   cell	   metaplasia	   (636,	   637),	   whereas	   the	   opposite	   conclusion	   was	   drawn	   from	  
experiments	   using	   BALB/c	   mice	   (492,	   500,	   638).	   Additionally,	   the	   activity	   of	   airway	  
epithelial	   cells	  was	   shown	   to	   be	   critical	   for	  OVA-­‐induced	   allergic	   airway	   inflammation	   in	  
BALB/c	  mice,	  but	  not	  in	  C57BL/6	  (635).	  As	  such,	  C57BL/6	  models	  often	  require	  increased	  
doses	  of	  allergen,	  or	  additional	  exposures,	  to	  mediate	  significant	  airway	  inflammation,	  due	  
to	  their	  apparent	  reduced	  susceptibility	  to	  develop	  allergic	  disease.	  These	  findings	  highlight	  
the	   significance	   of	   strain-­‐dependent	   differences	   in	   the	   characteristics	   of	   allergic	   disease,	  
and	  thus	  have	  implications	  for	  the	  deduction	  of	  conclusions	  from	  these	  models.	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1.4.4 Acute and chronic models of allergic airway inflammation 
A	  complete	  understanding	  of	  the	  pathogenesis	  of	  allergic	  asthma	  has	  not	  yet	  been	  grasped.	  
The	  initiation	  of	  allergy	  and	  the	  further	  development	  of	  chronicity	  involve	  distinct	  immune	  
pathology.	  As	  such,	  there	  is	  much	  that	  can	  be	  learned	  through	  the	  use	  of	  acute,	  short-­‐term	  
models	   of	   allergic	   airway	   inflammation	   as	   well	   as	   those	   that	   drive	   chronic,	   long	   lasting	  
disease.	  	  
	  
Many	   studies	   use	   experimental	   protocols	   involving	   the	   administration	   of	   a	   single	   airway	  
allergen	  challenge	   to	  sensitised	  mice,	  or	  multiple	  exposures	  over	  a	  short	  number	  of	  days.	  
Features	  of	  allergic	  inflammation	  are	  induced	  in	  the	  lung;	  BAL	  and	  lung	  eosinophilia,	  AHR,	  
and	   Th2	   cytokine	   production	   (639-­‐641).	   These	   models	   are	   particularly	   useful	   in	   the	  
examination	  of	  the	  early	  asthmatic	  response	  and	  late	  asthmatic	  response	  that	  occur	  during	  
the	   first	  8	  hours	  after	  allergen	  exposure	   (642,	  643).	  Early	   features	  of	  airway	  remodelling	  
may	  be	  evident	  even	  in	  the	  acute	  setting,	  however	  inflammation	  may	  resolve	  rapidly	  upon	  
discontinuation	   of	   allergen	   challenge,	   with	   limited	   residual	   disease	   (538,	   639-­‐641,	   644).	  
The	  value	  of	  these	  acute	  models	  is	  therefore	  applicable	  to	  the	  understanding	  of	  how	  allergic	  
disease	  is	  initiated,	  and	  the	  changes	  that	  occur	  during	  early	  pathogenesis	  that	  may	  facilitate	  
persistence	   of	   disease.	   Additionally,	   the	   preventative	   activity	   of	   novel	   vaccines	   may	   be	  
examined	  in	  this	  context.	  
	  
By	  definition,	  asthma	  is	  a	  chronic	  disease	  of	  the	  airways	  involving	  changes	  that	  persist	  even	  
in	  the	  absence	  of	  allergic	  stimuli.	  	  As	  such,	  modelling	  chronic	  asthmatic	  disease	  involves	  the	  
administration	  of	  multiple	  airway	  allergen	  challenges	  to	  sensitised	  mice,	  over	  a	  number	  of	  
weeks	  or	  months.	  These	  protocols	  can	  drive	  chronicity	  (618,	  632,	  645),	  or	  may	  in	  fact	  lead	  
to	  tolerance	  (646)	  depending	  on	  the	  co-­‐stimulatory	  factors	  present	  during	  airway	  allergen	  
challenge.	  Through	  the	  repeated	  stimulation	  of	  allergic	  inflammation	  and	  subsequent	  repair,	  
the	   characteristic	   features	   of	   asthma	  may	   be	   replicated	   by	   these	  models	   (618,	   647-­‐649).	  
Airway	   remodeling	   is	   evident	   through	   the	   presence	   of	  multiple	   contributing	   factors	   that	  
result	   in	  thickening	  of	  the	  airway	  wall	  (discussed	  in	  section	  1.2.2.3).	  As	  classic	  features	  of	  
established	  airway	   inflammation	  are	  generated,	   the	  effects	  of	   therapeutic	  vaccines	   for	   the	  
treatment	  of	  individuals	  who	  suffer	  from	  chronic	  asthma	  may	  be	  tested.	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These	  in	  vivo	  sensitisation	  models	  culminate	  in	  the	  development	  of	  an	  allergen-­‐specific	  Th2	  
response.	   	   It	   is	  difficult,	  however,	   to	  examine	   the	  activity	  of	   the	  critical	  CD4+	  Th2	  cells	   in	  
allergic	  airway	  disease,	  as	  limited	  techniques	  exist	  for	  the	  tracking	  of	  endogenous	  allergen-­‐
specific	   T	   cells.	   Some	   studies	   have	   shown	   that	   the	   direct	   adoptive	   transfer	   of	   in	   vitro-­‐
cultured,	   allergen-­‐specific	   Th2	   cells	   into	  mice	   can	   establish	   allergic	   airway	   inflammation	  
upon	   allergen	   exposure	   (650,	   651).	   While	   the	   focus	   of	   these	   studies	   was	   primarily	   to	  
investigate	   the	   capability	   of	   CD4+	   T	   cells	   to	   produce	   inflammation	   in	   naïve	   hosts,	   this	  
concept	  may	   be	   used	   to	   develop	   a	   standardised	  model	   of	   allergic	   airway	   disease	   within	  
which	   the	   activity	   and	  whereabouts	  of	  CD4+	  T	   cells	  may	  be	   studied.	  This	   could	   lead	   to	   a	  
better	  understanding	  of	  the	  role	  and	  intercellular	  interactions	  of	  the	  CD4+	  T	  cell	  that	  drive	  
allergic	  disease.	  	  
	  
	  
1.4.5.1 Visualising immune cells and the allergic response 
To	  develop	  an	  understanding	  of	  the	  involvement,	  localisation	  and	  intercellular	  interactions	  
of	   key	   immune	   cells	   in	   the	   allergic	   response,	   visual	   tools	   are	   invaluable.	   Numerous	  
transgenic	  mouse	  strains	  are	  now	  available	  where	  fluorescent	  reporter	  genes	  allow	  for	  the	  
identification	  of	  critical	  allergy-­‐driving	  cells	  such	  as	  DC	  and	  CD4+	  T	  cells.	  	  
	  
As	   important	   initiators	   of	   multiple	   immune	   responses,	   CD11ceYFP	   expressing	   mice	   were	  
developed	   to	   examine	   the	   roles	   and	   interactions	   of	   DCs	   (652).	   In	   tissue	   sections,	   these	  
fluorescent	   cells	  may	   be	   counterstained	   to	   reveal	  DC	   subpopulations;	   alternatively,	   some	  
specific	  DC	  subsets	  may	  be	  identified	  through	  the	  use	  of	  additional	  fluorescent	  mice.	  XCR1-­‐
venus	  mice,	  originally	  generated	  by	  Yamazaki	  and	  colleagues	  (653)	  display	  fluorescence	  in	  
the	   XCR1-­‐expressing	   CD103+	   lung	   DC	   population	   (654,	   655).	   Using	   the	   brighter	  
fluorophore,	   GFP,	   others	   subsequently	   generated	   XCR1GFP	   reporter	   mice	   (Generated	   by	  
Okada,	  Kaisho	  et	  al;	  Daniels,	  Muc	   Immunol,	  2015,	   In	  Press).	  Therefore,	   to	  differentiate	   the	  
main	   lung	   DC	   populations,	   the	   progeny	   of	   crossed	   CD11ceYFP	   and	   XCR1GFP	   mice	   reveal	  
CD11b+	  and	  CD103+	  DC	  subsets;	  CD11b+	  DC	  are	  solely	  YFP+	  whereas	  CD103+	  DC	  fluoresce	  
a	  combined	  signal	  of	  YFP+	  and	  GFP+.	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Many	   cell	   types	   from	   ubiquitously	   fluorescent	   mice	   may	   be	   isolated	   and	   adoptively	  
transferred	   into	   non-­‐fluorescent	   or	   differently	   fluorescent	   hosts	   to	   examine	   their	   fate.	  
Fluorophores	  such	  as	  yellow,	  green,	  red,	  or	  cyan	  fluorescent	  proteins,	  and	  their	  numerous	  
derivatives,	  have	  been	   integrated	   into	  cell	  nuclear	  genomic	  DNA	  by	  knock-­‐in,	  or	  bacterial	  
artificial	   chromosome	   (BAC)	   constructs	   that	   express	   fluorescence	   in	   the	   cell	   cytoplasm	  
(656-­‐659).	  These	  fluorophores	  are	  either	  constitutively	  expressed,	  or	  are	  under	  the	  control	  
of	   specific	   promoter	   genes	   responding	   to	   particular	   stimuli.	   	   Cells	   of	   interest,	   including	  
allergy-­‐driving	   CD4+	  T	   cells	   and	   allergy-­‐ameliorating	   CD8+	  T	   cells,	  may	   be	   sourced	   from	  
these	  mice	  to	  investigate	  their	  roles	  in	  allergic	  airway	  inflammation.	  Of	  particular	  relevance	  
to	   allergic	   disease,	   4C13R	   mice	   have	   been	   developed	   by	  William	   E	   Paul	   and	   colleagues,	  
within	   which	   AmCyan	   and	   dsRed	   report	   the	   production	   of	   IL-­‐4	   and	   IL-­‐13,	   respectively	  
(660).	   The	   production	   of	   one	   or	   both	   of	   these	   Th2	   cytokines	   has	   been	   demonstrated	   in	  
multiple	   cell	   types	   to	   varying	   degrees,	   evident	   by	   fluorescent	   reporting	   in	   T	   cells,	   ILC2,	  
nuocytes	  and	  innate	  helper	  cells,	  as	  well	  as	  eosinophils	  and	  basophils	  (147,	  332,	  660-­‐663).	  
This	  tool	  is	  invaluable	  to	  further	  our	  understanding	  of	  the	  distinct	  roles	  of	  these	  key	  Th2-­‐
polarising	  cytokines.	  	  
	  
1.4.5.2 Visualising lung inflammatory infiltrates  
A	  key	  measure	  of	  allergic	  airway	   inflammation	   is	   the	   infiltration	  of	   immune	  cells	   into	   the	  
lung	  and	  airway.	  A	  useful	   tool	   in	   the	  clinical	  setting,	  bronchoalveolar	   lavage	  (BAL)	  allows	  
for	   the	   diagnosis	   of	   multiple	   lung	   diseases	   (664,	   665).	   Similarly,	   experimental	   allergic	  
airway	   inflammation	   can	   be	   examined	   in	   this	   way,	   although	   mice	   are	   usually	   sacrificed	  
before	   the	   BAL	   procedure	   is	   carried	   out,	   and	   lungs	   are	   most	   often	   harvested	   for	   tissue	  
analysis.	   	   Single	   cell	   suspensions	   of	   processed	   lungs	   and	   BAL	   fluid	   were	   classically	  
examined	   by	   cytospin	   of	   a	   small	   sample	   onto	   a	   slide	   for	  microscopic	   analysis.	   A	  Wright-­‐
Giemsa	   or	   Haematoxylin	   and	   Eosin	   (H&E)	   stain	  was	   then	   used	   to	  manually	   differentiate	  
inflammatory	   cells.	  While	   this	  method	  was	   sufficient	   for	   the	   identification	   of	   eosinophils,	  
lymphocytes,	   monocytes,	   and	   neutrophils,	   some	   difficulty	   is	   experienced	   in	   the	  
differentiation	   of	   morphologically	   similar	   cells	   and	   there	   was	   no	   way	   to	   discriminate	  
specific	  sub-­‐populations	  of	  cells.	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Recently,	   an	   automated	  method	  was	   proposed	  whereby	   the	   cellularity	   of	   BAL	   samples	   is	  
analysed	  by	  flow	  cytometry	  (666).	  Using	  stains	  for	  CD11c,	  MHC-­‐II,	  B220,	  CCR3	  and	  CD3,	  the	  
authors	  were	  able	  to	  reliably	  identify	  (directly	  or	  by	  exclusion)	  DCs,	  alveolar	  macrophages,	  
eosinophils,	  neutrophils,	  T	  cells	  and	  B	  cells.	  This	  method	  has	  proven	  vastly	  superior	  to	  the	  
cytospin	  technique	  as	  cells	  may	  be	  identified	  more	  accurately,	  less	  user	  error	  is	  involved,	  a	  
larger	  volume	  of	  sample	  can	  be	  examined,	  and	  the	  analysis	  of	   individual	  samples	   is	  much	  
quicker.	  Adaptations	  to	  this	  BAL	  flow	  panel	  can	  be	  made	  to	  assess	  multiple	  additional	  cells	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1.5 Aims of this thesis  
	  
The	   pathogenesis	   of	   allergic	   asthma	   critically	   involves	   the	   activity	   of	   dendritic	   cells	   and	  
CD4+	  Th2	   cells.	   It	   has	   been	   shown	   that	   CTLs	   are	   capable	   of	   ameliorating	   allergic	   airway	  
inflammation	  in	  an	  acute	  model	  of	  disease,	  however	  it	  was	  not	  known	  whether	  CTLs	  may	  be	  
effective	   long-­‐term,	   or	   in	   the	   treatment	   of	   chronic	   disease	   such	   as	   that	   which	   presents	  
clinically.	  It	  was	  also	  reported	  that	  perforin	  is	  crucial	  to	  CTL-­‐mediated	  suppression	  of	  acute	  
disease,	   suggesting	   that	   target	   cell-­‐killing	   was	   an	   important	   mechanism	   through	   which	  
disease	   progression	   may	   be	   subverted.	   The	   critical	   targets	   of	   CTL-­‐mediated	   killing	  
remained	  to	  be	  elucidated.	  	  The	  hypothesis	  of	  this	  thesis	  was	  that	  CTLs	  may	  target	  allergy-­‐
driving	  cells	   such	  as	  DCs,	   subsequently	  reducing	   the	  pool	  of	  allergen-­‐presenting	  cells	  and	  
culminating	  in	  the	  abrogation	  of	  CD4+	  Th2	  cell-­‐mediated	  allergic	  disease.	  	  
	  
The	  specific	  aims	  of	  this	  thesis	  were:	  
• To	   determine	   the	   therapeutic	   potential	   for	   CTLs	   in	   established	   allergic	   airway	  
disease	  
• To	   investigate	   the	   effects	  of	  CTLs	  on	  disease-­‐mediating	  CD4+	  T	   cells	  during	   active	  
inflammation	  
• To	   elucidate	   the	   mechanism	   of	   CTL-­‐mediated	   suppression	   of	   allergic	   disease	   and	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Table	  2.1:	  Labware	  
Product	   Supplier	  
Optical	  adhesive	  covers	  for	  Real-­‐time	  
PCR	  
Applied	  Biosystems,	  Foster	  City,	  CA,	  
USA	  
Axygen	  sterile	  pipet	  tips	  10,	  200	  and	  
1000μL	  
Axygen	  Scientific	  Inc.,	  Union	  City,	  CA,	  
USA	  
Axygen	  Micro	  Tubes	  0.6	  and	  1.7mL	  
PCR	  thin	  wall	  tubes;	  8	  strips	  &	  Caps,	  
0.2mL	  
BD	  FalconTM	  polystyrene	  sterile	  conical	  
tubes:	  15mL	  and	  50mL	  
BD	  BioSciences,	  Bedford,	  MA,	  USA	  
BD	  FalconTM	  polystyrene	  sterile	  5mL	  
round	  bottom	  tubes	  
BD	  FalconTM	  polystyrene	  sterile	  
multiwall	  tissue	  culture	  plates:	  6	  well	  
and	  24	  well	  
BD	  FalconTM	  polystyrene	  sterile	  tissue	  
culture	  flasks:	  250	  mL	  and	  600	  mL	  
MicrotestTM	  U-­‐bottom	  96	  well	  plates
	   	  
BD	  FalconTM	  polystyrene	  sterile	  
serological	  pipettes:	  5,	  10	  and	  25	  mL	  
1	  mL	  tuberculin	  syringes	  and	  10mL	  
syringes	  
PrecisionGlideTM	  needles:	  18,	  20,	  25	  and	  
27.5	  gauge	  
BD	  FalconTM	  	  70μm	  nylon	  cell	  strainers	  
Ultra-­‐FineTM	  needle	  insulin	  syringes	  
(29G)	  0.5	  mL	   	  
BD	  Insyte	  TM18G	  intravascular	  catheters	  
Superfrost	  TM	  Plus	  microscope	  slides	   Biolab	  Ltd.,	  Auckland,	  NZ	  
Cover	  Slips	  22x22	  mm,	  No.	  1	  thickness	   Biolab	  Ltd.,	  Auckland,	  NZ	  
TitertubeTM	  Microtubes	  0.5mL	   Bio-­‐Rad	  Laboratories,	  Hercules,	  CA,	  
USA	  
CostarTM	  Stripette	  sterile	  serological	  
pipettes:	  5,	  10	  and	  25	  mL	  
Corning	  Incorporated,	  Pittston,	  PA,	  USA.	  	  
Cryo'sTM	  sterile	  cryotubes	  2mL	   Greiner	  Bio-­‐One,	  Frickenhausen,	  
Germany	  
Petri	  dishes	  90mm	   Labserv,	  Auckland,	  NZ	  
   
 
64 
Ultra	  Amp	  96-­‐well	  PCR	  plates	   SorensenTM	  Bioscience,	  Inc.,	  Salt	  Lake	  




2.1.2 Reagents and Buffers 
2-­‐Mercaptoethanol	  (2-­‐ME)	  
A	  55mM	  solution	  of	  2	  ME	  in	  PBS	  was	  purchased	  from	  Sigma	  (St.	  Louis,	  MO,	  USA),	  which	  was	  
stored	  at	  4°C.	  
	  
Agarose	  
Ultra-­‐PureTM	  agarose	  was	  purchased	  from	  Invitrogen	  (Auckland,	  NZ).	  
	  
Alsever's	  Solution	  
Dextrose	  (20.5mg/mL),	  NaCl	  (4.2mg/mL)	  and	  sodium	  citrate	  (8.0mg/mL)	  were	  purchased	  
from	  BDH	  Laboratory	  Supplies	  (Poole,	  England),	   from	  which	  a	  solution	  was	  generated	   in-­‐
house	  by	  dissolving	  the	  reagents	  to	  the	  concentrations	  indicated	  in	  distilled	  H2O.	  The	  pH	  of	  
the	  solution	  was	  adjusted	  to	  6.1	  using	  1M	  citric	  acid	  also	  purchased	  from	  BDH	  Laboratory	  
Supplies	  (Poole,	  England).	  The	  solution	  was	  stored	  at	  room	  temperature.	  	  
	  
Aluminium	  Hydroxide	  (Alum)	  
Alu-­‐Gel-­‐S	   alum	   (research	   grade)	   was	   purchased	   from	   SERVA	   Electrophoresis	   GmbH	  
(Heidelberg,	  Germany)	  and	  stored	  at	  room	  temperature.	  	  
	  
Ammonium	  Chloride	  Tris	  (ACT)	  Lysis	  Buffer	  
NH4Cl	  (0.16M)	  and	  Tris-­‐HCl	  (0.17M)	  were	  purchased	  from	  Sigma	  (St	  Louis,	  MO,	  USA)	  and	  
Merck	   (Darmstadt,	   Germany)	   respectively.	   Working	   buffer	   was	   prepared	   directly	   before	  
use	  by	  mixing	  9	  parts	  NH4Cl:	  1	  part	  Tris-­‐HCl	  to	  yield	  final	  concentrations	  of	  0.144M	  NH4Cl	  
and	  0.017M	  HCl,	  and	  stored	  at	  room	  temperature.	  	  
	  
BlueJuiceTM	  Loading	  Dye	  
BlueJuiceTM	  was	  purchased	  from	  Invitrogen	  (Auckland,	  NZ)	  and	  stored	  at	  4°C.	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Bovine	  Serum	  Albumin	  (BSA)	  
Low	  endotoxin	  BSA	  powder	  was	  purchased	  from	  ICPbio	  Ltd.	  (Auckland,	  NZ)	  and	  stored	  at	  
4°C.	  
	  
Diethylpyrocarbonate	  (DEPC)-­‐Treated	  Water	  
RNase-­‐free,	   DNase-­‐free,	   pyrogen-­‐free	   filtered	   DEPC	   treated	   water	   was	   purchased	   from	  
Ambion	  Inc.	  (Austin,	  TX,	  USA)	  and	  stored	  at	  room	  temperature.	  
	  
Dimethyl	  Sulfoxide	  (DMSO)	  
DMSO	  was	  purchased	  from	  Sigma	  (St	  Louis,	  MO,	  USA)	  and	  stored	  at	  room	  temperature.	  	  
	  
Discombe’s	  Solution	  	  
Discombe’s	  Solution	  was	  prepared	  by	  adding	  5	  volumes	  acetone	  to	  5	  volumes	  1%	  eosin	  Y	  
(both	  purchased	  from	  Sigma,	  St.	  Louis,	  MO,	  USA),	  and	  made	  up	  to	  100	  volumes	  in	  dH2O,	  as	  




DNase	  I	   lyophilised	  powder	  was	  purchased	  from	  Roche	  (Mannheim,	  Germany).	  A	  working	  
solution	  of	  10mg/mL	  was	  prepared	  by	  dissolving	  the	  powder	  in	  IMDM	  and	  then	  stored	  at	  -­‐
20°C.	  	  
	  
Dynabeads®	  Mouse	  T-­‐Activator	  CD3/CD28	  	  
Dynabeads®	  were	  purchased	  from	  GIBCO,	  Life	  technologies	  (Japan).	  	  	  
	  
Ethanol	  
100%	   ethanol	   (molecular	   grade)	  was	   purchased	   from	   Carlo	   Erba	   Reagents	   (Milan,	   Italy)	  
and	  stored	  at	  room	  temperature.	  	  
	  
Ethylendiaminetetraacetic	  Acid	  (EDTA)	  
EDTA	  powder	  was	  purchased	   from	  Sigma	   (St.	   Louis,	  MO,	  USA).	  Working	   solution	  of	  0.5M	  
were	  generated	  by	  dissolving	  in	  dH2O	  and	  then	  stored	  at	  room	  temperature.	  	  




Fluorescence-­‐activated	  cell	  sorting	  (FACS)	  Buffer	  
EDTA,	  NaN3	  (both	  from	  Sigma,	  St.	  Louis,	  MO,	  USA)	  and	  FBS	  (GIBCO,	  Invitrogen,	  
Auckland,	  NZ)	  were	  mixed	  with	  PBS	  to	  generate	  a	  working	  buffer	  containing	  10mM	  EDTA,	  
0.01%	  NaN3	  and	  2%	  FBS	  and	  stored	  at	  4°C.	  
	  
Foetal	  Bovine	  Serum	  (FBS)	  
FBS	  (27EU/mL)	  was	  purchased	  from	  GIBCO	  (Invitrogen,	  Auckland,	  NZ)	  and	  stored	  in	  25mL	  
aliquots	  at	  -­‐20°C.	  In-­‐use	  aliquots	  were	  thawed	  and	  stored	  at	  4°C	  for	  a	  maximum	  of	  3	  weeks.	  	  
	  
Formalin	  Solution	  
10%	  neutral	  buffered	  formalin	  was	  purchased	  from	  Sigma-­‐Aldrich	  (St.	  Louis,	  MO,	  USA).	  The	  
solution	  comprises	  4%	  formaldehyde	  w/v,	  and	  was	  stored	  at	  room	  temperature.	  	  
	  
Granulocyte-­‐Macrophage	  Colony	  Stimulating	  Factor	  (GM-­‐CSF)	  
Recombinant	  GM-­‐CSF	  (murine)	  was	  generated	  in	  house	  by	  culture	  of	  the	  modified	  murine	  
X63	   cell	   line	   in	   cIMDM.	   Culture	   supernatant	   was	   collected,	   filtered	   and	   titrated	   in	   bone	  
marrow	   DC	   cultures	   to	   determine	   the	   amount	   required	   for	   optimal	   cell	   yield.	   This	   was	  
stored	  at	  -­‐80°C	  until	  used,	  and	  then	  stored	  at	  4°C.	  	  
	  
House	  Dust	  Mite	  (HDM)	  
Dermatophagoides	  pteronyssinus	  (HDM,	  crushed	  whole	  mite	  preparation)	  was	  purchased	  
from	  Greer	  Laboratories	  (Lenoir,	  NC,	  USA)	  and	  stored	  at	  -­‐80°C	  until	  used.	  	  
	  
Interleukin	  2	  (IL-­‐2)	  
Recombinant	  IL-­‐2	  (human)	  was	  generated	  in	  house	  by	  culture	  of	  the	  IL2L6	  cell	  line.	  Culture	  
supernatant	  was	  collected,	   filtered	  and	  titrated	   in	  bone	  marrow	  DC	  cultures	  to	  determine	  
the	  amount	  required	  for	  optimal	  cell	  yield.	  Supernatant	  was	  stored	  at	  -­‐80°C	  until	  used,	  then	  
stored	  at	  4°C.	  
	  
Interleukin	  4	  (IL-­‐4)	  
Recombinant	  IL-­‐4	  (murine)	  was	  produced	  by	  culture	  of	  a	  modified	  Chinese	  Hamster	  Ovary	  
   
 
67 
cell	   line.	   Culture	   supernatant	   was	   collected,	   filtered	   and	   titrated	   in	   bone	   marrow	   DC	  
cultures	  to	  determine	  the	  amount	  required	  for	  optimal	  cell	  yield.	  Supernatant	  was	  stored	  at	  
-­‐80°C	  until	  used,	  then	  stored	  at	  4°C.	  
	  
Iscove's	  Modified	  Dulbecco's	  Medium	  (IMDM)	  
IMDM	  supplemented	  with	  GlutaMAX,	  25mM	  HEPES	  buffer	  and	  3.024	  mg/L	  NaHCO3	  
was	  purchased	  from	  GIBCO	  (Invitrogen,	  Auckland,	  NZ)	  and	  stored	  at	  4°C.	  	  	  
	  
Iscove's	  Modified	  Dulbecco's	  Medium,	  Complete	  (cIMDM)	  
1%	   Penicillin-­‐Streptomycin	   (GIBCO,	   Invitrogen,	   Auckland,	   NZ),	   55μM	   2-­‐ME	   and	   5%	   FBS	  
were	  added	  to	  IMDM	  to	  generate	  cIMDM,	  and	  stored	  at	  4°C	  for	  a	  maximum	  of	  3	  weeks.	  	  
	  
Isopropanol	  
Isopropanol	  (analytical	  grade)	  was	  purchased	  from	  Scharlau	  Chemie	  (Barcelona,	  Spain)	  and	  
stored	  at	  room	  temperature.	  	  
	  
Liberase	  TL	  
Liberase	   TL	   lyophilised	   powder	   was	   purchased	   from	   Roche	   (Mannheim,	   Germany).	   A	  
working	  solution	  of	  1mg/mL	  was	  prepared	  by	  dissolving	  in	  IMDM,	  and	  1mL	  aliquots	  were	  
stored	  at	  -­‐20°C.	  	  
	  
Lipopolysaccharide	  (LPS)	  
LPS	   lyophilised	   powder	   from	   Escherichia	   coli,	   serotype	   0111:B4,	   was	   purchased	   from	  
Sigma	  (St.	  Louis,	  MO,	  USA).	  A	  working	  solution	  of	  1mg/mL	  was	  prepared	  by	  dissolving	   in	  
IMDM	  and	  stored	  at	  4°C.	  
	  
Neomycin	  trisulfate	  salt	  hydrate	  	  
Neomycin	  powder	  was	  purchased	   from	  Sigma	   (St.	  Louis,	  MO,	  USA).	  Before	  use,	  neomycin	  
solution	  was	  generated	  by	  adding	  2mg/mL	  to	  autoclaved	  distilled	  H2O,	  and	  then	  stored	  at	  
room	  temperature.	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Ovalbumin	  protein	  (OVA)	  
Grade	  V	  OVA	  protein	  lyophilised	  powder	  was	  purchased	  from	  Sigma-­‐Aldrich	  (St.	  Louis,	  MO,	  
USA).	  Powder	  was	  reconstituted	  in	  PBS	  to	  1mg/mL	  aliquots,	  and	  stored	  at	  -­‐20°C.	  	  
	  
OVA	  protein,	  low	  endotoxin	  (EndoGrade	  OVA)	  
EndoGrade	  OVA	   (endotoxin	   levels	  <	  0.1	  EU/mg)	   lyophilised	  powder	  was	  purchased	   from	  
Hyglos	   GmbH	   (Bernried,	   Germany).	   Powder	   was	   reconstituted	   in	   PBS	   to	   1mg/mL	   and	  
10mg/mL	  aliquots,	  and	  stored	  at	  -­‐20°C.	  
	  
OVA257–264	  (SIINFEKL)	  
OVA257–264	  peptide	  lyophilised	  powder	  was	  purchased	  from	  Mimotopes	  (Victoria,	  Australia).	  
The	  powder	  was	  reconstituted	  in	  PBS	  to	  1mM,	  and	  stored	  at	  -­‐20°C.	  
	  
OVA323-­‐339	  (ISQAVHAAHAEINEAGR)	  	  
OVA323-­‐339	  peptide	  lyophilised	  powder	  was	  purchased	  from	  Mimotopes	  (Victoria,	  Australia).	  
The	  powder	  was	  reconstituted	  in	  PBS	  to	  1mM,	  and	  stored	  at	  -­‐20°C.	  
	  
Polymerase	  Chain	  Reaction	  (PCR)	  reagents	  	  
TaqMan®	   expression	   master	   mix	   and	   TaqMan®	   primers	   were	   purchased	   from	   Applied	  
Biosystems	   (Foster	   City,	   CA,	   USA).	   The	  master	  mix	  was	   stored	   at	   4°C	   and	   primers	  were	  
stored	  at	  -­‐20°C.	  	  
	  
Penicillin-­‐Streptomycin	  
Penicillin-­‐Streptomycin	   (liquid	   state,	   10	  000	  U/mL	   and	  10	  000	  μg/mL,	   respectively)	  was	  
purchased	  from	  GIBCO	  (Invitrogen,	  Auckland,	  NZ)	  and	  stored	  at	  -­‐20°C.	  	  
	  
Phosphate	  Buffered	  Saline	  (PBS)	  
PBS	   (CaCl2	   and	   MgCl2	   free)	   was	   purchased	   from	   GIBCO	   (Invitrogen,	   Auckland,	   NZ)	   and	  
stored	  at	  room	  temperature	  until	  opened,	  then	  stored	  at	  4°C.	  
	  
RNAlater®	  solution	  for	  RNA	  stabilisation	  and	  storage	  
RNAlater®	  was	  purchased	  from	  Ambion	  (Auckland,	  NZ)	  and	  stored	  at	  room	  temperature.	  	  




RPMI	  Medium	  1640	  (RPMI)	  
RPMI	   supplemented	   with	   4.5	   g/L	   D-­‐glucose,	   1.5	   g/L	   Sodium	   Bicarbonate,	   1mM	   Sodium	  
Pyruvate,	  10mM	  HEPES	  and	  300	  mg/L	  L-­‐Glutamine	  was	  purchased	  from	  GIBCO	  (Invitrogen,	  
Auckland,	  NZ)	  and	  stored	  at	  4°C.	  
	  
Sodium	  Chloride	  (NaCl)	  
NaCl	  powder	  was	  purchased	  from	  Sigma	  (St.	  Louis,	  MO,	  USA).	  A	  working	  solution	  of	  1.8%	  
NaCl	  was	  prepared	  by	  dissolving	  powder	  in	  dH2O	  and	  stored	  at	  room	  temperature.	  	  
	  
SYBRTM	  Safe	  DNA	  Gel	  Stain	  
SYBRTM	  Safe	  DNA	  Gel	  Stain	  was	  purchased	  from	  Invitrogen	  (Auckland,	  NZ).	  The	  stain	  was	  
added	  to	  agarose	  solution	  during	  gel	  preparation.	  In-­‐use	  stain	  solution	  was	  stored	  at	  4°C.	  
	  
Tris-­‐acetate-­‐EDTA	  (TAE)	  buffer	  
TAE	   buffer	   containing	   2M	   Tris	   acetate	   and	   50	   mM	   EDTA	   was	   purchased	   from	   GIBCO	  
(Invitrogen,	  Auckland,	  NZ).	  A	  working	  buffer	  was	  prepared	  by	  diluting	  50x	  with	  dH2O	  and	  
stored	  at	  room	  temperature.	  	  
	  
Trypan	  Blue	  Live/Dead	  exclusion	  stain	  





2.1.3 Commercial kits 
	  
Ambion®	  DNA-­‐free	  kit	  
For	   the	   removal	   of	  DNA	   contamination	   in	  RNA	   samples,	   the	  DNA-­‐free	   kit	  was	   purchased	  
from	  Invitrogen	  (Auckland,	  NZ).	  The	  kit	  was	  stored	  at	  4°C.	  
	  
Bio-­‐Plex	  ProTM	  Mouse	  Cytokine	  Group	  I,	  7-­‐plex	  Assay	  
For	  the	  detection	  of	  cytokines	  in	  BAL	  (IL-­‐3,	  IL-­‐4,	  IL-­‐5,	  IL-­‐10,	  IL-­‐13,	  TNF-­‐α	  and	  IFN-­‐γ),	  these	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cytokines	  were	  selected	  from	  the	  Bio-­‐Rad	  mouse	  cytokine	  assay	  options,	  and	  put	  together	  
in	  a	  Bio-­‐Plex	  kit,	  purchased	  from	  Bio-­‐Rad	  (Auckland,	  NZ).	  The	  kit	  was	  stored	  at	  4°C.	  
	  
CellTraceTM	  Violet	  (CTV)	  Cell	  Proliferation	  Kit	  
To	   investigation	   the	   proliferation	   of	   adoptively	   transferred	   T	   cells,	   a	   CTV	   stain	   was	  
employed.	  The	  kit	  was	  purchased	  from	  Molecular	  Probes,	  Life	  Technologies	  (Auckland,	  NZ)	  
and	  stored	  at	  -­‐20°C,	  protected	  from	  light.	  
	  
CCL11/Eotaxin	  Quantikine	  Kit	  	  
The	  Eotaxin	  ELISA	  kit	  was	  purchased	  from	  R&D	  (Minneapolis,	  MN,	  USA)	  for	  the	  detection	  of	  
eotaxin	  in	  lung	  and	  serum	  samples.	  The	  kit	  was	  stored	  at	  4°C.	  
	  
Granzyme	  B	  ELISA	  
For	   the	  detection	  of	   granzyme	  B	   in	   cell	   culture	   supernantants,	   the	   granzyme	  B	  ELISA	  kit	  
was	   purchased	   from	   Huntingtree	   Bioscience	   Supplies	   (Auckland,	   NZ),	   manufactured	   by	  
eBioscience.	  The	  kit	  was	  stored	  at	  4°C.	  
	  
MCPT-­‐1	  (mMCP-­‐1)	  ELISA	  
For	   the	  detection	  of	  mMCP-­‐1	   in	  serum	  samples,	   the	  mMCP-­‐1	  ELISA	  kit	  was	  used.	  This	  kit	  
was	   manufactured	   by	   eBioscience	   and	   purchased	   from	   Huntingtree	   Bioscience	   Supplies	  
(Auckland,	  NZ),	  and	  stored	  at	  4°C.	  
	  
Red	  SR	  FLIVOTM	  in	  vivo	  Apoptosis	  Kit	  
For	  the	  visualisation	  of	  pre-­‐apoptotic	  cells	  in	  ex	  vivo	  lung	  and	  MLN	  samples,	  FLIVOTM	  was	  
purchased	   from	   ImmunoChemistry	   Technologies	   (Bloomington,	   MN,	   USA).	   This	   kit	   was	  
stored	  at	  4°C.	  
	  
Reverse	  Transcription	  Kit	  
SuperScript	  ViloTM	  reverse	  transcription	  kit	  was	  purchased	  from	  Invitrogen	  (Auckland,	  NZ)	  
for	  the	  reverse	  transcription	  of	  RNA	  samples	  extracted	  from	  lung	  tissue,	   for	  PCR	  analysis.	  
The	  kit	  was	  stored	  at	  -­‐20°C.	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RNA	  Extraction	  Kit	  
NucleoSpinTM	  RNA	  L	  kit	  was	  purchased	  from	  Macherey-­‐Nagel	  GmbH	  (Düren,	  Germany)	  for	  
the	  extraction	  of	  RNA	  from	  lung	  tissue,	  for	  PCR	  analysis.	  The	  DNase	  powder	  was	  stored	  at	  






2.1.4 Antibodies and Fluorophores 
	  
	  
Table	  2.2:	  Antibodies	  and	  fluorophores	  
Specificity	   	   Clone	   Label	   Source	  
B220	   6B2	   PE-­‐Cy7	   eBioscience	  
CD3e	   17A2	   PE-­‐Cy7	   BioLegend	  
















Alexa	  Fluor	  647	  













CD11c	   HL3	   PE-­‐Cy7	   BD	  






CD19	   1D3	   APC-­‐H7	   BD	  
CD44	   IM7	  
IM7	  
IM7	  
Alexa	  Fluor	  700	  





CD45	   HI30	   Pacific	  Blue	   Invitrogen	  



























CD69	   H1.2F3	   Alexa	  Fluor	  488	   BioLegend	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H1.2F3	   PerCP	  Cy5.5	   BioLegend	  
CD86	   GL1	   Pacific	  Blue	   BD	  






CCR3	   83103	   Alexa	  Fluor	  647	   BD	  
FcγRII/III	  
(CD32/CD16)	  
2.4G2	   None	   Purified	  in-­‐house	  
Gr-­‐1	   RB6-­‐8C5	   Pacific	  Orange	   Invitrogen	  
ICOS-­‐L	   7E.17G9	   PE	   BioLegend	  
Ly6C	   HK1.4	   PE-­‐Cy7	   BioLegend	  





Alexa	  Fluor	  488	  









NK1.1	   PK136	   None	   Purified	  in-­‐house	  
PD-­‐1	  	   RMP1-­‐30	   PE-­‐Cy	  7	   BioLegend	  
Rabbit	  anti-­‐GFP	   MBL	   Alexa	  Fluor	  488	  (goat	  anti-­‐
rabbit	  IgG)	  
Life	  Technologies	  
Siglec	  F	   E50-­‐2440	   PE	   BD	  
Streptavidin	   Streptavidin	   PE	  Texas	  Red	   BD	  






Vβ5.1,5.2	   MR9-­‐4	   PE	   BD	  
	  
	  
4,6-­‐Diamidino-­‐2-­‐Phenylindole	  Dihydrochloride	  (DAPI)	  cell	  viability	  dye	  
For	   the	  exclusion	  of	  dead	  cells	  by	   flow	  cytometric	  analysis,	  DAPI	   lyophilised	  powder	  was	  
purchased	  from	  Invitrogen	  (Auckland,	  NZ)	  and	  diluted	   in	  dH2O	  to	  a	   final	  concentration	  of	  





2.1.5.1 Maintenance and ethical approval 
Mice	  were	  bred	  and	  maintained	  in	  the	  Biomedical	  Research	  Unit	  (BRU)	  at	  the	  Malaghan	  
Institute	  of	  Medical	  Research	  or	  RIKEN	  Center	  for	  Integrative	  Medical	  Sciences.	  Sterile	  
laboratory	  food	  and	  water	  were	  freely	  available	  to	  mice.	  Ethics	  approval	  was	  obtained	  for	  
all	  experimental	  protocols	  from	  the	  Victoria	  University	  Animal	  Ethics	  Committee	  or	  RIKEN	  
Animal	  Research	  Committee.	  Experimental	  procedures	  were	  carried	  out	  according	  to	  
institutional	  guidelines.	  	  	  




2.1.5.2 Mouse Strains 
Mouse	   strains	  were	  maintained	  by	   sibling	  breeding	  pairs.	   For	   all	   experiments	  mice	  were	  
sex	  matched	  and	  6-­‐8	  weeks	  old	  at	  the	  beginning	  of	  the	  experiments,	  with	  the	  exception	  of	  
chimeric	  mice	  that	  were	  12	  weeks	  old	  upon	  chimera	  generation	  and	  used	  for	  experiments	  8	  
weeks	   after	   that,	   to	   allow	   for	   regeneration	   of	   immune	   cells.	   	   All	   mice	   were	   housed	   in	  
conventional	   caging,	   except	   chimeric	  mice,	   which	  were	   housed	   in	   individually	   ventilated	  
cages	  to	  reduce	  the	  risk	  of	  infection.	  
	  
C57BL/6	  mice	  breeding	  pairs	  were	  obtained	  from	  the	  Jackson	  Laboratories	  (Bar	  Harbour,	  
ME,	  USA).	  Cells	  from	  these	  mice	  express	  CD45.2	  only.	  
	  
CD45 congenic B6.SJL-Ptprca Pepcb/BoyJ (B6-SJ) mice were originally from the Jackson 
Laboratory (Bar Harbor, ME, USA). Cells	  from	  these	  congenic	  mice	  express	  CD45.1.	  
	  
OT-­‐I	  and	  OT-­‐II	  mice	  were	  obtained	  from	  Dr	  Sarah	  Hook,	  School	  of	  Pharmacy,	  Dunedin,	  NZ	  
with	   the	   permission	   of	   Prof	   Frank	   Carbone,	  Melbourne	   University,	   Australia.	   These	  mice	  
have	  T	  cells	  that	  express	  Vα2+Vβ5.1/5.2+	  TCRs	  that	  are	  specific	  for	  OVA257-­‐264	  presented	  on	  
H2Kb	   (OT-­‐I)	   and	   OVA323-­‐339	   presented	   on	   I-­‐Ab	  (OT-­‐II).	   These	  mice	   were	   crossed	   with	   B6	  
mice	   at	   the	   Malaghan	   Institute	   of	   Medical	   Research	   to	   produce	   congenic	   OT-­‐I	   x	   B6.SJL-­‐
Ptprca	  and	  OT-­‐II	  x	  B6.SJL-­‐Ptprca	  mice.	  	  
	  
4C13R	  mice	  were	   generously	   gifted	  by	  Dr	  William	  Paul,	   Laboratory	   of	   Immunology,	  NIH,	  
USA.	   These	   mice	   were	   generated	   by	   use	   of	   a	   bacterial	   artificial	   chromosome	   (BAC)	  
construct	   that	   expresses	   AmCyan	   during	   IL-­‐4	   production	   and	   dsRed	   when	   IL-­‐13	   is	  
produced,	  as	  described	  by	  Roediger	  et	  al	  (Roediger	  et	  al,	  2013).	  These	  mice	  are	  IL-­‐4	  and	  IL-­‐
13	   sufficient.	   4C13R	  mice	   were	   crossed	   with	   OT-­‐II	   at	   the	   Malaghan	   Institute	   of	   Medical	  
Research	   to	  generate	  mice	  with	  OVA323-­‐339	  specific	  CD4+	  T	  cells	   that	  report	  production	  of	  
IL-­‐4	  and	  IL-­‐13.	  
	  
OT-­‐I	  mice	  were	  crossed	  to	  C57BL/6-­‐Prf1tm1Sdz/J	  mice	  to	  generate	  PKO	  OTI,	  or	  to	  B6;129S6-­‐
Gt(ROSA)26Sor	  tm14(CAG-­‐tdTomato)Hze/J,	  and	  CAG-­‐Cre	  mice	  to	  generate	  tdTomato+	  OT-­‐I.	  	  




XCR1GFP	   mice	   were	   generated	   by	   Dr	   Takaharu	   Okada	   and	   Dr	   Tsuneyasu	   Kaisho	   and	  
colleagues,	  at	  the	  RIKEN	  Center	  for	  Integrative	  Medical	  Sciences,	  Japan.	  For	  the	  generation	  
of	   XCR1GFP	   mice:	   A	   targeting	   vector	   was	   designed	   to	   replace	   the	   mouse	   Xcr1	   coding	  
sequences	  with	   a	   gene	   encoding	   GFP	   followed	   by	   a	   polyadenylation	   signal	   derived	   from	  
bGHpA.	  A	  neomycin	  resistance	  gene	  (neo)	  driven	  by	  the	  MC1	  promoter	  and	  flanked	  by	  the	  
yeast	  FRT	  sequences	  was	  used	  as	  a	  selection	  marker.	  An	  HSV	  thymidine	  kinase	  gene	  (HSV-­‐
TK)	   was	   inserted	   for	   negative	   selection.	   C57BL/6J	   ES	   cells	   were	   transfected	   with	   the	  
linearized	   targeting	   vector	   by	   electroporation	   and	   selected	   with	   G418.	   Then,	   correctly	  
targeted	   clones	   were	   aggregated	   with	   BALB/c	   morulas.	   Chimeric	   male	   offspring	   were	  
mated	  with	  C57BL/6J	   female	  mice.	  XCR1GFPCD11cYFP	  double	  positive	  mice	  were	  generated	  
by	  crossing	  XCR1GFP	  mice	  with	  established	  CD11cYFP	  mice.	  
	  
Foxp3GFP	   breeding	   pairs	   were	   obtained	   from	   Prof.	   Alexander	   Y	   Rudensky,	   University	   of	  
Washington,	  USA.	  Mice	  express	  enhanced	  green	  fluorescent	  protein	  fused	  to	  fully	  functional	  
Foxp3	   proteins	   upon	   translation	   of	   the	   Foxp3	   gene.	   These	  mice	  were	   crossed	  with	  OT-­‐II	  
mice	   at	   the	   Malaghan	   Institute	   of	   Medical	   Research	   to	   yield	   mice	   that	   reported	   Foxp3	  
expression	  in	  OVA323-­‐339	  specific	  CD4+	  T	  cells.	  	  
	  
Bone	   marrow	   from	   C57BL/6.H2Kbm-­‐1	   (bm-­‐1)	   mice	   was	   kindly	   provided	   by	   A.	   Prof.	  
Alexander	  McLellan	  at	  the	  University	  of	  Otago,	  Dunedin,	  NZ.	  	  bm-­‐1	  mice	  have	  a	  mutation	  in	  
the	  H-­‐2K	  molecule	  rendering	  their	  cells	  unable	  to	  present	  OVA257-­‐264.	  They	  are	  consequently	  
unable	  to	  interact	  with	  OT-­‐I	  cells,	  however	  they	  express	  wild	  type	  MHCII,	  thus	  retaining	  the	  
ability	   to	   present	   OVA323-­‐339	   to	   OT-­‐II	   cells.	   Bone	   marrow	   was	   extracted	   from	   mice	   and	  
frozen	   on	   site,	   then	   transported	   to	   the	   Malaghan	   Institute	   of	   Medical	   Research	   for	   the	  











2.2.1 In vitro methods 
	  
Cell culture 
All	  cultures	  were	  carried	  out	  at	  37°C	  with	  5%	  CO2	  and	  95%	  humidity.	  
	  
2.2.1.1 Bone marrow dendritic cell (BMDC) culture  
The	   femurs	   and	   tibias	   of	   euthanised	   C57BL/6	   mice	   were	   removed,	   separated	   from	  
surrounding	  tissue	  and	  briefly	  immersed	  in	  ethanol	  to	  sterilise.	  The	  ends	  of	  the	  bones	  were	  
cut	  and	  bone	  marrow	  flushed	  out	  with	   IMDM	  using	  a	  25	  gauge	  needle	  and	  10mL	  syringe.	  
Bone	  marrow	  was	  collected	  in	  a	  50mL	  tube,	  vortexed	  to	  disrupt	  clumps,	  and	  then	  filtered	  
through	  a	  70μm	  cell	  strainer.	  The	  solution	  was	  centrifuged	  at	  250	  g	  for	  10	  minutes	  to	  pellet	  
the	  BM	  cells.	  The	  supernatant	  was	  removed	  and	  cells	  resuspended	  in	  10mL	  IMDM;	  10μL	  of	  
this	   suspension	   was	   added	   to	   90μL	   trypan	   blue	   and	   a	   sample	   loaded	   onto	   a	  
haemocytometer	  to	  manually	  count	  live	  cells.	  Cells	  were	  again	  pelleted	  and	  resuspended	  in	  
cIMDM,	  then	  plated	  at	  0.4	  x	  106	  cells/mL	  in	  6-­‐well	  plates.	  GM-­‐CSF	  and	  IL-­‐4	  were	  added	  to	  
the	   culture	   to	   final	   concentrations	   of	   10ng/mL	   and	   20ng/mL	   respectively.	   Cells	   were	  
cultured	  at	  37°C	  for	  7	  days.	  Nutrients	  were	  replenished	  on	  day	  3	  and	  5	  by	  replacing	  2mL	  of	  
culture	   supernatant	   with	   fresh	   cIMDM	   supplemented	   with	   GM-­‐CSF	   and	   IL-­‐4	   to	   final	  
concentrations	  of	  10ng/mL	  and	  20ng/mL	  respectively.	  During	  the	  last	  24	  hours	  of	  culture,	  
100ng/mL	  LPS	  was	  added	  to	  activate	  BMDC.	  For	  co-­‐culture	  with	  OT-­‐I	  or	  OT-­‐II	  cells,	  BMDC	  
were	  harvested	   from	  culture	  plates	  by	   lightly	   flushing	   the	  well	   contents	  using	   IMDM	   in	  a	  
10mL	  pipette.	  The	  cells	  were	  pelleted	  and	  resuspended	  at	  1	  x	  106/mL	  and	  incubated	  with	  
0.1µM	  OVA257–264	  or	  0.01µM	  OVA323-­‐339	  peptide	  (for	  OT-­‐I	  or	  OT-­‐II	  respectively)	  for	  4	  hours	  
at	  37°C.	  
	  
2.2.1.2 OT-I culture, BMDC stimulated 
To	  generate	  OT-­‐I	  CTLs,	  lymph	  nodes	  (axial,	  brachial,	  inguinal,	  cervical)	  were	  removed	  from	  
OT-­‐I.B6	  or	  PKO	  OT-­‐I	  mice.	  LNs	  were	  mashed	  with	  a	  syringe	  plunger	  and	  flushed	  with	  IMDM	  
through	  a	  70μm	  cell	  strainer	  into	  a	  50mL	  tube.	  Cells	  were	  washed	  by	  centrifugation	  at	  250g	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for	   10	  minutes	   and	   resuspension	   of	   pelleted	   cells	   in	   fresh	   IMDM.	   A	   10μL	   sample	   of	   this	  
suspension	  was	  added	  to	  90μL	  trypan	  blue	  and	  a	  sample	  loaded	  onto	  a	  haemocytometer	  to	  
manually	  count	  live	  cells.	  Cells	  were	  again	  pelleted,	  and	  resuspended	  in	  cIMDM.	  Cells	  were	  
co-­‐cultured	   at	   0.5	   x	   106/mL	   with	   0.0625	   x	   106/mL	   OVA257–264–loaded	   BMDCs	   in	   6-­‐well	  
plates,	  incubated	  at	  37°C	  for	  4	  days.	  On	  day	  5,	  cells	  were	  harvested	  from	  culture	  plates	  by	  
lightly	  flushing	  the	  well	  contents	  using	  IMDM	  and	  a	  10mL	  pipette.	  Cells	  were	  centrifuged	  at	  
250	  g	  for	  10	  minutes	  and	  resuspended	  in	  fresh	  cIMDM,	  counted	  on	  a	  haemocytometer,	  and	  
adjusted	  to	  a	  concentration	  of	  0.25	  x	  106	  cells/mL.	  Cells	  were	  then	  cultured	  in	  sterile	  tissue	  
culture	  flasks	  (250mL	  or	  600mL)	  for	  2	  further	  days,	  with	  100U/mL	  IL-­‐2	  were	  added	  to	  the	  
culture	  each	  day.	  	  
	  
2.2.1.3 OT-II culture, BMDC stimulated 
To	   generate	   OT-­‐II	   CD4+	   Th2	   cells,	   lymph	   nodes	   (axial,	   brachial,	   inguinal,	   cervical)	   were	  
removed	  from	  OTII.B6	  or	  4C13R.OT-­‐II	  mice.	  LNs	  were	  mashed	  with	  a	  syringe	  plunger	  and	  
flushed	  with	   IMDM	  through	  a	  70μm	  cell	  strainer	   into	  a	  50mL	  tube.	  Cells	  were	  washed	  by	  
centrifugation	  at	  250	  g	  for	  10	  minutes	  and	  resuspension	  of	  pelleted	  cells	  in	  fresh	  IMDM.	  A	  
10μL	  sample	  of	  this	  suspension	  was	  added	  to	  90μL	  trypan	  blue	  and	  a	  sample	  loaded	  onto	  a	  
haemocytometer	  to	  manually	  count	  live	  cells.	  Cells	  were	  again	  pelleted,	  and	  resuspended	  in	  
cIMDM.	   Cells	   were	   co-­‐cultured	   at	   0.8	   x	   106/mL	   with	   0.2	   x	   106/mL	   OVA323-­‐339	   –loaded	  
BMDCs	  in	  6-­‐well	  plates.	   IL-­‐2	  and	  IL-­‐4	  were	  added	  to	  the	  culture	  at	  final	  concentrations	  of	  
20ng/mL	  and	  62ng/mL	  respectively,	  and	  then	  incubated	  at	  37°C	  for	  5	  days.	  Nutrients	  were	  
replenished	   on	   day	   2	   and	   4	   by	   replacing	   2mL	   of	   culture	   supernatant	   with	   fresh	   cIMDM	  
supplemented	   with	   IL-­‐2	   and	   IL-­‐4	   (final	   concentrations	   of	   20ng/mL	   and	   62ng/mL	  
respectively).	  	  
	  
For	   experiments	   where	   the	   proliferation	   of	   CD4+	   T	   cells	   in	   vivo	   was	   examined,	   5-­‐day	  
cultured	  cells	  were	  stained	  with	  CellTraceTM	  Violet	  as	  per	  the	  manufacturer’s	   instructions.	  
Briefly,	  cells	  were	  incubated	  in	  a	  10μM	  solution	  of	  CellTraceTM	  Violet	  for	  20	  minutes	  at	  37°C	  
and	  then	  washed	  in	  cold	  PBS	  with	  10%	  FCS.	  Cells	  were	  then	  manually	  counted	  for	  viability	  
using	  a	  haemocytometer.	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2.2.1.4 OT-I and OT-II culture, bead stimulated 
Cell	  suspensions	  were	  obtained	  from	  LNs	  as	  previously	  described.	  OT-­‐I	  or	  OT-­‐II	  cells	  were	  
resuspended	   at	   5	   x	   106	   cells/mL	   in	   RPMI	   media,	   with	   anti-­‐CD3/CD28	   T	   cell	   activating	  
Dynabeads	  at	  a	  concentration	  of	  0.2	  x	  106	  beads/mL.	  Cells	  and	  beads	  were	  co-­‐cultured	   in	  
90mm	   petri	   dishes	   (10mL	   per	   dish)	   for	   5	   days.	   Both	   cultures	   were	   supplemented	   with	  
20ng/ml	  IL-­‐2,	  OT-­‐II	  culture	  was	  also	  supplemented	  with	  62ng/ml	  IL-­‐4.	  On	  day	  3,	  cultures	  
were	  split	  by	  harvesting	  the	  10mL	  of	  cells	  from	  each	  petri	  dish	  and	  resuspending	  them	  in	  




2.2.2 In vivo methods 
 
	  
2.2.2.1 In vivo sensitisation model of airway inflammation  
C57BL/6	  mice	  were	   sensitised	   by	   intraperitoneal	   injection	   of	   2µg	   OVA	   (Grade	   V,	   Sigma-­‐
Aldrich)	  in	  200µl	  (1.36mg)	  alum	  adjuvant	  on	  days	  0	  and	  14.	  Some	  groups	  of	  mice	  received	  5	  
x	  106	  OT-­‐I	  CTLs	  (cultured	  as	  described	  in	  2.2.1.2),	  injected	  into	  the	  lateral	  tail	  vein,	  on	  either	  
day	  23,	  30,	  37	  or	  44.	  In	  some	  experiments,	  mice	  were	  treated	  with	  αGalCer	  drug	  conjugates	  
in	  the	  place	  of	  CTLs.	  On	  days	  24,	  31,	  38,	  and	  in	  some	  experiments,	  days	  45	  and	  52,	  100µg	  
low	   endotoxin	   OVA	   in	   50µl	   PBS	   was	   administered	   intranasally	   to	   systemically	  
anaesthetised	  mice.	  The	  solution	  was	  given	  drop-­‐wise	  to	  a	  single	  nostril	   through	  a	  200µL	  
pipette	   tip.	   Control	   mice	   received	   50µL	   PBS	   only.	   Mice	   were	   sacrificed	   by	   anaesthetic	  
overdose	  1	  and	  3	  days	  after	   the	   final	   intranasal	   challenge	  and	   tissues	  were	  harvested	   for	  
analysis.	  For	  time-­‐course	  experiments,	  mice	  were	  sacrificed	  1,	  2,	  3,	  6	  and	  9	  days	  after	  the	  
final	   intranasal	  challenge.	  For	  experiments	  where	  apoptotic	  cells	  were	  identified,	  100µl	  of	  
FLIVOTM,	  reconstituted	  as	  per	  kit	  instructions,	  was	  injected	  into	  the	  tail	  vein	  of	  each	  mouse	  
60	  minutes	  before	  mice	  were	  sacrificed.	  	  
	  
2.2.2.2 Adoptive transfer model of airway inflammation 
OT-­‐I	   CTLs	   and	   OT-­‐II	   CD4+	   T	   cells	   were	   cultured	   as	   described	   (see	   2.2.1.2	   and	   2.2.1.3).	  
Cultured	  cells	  were	  harvested	  and	  washed	  thrice	  by	  centrifugation	  of	  cells	  at	  250g,	  followed	  
by	   removal	   of	   supernatant	   and	   resuspension	   in	   sterile	  PBS.	   5	   x	   106	  CD4+	  T	   cells	  with	  or	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without	  5	  x	  106	  CTLs	  in	  a	  final	  volume	  of	  200µL	  PBS	  were	  injected	  into	  the	  lateral	  tail	  vein	  
of	  C57BL/6	  mice	  on	  day	  -­‐1.	  On	  day	  0,	  a	  single	  challenge	  of	  100µg	  low	  endotoxin	  OVA	  in	  50µl	  
PBS	  was	   administered	   intranasally,	   as	   previously	  described.	   	   Control	  mice	   received	  50µL	  
PBS	  only.	  On	  days	  1	  and	  3,	  mice	  were	  sacrificed	  by	  anaesthetic	  overdose	  and	  tissues	  were	  
harvested	  for	  analysis.	  
	  
	  
2.2.2.3 House Dust Mite model of airway inflammation 
C57BL/6	  mice	  were	  sensitised	  by	  intranasal	  instillation	  of	  100µg	  HDM	  in	  50µL	  PBS	  on	  day	  
0.	  Challenges	  were	  carried	  out	  on	  days	  14,	  15	  and	  16	  by	  intranasal	  administration	  of	  25µg	  
HDM	  in	  50µL	  PBS.	  Control	  mice	  received	  50µL	  PBS	  only.	  On	  day	  17,	  mice	  were	  sacrificed	  by	  
anaesthetic	  overdose	  and	  tissues	  were	  harvested	  for	  analysis.	  
	  
 
2.2.2.4 Generation of mixed bone marrow chimeras  
Bone	   marrow	   was	   obtained	   as	   previously	   described	   (see	   2.2.1.1)	   from	   naïve	   bm-­‐1	   and	  
naïve	  wt	  B6	  donor	  mice.	   	  Naïve	  recipient	  B6	  mice	   (12	  weeks	  old)	  were	  depleted	  of	  CD4+	  
and	  CD8+	  T	  cells	  as	  well	  as	  NK	  cells	  by	  intraperitoneal	  injection	  of	  anti-­‐CD4	  (clone	  GK1.5),	  
anti-­‐CD8	  (clone	  2.43)	  and	  anti-­‐NK1.1	  (clone	  PK136)	  (all	  generated	  in-­‐house),	  200µg	  of	  each	  
in	  a	  total	  volume	  of	  200µl	  PBS,	  on	  day-­‐1	  and	  fasted	  overnight.	  On	  day	  0,	  recipient	  mice	  were	  
irradiated	  with	  two	  rounds	  of	  550	  Rads,	  3	  hours	  apart.	  Immediately	  after	  the	  second	  round	  
of	  irradiation,	  a	  mixture	  of	  6	  x	  106	  bm-­‐1	  and	  4	  x	  106	  B6	  bone	  marrow	  cells	  in	  200µL	  IMDM	  
were	  injected	  into	  the	  lateral	  tail	  vein	  of	  recipient	  mice.	  A	  further	  CD4+,	  CD8+	  T	  cell	  and	  NK	  
cell	   depletion	   was	   carried	   out	   on	   day	   1.	   Mice	   were	   maintained	   on	   2mg/mL	   neomycin	  
supplemented	  autoclaved	  distilled	  water	  and	  housed	  in	  sterile	  Individual	  Ventilated	  Cages.	  
Eight	  weeks	  was	   allowed	   for	   regeneration	   of	   immune	   cell	   populations	   in	   recipient	  mice,	  
during	  which	   time	  mice	  were	  closely	  monitored	   for	  signs	  of	  bone	  marrow	  rejection.	  Mice	  
were	  then	  tested	  for	  success	  of	  bone	  marrow	  chimerism	  by	  taking	  peripheral	  blood	  samples	  
from	  the	  tail	  vein	  and	  analysing	  the	  %bm-­‐1	  (CD45.2+)	  and	  %wt	  B6	  (CD45.1+)	  of	  the	  white	  
blood	  cells	  by	  flow	  cytometry.	  Mice	  were	  excluded	  from	  experiments	  if	  chimerism	  was	  not	  
achieved	  –	  defined	  as	  more	   than	  60%	  of	   cells	  originating	   from	  one	  bone	  marrow	  source.	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The	  adoptive	  transfer	  model	  of	  airway	  inflammation	  was	  then	  tested	  in	  chimeric	  mice	  (as	  
described	  in	  2.2.2.2).	  	  	  
	  
2.2.2.5 Testing of αGalCer Drug Conjugates in airway inflammation models 
Drug	  conjugates	  were	  developed	  through	  collaboration	  by	  Dr	  Ian	  Hermans	  at	  the	  Malaghan	  
Institute	   of	   Medical	   Research,	   Wellington,	   NZ,	   with	   Dr	   Regan	   Anderson	   and	   Dr	   Gavin	  
Painter	  at	  the	  Ferrier	  Research	  Institute,	  Victoria	  University	  of	  Wellington,	  NZ,	  as	  described	  
(668).	   Briefly,	   CN152	   consisted	   of	   αGalCer	   conjugated	   to	   SIINFEKL	   peptide	   and	   CN178	  
consisted	   of	   αGalCer	   conjugated	   to	   gp33.	   An	   unconjugated	  mix	   of	   αGalCer	   and	   SIINFEKL	  
peptide	   was	   used	   as	   a	   control.	   For	   experiments,	   the	   molecular	   equivalent	   of	   500ng	  
SIINFEKL	  peptide	  was	   administered	   for	   each	  drug	   conjugate;	   1360ng	   for	   CN152,	   1400ng	  
for	  CN178	  and	  445ng	  αGalCer	  +	  500ng	  SIINFEKL	  (unconjugated).	  The	  respective	  amounts	  
of	  each	  compound	  were	  diluted	  in	  200μL	  PBS	  and	  injected	  into	  the	  lateral	  tail	  vein	  of	  mice.	  
Drug	  conjugates	  were	  tested	  in	  place	  of	  CTLs	  in	  the	  in	  vivo	  sensitisation	  model	  as	  well	  as	  the	  





2.2.3 Ex vivo methods 
 
2.2.3.1 Processing of tissues 
 
2.2.3.1.1 Bronchoalveolar Lavage 
To	  perform	  BAL,	  mice	  were	  administered	  a	  lethal	  overdose	  of	  anaesthetic,	  and	  an	  incision	  
was	  made	  into	  the	  skin	  covering	  the	  lungs,	  cutting	  upwards	  towards	  the	  head.	  The	  skin	  was	  
pulled	  back	  and	  tissue	  covering	  the	  trachea	  removed.	  A	  small	  hole	  was	  cut	  into	  the	  trachea	  
and	  an	  18G	  catheter	  tube	  (needle	  removed)	  attached	  to	  a	  1mL	  syringe	  of	  PBS	  was	  inserted	  
into	   the	  hole	   towards	   the	   lungs.	  BAL	  was	  performed	  by	   flushing	  PBS	   into,	  and	  out	  of,	   the	  
lungs	  three	  times.	  BAL	  fluid	  was	  then	  collected	  in	  a	  15mL	  tube,	  recovery	  volume	  recorded,	  
and	  kept	  on	  ice.	  Tubes	  were	  centrifuged	  at	  250	  g	  for	  5	  minutes	  to	  pellet	  cells.	  Supernatant	  
was	  collected	  in	  2mL	  cryotubes	  and	  stored	  at	  -­‐20°C	  for	   later	  cytokine	  analysis.	  Cells	  were	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resuspended	  in	  FACS	  buffer,	  manually	  counted	  on	  a	  haemocytometer	  and	  then	  stained	  for	  




Preparation of single cell suspensions 
After	  BAL,	  lungs	  were	  removed	  from	  mice	  and	  placed	  in	  individual	  wells	  of	  a	  24-­‐well	  plate,	  
each	  well	   containing	   1mL	   IMDM	  with	   0.5mg	  Liberase	  TL	   and	  0.5mg	  DNase	   I.	   Tissue	  was	  
finely	  diced	  with	  scissors	  and	   then	   incubated	   for	  45	  min	  at	  37°C.	   In	   the	   last	  5	  minutes	  of	  
incubation,	   20μL	   of	   0.5M	  EDTA	  was	   added	   to	   halt	   digestion.	   The	   suspension	  was	   passed	  
through	   an	   18G	   needle	   (attached	   to	   5mL	   syringe)	   to	   break	   down	   remaining	   tissue	  
fragments	  and	  filtered	  through	  a	  70μm	  cell	  strainer	  into	  50mL	  tubes.	  Cells	  were	  pelleted	  by	  
centrifugation	   at	   250	   g	   for	   5	  minutes,	   and	   resuspended	   in	   3mL	   ACT	   buffer.	   Tubes	  were	  
incubated	  for	  4	  minutes	  at	  37°C	  to	  lyse	  red	  blood	  cells,	  then	  neutralised	  by	  adding	  7mL	  PBS.	  
Cells	   were	   pelleted	   again	   and	   resuspended	   in	   FACS	   buffer.	   Total	   cells	   were	   counted	  
manually	  on	  a	  haemocytometer,	  and	  samples	  were	   then	  kept	  on	   ice	  and	  stained	   for	  FACS	  
analysis.	  	  
	  
Preparation of sections for histological analysis 
After	  BAL	  was	  performed,	   lungs	  were	   removed	  and	   fixed	  by	   immersion	   in	  10%	   formalin.	  	  
Both	  lobes	  of	  the	  lung	  were	  then	  embedded	  in	  paraffin	  wax.	  Airway	  histology	  was	  examined	  
by	  staining	  of	  4µm	  thick	  sections	  on	  microscope	  slides	  with	  Haemotoxylin	  and	  Eosin	  (H	  &	  
E),	  mucus-­‐producing	  goblet	  cells	  were	  detected	  by	  Alcian	  Blue	  and	  Periodic	  Acid-­‐Schiff	  (AB-­‐
PAS)	  stain,	  mast	  cells	  were	  visualized	  with	  Chloracetate	  Esterase	  (CAE)	  stain	  and	  collagen	  
deposition	   was	   identified	   using	   a	   Masson’s	   Trichrome	   stain.	   Slides	   were	   examined	   and	  
photographed	  using	  the	  Olympus	  BX51	  compound	  microscope.	  	  
	  
Preparation of sections for fluorescent and confocal microscopy 
Unstained	  fresh	  tissue	  sections	  (from	  inherently	  fluorescent	  XCR1GFP	  mice)	  were	  prepared	  
by	  manually	  cutting	  thin	  sections	  of	  lungs	  using	  a	  sterile	  scalpel	  blade.	  Sections	  were	  then	  
placed	   in	   a	   petri	   dish	   and	   immersed	   in	  PBS,	   then	  directly	   examined	  using	   a	   the	  BZ-­‐9000	  
(Keyence)	  fluorescent	  microscope.	  




Fluorescently	  labelled	  sections	  were	  prepared	  by	  fixing	  lungs	  in	  4%	  paraformaldehyde	  for	  
2	   h.	   Fixed	   tissues	   were	   washed	   with	   PBS	   for	   3	   h,	   placed	   in	   Tissue-­‐Tek	   OCT	   compound	  
(Sakura),	   and	   snap-­‐frozen	   in	   dry	   ice	   and	   ethanol.	   Cryosections	   12µm	   in	   thickness	   were	  
affixed	  to	  MAS-­‐GP–coated	  slides	  (Matsunami	  Glass)	  and	  stained	  at	  room	  temperature	  for	  2	  
h	  with	  APC-­‐conjugated	   anti-­‐CD11c	   (clone	  N418,	   eBioscience)	   and	   rabbit	   anti-­‐GFP	   (MBL),	  
which	  was	  detected	  by	  Alexa	  Fluor	  488-­‐conjugated	  goat	  anti–rabbit	  IgG	  (Life	  Technologies).	  
Nuclei	   were	   stained	   with	   3µM	   DAPI	   (Sigma-­‐Aldrich).	   Images	   were	   acquired	   on	   BZ-­‐9000	  
(Keyence,	  Osaka,	  Japan),	  and	  processed	  with	  Pixelmator	  (2.1.2,	  Pixelmator	  Team	  Ltd).	  
	  
Confocal	  microscopy	  was	  carried	  out	  on	  fresh	  tissue	  sections	  prepared	  as	  described.	  Whole	  
sections	   were	   stained	   with	   Cy5-­‐conjugated	   anti-­‐CD45.1	   (clone	   A20,	   eBioscience),	   and	  
imaged	   with	   the	   TCS	   SP5	   confocal	   laser	   microscope	   (Leica	   Microsystems)	   by	   collecting	  
emission	  signals	  of	  499-­‐514	  nm	  (488	  nm	  excitation),	  519-­‐540	  nm	  (488	  nm	  excitation),	  574-­‐
622	  nm	  (568	  nm	  excitation),	  and	  639-­‐680	  nm	  (647	  nm	  excitation).	  
	  
2.2.3.1.3 Lymph nodes 
Lung-­‐draining	  mediastinal	   lymph	  nodes	  were	  removed	  from	  sacrificed	  mice	  and	  collected	  
in	  24-­‐well	  plates	   containing	  1mL	   IMDM,	  0.1mg	  Liberase	  TL	  and	  100μg	  DNase.	  To	  extract	  
DCs,	  LNs	  were	  disrupted	  by	  teasing	  apart	  with	  18G	  needles,	  and	  digestion	  was	  carried	  out	  
for	  25	  minutes	  at	  37°C.	  Digestion	  was	  stopped	  by	  adding	  20μL	  of	  0.5M	  EDTA	  to	  each	  well.	  
LNs	  were	  then	  mashed	  through	  70μm	  cell	  strainers	  using	  a	  syringe	  plunger,	  and	  collected	  in	  
50mL	  tubes.	  Cells	  were	  washed	  by	  centrifugation	  at	  250	  g	  and	  resuspension	  in	  FACS	  buffer.	  
Cells	  were	  then	  manually	  counted	  using	  a	  haemocytometer,	  kept	  on	  ice	  and	  stained	  for	  flow	  
cytometry	  analysis.	  	  
	  
2.2.3.1.4 Spleen 
Spleens	  were	  removed	  from	  sacrificed	  mice	  and	  collected	  in	  24-­‐well	  plates	  containing	  1mL	  
IMDM,	   0.1mg	   Liberase	   TL	   and	   100μg	  DNase	   in	   each	  well.	   The	   solution	  was	   injected	   into	  
spleens	   to	   aid	   the	   release	   of	  DCs	   from	   the	   parenchyma,	   and	   digestion	   carried	   out	   for	   25	  
minutes	  at	  37°C.	  Digestion	  was	  stopped	  by	  adding	  20μL	  of	  0.5M	  EDTA	  to	  each	  well.	  Spleens	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were	   then	  mashed	   through	   70μm	   cell	   strainers	   using	   a	   syringe	   plunger,	   and	   collected	   in	  
50mL	  tubes.	  Cells	  were	  centrifuged	  at	  250	  g	  and	  resuspended	  in	  3mL	  ACT	  buffer	  to	  lyse	  red	  
blood	  cells.	  Tubes	  were	   incubated	   for	  4	  minutes	  at	  37°C,	   then	  neutralised	  by	  adding	  7mL	  
PBS.	   Cells	  were	  pelleted	   again	   and	   resuspended	   in	   FACS	  buffer.	   Total	   cells	  were	   counted	  




Blood	  was	  obtained	  from	  the	  lateral	  tail	  vein	  of	  live,	  restrained	  mice,	  by	  nicking	  the	  tail	  vein	  
with	   a	   sterile	   scalpel	   blade	   and	   collecting	   drops	   of	   blood.	   Alternatively,	   submandibular	  
bleeding	   was	   carried	   out	   by	   piercing	   the	   facial	   vein	   with	   a	   sterile	   scalpel	   blade	   and	  
collection	  of	  drops	  of	  blood.	  From	  sacrificed	  mice,	  the	  descending	  aorta	  was	  punctured	  by	  a	  
27G	  needle	  and	  blood	  was	  drawn	  into	  a	  1mL	  syringe.	  	  
	  
Whole blood 
Blood	   was	   immediately	   added	   to	   500μL	   Alsever’s	   Solution	   in	   1.7mL	   tubes,	   to	   prevent	  
clotting.	   Samples	   were	   centrifuged	   at	   420	   g	   for	   2	   minutes,	   supernatant	   removed,	   and	  
resuspended	  in	  1mL	  ACT	  buffer	  to	  lyse	  red	  blood	  cells.	  Tubes	  were	  incubated	  at	  37°C	  for	  4	  
minutes	   then	   again	   pelleted.	   Lysis	   was	   repeated	   if	   many	   red	   blood	   cells	   remained.	   Cells	  
were	  then	  resuspended	  in	  FACS	  buffer,	  stored	  on	  ice,	  and	  stained	  for	  FACS	  analysis.	  	  
	  
Serum  
Blood	   was	   collected	   directly	   into	   empty	   1.7mL	   tubes,	   left	   overnight	   at	   4°C	   to	   clot,	   and	  
centrifuged	  the	  next	  morning	  at	  420	  g	  for	  2	  minutes.	  Serum	  was	  removed	  by	  pipetting	  and	  
transferred	  into	  a	  fresh	  1.7mL	  tube,	  stored	  at	  -­‐20°C	  until	  analysed.	  	  
	  
	  
2.2.3.2 Flow Cytometry 
 
2.2.3.2.1 Staining of cells 
Single	  cell	  suspensions	  were	  obtained	  from	  tissues	  as	  described	  (see	  2.2.3.1)	  and	  0.5	  –	  2	  x	  
106	   cells	   were	   transferred	   into	   a	   96-­‐well	   plate.	   Plates	   were	   centrifuged	   at	   320	   g	   for	   2	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minutes	  and	  then	  flicked	  to	  remove	  supernatant.	  Cells	  were	  resuspended	  by	  light	  vortexing	  
of	   plates,	   and	   then	   incubated	   with	   2.4G2	   antibody	   for	   10	   minutes	   on	   ice	   to	   block	   non-­‐
specific	   binding.	   Fluorescent	   antibody	   mixes	   were	   added	   (at	   dilutions	   determined	   by	  
titration)	  to	  the	  wells,	  and	  plates	  incubated	  for	  an	  additional	  10	  minutes	  on	  ice,	  protected	  
from	  light.	  Cells	  were	  then	  washed,	  by	  pelleting	  and	  resuspension	  in	  FACS	  buffer,	  to	  remove	  
unbound	   antibodies.	  Where	   secondary	   fluorescent	   antibodies	   were	   required,	   these	   were	  
then	  added	  and	  plates	  incubated	  for	  a	  further	  10	  minutes	  on	  ice,	  protected	  from	  light.	  Cells	  
were	   then	  washed	   twice	   and	   individual	   samples	   resuspended	   in	  200μL	  FACS	  buffer	  with	  
0.008μg/mL	  of	  the	  cell	  viability	  dye	  DAPI.	  	  	  
	  
2.2.3.2.2 Staining of controls 
Single	  stain	  compensation	  controls	  were	  generated	  using	  OneComp	  eBeads	  (eBiosciences,	  
Huntingtree	   Bioscience	   Supplies,	   Auckland,	   NZ).	   Separate	   tubes	   of	   eBeads	   were	   stained	  
with	   a	   single	   fluorescent	   antibody	   (according	   to	   experiment)	   in	   FACS	  buffer,	   at	   a	   10-­‐fold	  
dilution	   to	   that	   used	   to	   stain	   cells.	   Tubes	   were	   incubated	   for	   10	   minutes	   at	   room	  
temperature,	  protected	  from	  light.	  Cells	  were	  then	  pelleted	  and	  resuspended	  in	  300μL	  FACS	  
buffer.	  	  
	  
Fluorescence	  minus	  one	  (FMO)	  controls	  were	  prepared	  by	  excluding	  one	  of	  the	  antibodies	  
from	  the	  complete	  antibody	  panel,	  and	  staining	  a	  sample	  of	  the	  cells	  of	  interest.	  Cells	  were	  
stained	  as	  described	  in	  2.2.3.2.1.	  	  	  
	  
2.2.3.2.3 Acquisition and analysis  
Acquisition	   of	   data	   was	   carried	   out	   using	   a	   LSRII	   SORP	   or	   LSR	   Fortessa	   flow	   cytometer	  
(Beckton-­‐Dickinson,	  San	  Jose,	  CA,	  USA)	  and	  analysis	  was	  performed	  using	  FlowJo	  software	  
(version	  9.6.1,	  Treestar	  Inc.,	  CA,	  USA).	  Unstained	  cells	  were	  used	  to	  set	  channel	  voltages	  and	  
single	   stained	   controls	   were	   used	   to	   compensate	   for	   any	   spectral	   overlap	   occurring	  
between	   fluorophores.	   FMO	  controls	  were	  used	   to	   identify	  positively	   stained	  populations	  
where	   this	   population	   was	   not	   easily	   defined	   (due	   to	   weakly	   positive	   cells,	   or	   a	   rise	   in	  
background	   fluorescence).	   Doublets	   were	   excluded	   by	   gating	   out	   aberrant	   cells	   on	   a	  
forward	  scatter	  (FSC)	  area	  versus	  height	  plot	  and	  subsequently	  on	  a	  side	  scatter	  (SSC)	  area	  
versus	  height	  plot.	  Dead	  cells	  were	  excluded	  by	  their	  uptake	  of	  DAPI	  viability	  dye,	  revealing	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live	  cells	  that	  were	  used	  for	  all	  further	  population	  discriminations.	  	  
	  
	  
2.2.3.3 Real-time PCR for analysis of gene expression 
	  
2.2.3.3.1 Extraction of RNA 
RNA	  was	  extracted	  using	  the	  NucleoSpinTM	  RNA	  L	  kit	  (Macherey-­‐Nagel	  GmbH),	  according	  to	  
the	  manufacturers	  instructions.	  In	  brief,	  tissue	  was	  disrupted	  by	  use	  of	  a	  homogeniser	  and	  
cells	  lysed	  by	  incubation	  in	  a	  chaotropic	  ion	  lysis	  buffer,	  which	  also	  inactivates	  RNases.	  The	  
cell	  solution	   is	   then	  centrifuged	  through	  a	   filter	   tube,	  where	  RNA	  remains	  attached	  to	  the	  
filter	  membrane.	  An	  rDNase	  solution	  is	  applied	  to	  the	  membrane	  to	  remove	  contaminating	  
DNA	   and	   two	   additional	   buffers	   are	   used	   to	   remove	   salts,	  metabolites	   and	   large	   cellular	  
components.	  RNase-­‐free	  water	  is	  finally	  added	  to	  elute	  RNA	  through	  the	  membrane.	  	  
	  
The	   concentration	   and	   quality	   of	   RNA	   samples	   were	   then	   measured	   on	   a	   ND-­‐100	  
spectrophotometer	  by	  absorption	  at	  230,	  260,	  280	  and	  340nm.	  The	  260:280	  and	  260:230	  
ratios	  were	   analysed,	   with	   a	   ratio	   greater	   than	   2	   revealing	   contamination	   of	   the	   sample	  
from	  DNA	  or	  protein,	  respectively,	  while	  absorption	  at	  340nm	  should	  be	  zero.	  	  
	  
Purity	  was	  also	  determined	  by	  running	  RNA	  on	  a	  2%	  agarose	  gel.	  Agarose	  was	  mixed	  with	  
TAE	  buffer	  and	  microwaved	  until	  dissolved.	  SYBRTM	  Safe	  DNA	  Gel	  Stain	  was	  then	  added	  and	  
gel	  left	  to	  solidify	  with	  a	  comb	  inserted	  to	  produce	  microwell	  chambers	  for	  sample	  loading.	  
A	   1kbp	   DNA	   size	   ladder	   (Invitrogen,	   Auckland,	   NZ),	   and	   RNA	   samples	   (2μg)	  mixed	  with	  
BlueJuiceTM	   loading	  dye	  were	  pipetted	   into	  microwells	   in	   the	  gel.	  Gel	  electrophoresis	  was	  
then	   carried	   out	   at	   100V	   for	   45	   minutes.	   The	   gel	   was	   then	   place	   in	   a	   Bio-­‐Rad	   Gel	   Doc	  
imaging	  system	  to	  visualise	  RNA.	  Samples	  showed	  clear	  bands	  on	  the	  gel	   for	  18S	  and	  28S	  
ribosomal	  RNA;	  DNA	  contamination	  was	  visible	  by	  the	  appearance	  of	  additional	  bands,	  or	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2.2.3.3.2 DNase digestion  
Additional	  DNase	  treatment	  was	  carried	  out	  on	  contaminated	  samples	  (260:280	  ratio	  <	  2,	  
additional	   bands	   on	   agarose	   gel)	   using	   the	   Ambion®	   DNA-­‐free	   kit.	   In	   brief,	   DNase	   was	  
added	  to	  RNA	  and	  incubated	  at	  37°C	  for	  30	  minutes	  to	  digest	  DNA.	  The	  reaction	  was	  then	  
stopped	   and	   samples	  were	   centrifuged.	   Supernatant	  was	   collected	   (containing	   RNA)	   and	  
transferred	   to	   fresh	   tubes,	   and	   re-­‐analysed	   for	   concentration	   and	   purity	   using	   the	  
spectrophotometer	  and	  agarose	  gel.	  	  
	  
2.2.3.3.3 Reverse transcription 
RNA	   samples	  were	   then	   reverse	   transcribed	   into	   cDNA	   by	   use	   of	   the	   SuperScript	   ViloTM	  
reverse	   transcription	   kit,	   according	   to	   the	  manufacturer’s	   instructions.	  Briefly,	   10μg	  RNA	  
samples	  were	  added	  to	  the	  kit’s	  reaction	  mix,	  enzyme	  mix,	  and	  made	  up	  to	  20μL	  with	  DEPC-­‐
treated	  H2O.	  Samples	  were	  added	  to	  PCR	  8-­‐strips	  and	  reverse	  transcription	  carried	  out	  for	  
60	  minutes	  at	  42°C,	  and	  then	  a	  5	  minute	  enzyme	  inactivation	  step	  at	  85°C.	  cDNA	  samples	  
were	  then	  stored	  at	  -­‐80°C	  until	  RT-­‐PCR	  was	  performed.	  	  
	  
2.2.3.3.4 Real-time PCR 
All	   RT-­‐PCR	   was	   carried	   out	   using	   Taqman	   expression	   master	   mix	   and	   Taqman	   primers	  
(Applied	  Biosystems,	  Foster	  City,	  CA,	  USA),	  and	  run	  on	   the	  Applied	  Biosystems	  7500	  Fast	  
Real-­‐Time	  PCR	  System.	  Primers	  and	  probes	  (lyophilised)	  were	  reconstituted	  and	  combined	  
with	  the	  master	  mix	   in	  96-­‐well	  PCR	  plates.	  RNA	  samples	  (20	  –	  100ng)	  were	  added	  to	  the	  
wells	   and	  DEPC-­‐treated	  water	  was	  used	   to	  make	  up	   a	   final	   volume	  of	  25μL.	  RT-­‐PCR	  was	  
then	  carried	  out	  by	  incubation	  at	  50°C	  for	  2	  minutes	  and	  95°C	  for	  15	  minutes,	  followed	  by	  
40	  cycles	  of	  95°C	  for	  15	  seconds	  and	  60°C	  for	  1	  minute.	  The	  cycle	  threshold	  (CT)	  value	  for	  
each	   primer	   was	   determined	   by	   the	   system	   software,	   from	   which	   ΔCT	   values	   were	  
manually	   calculated	   by	   normalising	   samples	   to	   the	   18S	   control	   and	   comparing	   with	   the	  
PBS-­‐treated	  controls.	  	  
	  
	  
2.2.3.3.5 Primers for Real-time PCR 
All	  primers	  and	  probes	  were	  TaqMan®	  Gene	  Expression	  Assays,	  purchased	   from	  Applied	  
Biosystems	  (Foster	  City,	  CA,	  USA).	  	  




Table	  2.3:	  RT-­‐PCR	  Primers	  
Target	   Assay	  
18S	  ribosomal	  RNA	   Mm03928990_g1	  
Matrix	  metalloproteinase	  9	  (Mmp-­‐9)	   Mm00442991_m1	  
Tenascin-­‐c	  (Tnc)	   Mm00495662_m1	  
Acidic	  mammalian	  chitinase	  (AMcase)	   Mm00458221_m1	  
Mucin	  5,	  subtypes	  A	  and	  C	  (Muc5ac)	   Mm01276718_m1	  
	  
	  
2.2.3.4 ELISA assays 
ELISA	  kits	  were	  used	  to	  measure	  serum	  IgE	  (generated	  in-­‐house	  by coating 96-microwell 
plates with 0.5µg/well anti-IgE (clone 6HD5) capture antibody),	   mMCP-­‐1	   (Huntingtree	  
Bioscience	  Supplies,	  Auckland,	  NZ),	  and	  eotaxin	  (R&D,	  Minneapolis,	  MN,	  USA),	  according	  to	  
the	  manufacturer’s	  instructions.	  Briefly,	  96-­‐microwell	  plates	  coated	  with	  capture	  antibodies	  
for	  the	  analyte	  of	  interest	  were	  blocked	  with	  10%	  FBS/PBS	  for	  2	  hours.	  Serum	  was	  diluted	  
1:2	  and	  1:10	  and	  added	  to	  the	  plates	  to	  incubate	  overnight	  at	  4°C.	  Detection	  antibody	  was	  
incubated	  in	  wells	  for	  2	  hours,	  then	  streptavidin	  HRP	  was	  then	  added	  for	  1	  hour	  and	  colour	  
developed	   by	   addition	   of	   substrate	   reagent,	   with	   reaction	   stopped	   by	   0.25M	   H2SO4.	  	  
Absorbance	  was	  measured	  at	  450nm	  on	  the	  Infinite	  M1000	  Pro	  plate	  reader	  (Tecan).	  	  
	  
2.2.3.5 Cytokine analysis assays 
Cytokines	   in	  BAL	  were	  measured	   using	   a	  Bio-­‐Plex	   ProTM	  Mouse	   Cytokine	  Group	   I,	   7-­‐plex	  
Assay	   (Bio-­‐Rad,	   Auckland,	   NZ),	   according	   to	   the	  manufacturer’s	   instructions.	   Briefly,	   96-­‐
microwell	   filter	   plates	  were	   pre-­‐wet	  with	   assay	   buffer,	   and	   samples	   and	   standards	  were	  
then	  added	  to	  the	  plate.	  Cytokine	  detection	  beads	  were	  added	  to	  each	  well	  and	  incubated	  on	  
a	  plate	  shaker,	  protected	  from	  light.	  Plates	  were	  then	  washed,	  with	  liquid	  removed	  using	  a	  
vacuum	  manifold	  (Bio-­‐Rad,	  Hercules,	  CA,	  USA).	  A	  biotinylated	  detection	  antibody	  mix	  was	  
added	   to	   each	  well,	   again	   incubated	   on	   a	   plate	   shaker.	   Streptavidin-­‐PE	  was	   then	   used	   to	  
stain	   samples.	   After	   washing	   the	   plate	   three	   times,	   samples	   were	   transferred	   to	   a	   flat-­‐
bottom	   96-­‐well	   plate	   and	   analysed	   on	   a	   Bio-­‐PlexTM	   Suspension	   Array	   System	   (Bio-­‐Rad,	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Hercules,	  CA,	  USA).	  The	  system	  software	  automatically	  calculated	  the	  concentration	  of	  the	  
cytokines	  in	  each	  sample	  by	  comparison	  with	  the	  kit	  standards.	  	  
	  	  
2.2.3.6 Enumeration of eosinophils in peripheral blood 
Blood	  was	  taken	  by	  abrasion	  of	  the	  lateral	  tail	  vein	  of	  mice	  with	  a	  sterile	  scalpel	  blade	  and	  
collection	   of	   a	   5μl	   drop	   using	   a	   pipette.	   The	   blood	   was	   immediately	   mixed	   with	   45μl	  
Discombe’s	   staining	   solution.	   Bright	   orange	   stained	   eosinophils	   were	   counted	   manually	  




2.2.4 Methods of data analysis 
 
2.2.4.1 Data analysis software 
FlowJo	  software	  (version	  9.6.1,	  Treestar	  Inc.,	  CA,	  USA)	  was	  used	  to	  analyse	  cell	  populations	  
by	  flow	  cytometry.	  Each	  population	  was	  calculated	  as	  a	  percentage	  of	  live	  cells	  and	  tabled	  
using	   the	   software.	   The	   data	   was	   then	   copied	   into	   Microsoft	   Excel	   2011	   for	   Mac	   OS	  
(Microsoft	   Corporation,	   Washington,	   USA)	   and	   GraphPad	   Prism	   5.0	   Macintosh	   Version	  
(GraphPad	   Software	   Inc.,	   California,	   USA)	   to	   generate	   graphs	   and	   carry	   out	   statistical	  
analysis.	  	  
	  
2.2.4.2 Calculation of cell numbers 
The	  total	  live	  cell	  number	  in	  each	  sample	  was	  counted	  manually	  by	  trypan	  blue	  exclusion	  as	  
previously	   described	   (see	   2.2.1).	   The	   percentage	   of	   each	   cell	   population	  within	   a	   sample	  
was	  determined	  by	  flow	  cytometry.	  To	  then	  calculate	  the	  number	  of	  cells	  of	  each	  population,	  
the	  percentage	  was	  used	  to	  determine	  cell	  number	  from	  the	  manual	  total	  live	  cell	  count.	  	  
	  
	  
2.2.4.3 Determination of representative histology   
All	   stained	  histological	   specimens	  were	   examined	   thoroughly,	  with	   at	   least	  3	   consecutive	  
sections	  of	  tissue	  examined	  per	  sample.	  Each	  section	  was	  labeled	  with	  a	  reference	  number,	  
rather	   than	   treatment	   group,	   to	   enable	   blinded	   analysis	   of	   the	   tissue.	   Photographs	  were	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then	   taken	  (as	   included	   in	   figures),	   that	  accurately	  depicted	   the	  most	  appropriate	   field	  of	  
view,	  representative	  of	  the	  trend	  across	  the	  whole	  tissue.	  Some	  stained	  sections	  were	  also	  
examined	   externally	   by	   a	   Clinical	   Pathologist,	   blinded	   to	   treatment	   groups,	   and	   graded	  
according	   to	   extent	   of	   pathology;	   this	   was	   found	   to	   correlate	   well	   with	   the	   measurable	  
inflammation	   reported	  by	   graphical	   enumeration	  of	   lung	   cellular	   infiltrates	   in	   this	   thesis,	  
therefore	  validating	  the	  selection	  of	  representative	  histology.	  	  
	  
	  
2.2.4.4 Statistical analysis 
Data	  was	  tested	  for	  normality	  using	  the	  D’Agostino-­‐Pearson	  omnibus	  test.	  Results	  showed	  
that	  the	  percentages	  of	  different	  cell	  types	  in	  BAL,	  mast	  cell	  numbers	  in	  histological	  sections	  
of	   lung,	   and	   cytokine	   concentrations	   in	  BAL	  were	   found	   to	  be	   consistent	  with	  a	  Gaussian	  
distribution	   (Appendix	  A).	  Experimental	  data	   from	  similar	   experiments	   to	   those	   found	   to	  
show	   Gaussian	   distribution	   were	   analysed	   for	   statistical	   significance.	  Where	   two	   groups	  
were	   compared,	   analysis	   was	   conducted	   using	   a	   Student’s	   t-­‐test.	   In	   experiments	   where	  
three	   or	   more	   groups	   were	   compared,	   one-­‐way	   Analysis	   of	   Variance	   (ANOVA)	   with	  
Bonferroni’s	   post	   test	   was	   used.	   In	   experiments	   that	   had	   small	   sample	   sizes,	   Gaussian	  
distribution	  could	  not	  be	  determined;	  these	  data	  were	  compared	  using	  the	  Kruskal-­‐Wallis	  
test	  with	  Dunn’s	  post	   test	  (does	  not	  assume	  normal	  distribution).	   	  Bonferroni	  and	  Dunn’s	  
post	   tests	   were	   used	   to	   correct	   for	   errors	   introduced	   when	   comparing	   multiple	   groups.	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Previous	  work	  from	  our	  Lab	  (described	  in	  section	  1.3,	  Chapter	  1)	  showed	  that	  in	  an	  acute	  
model	   of	   allergic	   airway	   inflammation,	   allergen-­‐specific	   CTLs,	   administered	   to	   sensitised	  
mice,	  can	  prevent	  airway	  inflammation	  upon	  allergen	  exposure	  (226).	  It	  has	  been	  reported,	  
however,	  that	  mice	  exposed	  to	  multiple	  airway	  allergen	  challenges	  over	  time	  may	  generate	  
a	  lung-­‐resident	  population	  of	  memory	  Th2	  cells	  (669).	  As	  such,	  it	  was	  not	  known	  whether	  
CTLs	   may	   be	   effective	   in	   the	   suppression	   of	   allergic	   airway	   inflammation	   in	   a	   model	   of	  
multiple	  allergen	  exposures	  (administered	  at	  time	  intervals),	  where	  established	  disease	  is	  
generated	  in	  the	  airway	  prior	  to	  treatment	  with	  CTLs.	  	  	  	  
	  
The	   hallmarks	   of	   allergic	   airway	   inflammation	   can	   be	   generated	   experimentally	   using	   in	  
vivo	  sensitisation	  models	  that	  vary	  considerably	   in	  the	   literature.	  The	  type	  and	  amount	  of	  
allergen,	   the	   number	   of	   allergen	   exposures,	   as	   well	   as	   the	   use	   of	   adjuvants	   may	   all	   be	  
modified;	   the	   characteristic	   features	   of	   disease	   differ	   accordingly,	   as	   does	   the	   resolution	  
phase	  (500,	  610,	  670).	  The	  pathological	  characteristics	  of	  a	  particular	  model,	  once	  defined,	  
serve	  as	  a	  platform	  for	  assessing	  the	  effects	  of	  treatment	  interventions.	  	   	  
	  
The	  complexity	  of	  the	  allergic	  immune	  response	  is	  such	  that	  increasing	  amounts	  of	  allergen	  
or	  additional	  allergen	  exposures	  do	  not	  necessarily	  result	  in	  a	  chronic	  condition.	  Additional	  
challenges	  may	  lead	  to	  increased	  tolerance	  (646)	  or	  chronicity	  (618,	  632,	  645),	  depending	  
on	   the	   immune	   environment.	   As	   such,	   key	   pathological	   features	   of	   disease	   are	   examined	  
including	   the	   extent	   of	   airway	   histopathology	   and	   remodelling,	   and	   the	   induction	   of	  
mastocytosis.	   A	   number	   of	   factors	   contribute	   to	   airway	   remodelling,	   defined	   broadly	   as	  
changes	  in	  the	  composition	  and	  organisation	  of	  the	  airway	  wall.	  Structural	  changes	  include	  
goblet	  cell	  hyperplasia,	  subepithelial	  fibrosis,	  increased	  airway	  smooth	  muscle	  (ASM)	  mass,	  
proliferation	  of	  blood	  vessels,	  airway	  oedema	  and	   tissue	  destruction,	  primarily	   leading	   to	  
thickening	  of	  the	  airway	  wall	  (560-­‐562).	  The	  extent	  of	  mastocytosis	  may	  also	  be	  indicative	  
of	  the	  development	  of	  chronic	  disease	  (443,	  541).	  
	  
In	  the	  model	  of	  acute	  asthma	  described	  by	  Enomoto	  and	  colleagues,	  it	  was	  shown	  that	  CTLs	  
require	  perforin	  to	  mediate	  amelioration	  of	  allergic	  airway	  inflammation	  (226),	  suggesting	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the	  killing	  of	  target	  cells	  is	  a	  key	  mechanism	  of	  suppression.	  Whether	  this	  approach	  would	  
be	  equally	  effective	   in	  established	  disease	  was	  not	  known.	  While	   the	  airway	  pathology	  of	  
persistent	   allergic	   inflammation	   is	   vastly	   different	   from	   early	   acute	   disease,	   the	  
immunology,	   in	   terms	   of	   the	   cells	   crucially	   involved	   in	   effector	   responses,	   has	   common	  
characteristics.	  	  	  
	  
Central	  and	  effector	  memory	  T	  cells	  are	  developed	  during	  sensitisation,	  resulting	  in	  lymph	  
node-­‐	  and	   lung-­‐resident	  allergen-­‐specific	  T	  cells	   that	  rapidly	  respond	  to	  challenge	  both	   in	  
the	  early	  and	  later	  phases	  of	  disease.	  Upon	  successive	  allergen	  challenges,	  more	  widespread	  
pathology	  is	  generated	  (272-­‐276).	  The	  long-­‐term	  persistence	  of	  allergen-­‐specific	  memory	  T	  
cells	   in	   the	   tissue	   during	   allergy,	   however,	   has	   not	   been	   fully	   elucidated.	   These	   cells	   are	  
activated	   by	   lung-­‐resident	   APCs	   upon	   exposure	   to	   allergen.	   It	   was	   initially	   thought	   that	  
while	   naïve	   cells	   required	   professional	   APCs	   such	   as	   DC	   to	   induce	   priming,	   the	   recall	  
response	  of	  primed	  cells	  could	  be	  induced	  by	  any	  MHC-­‐II	  expressing	  APC	  (671-­‐673).	  While	  
this	  is	  not	  untrue,	  it	  has	  recently	  been	  found	  that	  the	  induction	  of	  allergic	  responses	  during	  
the	  challenge	  phase	  is	  also	  critically	  dependent	  on	  allergen	  presentation	  by	  DCs	  (321,	  493).	  	  
	  
The	   investigation	   of	   the	   role	   of	   the	   airway	   epithelium	   and	   innate	   cells	   such	   as	   ILC2	   in	  
allergic	  asthma	  originally	  revealed	  their	  importance	  in	  the	  initiation	  of	  the	  allergic	  response	  
(332,	  334,	  336),	  as	  discussed	  in	  section	  1.2.	  In	  recent	  months,	  however,	  these	  cells	  have	  also	  
been	  implicated	  in	  the	  progression	  of	  allergic	  disease	  to	  chronicity;	  mediating	  persistence	  
of	   multiple	   features	   of	   immunopathology	   through	   interrelated	   feedback	   loops	   involving	  
epithelial-­‐derived	   IL-­‐33	   and	   ILC2-­‐derived	   IL-­‐13(674).	   Substantial	   collaborative	   interplay	  
between	  innate	  cells	  and	  Th2	  cells	  has	  also	  been	  described	  in	  the	  exacerbations	  of	  allergic	  
asthma	  (675).	  
	  
Perhaps	  a	  significant	  difference	  between	  acute	  and	  established	  allergic	  disease	  in	  humans	  is	  
the	  magnitude	   of	   the	   immediate	   hypersensitivity	   response	  mediated	   by	   allergen-­‐specific	  
IgE.	  Generated	  through	  the	  sensitisation	  phase,	  IgE	  persists	  throughout	  the	  progression	  of	  
disease.	  Over	  successive	  allergen	  exposures,	  however,	  IgE	  is	  generated	  to	  multiple	  epitopes	  
of	   the	   specific	   allergen	   and	   higher	   titres	   of	   IgE	  with	   greater	   affinity	   for	   the	   allergen	   are	  
produced	  (676).	  Together,	  the	  increased	  complexity,	  affinity	  and	  concentration	  of	  allergen-­‐
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specific	   IgE	   correlates	  with	   increased	   efficiency	   of	   facilitated	   antigen	   presentation	   (FAP);	  
translating	  to	  strengthened	  T-­‐cell	  proliferative	  responses	  as	  disease	  progresses	  (677).	  
	  
Collectively,	  these	  results	  reveal	  that	  while	  higher	  affinity	  responses	  may	  develop	  through	  
the	  progression	  of	  disease,	  critical	  cell	  populations	  including	  innate	  cells,	  DCs	  and	  CD4+	  Th2	  
cells	  are	  implicated	  in	  allergic	  exacerbations	  in	  both	  the	  early	  and	  later	  stages	  of	  disease.	  It	  
is	   possible	   then,	   that	   the	   mechanism	   of	   CTL-­‐mediated	   suppression	   -­‐	   presumably	   the	  
targeting	  of	  critical	  allergy-­‐driving	  cells	  -­‐	  may	  be	  as	  effective	  in	  established	  disease	  as	  it	  is	  in	  
the	  amelioration	  of	  inflammation	  upon	  initial	  allergen	  exposure.	  	  	  
	  
The	  development	  of	  a	  multiple	  allergen	  expsoure	  model	  of	  allergic	  airway	  inflammation	  is	  
reported	   in	   this	  chapter,	  within	  which	   the	  effects	  of	  CTL	   immunotherapy	  are	  determined.	  
The	   generation	   of	   key	   features	   of	   CD4+	   Th2	   cell-­‐mediated	   inflammation	   are	   examined,	  
including	   the	   infiltration	   of	   inflammatory	   cells	   into	   the	   lung	   and	   the	   production	   of	  
characteristic	  Th2	  cytokines	   IL-­‐4,	   IL-­‐5	  and	   IL-­‐13.	  Lung	  histological	   examination	   identifies	  
goblet	  cell	  hyperplasia	   that	   leads	   to	   increased	  mucus	  production,	  and	  airway	  remodelling	  
that	  drives	  hyperreactivity.	  To	  assess	  the	  infiltration	  of	  inflammatory	  immune	  cells	  into	  the	  
diseased	  airway,	  conventionally,	  white	  blood	  cells	  in	  bronchoalveolar	  lavage	  (BAL)	  samples	  
were	   manually	   differentiated	   under	   a	   microscope.	   As	   some	   key	   inflammatory	   cells	   (for	  
example,	   eosinophils	   and	   neutrophils)	   may	   be	   difficult	   to	   distinguish	   in	   murine	   blood	  
samples,	  Van	  Rijt	  et	  al	  recently	  proposed	  an	  automated	  method	  by	  which	  BAL	  cells	  may	  be	  
more	  reliably	   identified,	  utilising	  specific	   fluorescent	  conjugated	  antibody	  stains	  and	   flow	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3.2  Aims 
	  
The	   purpose	   of	   the	   experiments	   described	   in	   this	   chapter	   was	   to	   develop	   a	   multiple	  
allergen	  exposure	  model	  of	  allergic	  airway	  inflammation	  in	  which	  to	  test	  the	  effects	  of	  CTL	  
immunotherapy	  on	  airway	  disease.	  The	  hypothesis	  was	  that	   the	  known	  effect	  of	  allergen-­‐
specific	  CTLs	  preventing	  acute	  allergic	  disease	  may	  also	  translate	  to	  therapeutic	  effects	  on	  
established	   airway	   inflammation.	   Furthermore,	   if	   CTL	   immunotherapy	   mediates	  
suppressive	   activity	   on	   key	   allergy-­‐driving	   immune	   cells,	   this	   may	   facilitate	   long-­‐term	  
abrogation	  of	  allergic	  airway	  inflammation.	  	  	  
	  
The	  specific	  aims	  were:	  
• To	  develop	  and	  characterise	  a	  multiple	  allergen	  exposure	  model	  of	  allergic	  airway	  
inflammation	  	  
• To	  assess	  the	  preventative	  effects	  of	  CTL	  immunotherapy	  over	  multiple	  airway	  
allergen	  exposures	  




























3.3.1 A multiple airway allergen exposure model displays 
characteristic features of allergic airway inflammation  
	  
One	  of	   the	  key	   features	  of	  allergic	  airway	   inflammation	   is	   the	   infiltration	  of	   immune	  cells	  
into	   the	   diseased	   lung	   and	   airway.	   A	   panel	   of	   fluorescent	   conjugated	   antibodies	   was	  
developed	   to	   identify	   key	   inflammatory	   immune	   cells	   in	   BAL	   by	   flow	   cytometry.	   This	  
method	  was	  adapted	   from	  that	  described	  by	  Van	  Rijt	  et	  al.	   (666).	  Cells	  were	  stained	  with	  
antibodies	  to	  CD11c,	  Siglec	  F,	  Gr-­‐1,	  CD3,	  MHCII	  and	  CD19	  to	  identify	  alveolar	  macrophages,	  
eosinophils,	   T	   cells,	   neutrophils,	   DCs	   and	   B	   cells	   (Fig	   3.1).	   Cell	   doublets	   were	   gated	   out	  
using	   FSC-­‐A	   vs	   FSC-­‐H	   and	   SSC-­‐A	   vs	   SSC-­‐H	   plots,	   and	   then	   DAPI-­‐negative	   live	   cells	   were	  
gated	   for	   further	   analysis.	   Alveolar	   macrophages	   were	   identified	   as	   high	   FSC-­‐A,	   CD11c+	  
cells,	  while	   eosinophils	  were	   lower	   FSC-­‐A	   and	   Siglec	   F+.	   T	   cells	  were	   identified	   by	   CD3+	  
staining.	   After	   exclusion	   of	   alveolar	   macrophages,	   neutrophils	   were	   identified	   as	   Gr-­‐1+,	  
while	   DCs	   were	   CD11c+MHCII+.	   Cells	   expressing	   MHCII,	   but	   negative	   for	   CD11c,	   were	  
further	  gated	  to	  identify	  CD19+	  B	  cells.	  	  
	  
To	   examine	   changes	   in	   the	   airway	   inflammatory	   infiltrate	   over	  multiple	   airway	   allergen	  
exposures,	   a	   model	   of	   in	   vivo	   sensitisation	   and	   subsequent	   allergen	   challenge	   was	  
developed	  (Fig	  3.2	  A).	  Mice	  were	  sensitised	  by	  intraperitoneal	  (i.p.)	  injection	  of	  OVA	  in	  alum	  
adjuvant	   (OVA/Alum),	   or	   alum	   alone	   (Alum)	   on	   days	   0	   and	   14.	   Airway	   challenges	   were	  
carried	  out	  either	  1,	  2	  or	  3	   times,	  by	   intranasal	   instillation	  of	  OVA	  on	  days	  24	  and/or	  31,	  
and/or	   38;	   control	   mice	   received	   PBS.	   BAL	   was	   performed	   three	   days	   after	   the	   final	  
intranasal	  challenge	  for	  each	  group.	  	  
	  
The	  total	  cell	  number	   in	  BAL	  (Fig	  3.2	  B)	  was	   increased	   in	  all	  OVA/Alum-­‐primed	  and	  OVA	  
challenged	  mice	   compared	   to	  priming	  with	  OVA/Alum	  and	  PBS	   challenge,	  which	  was	  not	  
sufficient	   to	   induce	   immune	   cell	   infiltrate.	   Similarly,	   Alum-­‐primed	  mice	   did	   not	   show	   an	  
increase	  in	  BAL	  cellularity	  when	  challenged	  with	  additional	  OVA	  exposures.	  Therefore,	  mice	  
must	  be	  both	  primed	  with	  OVA/Alum	  and	  challenged	  with	  OVA	  to	  induce	  the	  infiltration	  of	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Figure	  3.1:	  BAL	  analysis	  by	  flow	  cytometry	   	  
BAL	  was	  performed	  on	  mice	  and	  cellular	  inflammatory	  infiltrate	  obtained	  by	  centrifugation.	  
Cells	  were	  stained	  with	  antibodies	  to	  CD11c,	  Siglec	  F,	  Gr-­‐1,	  CD3,	  MHCII	  (3JP)	  and	  CD19.	  Cell	  
doublets	  were	  gated	  out	  using	  FSC-­‐A	  vs	  FSC-­‐H	  and	  SSC-­‐A	  vs	  SSC-­‐H	  and	  DAPI-­‐negative	  live	  
cells	  gated	   for	  population	  analysis.	  Percentages	  represent	   the	  proportion	  of	  a	  specific	  cell	  
type	   in	   each	   depicted	   histogram.	   Representative	   flow	   gating	   and	   determination	   of	  
populations	  are	  depicted.	  




Figure	  3.2:	  Multiple	  intranasal	  allergen	  exposures	  provokes	  significant	  immune	  cell	  
infiltrate	  in	  BAL,	  comprised	  primarily	  of	  eosinophils	  and	  lymphocytes	  
(A)	  Mice	  were	   sensitised	   by	   i.p.	   injection	   of	  OVA	   in	   alum	   adjuvant	   (OVA/Alum),	   or	   alum	  
alone	   (Alum)	   on	   days	   0	   and	   14.	   Airway	   challenges	  were	   carried	   out	   either	   1	   (day	   38),	   2	  
(days	  31	  and	  38)	  or	  3	  times	  (days	  24,	  31	  and	  38),	  by	  intranasal	  instillation	  of	  OVA;	  control	  
mice	  received	  PBS.	  BAL	  was	  performed	  on	  day	  41.	  (B)	  Total	  cells,	  eosinophils,	  lymphocytes,	  
neutrophils,	  alveolar	  macrophages	  and	  DCs	  were	  enumerated	  by	  flow	  cytometry.	  Mean	  cell	  
number	  in	  BAL	  +	  SEM	  are	  shown.	  Data	  are	  from	  one	  representative	  experiment	  of	  two	  that	  
gave	  similar	  results,	  each	  with	  5	  mice	  per	  group.	  **p	  <	  0.01,	  ****p	  <0.0001	  as	  assessed	  by	  
one	  way	  ANOVA	  with	  Bonferroni’s	  post	  test.	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inflammatory	  cells	  into	  the	  BAL.	  Eosinophils	  and	  lymphocytes	  (including	  both	  T	  cells	  and	  B	  	  
cells)	  showed	  a	  dose-­‐dependent	  trend	  towards	  increase	  in	  BAL	  in	  OVA/Alum	  primed	  mice	  
as	  additional	  OVA	  challenges	  were	  performed,	  compared	  to	  Alum	  only	  mice	  (Fig	  3.2	  B);	  this	  
was	  statistically	  significant	  after	  two	  OVA	  challenges.	  While	  neutrophil	  infiltration	  was	  low	  
overall,	  significant	  numbers	  of	  neutrophils	  were	  present	  in	  both	  the	  acute,	  primary	  setting	  
after	   a	   single	   intranasal	   challenge,	   as	   well	   as	   after	   three	   challenges	   in	   OVA	   primed	   and	  
challenged	  mice,	  compared	  to	  Alum	  primed	  mice.	  This	  was	  not	  a	  consistent	  trend,	  however,	  
as	  two	  challenges	  did	  not	  result	  in	  significant	  neutrophilia,	  which	  suggests	  variation	  exists	  
in	  neutrophil	  infiltration.	  Alveolar	  macrophages	  did	  not	  appear	  to	  be	  significantly	  increased	  
in	   this	  experiment,	  nor	  were	  DCs.	  Thus,	   three	   intranasal	  allergen	  exposures	  provokes	   the	  
strongest	   immune	   cell	   infiltrate	   in	   BAL,	   comprised	   primarily	   of	   eosinophils	   and	  
lymphocytes.	  	  
	  
It	   was	   necessary	   to	   characterise	   the	   resolution	   phase	   of	   the	   inflammatory	   response	   to	  
determine	  how	  long	  the	  infiltration	  of	  BAL	  inflammatory	  cell	  populations	  persisted	  before	  
resolving	  on	  its	  own.	  To	  this	  end,	  a	  time	  course	  was	  carried	  out	  where	  mice	  were	  sensitised	  
with	   OVA/Alum	   or	   Alum	   only	   and	   challenged	   with	   3	   OVA	   intranasal	   exposures	   as	  
previously	   described	   (Fig	   3.2	   A).	   Groups	   of	   mice	   were	   culled	   and	   BAL	   inflammatory	  
infiltrate	   examined	   on	   days	   41,	   44	   and	   48:	   3,	   6	   and	   10	   days	   after	   intranasal	   allergen	  
exposure.	  On	  day	  3,	  in	  accordance	  with	  previous	  findings	  (Fig	  3.2	  B),	  total	  cells,	  eosinophils	  
and	   lymphocytes	   were	   significantly	   increased	   in	   OVA/Alum	   treated	   mice,	   compared	   to	  
Alum	  controls	  (Fig	  3.3).	  By	  day	  6,	  there	  was	  a	  marked	  decrease	  in	  all	  cell	  populations	  shown	  
in	  the	  BAL	  in	  OVA/Alum	  treated	  mice,	  while	  still	  remaining	  significantly	  elevated	  in	  number	  
compared	   to	  Alum	  treated	  mice,	  with	   the	  exception	  of	   lymphocytes.	  Day	  10	  cell	  numbers	  
were	  similar	   in	  both	  groups.	  Thus,	   these	  data	  show	  that	   inflammatory	   infiltrate	   improves	  
within	  6	  days	  and	  resolves	  by	  10	  days	  after	  the	  last	  intranasal	  challenge.	  This	  also	  suggests	  
a	  3	  day	  (day	  41)	  time	  point	  for	  assessing	  differences	  in	  cellular	  infiltrate	  in	  BAL	  where	  the	  
efficacy	  of	  an	  additional	  treatment	  intervention	  is	  being	  tested.	  
	  
Another	  hallmark	  of	  allergic	  airway	  inflammation	  is	  the	  production	  of	  Th2	  cytokines.	  As	  the	  
cytokine	   response	   usually	   precedes	   substantial	   cellular	   infiltration	   into	   the	   tissue,	   it	  was	  
hypothesised	  that	  the	  peak	  of	  measureable	  cytokine	  production	  in	  the	  BAL	  would	  be	  earlier	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Figure	  3.3:	  Inflammatory	  infiltrate	  is	  maximised	  at	  day	  3,	  improves	  within	  6	  days	  and	  
resolves	  by	  10	  days	  after	  intranasal	  challenge	  	   	  
Mice	  were	  sensitised	  by	  i.p.	  injection	  of	  OVA	  in	  alum	  adjuvant	  (OVA/Alum),	  or	  alum	  alone	  
(Alum)	  on	  days	  0	  and	  14.	  Three	  OVA	  challenges	  were	  carried	  out	  on	  days	  24,	  31	  and	  38.	  
Groups	  of	  mice	  were	  culled	  and	  BAL	  performed	  on	  days	  3,	  6	  and	  10	  after	  airway	  allergen	  
challenge.	   Total	   cells,	   eosinophils	   and	   lymphocytes	  were	   enumerated	   by	   flow	   cytometry.	  
Mean	  cell	  number	  in	  BAL	  +	  SEM	  are	  shown.	  Data	  are	  from	  one	  representative	  experiment	  of	  
two	   that	   gave	   similar	   results,	   each	   with	   3	   mice	   per	   group.	   *p	   <	   0.05,	   **p	   <	   0.01,	   ****p	  
<0.0001	  as	  assessed	  by	  two	  way	  ANOVA	  with	  Bonferroni’s	  post	  test.	  
	  
	  
than	  day	  3.	  Mice	  were	  sensitised	  with	  OVA/Alum	  or	  Alum	  only	  and	  challenged	  with	  3	  OVA	  
intranasal	  exposures	  as	  previously	  described	   (Fig	  3.2	  A).	  Groups	  of	  mice	  were	  culled	  and	  
cytokines	   were	  measured	   in	   BAL	   on	   days	   39	   and	   41;	   1	   day	   and	   3	   days	   after	   intranasal	  
allergen	  exposure.	  On	  day	  1,	  there	  was	  a	  significant	  increase	  measured	  in	  key	  Th2	  cytokines	  
IL-­‐4	  and	  IL-­‐5,	  as	  well	  as	  a	  trend	  towards	  increase	  in	  IL-­‐13,	  in	  OVA/Alum	  groups	  compared	  
to	  Alum	  only	  (Fig	  3.4).	  Cytokines	  indicative	  of	  alternative	  immune	  responses,	  IL-­‐10,	  IFN-­‐γ	  
and	   IL-­‐17	   were	   not	   measurable	   for	   either	   treatment	   group.	   By	   day	   3,	   there	   was	   no	  
difference	  in	  the	  concentration	  of	  any	  of	  the	  cytokines	  in	  the	  OVA/Alum	  group	  compared	  to	  
the	  day	  1	  Alum	  control.	  Therefore,	  it	  is	  better	  to	  measure	  Th2	  cytokine	  levels	  on	  day	  1	  post	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Figure	  3.4:	  Peak	  of	  cytokine	  production	  is	  day	  1	  after	  airway	  allergen	  challenge	   	  
Mice	  were	  sensitised	  by	  i.p.	  injection	  of	  OVA	  in	  alum	  adjuvant	  (OVA/Alum),	  or	  alum	  alone	  
(Alum)	  on	  days	  0	  and	  14.	  Three	  OVA	  challenges	  were	  carried	  out	  on	  days	  24,	  31	  and	  38.	  
Groups	  of	  mice	  were	  culled	  and	  BAL	  performed	  on	  day	  1	  and	  day	  3	  after	  allergen	  challenge.	  
IL-­‐4,	   IL-­‐5,	   IL-­‐13,	   IL-­‐10,	   IFN-­‐γ	   and	   IL-­‐17	   in	   BAL	   were	   measured	   by	   Bio-­‐Plex.	   Mean	  
concentration	   in	  BAL	  +	   SEM	   are	   shown.	  Data	   are	   from	  one	   representative	   experiment	   of	  
two	  that	  gave	  similar	  results,	  each	  with	  3-­‐5	  mice	  per	  group.	  **p	  <	  0.001	  as	  assessed	  by	  one	  
way	  ANOVA	  with	  Bonferroni’s	  post	  test.	  	   	  
 
3.3.2 CTLs suppress the development of allergic airway inflammation  
	  
To	  determine	  the	  ability	  of	  allergen-­‐specific	  CTLs	  to	  prevent	  allergic	  airway	   inflammation	  
over	  multiple	   airway	   allergen	   challenges,	   mice	   were	   sensitised	  with	   OVA/Alum	   or	   Alum	  
only	  and	  challenged	  with	  3	  OVA	   intranasal	  exposures	  as	  previously	  described	  (Fig	  3.2	  A).	  
OVA-­‐specific	  CD8+	  OT-­‐I	  T	  cells	  were	  activated	  in	  vitro	  and	  5	  x	  106	  cells	  were	  administered	  
in	   the	   tail	   vein	   of	  mice	   one	   day	   before	   the	   first	   allergen	   challenge	   -­‐	   on	   day	   23.	   BAL	  was	  
performed	   for	  cytokine	  analysis	  on	  day	  39	  (1	  day	  after	  allergen	  challenge),	  and	  both	  BAL	  
and	   lungs	  were	   harvested	   on	   day	   41	   (3	   days	   after	   allergen	   challenge)	   for	   assessment	   of	  
inflammatory	  infiltrate	  and	  histological	  sectioning,	  respectively.	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On	  day	  41,	   there	  was	  a	  decrease	   in	  BAL	  total	  cellularity	   in	  CTL	  treated	  mice	  compared	  to	  
OVA/Alum	  groups	  (Fig	  3.5	  A),	  with	  a	  strong	   inhibition	  of	  eosinophilia	  and	   lymphocytosis.	  
Alum	   only	   treated	   mice	   did	   not	   display	   significant	   cell	   infiltration,	   and	   the	   number	   of	  
alveolar	  macrophages	  were	  similar	  in	  all	  groups,	  as	  were	  neutrophils.	  
	  
The	   Th2	   cytokines	   IL-­‐4,	   IL-­‐5	   and	   IL-­‐13	   were	   increased	   in	   concentration	   in	   OVA/Alum	  
groups	  compared	  to	  Alum	  only	  (Fig	  3.5	  B),	  although	  not	  significantly	  so	  for	  IL-­‐13.	  There	  did	  
not,	  however,	  appear	  to	  be	  strong	  inhibition	  of	  IL-­‐4	  in	  CTL-­‐treated	  mice	  in	  this	  experiment,	  
though	  IL-­‐5	  and	  IL-­‐13	  were	  decreased	  in	  concentration,	  again	  this	  did	  not	  reach	  statistical	  
significance.	  Histological	  sections	  of	   lungs	  were	  stained	  with	  H&E	  and	  AB	  PAS	  to	  examine	  
airway	  congestion	  and	  mucus	  production	  (respectively).	  The	  H&E	  staining	  revealed	  that	  the	  
OVA/Alum	   mice	   had	   strong	   inflammatory	   infiltrate	   and	   congested	   alveolar	   spaces	  
compared	  to	  Alum	  controls.	  In	  contrast,	  mice	  treated	  with	  CTLs	  at	  day	  23	  had	  airways	  that	  
remained	   clear	   after	   the	   three	   allergen	   exposures	   (Fig	   3.5	   C,	   upper	   panel).	   Goblet	   cell	  
hyperplasia	   and	   mucus	   production	   (visible	   as	   dark	   purple-­‐stained	   cells)	   were	   similarly	  
affected	  by	  CTL	   treatments,	  with	  reduction	   in	   the	  strongly	  AB	  PAS-­‐positive	  airway	  goblet	  
cells	  seen	  in	  CTL	  treated	  groups,	  compared	  to	  the	  OVA/Alum	  group	  (Fig	  3.5	  C,	  lower	  panel).	  
These	   data	   suggest	   that	   CTL	   therapy	   can	   prevent	   key	   features	   of	   allergic	   airway	  
inflammation	  over	  multiple	  airway	  allergen	  exposures.	  	  
	  
3.3.3 CTLs have therapeutic effects on established allergic airway 
inflammation 
	  
After	  observing	  preventative	  effects	  of	  CTL	  therapy	  throughout	  multiple	  challenges,	  it	  was	  
necessary	  to	  determine	  what	  the	  effect	  of	  CTLs	  may	  be	  on	  established	  airway	  inflammation,	  
as	   individuals	   suffering	   from	  allergic	   asthma	  present	   clinically	   after	   airway	   inflammation	  
has	  already	  developed.	  In	  an	  experimental	  model	  similar	  to	  that	  previously	  described,	  mice	  
were	   sensitised	  with	   OVA/Alum	   or	   Alum	   only	   and	   challenged	  with	   three	   OVA	   intranasal	  
exposures	  (Fig	  3.6	  A).	  5	  x	  106	  CTLs	  were	  administered	  to	  different	  groups	  of	  mice	  at	  one	  of	  
two	   therapeutic	   time	  points;	   either	  before	   the	   second	   intranasal	   challenge,	   on	  day	  30,	   or	  
before	  the	  third	  intranasal	  challenge,	  on	  day	  37.	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Figure	  3.5:	  CTLs	  prevent	  inflammation	  over	  multiple	  airway	  challenges	   	  
Mice	  were	  sensitised	  by	  i.p.	  injection	  of	  OVA	  in	  alum	  adjuvant	  (OVA/Alum),	  or	  alum	  alone	  
(Alum)	  on	  days	  0	  and	  14.	  Three	  OVA	  challenges	  were	  carried	  out	  on	  days	  24,	  31	  and	  38.	  5	  x	  
106	   in	   vitro-­‐activated	   OT-­‐I	   CTLs	  were	   administered	   into	   the	   tail	   vein	   of	  mice	   on	   day	   23.	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Groups	  of	  mice	  were	  culled	  and	  BAL	  performed	  on	  days	  1	  and	  3	  after	  allergen	  challenge.	  
(A)	   Total	   cells,	   eosinophils,	   lymphocytes,	   alveolar	   macrophages	   and	   neutrophils	   were	  
enumerated	  on	  day	  3	  after	  allergen	  challenge	  by	  flow	  cytometry.	  Mean	  cell	  number	  in	  BAL	  +	  
SEM	  are	  shown.	  **p	  <	  0.01,	  ****p	  <0.0001	  as	  assessed	  by	  one	  way	  ANOVA	  with	  Bonferroni’s	  
post	  test.	  (B)	  IL-­‐4,	  IL-­‐5	  and	  IL-­‐13	  were	  measured	  in	  BAL	  on	  day	  1	  after	  allergen	  challenge	  
by	  Bio-­‐Plex.	  Mean	  concentration	  in	  BAL	  +	  SEM	  are	  shown.	  (C)	  Lungs	  were	  removed	  on	  day	  
3,	  embedded	  in	  paraffin	  wax	  and	  sections	  were	  stained	  with	  hematoxylin	  and	  eosin	  (H&E)	  
for	  assessing	  general	   infiltrate,	  and	  with	  alcian	  blue	  periodic	  acid	  schiff	   stain	  (AB	  PAS)	   to	  
visualise	   goblet	   cell	   hyperplasia.	   Multiple	   consecutive	   sections	   of	   lung	   tissue	   were	  
examined	   thoroughly,	   and	   photographs	   most	   clearly	   representing	   the	   trend	   across	   the	  
whole	   tissue	  were	   included	   in	   figures	   to	  depict	  histology.	   Scale	  bars	   show	  500μm	  (upper	  
panel)	   and	  200μm	   (lower	   panel).	   	   Data	   are	   from	  one	   representative	   experiment	   of	   three	  
that	  gave	  similar	  results,	  each	  with	  5	  mice	  per	  group.	  
	  
Day	   41	   BAL	   samples	   showed	   reduced	   total	   cellularity,	   eosinophilia	   and	   alveolar	  
macrophages	  in	  mice	  treated	  with	  CTLs	  at	  either	  day	  30	  or	  day	  37,	  compared	  to	  OVA/Alum	  
mice	   (Fig	   3.6	  B).	   Interestingly,	   the	   decrease	   in	   these	   cells	  was	  more	   pronounced	   in	  mice	  
treated	  with	  CTLs	   at	  day	  30	   than	  day	  37,	   suggesting	   that	   earlier	   treatment	  may	  be	  more	  
effective.	  Lymphocyte	  numbers	  in	  BAL	  were	  not	  significantly	  different	  between	  OVA/Alum	  
treated	  mice,	  with	  or	  without	  CTL	  treatment.	  IL-­‐4,	  IL-­‐5	  and	  IL-­‐13	  were	  increased	  in	  BAL	  in	  
OVA/Alum	  groups	  compared	  to	  Alum	  only	  controls	  (Fig	  3.6	  C).	  A	  lower	  concentration	  of	  all	  
three	   cytokines	   was	   measured	   in	   both	   day	   30	   and	   day	   37	   CTL-­‐treated	   groups,	   in	  
comparison	  with	  OVA/Alum	  mice,	  although	  this	  only	  reached	  statistical	  significance	  for	  IL-­‐5,	  
as	  depicted.	  	  
	  
The	   airways	   of	   OVA/Alum	   treated	  mice	   showed	  widespread	   infiltration	   of	   immune	   cells	  
(Fig	  3.7,	   left	  panel)	  and	  extensive	  goblet	   cell	  mucus	  production	   (Fig	  3.7,	   right	  panel)	   that	  
was	   not	   seen	   in	   the	   Alum	   controls.	   Treating	   with	   CTLs	   on	   day	   30	   resulted	   in	   effective	  
maintenance	  of	  clear	  air	  spaces	  and	  minimal	  mucus	  production.	  Mice	  treated	  with	  CTLs	  on	  
day	   37	   also	   presented	   with	   ameliorated	   histopathology	   compared	   to	   OVA/Alum	   mice,	  
however	  the	  improvement	  was	  not	  as	  marked	  as	  the	  day	  30	  treated	  mice.	  These	  data	  show	  
that	   CTLs	   are	   capable	   of	   preventing	   further	   inflammation	   in	  mice	   that	   have	   experienced	  
previous	  episodes	  of	  allergic	  airway	  inflammation.	  Additionally,	  BAL	  and	  histology	  results	  
collectively	  suggest	  that	  earlier	  treatment	  may	  result	  in	  a	  better	  therapeutic	  outcome.	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Figure	  3.6:	  CTLs	  have	  therapeutic	  effects	  on	  allergic	  airway	  inflammation	   	  
(A)	  Mice	  were	   sensitised	   by	   i.p.	   injection	   of	  OVA	   in	   alum	   adjuvant	   (OVA/Alum),	   or	   alum	  
alone	  (Alum)	  on	  days	  0	  and	  14.	  Three	  OVA	  challenges	  were	  carried	  out	  on	  days	  24,	  31	  and	  
38.	  CTLs	  were	  administered	  i.v.	  on	  day	  30	  or	  day	  37.	  Groups	  of	  mice	  were	  culled	  and	  BAL	  
performed	   on	   days	   39	   and	   41.	   (B)	   Total	   cells,	   eosinophils,	   lymphocytes,	   alveolar	  
macrophages	   and	   neutrophils	  were	   enumerated	   on	   day	   41	   by	   flow	   cytometry.	  Mean	   cell	  
number	  in	  BAL	  +	  SEM	  are	  shown.	  *p	  <0.05,	  **p	  <	  0.01,	  ***	  p	  <	  0.001	  as	  assessed	  by	  one	  way	  
ANOVA	  with	  Bonferroni’s	  post	  test.	  (C)	   IL-­‐4,	  IL-­‐5	  and	  IL-­‐13	  were	  measured	  in	  BAL	  on	  day	  
39	   by	   Bio-­‐Plex.	   Mean	   concentration	   in	   BAL	   +	   SEM	   are	   shown.	   	   Data	   are	   from	   one	  
representative	  experiment	  of	  two	  that	  gave	  similar	  results,	  each	  with	  5	  mice	  per	  group.	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Figure	  3.7:	  CTLs	  have	  therapeutic	  effects	  on	  airway	  congestion	  and	  goblet	  cell	  mucus	  
production.	  	  
Mice	  were	  sensitised	  by	  i.p.	  injection	  of	  OVA	  in	  alum	  adjuvant	  (OVA/Alum),	  or	  alum	  alone	  
(Alum)	  on	  days	  0	  and	  14.	  Three	  OVA	  challenges	  were	  carried	  out	  on	  days	  24,	  31	  and	  38.	  
CTLs	   were	   administered	   i.v.	   on	   day	   30	   or	   day	   37.	   Lungs	   were	   removed	   on	   day	   41,	  
embedded	  in	  paraffin	  wax	  and	  sections	  were	  stained	  with	  hematoxylin	  and	  eosin	  (H&E)	  for	  
assessing	   general	   infiltrate,	   and	   with	   alcian	   blue	   periodic	   acid	   schiff	   stain	   (AB	   PAS)	   to	  
visualise	   goblet	   cell	   hyperplasia.	   Multiple	   consecutive	   sections	   of	   lung	   tissue	   were	  
examined	   thoroughly,	   and	   photographs	   most	   clearly	   representing	   the	   trend	   across	   the	  
whole	   tissue	   were	   included	   in	   figures	   to	   depict	   histology.	   Scale	   bars	   show	   500μm	   (left	  
panel)	  and	  200μm	  (right	  panel).	  Data	  are	  from	  one	  representative	  experiment	  of	  two	  that	  
gave	  similar	  results,	  each	  with	  5	  mice	  per	  group.	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As	  IL-­‐5	  has	  a	  role	  in	  stimulating	  the	  proliferation,	  differentiation	  and	  subsequent	  release	  of	  
mature	  eosinophils	   from	  the	  bone	  marrow	   into	   the	  blood	   (678),	   it	  was	  assessed	  whether	  
the	  decrease	  in	  IL-­‐5	  in	  BAL	  was	  also	  affecting	  the	  mobilization	  of	  eosinophils	  from	  the	  bone	  
marrow.	  Mice	  were	  treated	  as	  described	  in	  Fig	  3.2	  A,	  and	  blood	  was	  collected	  from	  the	  tail	  
vein	   on	   days	   39,	   40,	   41	   and	   44.	   A	   lower	   number	   of	   eosinophils	   was	   observed	   in	   the	  
circulating	   blood	   of	   CTL-­‐treated	   mice	   compared	   to	   OVA/Alum	   mice	   at	   all	   time	   points	  
measured	   (Fig	   3.8	   A);	   becoming	   statistically	   significant	   on	   day	   41	   (corresponding	   to	   the	  
peak	   of	   BAL	   cellular	   infiltration)	  which	   showed	   the	  most	  marked	   decrease	   in	   eosinophil	  
numbers	  between	   these	  groups.	  Lungs	  were	  harvested	  on	  day	  39	  and	  homogenised,	   then	  
tested	   for	   the	   presence	   of	   eotaxin,	   a	   potent	   eosinophil	   chemoattractant	   cytokine	   (503).	  
Eotaxin	  did	  not	  appear	   to	  be	  expressed	  significantly	  differently	   in	   the	   lungs	  of	  mice	   from	  
any	  of	  the	  treatment	  groups	  at	  this	  time	  (Fig	  3.8	  B).	  	  
	  
 
Figure	  3.8:	   CTL	   immunotherapy	   reduces	  mobilisation	  of	   eosinophils	   from	   the	  bone	  
marrow	  	  
Mice	  were	  sensitised	  by	  i.p.	  injection	  of	  OVA	  in	  alum	  adjuvant	  (OVA/Alum),	  or	  alum	  alone	  
(Alum)	  on	  days	  0	  and	  14.	  Three	  OVA	  challenges	  were	  carried	  out	  on	  days	  24,	  31	  and	  38.	  	  
(A)	  Blood	  was	  collected	  from	  the	  tail	  vein	  of	  mice	  on	  days	  39,	  40,	  41	  and	  44	  and	  eosinophils	  
were	   identified	  using	  Discombe’s	   solution.	  Mean	   cell	   number	  per	  mL	  of	   blood	  +	   SEM	  are	  
shown.	   **p	  <	  0.01	  as	  assessed	  by	   two	  way	  ANOVA	  with	  Bonferroni’s	  post	   test.	   (B)	  Lungs	  
were	  harvested	  on	  day	  39	  and	  homogenised,	  ELISA	  was	  then	  carried	  out	  to	  determine	  the	  
concentration	   of	   eotaxin	   in	   lung	   homogenates.	   Data	   are	   from	   one	   representative	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3.3.4 CTLs decrease mastocytosis in the allergic airway  
	  
Mast	   cell	   numbers	   increase	   in	   tissue	  with	   chronic	   exposure	   to	   allergens	   (443).	   Thus,	   the	  
presence	   of	   increasing	   numbers	   of	  mast	   cells	   in	   lungs	   can	   reveal	   progression	   to	   chronic	  
allergic	   airway	   disease.	   Histological	   examination	   was	   carried	   out	   to	   determine	   when	   a	  
significant	  increase	  in	  mast	  cells	  could	  be	  observed	  in	  lung	  tissue.	  Mice	  were	  sensitized	  and	  
given	  1,	  2	  or	  3	  OVA	  challenges,	  with	  lungs	  harvested	  3	  days	  after	  each	  challenge	  at	  day	  27,	  
34	  or	  41	  respectively	  (Fig	  3.9	  A).	  Sections	  were	  stained	  with	  chloracetate	  esterase	  (CAE)	  to	  
visualize	  mast	  cells,	  which	  appear	  as	   large	  pink/red	  cells	  accumulating	  around	  airways	   in	  
the	   lung,	   as	   represented	   in	  Fig	  3.9	  B.	   It	  was	   found,	   by	   light	  microscopy	  analysis,	   that	   the	  
number	  of	  mast	  cells	  per	   field	  of	  view	   increased	  mildly	  after	  1	  and	  2	  challenges,	  but	  was	  
most	  markedly	  increased	  after	  3	  allergen	  exposures	  (Fig	  3.9	  C).	  	  
	  
The	  effect	  of	  CTLs	  on	  the	  induction	  of	  mast	  cells	  was	  also	  examined.	  Mice	  were	  exposed	  to	  
three	   OVA	   challenges	   and	   administered	   CTLs	   at	   either	   day	   23,	   day	   30,	   or	   day	   37.	  
Histological	   sections	   revealed	   that	   few	  mast	   cells	  were	  present	   in	   any	  of	   the	  CTL-­‐treated	  
groups	   (Fig	   3.9	   D).	   These	   results	   demonstrate	   that	   CTL	   treatment	   results	   in	   decreased	  
mastocytosis	  in	  the	  lungs	  of	  allergen	  sensitised	  and	  challenged	  mice.	  However,	  as	  mast	  cells	  
only	  begin	  to	  appear	  in	  significantly	  high	  numbers	  after	  the	  third	  allergen	  challenge,	  it	  was	  
not	  conclusively	  shown	  whether	  mast	  cell	  influx	  in	  a	  chronic	  condition	  may	  be	  reversed	  by	  
CTL	  therapy,	  or	  rather	  instead,	  that	  mast	  cells	  did	  not	  increase	  in	  number.	  	  
	  
The	  effect	  of	  CTL	  therapy	  on	  total	  IgE	  and	  OVA-­‐specific	  IgE	  in	  serum	  was	  then	  examined,	  as	  
IgE	  is	  known	  to	  sensitize	  mast	  cells	  leading	  to	  degranulation	  upon	  allergen	  exposure.	  Mice	  
were	   sensitised	   and	   challenged	   as	   previously	   described	   (Fig	   3.9	   A),	   with	   some	   mice	  
receiving	   CTLs	   at	   day	   23,	   before	   intranasal	   allergen	   exposure.	   On	   day	   41,	   after	   three	  
intranasal	  challenges,	  mice	  were	  sacrificed	  and	  blood	  was	  collected	  from	  the	  descending	  
   110 
 
 
   111 
 
Figure	  3.9:	  Mast	  cell	  accumulation	   in	  tissue	   is	  prevented,	   IgE	  production	  unaffected	  
by	  CTL	  therapy	   	  
(A)	  Mice	  were	   sensitised	   by	   i.p.	   injection	   of	  OVA	   in	   alum	   adjuvant	   (OVA/Alum),	   or	   alum	  
alone	  (Alum)	  on	  days	  0	  and	  14.	  One,	  two	  or	  three	  OVA	  challenges	  were	  carried	  out	  on	  days	  
24,	   31	   and	   38.	   Lungs	   were	   taken	   3	   days	   after	   each	   intranasal	   challenge,	   sectioned	   and	  
stained	  with	  CAE	  to	  visualize	  mast	  cells	  in	  tissue.	  (B)	  Representative	  staining	  shows	  mast	  
cell	   accumulation	  around	  airways,	   scale	  bar	  200μm.	   (C)	  CAE+	  cells	  were	   counted	   in	   lung	  
tissue	  taken	  3	  days	  after	  1,	  2	  or	  3	  OVA	  intranasal	  exposures.	  Bar	  graphs	  show	  mean	  +	  SEM	  
number	   of	   CAE+	   cells	   per	   10	   fields	   of	   view	   under	   a	   40x	   objective	   lens.	   (D)	  Mice	   were	  
exposed	  to	  three	  OVA	  challenges	  and	  administered	  CTLs	  at	  either	  day	  23,	  day	  30,	  or	  day	  37.	  
Bar	   graphs	   show	  mean	   +	   SEM	   number	   of	   CAE+	   cells	   per	   10	   fields	   of	   view	   under	   a	   40x	  
objective	  lens.	  Data	  are	  from	  one	  representative	  experiment	  of	  two	  that	  gave	  similar	  results,	  
each	  with	  3	  mice	  per	  group.	  (E)	  Blood	  extracted	  from	  mice	  treated	  with	  CTLs	  at	  day	  23,	  or	  
no	  cells,	  was	  tested	  for	  total	  and	  OVA-­‐specific	  serum	  IgE	  3	  days	  after	  the	  final	  of	  3	  intranasal	  
challenges.	  Bar	  graphs	  show	  mean	  +	  SEM	  of	   total	  ng/ml	  of	   IgE	   in	  serum,	  and	   the	  relative	  
absorbance	  (OD)	  of	  OVA-­‐specific	  IgE	  measured	  at	  450nm.	  Data	  are	  from	  one	  representative	  
experiment	  of	  two	  that	  gave	  similar	  results,	  each	  with	  4-­‐5	  mice	  per	  group.	  	   *p	   <0.05,	   **p	  




aorta	   from	   which	   serum	   was	   obtained.	   All	   OVA/Alum	   primed	   mice	   showed	   a	   similar	  
increase	  in	  both	  total	  IgE	  (Fig	  3.9	  E,	  left	  panel)	  and	  OVA-­‐specific	  IgE	  (Fig	  3.9	  E,	  right	  panel),	  
compared	   to	   mice	   primed	   solely	   with	   Alum.	   	   The	   IgE	   response	   was	   not	   exacerbated	   by	  
intranasal	   OVA	   challenges,	   as	   OVA/Alum	   primed	   mice	   that	   were	   challenged	   with	   OVA	  
showed	   similar	   levels	   of	   serum	   IgE	   as	   OVA/Alum	   primed	   mice	   that	   received	   PBS	  
intranasally.	  Additionally,	  IgE	  was	  not	  induced	  in	  mice	  given	  solely	  intranasal	  exposure	  to	  
OVA	   (Alum	   primed	   group).	   	   This	   suggests	   that	   the	   OVA/Alum	   priming	   regime	   alone	   is	  
sufficient	  to	  induce	  an	  IgE	  response.	  Treatment	  with	  CTLs	  on	  day	  23	  did	  not	  affect	  IgE	  levels	  
in	   serum.	  Therefore,	   CTL	   immunotherapy	  affects	   the	  number	  of	  mast	   cells	   in	   lung	   tissue,	  
but	  may	  not	  be	  effective	  in	  preventing	  activation	  of	  mast	  cells	  by	  IgE.	  
	  
As	  questions	  remained	  about	  the	  effects	  of	  CTLs	  on	  mast	  cells,	  it	  was	  necessary	  to	  perform	  
an	   extended	   model	   of	   allergic	   airway	   inflammation	   to	   further	   elucidate	   whether	  
mastocytosis	   was	   reversible	   as	   a	   therapeutic	   outcome	   of	   CTL	   therapy.	   To	   this	   end,	   a	   5-­‐
challenge	  model	   of	   allergic	   airway	   inflammation	  was	   carried	   out	   as	   shown	   in	   Fig	   3.10	  A,	  
where	   CTLs	   were	   administered	   before	   the	   first	   allergen	   challenge,	   or	   after	   the	   third	  
challenge.	   	  The	  number	  of	  mast	   cells	   in	   lung	   tissue	  was	   increased	   four-­‐fold	   in	  OVA/Alum	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mice	  compared	  to	  Alum	  only	  mice,	  after	  the	  5	  intranasal	  allergen	  exposures	  (Fig	  3.10	  B).	  	  In	  
CTL-­‐treated	   groups,	   mast	   cells	   were	   similarly	   low	   in	   both	   the	   day	   23	   and	   day	   44	   CTL	  
treatments,	  and	  only	  marginally	  higher	  than	  in	  mice	  treated	  with	  alum	  only.	  As	  the	  data	  in	  
Figure	  3.9	  C	  show	  that	  mast	  cell	  numbers	  were	  already	  high	  after	  the	  3rd	  challenge,	   these	  
results	  suggest	  that	  CTL	  therapy	  can	  reverse	  the	  accumulation	  of	  mast	  cells	  that	  occurs	  over	  
successive	  allergen	  exposures.	  	  
	  
The	   activity	   of	   mucosal	   mast	   cells	   was	   additionally	   examined	   by	   measuring	   the	  
concentration	  of	  mouse	  mast	  cell	  protease	  –	  1	  (mMCP-­‐1)	  in	  serum	  4	  hours	  after	  the	  third,	  
fourth,	  and	  fifth	  intranasal	  challenges;	  on	  days	  38,	  45	  and	  52	  respectively.	  On	  day	  38	  and	  45,	  
mMCP-­‐1	   levels	  were	   variable,	   and	   there	   did	   not	   appear	   to	   be	   a	   clear	   difference	   between	  
CTL-­‐treated	   groups	   and	   non	   CTL-­‐treated	   groups	   (Fig	   3.10	   C).	   After	   the	   fifth	   allergen	  
challenge,	   there	  was	  an	   increase	   in	  serum	  mMCP-­‐1	   in	  OVA/Alum	  mice	  compared	  to	  Alum	  
only,	  and	  this	  was	  ameliorated	  in	  mice	  treated	  with	  CTLs	  at	  either	  day	  23	  or	  day	  44;	  at	  this	  
time	  point,	  the	  amount	  of	  mMCP-­‐1	  in	  serum	  reflected	  the	  mast	  cell	  numbers	  reported	  in	  B.	  	  
	  
The	   overall	   trend	   revealed	   that	   CTL-­‐treated	   groups	   had	   a	   decrease	   in	   mMCP-­‐1	   over	  
successive	   intranasal	   allergen	   exposures,	   whereas	   OVA/Alum	   mice	   that	   did	   not	   receive	  
CTLs	  showed	  an	   increase	   in	  mMCP-­‐1	  over	  time.	  This	  may	  be	  due	  to	  changes	   in	   lung	  mast	  
cell	  populations	  with	  consecutive	  allergen	  exposures;	   in	  earlier	   time	  points,	  mMCP-­‐1	  may	  
be	  produced	  primarily	  by	  lung	  resident	  mast	  cells,	  but	  as	  additional	  allergen	  challenges	  are	  
carried	  out,	   the	  induced	  mast	  cell	  population	  increases	  in	  OVA/Alum	  mice,	  (though	  not	   in	  
CTL-­‐treated	  mice)	  and	  consequently,	  the	  production	  of	  mMCP-­‐1	  increases.	  	  
	  
The	  localisation	  of	  mast	  cells	  in	  lung	  tissue	  revealed	  that	  numerous	  mast	  cells	  were	  present	  
within,	   or	   directly	   in	   contact	   with,	   the	   airway	   smooth	   muscle	   layer	   (Representative	  
histology,	   Fig	   3.10	  D).	   In	   this	   location,	  mast	   cells	   have	  been	   reported	   to	   promote	   a	  more	  
contractile	   phenotype	   of	   airway	   smooth	  muscle	   cells,	   contributing	   to	   the	  development	   of	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Figure	   3.10:	   Mast	   cell	   number,	   protease	   production,	   and	   localisation	   in	   a	   chronic	  
model	  of	  allergic	  airway	  inflammation	  	  
(A)	  Mice	  were	   sensitised	   by	   i.p.	   injection	   of	  OVA	   in	   alum	   adjuvant	   (OVA/Alum),	   or	   alum	  
alone	  (Alum)	  on	  days	  0	  and	  14.	  Five	  OVA	  challenges	  were	  carried	  out	  on	  days	  24,	  31,	  38,	  45	  
and	  52.	  CTLs	  were	  administered	  i.v.	  on	  either	  day	  23	  or	  day	  44.	  Lungs	  were	  taken	  on	  day	  55,	  
sectioned	   and	   stained	   with	   CAE	   to	   visualize	   mast	   cells	   in	   tissue.	   (B)	   CAE+	   cells	   were	  
counted	  in	  lung	  tissue.	  Bar	  graphs	  show	  mean	  +	  SEM	  number	  of	  CAE+	  cells	  per	  10	  fields	  of	  
view	   under	   a	   40x	   objective	   lens.	   (C)	   The	   concentration	   of	  mouse	  mast	   cell	   protease	   –	   1	  
(mMCP-­‐1)	  in	  serum	  was	  measured	  4	  hours	  after	  the	  3rd,	  4th	  and	  5th	  intranasal	  challenges,	  
by	   ELISA	   analysis.	   (D)	   Representative	   histology	   shows	   numerous	   mast	   cells	   localised	  
within,	  or	  directly	  associated	  with,	  airway	  smooth	  muscle,	  scale	  bar	  100μm.	  Data	  are	  from	  
one	   representative	   experiment	   of	   two	   that	   gave	   similar	   results,	   each	   with	   3-­‐5	   mice	   per	  
group.	  *p	  <	  0.05,	  ****p	  <	  0.01	  as	  assessed	  by	  one	  way	  ANOVA	  with	  Bonferroni’s	  post	  test.	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3.3.5 CTLs have therapeutic effects in a multiple challenge model of 
allergic asthma that displays markers of chronicity 
	  
As	   the	  5-­‐challenge	  model	  showed	  evidence	  of	   increased	  chronicity,	   in	   terms	  of	  significant	  
mastocytosis,	  we	  wanted	  to	  determine	  the	  potential	  for	  CTL	  immunotherapy	  to	  ameliorate	  
allergic	   airway	   inflammation	   under	   these	   conditions,	   as	   well	   as	   examine	   the	   long	   term	  
preventative	   effects	   of	   CTLs.	   Utilising	   the	   model	   described	   in	   Fig	   3.10	   A,	   mice	   were	  
sensitised	  and	  challenged	  with	  OVA	  allergen,	  with	  CTLs	  administered	  on	  either	  day	  23	  or	  
day	   44.	   Mice	   were	   culled	   on	   day	   53	   and	   55	   and	   BAL	   obtained	   for	   analysis	   of	   cytokine	  
production	  and	  cellular	  infiltrate,	  respectively.	  	  
	  
It	  was	   found	   that	   a	   single	   CTL	   treatment	   on	  day	  23	   could	   suppress	   airway	   inflammation	  
even	  after	  5	  allergen	  challenges.	  There	  was	  a	  decrease	  in	  BAL	  cellularity	  (Fig	  3.11	  A),	  with	  a	  
strong	   inhibition	   of	   eosinophilia	   as	  well	   as	   a	   decrease	   in	   lymphocyte	   infiltration	   in	   CTL-­‐
treated	  groups,	  compared	  to	  OVA/Alum	  treatment.	  The	  numbers	  of	  alveolar	  macrophages	  
were	   similar	   in	   all	   groups.	   In	   mice	   treated	   with	   CTLs	   on	   day	   44,	   a	   time	   when	   a	   robust	  
inflammatory	  response	  was	  already	  evident	  (see	  Fig	  3.5),	  BAL	  cellularity,	  eosinophils	  and	  
lymphocytes	  were	  reduced	  to	  a	  level	  comparable	  to	  mice	  treated	  with	  CTL	  on	  day	  23.	  These	  
data	  suggest	  that	  one	  treatment	  with	  CTL	  is	  sufficient	  to	  achieve	  long	  lasting	  prophylaxis,	  as	  
well	  as	  an	  effective	  therapeutic	  treatment	  for	  reducing	  Th2	  responses	  in	  a	  model	  of	  allergic	  
airway	  inflammation	  with	  features	  of	  chronic	  disease.	  
	  
In	   a	   similar	   experiment,	   airway	   histology	   revealed	   that	   the	   OVA/Alum	   mice	   had	   strong	  
inflammatory	  infiltrate	  and	  congested	  alveolar	  spaces.	  In	  contrast,	  mice	  treated	  with	  CTLs	  
at	  day	  23	  had	  airways	  that	  remained	  clear	  after	  the	  repeated	  allergen	  exposures	  (Fig	  3.11	  B,	  
upper	  panel).	  The	  mice	  treated	  with	  CTL	  on	  day	  44,	  also	  presented	  on	  day	  55	  with	  reduced	  
infiltration	   of	   immune	   cells	   in	   the	   alveolar	   spaces.	   Thus,	   treatment	   with	   CTL	   on	   day	   44	  
could	  reverse	  established	  inflammation.	  Goblet	  cell	  hyperplasia	  and	  mucus	  production	  	  
   115 
 
 
Figure	   3.11:	   Allergen-­‐specific	   CTLs	   have	   therapeutic	   and	   long	   term	   preventative	  
effects	  on	  allergic	  airway	  inflammation	  	  
Mice	  were	  sensitised	  by	  i.p.	  injection	  of	  OVA	  in	  alum	  adjuvant	  (OVA/Alum),	  or	  alum	  alone	  
(Alum)	  on	  days	  0	  and	  14.	  Five	  OVA	  challenges	  were	  carried	  out	  on	  days	  24,	  31,	  38,	  45	  and	  
52.	   CTLs	  were	   administered	   i.v.	   on	   either	   day	   23	   or	   day	   44.	   (A)	   Total	   cells,	   eosinophils,	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lymphocytes	   and	   alveolar	   macrophages	   were	   enumerated	   on	   day	   55	   by	   flow	   cytometry.	  
Mean	   cell	   number	   in	   BAL	   +	   SEM	   are	   shown.	   **p	   <	   0.01,	   ***p	   <	   0.001,	   ****p	   <0.0001	   as	  
assessed	  by	  one	  way	  ANOVA	  with	  Bonferroni’s	  post	  test.	  (B)	  Lungs	  were	  removed	  on	  day	  
55,	  embedded	  in	  paraffin	  wax	  and	  sections	  were	  stained	  with	  hematoxylin	  and	  eosin	  (H&E)	  
for	  assessing	  general	   infiltrate,	  and	  with	  alcian	  blue	  periodic	  acid	  schiff	   stain	  (AB	  PAS)	   to	  
visualise	   goblet	   cell	   hyperplasia.	   Multiple	   consecutive	   sections	   of	   lung	   tissue	   were	  
examined	   thoroughly,	   and	   photographs	   most	   clearly	   representing	   the	   trend	   across	   the	  
whole	   tissue	  were	   included	   in	   figures	   to	  depict	  histology.	   Scale	  bars	   show	  200μm	  (upper	  
panel)	  and	  100μm	  (lower	  panel).	  (C)	  RNA	  was	  extracted	  from	  lungs	  and	  Muc5AC,	  AMCase,	  
Tenascin-­‐c	   and	   MMP-­‐9	   RNA	   were	   measured	   by	   RT-­‐PCR.	   Relative	   expression	   of	   RNAs	  
between	   treatment	   groups	   were	   examined	   by	   comparing	   RNA	   expression	   from	   lungs	   of	  
OVA/Alum	  +	  CTL-­‐treated	  mice	  to	  that	  of	  OVA/Alum	  mice	  that	  did	  not	  receive	  CTL	  treatment.	  
Data	  are	  from	  one	  representative	  experiment	  of	  two	  that	  gave	  similar	  results,	  each	  with	  4-­‐5	  
(A	  and	  B)	  or	  3	  (C)	  mice	  per	  group.	  
	  
	  
were	  similarly	  affected	  by	  CTL	  treatments,	  with	  reduction	  in	  the	  strongly	  AB	  PAS-­‐positive	  
airway	   goblet	   cells	   in	   both	   day	   23	   and	   day	   44	   CTL	   treated	   groups,	   compared	   to	   the	  
OVA/Alum	   group	   (Fig	   3.11	   B,	   lower	   panel).	   Due	   to	   variation	   in	   samples,	   no	   statistically	  
significant	  differences	  were	  observed	   in	   the	  expression	  of	  RNA	   for	   the	  epithelial	  damage,	  
remodelling	   and	   repair	   markers,	   AMCase,	   Tenascin-­‐c,	   Muc5AC	   and	   MMP-­‐9,	   however	  
AMCase	  and	  Tenascin-­‐c	  did	  show	  a	   trend	   towards	  reduction	  by	  CTL	  therapy	  (Fig	  3.11	  C).	  
Together,	  these	  data	  show	  that	  immunotherapy	  with	  CTLs	  prevents	  congestion	  of	  airways	  
caused	  by	  immune	  cell	  infiltrate	  and	  overproduction	  of	  mucus,	  and	  is	  additionally	  capable	  
of	  reversing	  pathological	  effects	  on	  the	  airway	  after	  multiple	  episodes	  of	  inflammation	  have	  
occurred.	  	  
	  
Additional	  to	  mastocytosis,	  chronic	  allergic	  airway	  inflammation	  is	  characterised	  by	  airway	  
remodelling	  including	  thickening	  of	  the	  airway	  smooth	  muscle	  layer	  and	  increased	  collagen	  
deposition	  (560-­‐562).	  These	  features	  of	  disease	  were	  examined,	  and	  it	  was	  discovered	  that	  
significant	   airway	   remodelling	  was	   induced	   in	   OVA/Alum	  mice,	   with	   a	   thickening	   of	   the	  
airway	   smooth	   muscle	   layer	   (Fig	   3.12,	   left	   panel,	   ASM	   thickness	   highlighted)	   and	   an	  
increase	  in	  collagen	  deposition	  evident	  as	  darker,	  more	  dense	  blue	  staining	  (Fig	  3.12,	  right	  
panel),	  compared	  to	  Alum	  controls.	  In	  prophylactic	  day	  23	  CTL-­‐treated	  mice,	  ASM	  remained	  
a	  similar	  thickness	  to	  that	  seen	  in	  Alum	  mice,	  and	  therapeutic	  day	  44	  treatment	  successfully	  
retracted	  ASM	  to	  a	  baseline	  level.	  Therefore,	  CTL	  treatment	  results	  in	  the	  healing	  of	  airway	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Figure	  3.12:	  CTL	  immunotherapy	  resolves	  features	  of	  allergen-­‐induced	  airway	  
remodelling	  	  
Mice	  were	  sensitised	  by	  i.p.	  injection	  of	  OVA	  in	  alum	  adjuvant	  (OVA/Alum),	  or	  alum	  alone	  
(Alum)	  on	  days	  0	  and	  14.	  Five	  OVA	  challenges	  were	  carried	  out	  on	  days	  24,	  31,	  38,	  45	  and	  
52.	  CTLs	  were	  administered	   i.v.	  on	  either	  day	  23	  or	  day	  44.	  Lungs	  were	   taken	  on	  day	  55,	  
sectioned	   and	   stained	   with	   H&E	   and	   Massons	   Trichrome.	   Representative	   sections	   show	  
ASM	   (left	   panel,	   thickness	   indicated)	   and	   collagen	  deposition	   (right	   panel,	   blue	   staining),	  
scale	  bars	  200μm.	  Multiple	  consecutive	  sections	  of	  lung	  tissue	  were	  examined	  thoroughly,	  
and	  photographs	  most	  clearly	  representing	  the	  trend	  across	  the	  whole	  tissue	  were	  included	  
in	  figures	  to	  depict	  histology.	  Data	  are	  from	  one	  representative	  experiment	  of	  two	  that	  gave	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smooth	   muscle	   hyperplasia.	   Fibrosis	   around	   airways	   did	   not	   follow	   the	   same	   trend,	  
however;	  while	  day	  23	  treated	  mice	  had	  similar	  collagen	  deposition	  to	  Alum	  controls,	   the	  
day	  44	  mice	  appeared	  to	  have	  more	  collagen	  than	  both	  the	  day	  23	  treated	  mice	  as	  well	  as	  
Alum	  mice,	   although	   not	   as	  much	   as	   the	  OVA/Alum	  untreated	  mice.	   This	   result	   suggests	  
that	   collagen	   deposition	   may	   be	   prevented	   by	   CTL	   immunotherapy	   in	   a	   prophylactic	  
context	  and	  prevented	  from	  worsening	  in	  a	  therapeutic	  context,	  however	  repair	  of	  fibrotic	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3.4 Discussion 	  
	  
The	   critical	   shortcoming	   of	   many	   models	   of	   acute	   allergic	   airway	   inflammation	   is	   that	  
treatments	   are	   only	   be	   tested	   for	   prophylactic	   effects.	   For	   clinical	   relevance,	   a	   model	   of	  
allergic	  airway	  inflammation	  with	  features	  of	  chronic	  disease	  is	  preferable	  to	  determine	  the	  
therapeutic	   potential	   for	   novel	   treatments.	   	   This	   chapter	   aimed	   to	   establish	   a	   multiple	  
challenge	  model	   of	   allergic	   airway	   inflammation	   in	  which	   to	   assess	   the	   preventative	   and	  
therapeutic	  potential	  for	  CTL	  immunotherapy.	  
	  
	  
Developing a multiple challenge model of allergic airway inflammation  
	  
Defined	  as	  a	  chronic	  inflammatory	  disease	  of	  the	  airways,	  asthma	  is	  a	  complex	  disease	  and	  
the	  physiological	  and	  immunological	  changes	  associated	  have	  not	  been	  fully	  elucidated.	  As	  
such,	   it	   is	   difficult	   to	   replicate	   all	   the	   features	   of	   pathology	   in	   an	   experimental	   murine	  
model;	  numerous	  models	  exist	  where	  the	  mouse	  strain,	  method	  of	  sensitisation,	  number	  of	  
challenges	  and	  amount	  of	  allergen	  administered	  are	  widely	  varied.	  This	  makes	  comparing	  
results	   across	   studies	   difficult	   (500,	   610).	   It	   is	   possible,	   however,	   to	   develop	   a	  model	   of	  
allergic	  airway	  inflammation	  in	  which	  important	  measureable	  traits	  of	  established	  disease	  
may	   be	   well	   characterised,	   such	   that	   specific	   effects	   of	   treatment	   interventions	   may	   be	  
examined.	  	  
	  
In	   this	   chapter,	   a	   model	   was	   established	   that	   comprised	   three	   or	   five	   airway	   allergen	  
exposures	   after	   systemic	   sensitisation	   with	   OVA.	   This	   led	   to	   a	   robust	   lung	   immune	   cell	  
infiltrate,	  eosinophilia	  and	  lymphocytosis	  as	  well	  as	  Th2	  cytokine	  production.	  The	  nature	  of	  
the	   resolution	   of	   this	   inflammation	   was	   such	   that	   immune	   cell	   infiltrate	   was	   no	   longer	  
detected	   in	   BAL	   10	   days	   after	   the	   last	   allergen	   challenge.	   Nevertheless,	   the	   timecourse	  
carried	  out	  also	  revealed	  that	  BAL	  cellularity	  continued	  to	  be	  elevated	  6	  days	  after	  allergen	  
exposure,	   so	   inflammation	  was	   still	   present	  when	   the	   subsequent	   allergen	   challenge	  was	  
administered.	   It	   has	   been	   argued	   that	   inflammation	   that	   rapidly	   resolves	   is	   not	   truly	  
reflective	   of	   a	   chronic	   asthmatic	   condition	   (500,	   610,	   645).	   However,	   this	   acute	  
inflammatory	   phase	   also	   occurs,	   and	   resolves,	   repeatedly	   in	   chronic	   disease	   and	   many	  
patients	   suffer	   from	   acute	   exacerbations	   of	   asthmatic	   disease.	   It	   is,	   then,	   appropriate	   to	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assess	   lung	   histopathology	   to	   determine	  whether	   changes	   have	   developed	  where	   airway	  
remodelling	  and	  AHR	  may	  remain	  long	  after	  exposure	  to	  allergen	  has	  ceased	  (645,	  679).	  	  	  
	  
Extensive	  histological	  pathology	  was	  identified	  in	  the	  model	  of	  allergic	  airway	  inflammation	  
described	   in	   this	   chapter;	   tissue	   destruction,	   goblet	   cell	   hyperplasia,	   increased	   airway	  
smooth	  muscle	  and	  collagen	  deposition,	  and	  an	   increase	   in	  mast	  cell	  numbers	   in	   the	   lung	  
were	   observed,	   replicating	   the	   key	   features	   of	   airway	   remodelling	   (560-­‐562).	   It	   could	  be	  
concluded,	  then,	  that	  in	  this	  model	  of	  airway	  allergy,	  several	  important	  features	  of	  chronic	  
disease	  were	  effectively	  replicated.	  	  
	  
A	   number	   of	   the	   parameters	   examined	   in	   the	   experiments	   in	   this	   chapter	   also	   reflect	  
changes	  in	  the	  airway	  that	  may	  be	  indicative	  of	  airway	  hyperreactivity.	  Firstly,	  an	  increase	  
in	  IL-­‐13	  was	  consistently	  measured	  in	  OVA/Alum	  groups.	  It	  has	  been	  widely	  reported	  both	  
in	  murine	  experimental	  models,	  as	  well	  as	  human	  asthmatics,	  that	  IL-­‐13	  has	  a	  critical	  role	  in	  
the	   development	   of	   AHR	   (525,	   680-­‐683).	   Additionally,	   there	   was	   an	   increase	   in	   airway	  
smooth	  muscle	  (ASM)	  observed.	  While	  the	  relationship	  between	  ASM	  and	  AHR	  is	  not	  clear	  
(that	   is,	   a	   greater	   mass	   of	   ASM	   does	   not	   necessarily	   equate	   to	   increased	   potential	   for	  
contractility),	  it	  has	  been	  found	  that	  the	  removal	  of	  ASM	  in	  asthmatic	  patients	  by	  bronchial	  
thermoplasty	  (the	  delivery	  of	  radiofrequency	  energy	  to	  the	  airway	  wall	  to	  heat	  tissue	  in	  a	  
way	  that	  reduces	  muscle	  mass)	  leads	  to	  an	  improvement	  in	  AHR,	  suggesting	  increased	  ASM	  
plays	   a	   pathological	   role	   (500,	   610,	   684).	   Interestingly,	   another	   study	  has	   found	   that	   the	  
presence	  of	  mast	  cells	  within	  ASM	  is	  a	  key	  factor	  in	  the	  development	  of	  airway	  resistance	  
and	  hyperreactivity	  in	  human	  asthmatics	  (542,	  645),	  and	  contributes	  to	  AHR	  by	  increasing	  
contractility	   of	   ASM	   cells	   (543,	   645,	   679);	   this	   pattern	   of	   mast	   cell	   localisation	   has	   not	  
previously	   been	   reported	   in	   murine	   models,	   but	   was	   identified	   in	   the	   present	   study.	   A	  
limitation	   of	   this	   study	   was	   that	   AHR,	   airway	   resistance	   and	   other	   parameters	   of	  
physiological	   lung	   function	  were	   not	   directly	  measured.	   However,	   the	   findings	   discussed	  
here	  suggest	  pathological	  changes	  that	  induce	  AHR	  may	  be	  present	  in	  this	  model.	  	  
	  
CTL-mediated immunotherapy of allergic airway disease 
	  
The	  suppression	  of	  acute	  airway	  inflammation	  by	  allergen-­‐specific	  CTLs	  has	  been	  reported	  
(226,	  560-­‐562).	  The	  present	  study	  evaluated	  the	  ability	  of	  CTLs	  to	  prevent	  allergic	  airway	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inflammation	  over	  multiple	  allergen	  exposures,	  as	  well	  as	  the	  therapeutic	  potential	  during	  
established	   inflammation.	   It	   was	   clear	   that	   CTLs	   mediated	   significant	   effects	   on	   airway	  
immune	  cell	  infiltrate,	  Th2	  cytokine	  production	  and	  airway	  histology.	  	  
	  
The	   characterisation	   of	   BAL	   cellularity	   revealed	   that	   mice	   treated	   with	   CTLs,	   in	   both	  
preventative	   and	   therapeutic	   contexts,	   had	   significantly	   reduced	   eosinophilia.	   As	  
eosinophils	  are	  critical	  mediators	  in	  the	  deposition	  of	  collagen,	  airway	  smooth	  muscle	  and	  
mucus	   production	   (506,	   525,	   638,	   680-­‐683),	   this	   finding	   was	   an	   acute-­‐phase	   primary	  
indicator	   that	   a	   reduction	   in	   airway	   remodelling	   could	   become	   evident.	   A	   reduction	   in	  
lymphocytosis	  was	   also	   observed	  with	   both	  preventative	   and	   therapeutic	   CTL	   treatment,	  
however	   in	   some	   experiments	   where	   CTLs	   were	   given	   4	   –	   11	   days	   before	   mice	   were	  
sacrificed,	  lymphocytes	  remained	  elevated.	  As	  host	  lymphocytes	  and	  adoptively	  transferred	  
CTLs	  were	  not	  differentiated	  in	  these	  experiments,	   it	  was	  possible	  that	  the	   lymphocytosis	  
observed	   in	   CTL-­‐treated	   groups	   comprised	   both	   of	   these	   populations,	   and	   that	   CTLs	  
administered	  closer	  to	  the	  time	  of	  the	  experimental	  end	  point	  may	  be	  present	  in	  the	  lung	  in	  
higher	  numbers.	  This	  hypothesis	  is	  examined	  and	  reported	  on	  in	  Chapter	  4.	  	  
	  
A	   reduction	   in	   key	   Th2	   cytokines	   IL-­‐4,	   IL-­‐5	   and	   IL-­‐13	   was	   consistently	   seen	   in	  
therapeutically	   CTL-­‐treated	   groups,	   however	   the	   variation	   of	   measured	   concentrations	  
within	  OVA/Alum	  groups	  meant	  that	  statistical	  significance	  was	  not	  reached.	   	  An	  anomaly	  
encountered	   in	   some	   experiments	  was	   the	   inability	   of	   CTLs	   to	   suppress	   IL-­‐4	   production	  
when	   CTLs	   were	   given	   in	   a	   prophylactic	   manner.	   This	   could	   be	   due	   to	   differences	   in	  
cytokine	   production	   by	   key	   cell	   populations	   between	   the	   primary	   acute	   response	   and	  
subsequent	  responses	  in	  the	  established	  Th2	  inflammatory	  environment,	  and	  the	  effects	  of	  
the	  introduction	  of	  CTLs	  before	  or	  after	  the	  initiation	  of	  these	  events.	  	  
	  
There	  are	  a	  number	  of	  cells	  involved	  in	  the	  pathology	  of	  allergic	  airway	  inflammation	  that	  
may	  produce	  IL-­‐4	  during	  allergen	  challenge.	  In	  addition	  to	  CD4+	  T	  cells,	  basophils	  and	  NK	  
cells	  have	  been	  reported	  as	  important	  producers	  of	  this	  key	  cytokine	  in	  both	  helminth	  and	  
allergen-­‐induced	   models	   of	   Th2	   immune	   responses.	   Basophils	   have	   been	   deemed	   a	   key	  
early	   source	   of	   IL-­‐4	   in	   Th2	   immunity,	   (430,	   433,	   434)	   however,	   the	   priming	   and	  
differentiation	   of	   Th2	   cells	   occurs	   independently	   of	   basophils	   (435,	   550,	   685).	   The	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requirement	  for	  NK	  and	  NKT	  cells	  in	  allergic	  asthma	  has	  been	  disputed,	  with	  studies	  using	  
various	  knock-­‐out	  models	  revealing	  both	  essential	  and	  non-­‐essential	  roles	  (149,	  424,	  686-­‐
688).	  Recent	  work	  has	  more	  definitively	  shown	  that	  while	  these	  cells	  may	  amplify	  effector	  
responses,	  the	  contribution	  of	  NK	  and	  NKT	  cells	  is	  not	  crucial	  for	  the	  initiation	  of	  the	  Th2	  
response	  (425),	  and	  may	  only	  be	   important	   in	  acute	  responses	  rather	  than	   in	  the	  chronic	  
setting	  (689).	  Eosinophils	  and	  mast	  cells	  additionally	  produce	  IL-­‐4	  under	  Th2	  conditions,	  in	  
a	   redundant	   manner	   (690-­‐693).	   As	   IL-­‐4-­‐producing	   populations	   were	   not	   enumerated	   in	  
these	   experiments,	   their	   contribution	   to	   disease	   and	   subsequent	   response	   to	   CTL	  
immunotherapy	  in	  this	  model	  cannot	  be	  defined,	  however	  the	  lack	  of	  suppression	  of	  IL-­‐4	  in	  
these	  experiments	  did	  not	   translate	   to	   increased	  pathology	   in	   terms	  of	  BAL	   inflammatory	  
infiltrates	  or	  airway	  histopathology,	  so	  amelioration	  of	  disease	  was	  still	  evident.	  	  
	  
The	   observed	   reduction	   in	   IL-­‐5	   prompted	   further	   investigation	   of	   the	   systemic	   effects	   of	  
CTL	   immunotherapy,	   as	   IL-­‐5	   is	   important	   for	   the	   proliferation	   and	   differentiation	   of	  
eosinophils	  as	  well	  as	  their	  release	  from	  bone	  marrow	  (678).	  The	  reduction	  in	  peripheral	  
blood	  eosinophils	  that	  was	  observed	  mirrors	  the	  response	  seen	  in	  corticosteroid	  treatment	  
that	   is	   associated	   with	   improved	   clinical	   outcome	   (694,	   695).	   This	   finding	   suggests	   CTL	  
therapy	  reflects	  clinically	  relevant	  parameters	  in	  the	  treatment	  of	  allergic	  airway	  disease.	  
	  
It	  is	  clear	  that	  lung	  histopathology	  was	  significantly	  improved	  by	  CTL	  immunotherapy,	  with	  
reductions	  in	  tissue	  destruction,	  goblet	  cell	  hyperplasia,	  airway	  smooth	  muscle	  and	  collagen	  
deposition,	  and	  mast	  cell	  infiltration.	  What	  is	  more	  difficult	  to	  ascertain	  is	  whether	  CTLs	  are	  
capable	   of	   reversing	   airway	   pathology,	   or	   rather	   that	   pathology	   is	   prevented	   from	  
worsening	  after	  the	  time	  of	  CTL	  administration.	  It	  appears	  that	  mastocytosis	  and	  goblet	  cell	  
hyperplasia	   were,	   in	   fact,	   reversed	   in	   CTL	   treated	  mice.	   The	   pathology	   of	   three	   allergen	  
challenges	  showed	  significant	  mucus	  production	  and	  mast	  cell	  numbers	  in	  the	  lung	  tissue	  at	  
this	   time	  point;	   subsequent	   administration	  of	   CTLs	   resulted	   in	   the	   reduction	  of	  mast	   cell	  
numbers	  and	  regression	  of	  goblet	  cell	  hyperplasia	  to	  the	   level	  of	  healthy	  controls,	  despite	  
further	  airway	  allergen	  exposures.	  Others	  have	  reported	  that	  mast	  cells	  may	  rapidly	  return	  
to	  baseline	  levels	  after	  treatment	  interventions	  (696-­‐698),	  and	  goblet	  cell	  hyperplasia	  may	  
also	  be	  reduced	  (699).	  Airway	  function	  may	  be	  significantly	  enhanced	  by	  an	  improvement	  
in	  these	  parameters,	  however	  aspects	  of	   long	  term	  damage	  may	  remain;	  CTL	  therapy	  was	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capable	  of	  preventing	  collagen	  deposition,	  and	  therapeutic	  administration	  of	  CTLs	  resulted	  
in	   fibrosis	  not	  continuing	  to	  worsen,	  however	   lung	  tissue	  did	  not	  return	  to	  a	  healthy	  pre-­‐
challenge	  state	  in	  the	  time	  frame	  of	  these	  experiments.	  This	   is	   in	  accordance	  with	  what	  is	  
known	  about	  healing	  and	  repair	  in	  chronic	  disease.	  Significantly	  fibrotic	   lung	  parenchyma	  
loses	   the	   ability	   to	   be	   regenerated	   into	   physiologically	   functional	   tissue,	   and	   there	   is	  
currently	   no	   effective	   therapeutic	   intervention	   that	   can	   lead	   to	   repair	   of	   tissue	   fibrosis	  
(699-­‐701).	  It	  would	  be	  useful	  to	  measure	  AHR,	  airway	  resistance	  and	  other	  parameters	  of	  
lung	   function	   in	   this	   model	   to	   translate	   these	   findings	   into	   functional	   readouts	   of	   lung	  
physiology.	   Nevertheless,	   the	   combined	   reduction	   of	   airway	   inflammatory	   infiltrate,	   Th2	  
cytokines,	   and	   mucus	   production	   represent	   significant	   parameters	   that	   correlate	   with	  
improved	  lung	  function	  (525,	  680-­‐683,	  694,	  695).	  	  
	  
It	  was	   interesting	   that	   a	   reduction	   in	  mast	   cells	  was	  observed	  with	  CTL	   immunotherapy,	  
while	   IgE	   remained	   unaffected.	   The	   roles	   of	   mast	   cells	   and	   IgE	   in	   allergic	   airway	  
inflammation	   have	   not	   been	   fully	   elucidated.	   Kobayashi	   et	   al	   suggest	   that	   two	   distinct	  
pathways	  exist	  for	  the	  development	  of	  AHR:	  an	  IgE/mast	  cell	  dependent	  mechanism,	  as	  well	  
as	  an	  eosinophil/IL-­‐5	  dependent	  mechanism	  (702).	  However,	  Williams	  and	  Galli	  argue	  that	  
the	  Kobayashi	  model	  was	  “weak”	  (in	  the	  induction	  of	  eosinophilia)	  and	  thus	  does	  not	  prove	  
a	   mast	   cell	   dependent	   mechanism	   for	   AHR	   (541).	   In	   a	   model	   that	   induces	   substantial	  
eosinophilia,	   mast	   cells	   were	   shown	   not	   to	   be	   critical	   for	   the	   induction	   of	   the	   hallmark	  
features	   of	   airway	   disease	   (444).	   However,	   mast	   cells	   are	   recognized	   as	   amplifiers	   of	  
antigen-­‐dependent	   chronic	   inflammation	   in	   the	   airway	   (541).	   Therefore,	   CTL	   therapy	  
effectively	   reduces	   the	   amplification	   of	   chronic	   inflammation.	   Importantly,	   and	   directly	  
related	   to	  mast	   cell	   activation,	   IgE	   has	   an	   important	   role	   only	   in	   experimental	   protocols	  
where	  strong	  eosinophilia	  is	  not	  induced	  (540).	  Thus,	  the	  presence	  of	  IgE	  in	  serum	  is	  less	  
indicative	  of,	  and	  has	  less	  impact	  on,	  disease	  severity	  in	  our	  model	  than	  the	  suppression	  of	  
eosinophilia,	  which	  is	  effectively	  achieved	  by	  CTL	  immunotherapy.	  	  
	  
Alterations	   in	   the	   temporal	   administration	   of	   CTLs	   revealed	   important	   insights	   into	   the	  
mechanism	   of	   action	   of	   immunotherapy.	   The	   suppression	   of	   allergic	   airway	   disease	  
appeared	  to	  be	  least	  effective	  when	  CTLs	  were	  administered	  immediately	  before	  the	  final	  of	  
three	  airway	  allergen	  challenges,	  4	  days	  before	  mice	  were	  sacrificed.	  This	  finding	  seemed	  to	  
   124 
 
initially	   suggest	   that	   with	   additional	   airway	   challenges,	   inflammation	   is	   less	   well	  
suppressed;	  however,	  this	  was	  tested	  in	  experiments	  where	  CTLs	  were	  administered	  after	  
three	  challenges,	  with	  two	  further	  challenges	  then	  carried	  out	  –	  the	  result	  of	  which	  showed	  
that	   inflammation	   did	   not	   become	   worse.	   In	   light	   of	   these	   results,	   it	   appeared	   that	   the	  
reduced	  efficacy	  of	  CTL	  therapy	  was	  not	  related	  to	  the	  number	  of	  allergen	  challenges,	  but	  
potentially	   due	   to	   the	   administration	   of	   treatment	   being	   closer	   to	   the	   end	   point	   of	   the	  
experiment,	   allowing	   less	   time	   for	   CTL-­‐mediated	   resolution	   of	   inflammation.	   However,	   if	  
we	   consider	   that	   mice	   treated	   preventatively,	   4	   days	   before	   the	   end	   point,	   in	   an	   acute	  
setting	   show	   effectively	   reduced	   airway	   inflammation	   (226),	   this	   suggests	   that	   CTL-­‐
mediated	  suppression	  of	  disease	  does	  not	  require	  extended	  resolution	  time-­‐	  at	  least	  in	  the	  
acute	   context.	   The	  kinetics	   of	   CTL	   immunotherapy	   in	   the	   context	   of	   acute	   vs.	   established	  
airway	  inflammation	  is,	  then,	  the	  remaining	  factor	  to	  consider.	  	  
	  
In	   chronic	   disease,	   there	   is	   an	   increase	   in	   DC	   numbers	   in	   lung	   tissue,	   with	   increased	  
maturation	   markers	   and	   allergen-­‐presenting	   capability	   (703-­‐706).	   Additionally	   and	  
subsequently,	  an	  increase	  in	  CD69	  expression	  has	  been	  reported	  on	  CD4+	  T	  cells,	  indicative	  
of	  increased	  antigen	  presentation	  (706).	  In	  a	  model	  of	  multiple	  allergen	  exposures,	  then,	  a	  
larger	   pool	   of	   allergen-­‐presenting	  DCs	   stimulate	   CD4+	  T	   cell	   responses,	   compared	   to	   the	  
acute	  model	  where	  there	  are	  fewer	  allergen-­‐presenting	  cells,	  yet	  a	  strong	  primary	  immune	  
response	  is	  still	  induced.	  If	  the	  suppressive	  effects	  of	  CTL	  immunotherapy	  are	  mediated	  by	  
the	  killing	  of	  DCs,	  as	  has	  been	  proposed	  (226),	  this	  could	  explain	  why	  in	  the	  acute	  scenario	  
(where	  fewer	  allergen-­‐presenting	  DC	  are	  present)	  CTLs	  may	  be	  able	  to	  diminish	  allergen-­‐
presenting	  DC	  populations	  more	  efficiently,	  such	  that	  inflammation	  is	  resolved	  quickly;	  the	  
progression	   of	   allergic	   inflammation	   after	   multiple	   allergen	   challenges	   may	   be	   more	  
difficult	  to	  restrain,	  as	  appears	  to	  be	  the	  case	  in	  mice	  treated	  with	  CTLs	  one	  day	  before	  the	  
final	  of	  three	  challenges.	  This	  does	  not,	  however,	  fully	  explain	  why	  mice	  treated	  with	  CTLs	  
after	   three	  challenges	  have	  strongly	  abrogated	  airway	   inflammation	  even	  after	  additional	  
allergen	  challenges;	  a	  result	  that	  suggests	  CTL	  immunotherapy	  may	  be	  more	  effective	  over	  
time.	   A	   possible	   explanation	   for	   this	   phenomenon	   is	   that	   successive	   allergen	   exposures	  
stimulate	   increased	  CTL	  proliferation	   and	   activation	   allowing	   for	   the	   targeting	   of	   greater	  
numbers	   of	   DCs.	   The	   work	   of	   other	   authors	   has	   described	   similar	   effects	   of	   treatment	  
during	  early	  versus	  later	  stages	  of	  chronic	  disease	  (699).	  Alternatively,	  as	  the	  targeting	  of	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DCs	  would	  require	  cell-­‐cell	  contact	  with	  CTLs,	  it	  is	  worth	  considering	  that	  the	  localisation	  of	  
DCs	  in	  tissue	  may	  affect	  the	  ability	  of	  CTLs	  to	  interact	  with	  and	  target	  allergen-­‐presenting	  





In	   this	   chapter,	   allergic	   airway	   inflammation	  was	   induced	  by	  multiple	   allergen	  exposures	  
that	   led	   to	   increased	   immune	  cell	   infiltrate	   into	  airways	  and	   lungs,	   the	  production	  of	  Th2	  
cytokines,	   and	   airway	   remodelling	   evident	   as	   goblet	   cell	   hyperplasia,	   increased	   collagen	  
deposition	  and	  airway	  smooth	  muscle.	  Within	  this	  model,	  allergen-­‐specific	  CTLs	  were	  found	  
to	  mediate	  suppression	  of	  all	  features	  of	  allergic	  disease	  in	  long-­‐term	  preventative	  as	  well	  
as	   therapeutic	   contexts.	   These	   results	   suggest	   that	   CTL-­‐mediated	   immunotherapy	   may	  



















































































CTL-mediated suppression of allergic airway 
inflammation is associated with a reduction in 








































The	   preventative	   and	   therapeutic	   effects	   of	   allergen-­‐specific	   CTLs	   on	   established	   allergic	  
airway	  inflammation	  have	  been	  described	  (Chapter	  3).	  However,	  the	  mechanism	  by	  which	  
CTLs	  ameliorate	  inflammation	  was	  not	  revealed	  through	  the	  examination	  of	  lung	  pathology.	  
The	  ability	  of	  CTLs	  to	  suppress	  hallmark	  features	  of	  Th2	  disease	  suggests	  that	  CTLs	  may	  be	  
mediating	  direct	  or	  indirect	  effects	  on	  key	  drivers	  of	  the	  allergic	  response:	  CD4+	  Th2	  cells.	  	  
	  
CD4+	  T	   cells	   are	  widely	   recognised	  as	   critical	  mediators	  of	   allergic	  pathology,	   (472,	  707-­‐
710),	   although	   their	   role	   and	   activity	   during	   allergic	   inflammation	   is	   still	   not	   fully	  
understood.	  Additionally,	  the	  direct	  or	  consequential	  effects	  of	  CD8+	  T	  cells	  on	  CD4+	  T	  cells	  
during	  allergic	  airway	  inflammation,	  especially	  in	  a	  context	  critically	  dependent	  on	  perforin,	  
have	   not	   been	   thoroughly	   examined.	   Interestingly,	   in	   asthmatic	   patients,	   an	   increase	   in	  
CD4+	  T	  cells	  in	  the	  lung	  and	  BAL	  is	  directly	  related	  to	  the	  severity	  of	  airway	  hyperreactivity,	  
while	   an	   inverse	   correlation	   exists	   with	   CD8+	   T	   cells	   (708,	   711).	   These	   studies	   suggest	  
there	  may	  be	  an	   important	  balance	  between	  the	  activity	  of	  CD4+	  T	  cells	  and	  CD8+	  T	  cells	  
that	   maintains	   airway	   homeostasis,	   and	   potentially	   implicates	   CD8+	   T	   cells	   in	   the	  
diminution	  of	  human	  atopic	  asthmatic	  disease.	  	  
	  
The	  ex	  vivo	  analysis	  of	  antigen-­‐specific	  CD4+	  T	  cells	  and	  CD8+	  T	  cells	  is	  difficult,	  due	  to	  their	  
low	   frequency;	   indeed,	   even	   upon	   successful	   identification	   of	   these	   cells,	   the	   meagre	  
population	  may	   not	   be	   sufficient	   to	   draw	  meaningful	   conclusions	   about	   their	   phenotype	  
and	   function	   during	   inflammatory	   disease.	   An	   alternative	  method	  may	   be	   employed:	   the	  
utilisation	  of	  exogenously	  enriched	  antigen-­‐specific	  T	  cells	  that	  may	  be	  identified	  based	  on	  
cell	  surface	  expression	  of	  unique	  markers.	  The	  adoptive	  transfer	  of	   in	  vitro-­‐cultured	  CD4+	  
Th2	  cells	  into	  naïve	  mice	  has	  been	  shown	  to	  induce	  lung	  eosinophilia	  and	  recapitulate	  the	  
characteristics	  of	  allergic	  disease	  upon	  airway	  allergen	  exposure	  (472,	  650,	  651,	  707-­‐710).	  
In	  this	  context,	  adoptively	  transferred	  T	  cells	  migrate	  to	  peripheral	  tissues	  where	  antigen	  is	  
present	  (486,	  711,	  712).	  CD8+	  and	  CD4+	  T	  cells	  from	  congenic	  OT-­‐I	  x	  B6.SJL-­‐Ptprca	  and	  OT-­‐
II	   x	   B6.SJL-­‐Ptprca	   mice,	   respectively,	   may	   be	   injected	   into	   C57BL/6	   hosts	   without	  
compatibility	   issues;	   the	   CD45.1+	   congenic	   lymphocytes	   may	   then	   be	   isolated	   and	  
distinguished	  from	  C57BL/6	  host	  cells	  that	  are	  CD45.2+.	  This	  concept	  provides	  the	  basis	  for	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the	  development	  and	  characterisation	  of	  a	  model	  of	  allergic	  airway	  inflammation	  in	  which	  
adoptively	   transferred,	   allergen-­‐specific	   CD4+	   and	   CD8+	   T	   cells	   may	   be	   tracked	   and	  
examined.	  	  
	  
Recently,	  4C13R	  mice	  were	  developed	  by	  William	  E	  Paul	  and	  associates,	  providing	  a	  useful	  
model	   for	   studying	   CD4+	   T	   cell	   production	   of	   IL-­‐4	   and	   IL-­‐13	   in	   vivo.	   The	   fluorescent	  
markers	  AmCyan	   and	  dsRed	   report	   expression	  of	   IL-­‐4	   and	   IL-­‐13,	   respectively.	  Generated	  
using	   a	   bacterial	   artificial	   chromosome	   construct,	   these	   mice	   remain	   IL-­‐4	   and	   IL-­‐13	  
sufficient	   –	   a	   significant	   advantage	   over	   previously	   available	   IL-­‐4	   reporter	   mice	   (660).	  
Additionally,	  as	   IL-­‐4	  and	   IL-­‐13	  have	  distinct	   roles	   in	  asthma	  pathogenesis	   (680),	   the	  dual	  
reporting	  capability	  of	  4C13R	  mice	   is	  a	  valuable	   tool	   in	   revealing	   the	  production	  of	   these	  
cytokines	   that	   are	   not	   always	   regulated	   in	   the	   same	  way.	   In	   an	   adoptive	   transfer	  model,	  
CD4+	  T	  cells	  from	  these	  mice	  could	  be	  utilised	  to	  investigate	  cytokine	  production	  on	  a	  per-­‐
cell	  basis.	  	  
	  
The	  adoptive	  transfer	  model	  of	  allergic	  airway	  inflammation,	  as	  proposed,	  would	  primarily	  
replicate	  the	  T-­‐cell-­‐driven	  late	  asthmatic	  response.	  During	  this	  phase,	  allergen	  exposure	  in	  
the	  airway	  drives	  Th2	  cell	  activation,	  proliferation,	  migration	  to	  the	  lung	  and	  production	  of	  
key	   cytokine	  mediators	   IL-­‐4,	   IL-­‐5	   and	   IL-­‐13.	   These	   factors,	   in	   concert	  with	   subsequently	  
infiltrating	   inflammatory	   cell	   subsets,	   drive	   characteristic	   pathology	   of	   allergic	   airway	  
inflammation	  (503,	  504,	  510,	  511,	  524,	  525).	  Examination	  of	  the	  effects	  of	  allergen-­‐specific	  
CTLs	   on	   these	   parameters	   of	   the	   effector	   Th2	   cell	   response	   may	   therefore	   be	   useful	   to	  













The	  purpose	  of	  this	  chapter	  was	  to	  develop	  and	  characterise	  an	  adoptive	  transfer	  model	  of	  
allergic	  airway	  inflammation	  to	  track	  and	  examine	  the	  activity	  of	  CD4+	  T	  cells	  and	  CD8+	  
CTLs,	  and	  investigate	  the	  effects	  of	  these	  CTLs	  on	  the	  disease-­‐mediating	  CD4+	  T	  cells.	  The	  
hypothesis	  was	  that	  the	  activation,	  proliferation,	  migration	  and	  cytokine	  production	  of	  
CD4+	  T	  cells	  may	  be	  affected	  by	  CTLs	  due	  to	  the	  observation	  (Chapter	  3)	  that	  CTLs	  are	  
capable	  of	  suppressing	  and	  treating	  the	  pathological	  outcomes	  of	  allergic	  airway	  disease	  
that	  are	  largely	  driven	  by	  a	  Th2	  response.	  	  
	  
The	  specific	  aims	  were:	  
• To	  develop	  and	  characterise	  an	  adoptive	  transfer	  model	  of	  allergic	  airway	  
inflammation	  that	  replicates	  the	  pathology	  observed	  after	  in	  vivo	  sensitisation	  
• To	  investigate	  the	  effects	  of	  CTLs	  on	  the	  proliferation	  of	  CD4+	  T	  cells	  and	  their	  
number	  in	  the	  lung	  and	  airways	  
• To	  assess	  the	  effects	  of	  CTLs	  on	  the	  activation	  status	  of	  disease-­‐mediating	  CD4+	  T	  
cells	  	  
• To	  determine	  whether	  CD4+	  T	  cells	  have	  a	  diminished	  ability	  to	  produce	  

















4.3.1 Optimisation of CD4+ T cell culture system 
	  
To	   identify	   and	   investigate	   the	   in	  vivo	  mechanisms	  of	   action	  of	  CD4+	  T	   cells,	   an	   adoptive	  
transfer	  model	  of	  allergic	  airway	  inflammation	  was	  developed.	  CD4+	  T	  cells	  were	  isolated	  
from	  the	  lymph	  nodes	  of	  OTII	  mice	  and	  co-­‐cultured	  with	  OVA323-­‐339-­‐pulsed	  DCs	  in	  IL-­‐2	  and	  
IL-­‐4	  supplemented	  media	  to	  generate	  OVA-­‐specific	  Th2	  cells.	  	  
	  
To	  optimise	  the	  yield	  and	  activation	  status	  of	  CD4+	  T	  cells,	  in	  vitro	  culture	  conditions	  were	  
varied	   by	   modifying	   the	   ratio	   and	   number	   of	   CD4+	   T	   cells	   and	   DCs	   in	   co-­‐culture.	  
Additionally,	  some	  cultures	  were	  split	  at	  day	  4,	  while	  others	  were	  cultured	  continuously	  for	  
5	   days	   (Conditions	   1-­‐4	   outlined	   in	  Table	   4.1).	   The	   cell	   yield	   and	   expression	   of	   activation	  
markers	  CD44,	  CD69	  and	  CD62L	  were	  examined	  to	  determine	  optimal	  culture	  conditions.	  
The	   cell	   yield	   at	   the	   completion	   of	   culture	   varied	   considerably	   between	   conditions	  
examined;	   a	   1:4	   ratio	   of	   DC:CD4+	   T	   cells	   resulted	   in	   the	   largest	   increase	   in	   CD4+	   T	   cell	  
numbers,	  compared	  to	  1:2	  ratio	  (Table	  4.1).	  Continuous	  5	  day	  culture	  of	  1	  x	  106	  DC	  with	  4	  x	  
106	  CD4+	  T	  cells	  showed	  an	  approximately	  5-­‐fold	  increase	  in	  cell	  numbers,	  and	  cultures	  of	  
0.5	   x	   106	   DC	   with	   2	   x	   106	   CTL	   that	   were	   split	   at	   day	   4	   increased	   7-­‐fold.	  
 
Table	  4.1:	  Optimisation	  of	  CD4+	  Th2	  cell	  generation	  –	  conditions	  for	  culture	   	  
CD4+	   T	   cells	   were	   isolated	   from	   the	   lymph	   nodes	   of	   OTII	   mice	   and	   co-­‐cultured	   with	  
OVA323-­‐339-­‐pulsed	   DCs	   in	   IL-­‐2	   and	   IL-­‐4	   supplemented	   media	   to	   generate	   OVA-­‐specific	  
Th2	   cells.	   The	   ratio	   and	   number	   of	   CD4+	   T	   cells	   and	   DCs	   in	   co-­‐culture	   were	   varied	   as	  
indicated.	  Some	  cultures	  were	  split	  at	  day	  4,	  while	  others	  were	  cultured	  continuously	  for	  5	  
days.	  Data	  are	  representative	  of	  three	  separate	  cell	  culture	  experiments,	  within	  which	  the	  
yield	  of	  3	  wells	  was	  averaged.	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Cells	   were	   analysed	   by	   flow	   cytometry	   to	   assess	   the	   proportion	   of	   live	   cells	   by	   DAPI	  
exclusion,	  of	  which	  FSC-­‐Hhi,	  CD4+,	  OVA-­‐specific	  T	  cells	   (Vα2+,	  Vβ5.1,5.2+)	  were	   identified	  
(representative	   flow	   gating,	   Fig	   4.1	   A).	   The	   proportion	   of	   live,	   antigen-­‐specific	   cells	  
generated	  through	  culture	  was	  best	  where	  fewer	  cells	  per	  well	  were	  plated	  initially	  (Table	  
4.1).	  The	  activation	  status	  of	  cells	  was	  additionally	  examined	  by	  the	  expression	  of	  activation	  
markers	   CD44,	   CD69	   and	   CD62L	   (Representative	   flow	   gating,	   Fig	   4.1	   A).	   An	   increase	   in	  
CD44,	  CD69	  and	  decrease	   in	  CD62L,	   characteristic	   of	  T	   cell	   activation,	  was	  observed	   to	   a	  
similar	  extent	   in	  all	  conditions	  tested	  (Fig	  4.1	  B),	  compared	  to	  FSC-­‐Hlo	  non-­‐activated	  cells	  
from	   the	   same	   culture	  well;	   however,	   CD44	  was	  notably	   higher	   in	   cells	   cultured	   at	   a	   1:4	  
ratio,	  with	  1	  x	  106	  DC	  and	  4	  x	  106	  CD4+	  T	  cells.	  Considered	  together,	  the	  results	  of	  culturing	  
CD4+	  T	  cells	  under	  the	  conditions	  described	  showed	  that	  a	  1:4	  ratio	  of	  DC:CD4+	  T	  cells	  was	  
superior	  to	  	  1:2.	  While	  0.5	  x	  106	  DC	  with	  2	  x	  106	  CD4+	  T	  cells	  split	  at	  day	  4	  produced	  a	  high	  
cell	   yield	   and	   proportion	   of	   live	   antigen-­‐specific	   cells,	   the	   CD44	   expression	   was	   most	  
increased	  in	  cells	  cultured	  at	  1	  x	  106	  DC	  with	  4	  x	  106	  CD4+	  T	  cells	  –	  a	  condition	  that	  showed	  
reasonably	  similar	  cell	  yield	  after	  5	  days	  continuous	  culture.	  Therefore,	  a	  method	  of	  1	  x	  106	  
DC	  co-­‐cultured	  with	  4	  x	  106	  CD4+	  T	  cells	  for	  5	  days	  was	  employed	  in	  all	  further	  experiments.	  	  
	  
4.3.2 Optimisation of an adoptive transfer model of allergic airway 
inflammation 
	  
To	  determine	  the	  number	  of	  CD4+	  T	  cells	  required	  to	   induce	  strong,	  reproducible	  allergic	  
airway	  inflammation	  in	  vivo	  a	  titration	  was	  carried	  out,	  initially	  by	  administration	  of	  2	  x	  106,	  
5	  x	  106	  or	  10	  x	  106	  CD4+	  T	  cells.	  The	  cells	  were	  injected	  intravenously	  into	  naïve	  C57BL/6J	  
mice	  and	  a	  single	  airway	  allergen	  challenge	  was	  carried	  out	  one	  day	  later	  (Fig	  4.2	  A).	  BAL	  
was	   performed	   3	   days	   after	   intranasal	   challenge	   and	   the	   inflammatory	   cell	   infiltrate	  
assessed	  by	  flow	  cytometry	  as	  described	  in	  Chapter	  3,	  Fig	  3.1.	  	  
	  
The	  number	  of	   total	   cells	  and	  eosinophils	   in	  BAL	  was	   increased	  significantly	   in	  mice	   that	  
received	   5	   x	   106	  and	   10	   x	   106	   cells	   compared	   to	   naïve	   controls,	   however	   no	   significant	  
increase	  was	  present	  in	  mice	  that	  received	  2	  x	  106	  cells	  (Fig	  4.2).	  Administration	  of	  5	  x	  106	  
CD4+	   T	   cells	   provoked	   higher	   numbers	   of	   total	   cells	   and	   eosinophils	   to	   infiltrate	   than	  
administration	  of	  2	  x	  106	  cells;	  no	  further	  increase	  was	  observed	  in	  mice	  given	  10	  x	  106	  cells.	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Figure	   4.1:	   Optimisation	   of	   CD4+	   T	   cell	   culture	   conditions	   for	   adoptive	   transfer	  
experiments	  	  
CD4+	  T	  cells	  were	  isolated	  from	  the	  lymph	  nodes	  of	  OTII	  mice	  and	  co-­‐cultured	  with	  OVA323-­‐
339-­‐pulsed	  DCs	   in	   IL-­‐2	   and	   IL-­‐4	   supplemented	  media	   to	   generate	   OVA-­‐specific	   CD4+	   Th2	  
cells.	   Cells	  were	   cultured	  under	   conditions	   outlined	   in	  Table	   4.1.	   (A)	   Cultured	   cells	  were	  
examined	  by	  flow	  cytometry	  for	  viability,	  activation	  and	  Vα2,Vβ5.1,5.2	  TCR	  specificity.	  (B)	  
The	  expression	  of	  activation	  markers	  CD44,	  CD69	  and	  CD62L	  on	  activated	  Vα2,Vβ5.1,5.2+	  
cells	   identified	   in	   (A)	   were	   then	   examined	   and	   compared	   to	   non-­‐activated	   FSC-­‐Hlo	   cells	  
within	   the	   same	   sample.	   Staining	   and	   marker	   expression	   are	   representative	   of	   three	  
separate	   cell	   culture	   experiments,	  within	  which	   the	   cells	   of	   3	   culture	  wells	   per	   condition	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Figure	   4.2:	   Airway	   inflammation	   induced	   by	   varying	   numbers	   of	   adoptively	  
transferred	  CD4+	  T	  cells	   	  	  
(A)	   2	   x	   106,	   5	   x	   106	   or	   10	   x	   106	  CD4+	  T	   cells	  were	   injected	   into	  naïve	  mice	   and	   a	   single	  
airway	   allergen	   challenge	   carried	   out	   one	   day	   later.	   BAL	   was	   performed	   3	   days	   after	  
intranasal	   challenge.	   (B)	   Inflammatory	   cell	   infiltrate	   was	   assessed	   by	   flow	   cytometry	   as	  
described	  in	  Fig	  3.1	  to	  enumerate	  eosinophils,	  neutrophils,	  alveolar	  macrophages	  and	  DCs	  
in	   BAL.	   Mean	   cell	   number	   in	   BAL	   +	   SEM	   are	   shown.	   Data	   are	   from	   one	   representative	  
experiment	  of	   two	   that	  gave	  similar	   results,	   each	  with	  5	  mice	  per	  group.	   *p	  <0.05,	   	   **p	  <	  
0.01,	  ***p	  <0.001,	  ns=	  not	  significant	  as	  assessed	  by	  one	  way	  ANOVA	  with	  Bonferroni’s	  post	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Neutrophils	   were	   not	   elevated	   in	   number	   in	   mice	   that	   received	   2	   x	   106	   CD4+	   T	   cells	  
compared	  to	  naïve	  controls,	  however	  a	  higher	  number	  were	  counted	  in	  mice	  treated	  with	  5	  
x	  106	  or	  10	  x	  106	  CD4+	  T	  cells;	  this	  only	  reached	  statistical	  significance	  in	  the	  10	  x	  106	  group,	  
which	   had	   significantly	   stronger	   neutrophilia	   than	   mice	   treated	   with	   5	   x	   106	   cells.	  
Compared	  to	  the	  influx	  of	  eosinophils,	  however,	  the	  number	  of	  infiltrating	  neutrophils	  was	  
much	  lower.	  The	  number	  of	  lymphocytes,	  alveolar	  macrophages	  and	  DCs,	  while	  increased	  in	  
number	  in	  all	  CD4+	  T	  cell	  treated	  groups	  compared	  to	  naïve	  controls,	  were	  not	  statistically	  
significantly	  higher	  in	  these	  experiments.	  These	  results	  show	  that	  5	  x	  106	  CD4+	  T	  cells	  are	  
sufficient	  to	  induce	  a	  strong	  allergic	  response,	  and	  the	  administration	  of	  10	  x	  106	  cells	  only	  
provokes	  a	  significantly	  stronger	  response	  in	  terms	  of	  neutrophilia.	  As	  neutrophils	  may	  be	  
more	   closely	   linked	   with	   tissue	   damage	   rather	   than	   indicative	   of	   an	   amplified	   allergic	  
response	  (713),	  eosinophils	  are	  the	  more	  pertinent	  measure	  of	  allergy,	  as	  critical	  mediators	  
of	  collagen	  deposition,	  airway	  smooth	  muscle	  thickening	  and	  mucus	  production	  (506,	  638).	  	  
	  
As	  5	  x	  106	  CD4+	  T	  cells	  mediated	  a	  robust	  inflammatory	  infiltrate	  in	  BAL,	  it	  was	  not	  known	  
whether	  this	  response	  would	  overwhelm	  the	  effectiveness	  of	  CTL	  immunotherapy	  such	  that	  
it	  may	  not	  be	  evident	  whether	  CTLs	  suppress	  allergic	  airway	  inflammation	  in	  the	  described	  
adoptive	   transfer	  model.	  To	   this	  end,	  5	  x	  106	  CD4+	  T	  cells	  were	  co-­‐administered	  with	  5	  x	  
106	  CTLs	  into	  naïve	  C57BL/6	  recipients,	  and	  additionally,	  two	  groups	  received	  3	  x	  106	  CD4+	  
T	  cells	  (with	  5	  x	  106	  CTLs),	  hypothesised	  to	  generate	  stronger	  inflammatory	  infiltrate	  than	  
that	   previously	   seen	   when	   2	   x	   106	  CD4+	   T	   cells	   were	   given,	   but	   possibly	   less	   than	   that	  
induced	  by	  5	  x	  106	  cells,	  due	  to	  the	  lower	  number	  of	  effector	  cells	  immediately	  responding	  
to	  allergen	  challenge	  (Fig	  4.3	  A).	  The	  resulting	  BAL	  on	  day	  3	  revealed	  that	   the	  number	  of	  
infiltrating	  total	  cells,	  eosinophils,	  lymphocytes	  and	  neutrophils	  were	  higher	  in	  OVA-­‐treated	  
mice	   that	   received	   3	   x	   106	  CD4+	   T	   cells	   or	   5	   x	   106	  CD4+	   T	   cells,	   compared	   to	  mice	   that	  
received	   5	   x	   106	   CD4+	   T	   cells	   without	   OVA	   challenge;	   though	   this	   was	   not	   statistically	  
significant	   for	   neutrophils	   (Fig	   4.3	   B).	   These	   cell	   populations	   showed	   a	   trend	   towards	  
additional	   increase	   in	   mice	   that	   received	   5	   x	   106	   CD4+	   T	   cells	   compared	   to	   those	   that	  
received	  3	  x	  106	  CD4+	  T	  cells;	  a	  statistically	  significant	  increase	  in	  eosinophilia	  was	  evident.	  
DCs	  showed	  a	  similar	  trend	  in	  terms	  of	  increased	  numbers	  in	  3	  x	  106	  and	  5	  x	  106	  CD4+	  T	  cell	  
treated	  groups	  compared	  to	  naïve	  controls,	  although	  statistical	  significance	  was	  not	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Figure	  4.3   
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Figure	   4.3:	   The	   induction	   and	   suppression	   of	   airway	   inflammation	   by	   adoptively	  
transferred	  T	  cells	   	  
(A)	  3	  x	  106	  or	  5	  x	  106	  CD4+	  T	  cells	  were	  injected	  with	  or	  without	  5	  x	  106	  CTLs	  into	  naïve	  
mice	   and	   a	   single	   airway	   allergen	   challenge	   was	   carried	   out	   one	   day	   later.	   BAL	   was	  
performed	  3	  days	  after	   intranasal	  challenge.	  (B)	   Inflammatory	  cell	   infiltrate	  was	  assessed	  
by	   flow	  cytometry	  as	  described	   in	  Fig	  3.1	   to	  enumerate	  eosinophils,	  neutrophils,	  DCs	  and	  
alveolar	  macrophages	   in	  BAL.	  Mean	  cell	  number	   in	  BAL	  +	  SEM	  are	   shown.	  Data	  are	   from	  
one	  representative	  experiment	  of	  two	  that	  gave	  similar	  results,	  each	  with	  5	  mice	  per	  group.	  
*p	  <0.05,	   ***p	  <0.001,	   ****p	  <0.0001,	   ns=	  not	   significant	   as	   assessed	  by	  one	  way	  ANOVA	  
with	  Bonferroni’s	  post	  test.	    
	  
	  
reached.	  Alveolar	  macrophages	  were	  not	  significantly	  altered	  in	  number	  between	  any	  of	  the	  
groups.	   Interestingly,	   when	   5	   x	   106	   CTLs	   were	   administered,	   CTLs	   suppressed	   the	  
inflammatory	  infiltration	  of	  all	  cell	  populations,	  regardless	  of	  whether	  it	  was	  3	  x	  106	  or	  5	  x	  
106	  CD4+	   T	   cells	   that	   had	   been	   co-­‐injected;	   this	   was	   statistically	   significant	   in	   terms	   of	  
suppression	  of	  eosinophilia	  and	  lymphocytosis.	  These	  results	  reveal	  that	  BAL	  inflammatory	  
infiltrates	  in	  an	  adoptive	  transfer	  model	  of	  strong	  allergic	  airway	  inflammation	  induced	  by	  
5	  x	  106	  CD4+	  T	  cells	  may	  be	  effectively	  ameliorated	  by	  immunotherapy	  with	  5	  x	  106	  CTLs.	  	  
	  
4.3.3 CTLs suppress inflammation in an adoptive transfer model of 
allergic airway disease in a manner dependent on perforin 
	  
Having	   established	   the	   conditions	   of	   an	   adoptive	   transfer	   model	   where	   substantial	   BAL	  
inflammatory	   infiltrate	   was	   inducible,	   and	   additionally	   effectively	   abrogated	   by	   CTL	  
immunotherapy,	   the	   effects	   of	   CTLs	   on	   multiple	   disease	   parameters	   of	   allergic	   airway	  
inflammation	  were	  then	  examined	  within	  this	  model.	  
	  
The	  in	  vivo	  sensitisation	  model	  described	  in	  Chapter	  3,	  in	  accordance	  with	  published	  work	  
(226),	   demonstrated	   the	   ability	   of	   CTLs	   to	   suppress	   allergic	   airway	   inflammation	   in	   a	  
manner	  that	  was	  dependent	  on	  the	  expression	  of	  perforin.	  As	  the	  adoptive	  transfer	  model	  
employs	  in	  vitro-­‐generated	  CD4+	  T	  cells,	  it	  was	  not	  known	  whether	  this	  system	  would	  also	  
require	   the	   cytotoxic	   function	   of	   CTLs	   for	   suppression	   of	   airway	   inflammation.	   To	  
investigate	  this	  question,	  mice	  were	  exposed	  to	  the	  adoptive	  transfer	  model	  depicted	  in	  Fig	  
4.3	  A,	  with	  5	  x	  106	  CD4+	  T	  cells	  alone,	  or	  with	  5	  x	  106	  WT	  or	  perforin	  knock	  out	  (PKO)	  CTLs	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co-­‐administered.	  A	  titration	  of	  the	  dose	  of	  OVA	  for	  the	  intranasal	  challenge	  was	  additionally	  
performed,	  with	  mice	   receiving	   either	   1,	   10	   or	   100μg	   of	   OVA	   i.n.,	   to	   determine	  whether	  
changes	   occur	   in	   disease	   parameters	   that	   may	   not	   be	   evident	   in	   the	   presence	   of	   excess	  
allergen.	  	  	  
	  
As	  shown	  in	  Figure	  4.4,	  in	  mice	  injected	  with	  CD4+	  T	  cells	  and	  no	  CTL,	  the	  number	  of	  total	  
cells	  and	  eosinophils	  was	  only	  marginally	   increased	  after	  challenge	  with	  1μg	  OVA,	  further	  
increased	  with	  10μg	  OVA	  challenge,	  and	  was	  significantly	  elevated	  in	  mice	  challenged	  with	  
100μg	  OVA.	  In	  contrast,	   in	  mice	  co-­‐injected	  with	  CD4+	  T	  cells	  and	  WT	  CTLs,	  there	  was	  no	  
increase	   in	   the	   number	   of	   total	   cells	   and	   eosinophils	   at	   any	   of	   the	   OVA	   doses	   used,	  
suggesting	   that	   10μg	   OVA	   was	   sufficient	   to	   elicit	   the	   suppressive	   activity	   of	   CTL.	   Co-­‐
injection	  of	  PKO	  CTLs	  had	  no	  effect	  on	  airway	  eosinophilia	  induced	  by	  CD4+	  T	  cells.	  T	  cells,	  
alveolar	  macrophages	  and	  neutrophils	  were	  not	  significantly	  different	  in	  number	  between	  
groups	   or	   OVA	   concentrations.	   B	   cells	   showed	   a	   trend	   towards	   a	   marked	   decrease	   in	  
number	  in	  all	  CTL	  and	  PKO	  CTL	  treated	  groups,	  compared	  to	  all	  CD4	  only	  groups,	  however	  
overall	  their	  numbers	  were	  potentially	  too	  low	  to	  be	  confident	  of	  the	  data,	  as	  they	  are	  near	  
background	   levels.	   While	   there	   was	   little	   difference	   in	   DC	   numbers	   between	   1μg	   OVA	  
groups,	  both	  10μg	  and	  100μg	  treatments	  showed	  DCs	  were	  significantly	  decreased	   in	  WT	  
CTL-­‐treated	  mice	  compared	  to	  CD4	  only.	  DC	  numbers	  were	  also	  partially	  reduced	  in	  100μg	  
OVA	  and	  PKO	  CTL	  treated	  mice,	  compared	  to	  100μg	  OVA	  and	  CD4	  treated	  mice,	  however,	  
they	  remained	  significantly	  elevated	  in	  comparison	  to	  DCs	  in	  mice	  treated	  with	  WT	  CTL	  in	  
the	   100μg	   OVA	   group.	   Together,	   these	   data	   indicate	   that	   CTLs	   must	   be	   able	   to	   mediate	  
cytotoxic	   function	   in	   order	   to	   effectively	   suppress	   airway	   inflammation	   in	   the	   adoptive	  
transfer	   model.	   The	   titration	   of	   OVA	   i.n.	   showed	   that	   100μg	   OVA	   induced	   the	   clearest	  
separation	  between	  cell	  numbers	  in	  mice	  treated	  with	  or	  without	  CTLs.	  	  
	  
To	   establish	   whether	   Th2	   cytokine	   production	   was	   affected	   by	   CTLs,	   a	   similar	   adoptive	  
transfer	  experiment	  was	  carried	  out	  where	  mice	  were	  injected	  with	  CD4+	  T	  cells,	  with	  or	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Figure	  4.4:	  CTLs	  suppress	   inflammatory	   infiltrates	   in	  an	  adoptive	  transfer	  model	  of	  
allergic	  airway	  inflammation	  in	  a	  manner	  dependent	  on	  perforin	  	  	  
Mice	  were	   treated	  as	  depicted	   in	  Fig	  4.3	  A;	  5	  x	  106	  CD4+	  T	  cells	  were	   injected	   into	  naive	  
mice	  with	  or	  without	  5	  x	  106	  WT	  or	  PKO	  CTLs.	  1,	  10	  or	  100μg	  of	  OVA	  was	  administered	  i.n	  
one	   day	   later	   and	   inflammatory	   cell	   populations	   measured	   in	   BAL	   3	   days	   after	   airway	  
challenge.	   	  Mean	  cell	  number	   in	  BAL	  +	  SEM	  are	  shown.	  Data	  are	   from	  one	  representative	  
experiment	   of	   two	   that	   gave	   similar	   results,	   each	  with	   3-­‐5	  mice	   per	   group.	   *p	   <0.05,	   **p	  
<0.01,	  ***p	  <0.001,	  as	  assessed	  by	  two-­‐tailed,	  unpaired	  t	  test.	  
	  
	  
without	  WT	   CTLs,	   and	   BAL	  was	   performed	   1	   day	   after	   intranasal	   challenge,	   while	   lungs	  
were	  harvested	  for	  histological	  examination	  after	  3	  days	  (Fig	  4.5	  A).	  The	  concentration	  of	  
the	   characteristic	   Th2	   cytokines	   IL-­‐4,	   IL-­‐5	   and	   IL-­‐13	   were	   measured,	   all	   of	   which	   were	  
elevated	  in	  BAL	  in	  the	  OVA-­‐treated	  CD4	  only	  group,	  but	  not	  in	  the	  other	  groups	  tested	  (Fig	  
4.5	  B).	  CTL	  transfer	  significantly	  inhibited	  the	  production	  of	  IL-­‐4,	  IL-­‐5	  and	  IL-­‐13	  to	  similar	  
levels	  to	  those	  observed	  in	  PBS	  control	  mice	  and	  mice	  that	  did	  not	  receive	  CD4+	  T	  cells.	  IFN-­‐
γ	   was	   only	   detected	   in	   CTL-­‐treated,	   OVA-­‐challenged	  mice;	   surprisingly	   IL-­‐10	   production	  
was	   also	   induced	   in	   this	   group.	  No	   IL-­‐17	   response	  was	   detectable.	   Consistent	  with	   these	  
observations,	   the	   lungs	   of	   mice	   adoptively	   transferred	   with	   CD4+	   T	   cells	   displayed	  
characteristic	  allergic	  histopathology	  with	  an	   increase	   in	   immune	  cell	   infiltrate	  (Fig	  4.5	  C,	  
upper	   panel)	   and	   concomitant	   goblet	   cell	   hyperplasia	   and	   mucus	   production	   (Fig	   4.5	   C,	  
lower	  panel).	  This	  response	  required	  CD4+	  T	  cell	  transfer	  as	  no	  immune	  cell	  infiltration	  and	  
no	  mucus	  production	  were	  observed	  in	  mice	  that	  received	  no	  CD4+	  T	  cells	  before	  intranasal	  
challenge	  with	  OVA.	   In	  addition,	   reduced	   immune	  cell	   infiltrate	  and	  no	   increase	   in	  mucus	  
production	   were	   observed	   in	   mice	   injected	   with	   WT	   CTL	   together	   with	   CD4+	   T	   cells.	  
Therefore,	  this	  adoptive	  transfer	  model	  generates	  the	  hallmarks	  of	  allergic	  airway	  disease,	  
similar	  to	  an	  in	  vivo	  sensitisation	  model,	  and	  can	  be	  suppressed	  by	  CTLs.	  	  
	  
	  
4.3.4 Time course of the infiltration of adoptively transferred CD4+ 
and CD8+ T cells into the lung and BAL 
	  
The	   adoptive	   transfer	  model	   provided	   a	   platform	   for	   investigating	   effects	   on,	   and	   effects	  
mediated	  by,	  disease-­‐driving	  CD4+	  T	  cells.	  In	  this	  experiment,	  CD4	  T	  cells	  were	  generated	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Figure	  4.5:	  Adoptive	  transfer	  of	  OTII	  cells	  recapitulates	  in	  vivo	  sensitization	  models	  of	  
allergic	  airway	  inflammation	  and	  the	  inhibitory	  effect	  of	  allergen-­‐specific	  CTL	   	  	  
(A)	  5	  x	  106	  CD4+	  T	  cells	  were	   injected	   into	  naive	  mice	  with	  or	  without	  5	  x	  106	  WT	  CTLs.	  
OVA	  or	  PBS	  were	  administered	  i.n	  one	  day	  later.	  (B)	  Cytokines	  were	  measured	  in	  day	  1	  BAL	  
samples	  by	  Bio-­‐Plex.	  Bar	  graphs	  show	  mean	  +	  SEM	  amount	  of	  each	  cytokine	  in	  pg/ml,	  from	  
one	  representative	  experiment	  of	  two	  that	  gave	  similar	  results,	  each	  with	  5	  mice	  per	  group.	  
**p	  <	  0.01,	  ***p	  <	  0.001,	  as	  determined	  by	  one	  way	  ANOVA	  with	  Bonferroni’s	  post	  test.	  (C)	  
Day	   3	   lung	   histology	   shows	   cellular	   infiltrate	   by	   H&E	   stain	   (upper	   panel)	   and	   mucus	  
producing	  goblet	  cells	  by	  ABPAS	  staining	  (lower	  panel).	  Scale	  bars	  represent	  200μm	  (upper	  
panel)	   and	   100μm	   (lower	   panel).	   Stained	   sections	   are	   from	   one	   experiment	   that	   shows	  
representative	  histopathology	  of	  three	  experiments,	  each	  with	  5	  mice	  per	  group.	  
	  
from	  OTII	   x	   B6SJ	   lymph	   node	   cells	   and	   CTL	  were	   generated	   from	  OTI	   x	   B6SJ	   cells.	   Both	  
CD4+	  T	  cells	  and	  CTLs	  were	  injected	  into	  C57BL/6	  hosts	  and	  the	  transferred	  cells	  could	  be	  
distinguished	   by	   CD45.1+	   staining.	   As	   described	   in	   Fig	   4.5	   A,	   analysis	   of	   the	   cellular	  
composition	   of	   the	   lung	   was	   carried	   out	   3	   days	   after	   intranasal	   allergen	   exposure.	  
Representative	   flow	   cytometric	   staining	   for	   the	   identification	   of	   host	   and	   adoptively	  
transferred	  CD4+	  and	  CD8+	  T	  cells	  in	  the	  lung	  is	  shown	  in	  Fig	  4.6	  A.	  	  
	  
Adoptively	   transferred	   CD4+	   T	   cells	   did	   not	   migrate	   to	   the	   lung	   in	   significant	   numbers	  
when	   PBS	   was	   administered	   intranasally,	   but	   OVA	   allergen	   challenge	   induced	   markedly	  
elevated	  numbers	  of	  transferred	  CD4+	  T	  cells	  in	  the	  lung	  (Fig	  4.6	  B).	  The	  co-­‐administration	  
of	  CTLs	  resulted	   in	  a	  significant	  decline	   in	  adoptively	   transferred	  CD4+	  T	  cell	  numbers	   in	  
the	   lung.	   	   Interestingly,	   the	   same	   pattern	   was	   evident	   for	   host	   CD4+	   and	   CD8+	   T	   cells;	  
infiltration	   increased	   in	  OVA-­‐treated	  CD4	  only	  groups,	   and	   this	   increase	  was	   significantly	  
diminished	  in	  the	  presence	  of	  allergen-­‐specific	  CTLs.	  Lung	  infiltrates	  in	  PBS	  treated	  groups	  
were	   unaffected	   by	   cell	   transfer.	   A	   similar	   experiment	   showed	   that	   the	   suppression	   of	  
infiltrating	  adoptively	  transferred	  CD4+	  T	  cells	   in	  the	  lung	  was	  not	  achieved	  by	  PKO	  CTLs	  
(Fig	   4.6	   C).	   	   Therefore,	   disease-­‐mediating	   CD4+	  T	   cells	   are	   present	   in	   significantly	   lower	  
numbers	  in	  the	  lungs	  of	  mice	  treated	  with	  CTLs,	  and	  this	  suppression	  occurs	  in	  a	  perforin-­‐
dependent	  manner.	  	  
	  
As	  the	  infiltration	  of	  CD4+	  T	  cells	  was	  strongly	  decreased	  in	  the	  lungs	  of	  CTL-­‐treated	  mice,	  
the	  question	  was	  raised	  as	  to	  whether	  the	  ability	  of	  these	  cells	  to	  migrate	  and	  infiltrate	  into	  
the	  lungs	  had	  been	  affected,	  and	  whether	  this	  dynamic	  was	  altered	  over	  time.	  To	  address	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Figure	   4.6:	   CTLs	   suppress	   the	   infiltration	   of	   adoptively	   transferred	   and	   host	   CD4+	  
and	  CD8+	  T	  cells	   	  	  
Mice	  were	  exposed	  to	  the	  adoptive	  transfer	  model	  depicted	  in	  Fig	  4.3	  A.	  5	  x	  106	  CD4+	  T	  cells	  
were	   injected	   into	   naive	   mice	   with	   or	   without	   5	   x	   106	   WT	   CTLs.	   OVA	   or	   PBS	   were	  
administered	  i.n	  one	  day	  later.	  (A)	  Lungs	  were	  harvested	  on	  day	  3,	  processed	  to	  a	  single	  cell	  
suspension	  and	  stained	  for	  the	  identification	  of	  adoptively	  transferred	  and	  host	  CD4+	  and	  
CD8+	  T	  cells	  by	  flow	  cytometry,	  as	  depicted	  by	  representative	  flow	  panels.	  Panels	  in	  shaded	  
area	  (far	  right)	  shows	  background	  staining	  in	  the	  absence	  of	  adoptively	  transferred	  T	  cells.	  
(B)	   Mean	   cell	   number	   in	   lungs	   +	   SEM	   are	   shown.	   Data	   are	   from	   one	   representative	  
experiment	  of	  two	  that	  gave	  similar	  results,	  each	  with	  5	  mice	  per	  group.	  (C)	  5	  x	  106	  CD4+	  T	  
cells	  were	  injected	  into	  naive	  mice	  with	  or	  without	  5	  x	  106	  WT	  or	  PKO	  CTLs.	  Control	  mice	  
received	   no	   cell	   transfer.	   OVA	   was	   administered	   i.n	   to	   all	   groups	   one	   day	   later	   and	  
adoptively	  transferred	  CD4+	  T	  cells	  identified	  in	  lungs	  on	  day	  3.	  	  Mean	  cell	  number	  in	  lungs	  
+	   SEM	  are	   shown.	  Data	   are	   from	  one	   representative	   experiment	   of	   two	   that	   gave	   similar	  
results,	   each	   with	   5	   mice	   per	   group.	   **p	   <	   0.01,	   ****p	   <	   0.0001,	   ns	   =	   not	   significant	   as	  
determined	  by	  one	  way	  ANOVA	  with	  Bonferroni’s	  post	  test.	  
	  
	  
this,	   a	   time-­‐course	   was	   carried	   out	   to	   determine	   whether	   CD4+	   T	   cells	   preferentially	  
relocated	   to	  alternate	   tissues;	  BAL,	   lung-­‐draining	  mediastinal	   lymph	  nodes	   (MLN),	   spleen	  
and	  peripheral	  blood,	  and	  non-­‐draining	  lymph	  nodes	  (brachial,	  axial,	  inguinal,	  cervical).	  An	  
adoptive	  transfer	  experiment	  was	  carried	  out	  as	  previously	  described	  (Fig	  4.5	  A),	  with	  end	  
points	  on	  days	  1,	  2,	  3	  and	  6	  after	  intranasal	  challenge	  for	  the	  harvesting	  of	  tissues.	  	  
	  
The	  kinetics	  of	  the	  infiltration	  of	  CD4+	  T	  cells	  into	  BAL	  resembled	  that	  of	  the	  lung.	  In	  CD4	  
only-­‐treated	  mice,	  CD4+	  T	  cells	  were	  present	   in	   low	  numbers	  on	  days	  1	  and	  2,	  peaked	  at	  
day	   3,	   and	   then	   dropped	   greatly	   by	   day	   6;	   CTL	   treated	   mice	   experienced	   only	   a	   minor	  
increase	  in	  CD4+	  T	  cells	  over	  time,	  significantly	  lower	  at	  the	  day	  3	  peak	  compared	  to	  CD4	  
only	  mice	  (Fig	  4.7	  A).	  Cell	  numbers	  in	  the	  lung-­‐draining	  MLN	  were	  similar	  in	  both	  CD4	  only	  
and	  CD4	  +	  CTL	   groups,	   and	  were	   raised	   in	   number	  during	   the	   early	   stage,	   days	  1	   and	  2,	  
before	  decreasing	  on	  day	  3.	  Spleen	  tissue	  had	  the	  highest	  number	  of	  CD4+	  T	  cells,	  steadily	  
increasing	   from	   days	   1	   –	   6	   in	   both	   CD4	   and	   CD4	   +	   CTL	   treated	   groups.	   	   Adoptively	  
transferred	  CD4+	  or	  CD8+	  T	  cells	  were	  not	  able	  to	  be	  detected	  in	  peripheral	  blood	  or	  non-­‐
draining	   lymph	  nodes	  at	   any	  of	   the	   time	  points	   tested	   (therefore,	  data	  not	   shown).	   In	   all	  
tissues	  examined	  as	  depicted,	  the	  general	  trend	  showed	  CD4+	  T	  cell	  numbers	  were	  lower	  in	  
CTL-­‐treated	  mice	  compared	  to	  the	  CD4	  only	  group,	  significantly	  so	  in	  the	  lung	  and	  BAL	  on	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Figure	  4.7	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Figure	   4.7:	   Tissue	   infiltration	   kinetics	   of	   adoptively	   transferred	   CD4+	   and	   CD8+	   T	  
cells	  in	  vivo	   	  	  
Mice	  were	  exposed	  to	  the	  adoptive	  transfer	  model	  depicted	  in	  Fig	  4.5	  A.	  5	  x	  106	  CD4+	  T	  cells	  
were	  injected	  into	  naive	  mice	  with	  or	  without	  5	  x	  106	  WT	  CTLs.	  OVA	  was	  administered	  i.n	  
one	  day	  later.	  Lungs,	  BAL,	  MLN	  and	  spleens	  were	  harvested	  on	  days	  1,	  2,	  3	  and	  6,	  processed	  
to	  a	  single	  cell	  suspension	  and	  stained	  for	  the	  identification	  of	  adoptively	  transferred	  CD4+	  
T	  cells	  (A)	   or	  both	  CD4+	  T	  cells	  and	  CD8+CTLs	  (B)	   by	   flow	  cytometry.	  (A)	  The	  effects	  of	  
CTLs	  on	  the	  number	  of	  CD4+	  T	  cells	   in	  tissue	  over	  time	  is	  shown;	  mice	  were	  treated	  with	  
CD4+	  T	  cells	  only,	  or	  with	  CD4+	  and	  CTLs.	  (B)	  A	  comparison	  of	  the	  number	  of	  CD4+	  T	  cells	  
versus	   the	  number	   of	   CTLs	  within	   each	   tissue	   is	   shown;	   all	  mice	  were	   treated	  with	   both	  
CD4+	  T	   cells	   and	   CTLs.	  Mean	   cell	   number	   in	   lungs	   +	   SEM	   are	   shown.	  Data	   are	   from	  one	  
representative	  experiment	  of	  two	  that	  gave	  similar	  results,	  each	  with	  3	  mice	  per	  group.	  **p	  
<	  0.01,	  ***p	  <	  0.001,	  ****p	  <	  0.0001,	  as	  determined	  by	  two	  way	  ANOVA	  with	  Bonferroni’s	  
post	  test.	  	  
	  
	  
day	  3;	  therefore,	  CD4+	  T	  cells	  do	  not	  appear	  to	  be	  migrating	  differently	  in	  the	  presence	  of	  
CTL	  immunotherapy,	  but	  rather	  are	  decreased	  in	  number	  overall.	  The	  number	  of	  adoptively	  
transferred	  CTLs	   infiltrating	  each	   tissue	  was	  also	  examined	  and	  compared	   to	  CD4+	  T	  cell	  
numbers	  within	  the	  same	  mice.	  In	  CD4	  +	  CTL	  treated	  mice,	  the	  number	  of	  CTLs	  in	  the	  lung	  
and	  BAL	  showed	  a	  trend	  of	  being	  consistently	  higher	  than	  the	  number	  of	  CD4+	  T	  cells	  at	  the	  
time	  points	  measured;	   significantly,	   on	   the	   day	   3	   peak	   of	   inflammation	   in	   the	   lung,	   CTLs	  
outnumbered	  CD4+	  T	  cells	  three-­‐fold,	  a	  result	  not	  mirrored	  in	  the	  BAL	  (Fig	  4.7	  B).	  	  MLN	  and	  
spleen	   did	   not	   show	   significant	   differences	   between	   cell	   numbers	   throughout	   the	   time-­‐
course,	   with	   the	   exception	   of	   day	   1	   spleen	   tissue	   where	   CTLs	   were	   present	   in	   higher	  
proportion	   than	   CD4+	   T	   cells.	   These	   data	   show	   that	   in	   CTL-­‐treated	   mice,	  
immunosuppressive	  CTLs	  are	  more	  frequent	  in	  the	  airways	  than	  disease-­‐mediating	  CD4+	  T	  
cells;	  the	  significance	  of	  this	  finding	  is	  unclear.	  It	  is	  also	  not	  known	  whether	  this	  is	  a	  feature	  






   148 
 
4.3.5 CTL immunotherapy partially reduces the proliferation of 
disease mediating CD4+ T cells in a model of allergic airway 
inflammation 
	  
As	  CTL	  immunotherapy	  results	  in	  a	  decrease	  in	  disease-­‐mediating	  CD4+	  T	  cell	  numbers	  in	  
the	  airway	  without	  apparent	  redirection	  of	  these	  cells	  to	  the	  spleen,	  MLN	  and	  non-­‐draining	  
lymph	  nodes,	  it	  was	  investigated	  whether	  the	  decrease	  in	  CD4+	  T	  cells	  was	  instead	  due	  to	  
reduced	  proliferation.	   In	  vitro	   cultured	  CD4+	  T	  cells	  were	   labelled	  with	  CellTrace	  VioletTM	  
(CTV)	  before	   adoptive	   transfer	   into	  naïve	  C57BL/6	  hosts,	  with	   allergen	   challenge	   carried	  
out	  as	  per	  Fig	  4.5	  A.	  Three	  days	  after	  intranasal	  challenge,	  adoptively	  transferred	  cells	  were	  
identified	  in	  lungs	  by	  flow	  cytometry	  as	  previously	  described	  (Fig	  4.6	  A)	  and	  proliferation	  
was	  examined	  by	  evaluating	  the	  decrease	  in	  CTV	  labelling.	  A	  decrease	  in	  the	  strength	  of	  CTV	  
signal	   could	  be	  observed	   in	   cells	   that	  had	  undergone	  proliferation,	  however	  proliferation	  
peak	   analysis	   was	   not	   able	   to	   be	   carried	   out	   by	   analysis	   software	   as	   clearly	   separated	  
proliferation	   bands	   were	   not	   evident	   in	   all	   samples,	   likely	   due	   to	   the	   variation	   in	   CTV	  
retention	  in	  pre-­‐activated	  cells.	  As	  such,	  cells	  at	  all	  stages	  of	  proliferation	  were	  grouped	  as	  
“CTV	  low”	  and	  those	  that	  had	  undergone	  little	  or	  no	  proliferation	  were	  “CTV	  high”	  (Example	  
of	  staining,	  Fig	  4.8	  A).	  	  
	  
As	  there	  was	  no	  allergen	  administered	  intranasally	  in	  the	  PBS-­‐challenged	  CD4	  only	  mice,	  no	  
direct	  stimulus	  for	  proliferation	  of	  CD4+	  T	  cells	  was	  present	  in	  this	  group;	  therefore,	  the	  cell	  
populations	   that	   appear	   CTV	   low	   comprise	   cells	   that	   have	   either	   undergone	   homeostatic	  
proliferation	   upon	   transfer,	   or	   continued	   residual	   proliferation	   as	   a	   result	   of	   in	   vitro	  
stimulation,	  as	  well	  as	  cells	  in	  which	  the	  CTV	  stain	  has	  faded	  or	  leaked	  out	  within	  the	  course	  
of	  the	  experiment.	  This	  sets	  the	  background	  for	  comparison	  with	  all	  OVA-­‐challenged	  groups	  
where	  allergen	  was	  administered	  to	  induce	  proliferation.	  The	  CTV	  high	  population,	  on	  the	  
other	  hand,	  more	  reliably	  reports	  cells	  in	  which	  no	  proliferation,	  or	  little	  proliferation,	  has	  
occurred	  –	  shown	  in	  Fig	  4.8	  B.	  The	  proportion	  of	  CTV	  high	  CD4+	  T	  cells	  in	  OVA-­‐challenged	  
CD4	  only	  mice	  was	  reduced	  to	  a	  little	  over	  half	  (55%)	  that	  of	  PBS-­‐challenged	  CD4	  only	  mice,	  
indicating	   that	   increased	   proliferation	   had	   occurred	   in	   the	   presence	   of	   OVA	   allergen,	  
although	  this	  did	  not	  reach	  statistical	  significance.	  OVA-­‐challenged	  CD4	  +	  WT	  CTL-­‐treated	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Figure	   4.8:	   Partial	   suppression	   of	   CD4+	   T	   cell	   proliferation	   in	   CTL-­‐treated	   mice	  	  
In	   vitro	   cultured	   CD4+	   T	   cells	   were	   stained	   with	   CellTrace	   Violet	   (CTV)	   before	   adoptive	  
transfer	   into	   naïve	  mice.	   Allergen	   challenge	  with	   OVA,	   or	   PBS	   control,	   and	   harvesting	   of	  
lungs	  was	  carried	  out	  as	  per	  Fig	  4.5	  A.	  	  Adoptively	  transferred	  cells	  were	  identified	  in	  lungs	  
by	   flow	  cytometry	  as	  previously	  described	  (Fig	  4.6	  A).	  (A)	  Proliferation	  was	  examined	  by	  
CTV	  staining	  as	  depicted	  by	  a	  representative	  flow	  panel.	  (B)	  Percentage	  of	  CTV	  high	  CD4+	  T	  
cells	  reveals	  cells	  that	  have	  undergone	  little	  or	  no	  proliferation.	  (C)	  CTV	  MFI	  of	  adoptively	  
transferred	  CD4+	  T	  cell	  population,	  comprising	  both	  CTV	  high	  and	  CTV	  low	  cells.	  Mean	  cell	  
number	  in	  lungs	  +	  SEM	  are	  shown.	  Data	  are	  from	  one	  experiment	  of	  two	  that	  gave	  similar	  
results,	  each	  with	  5	  mice	  per	  group.	  *p	  <0.05,	  **p	  <0.01,	  ns=	  not	  significant,	  as	  determined	  
by	  two-­‐tailed,	  unpaired	  t	  test.	  
 
	  
mice	  had	  a	  proportion	  of	  CTV	  high	  cells	  that	  was	  double	  that	  seen	  in	  OVA-­‐challenged	  CD4	  
only	  mice;	  this	  result	  revealed	  that	  less	  proliferation	  was	  occurring	  in	  WT	  CTL-­‐treated	  mice,	  
however,	  this	  result	  was	  again	  not	  statistically	  significant.	  Contrarily,	  OVA-­‐challenged	  CD4	  +	  
PKO	  CTL-­‐treated	  mice	  displayed	  a	  similar	  proportion	  of	  CTV	  high	  cells	  as	  OVA-­‐challenged	  
CD4	  only-­‐treated	  mice,	  showing	  that	  comparable	  proliferation	  had	  occurred	  in	  these	  groups,	  
while	  WT	  CTLs	  suppressed	  proliferation	  significantly	  more	  than	  PKO	  CTL.	  	  	  	  	  
	  
To	   account	   for	   differences	   in	   the	   fluorescence	   within	   groups,	   cells	   at	   all	   stages	   of	  
proliferation	   (including	   both	   “CTV	   high”	   and	   “CTV	   low”)	  were	   grouped	   together	   and	   the	  
mean	   fluorescent	   intensity	   of	   CTV	   was	   determined;	   the	   higher	   the	   MFI,	   the	   less	  
proliferation	   that	  had	  occurred.	  Results	   showed	   that	   the	  MFI	  of	   CTV	  was	  highest	   in	  PBS-­‐
challenged	   mice,	   indicating	   that	   CD4+	   T	   cells	   in	   this	   group	   had	   undergone	   the	   least	  
proliferation	   (Fig	  4.8	  C).	  The	  MFI	  of	  CTV	   in	  OVA-­‐challenged	  CD4	  +	  WT	  CTL-­‐treated	  mice,	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while	   not	   statistically	   significant,	   was	   lower	   than	   PBS-­‐challenged	   CD4	   only-­‐treated	   mice	  
revealing	   that,	   in	   fact,	   some	   proliferation	   had	   occurred	   in	   CTL-­‐treated	   mice.	   This	  
proliferation	  was	  greater,	  however,	  in	  both	  OVA-­‐challenged	  CD4	  only-­‐treated	  mice	  as	  well	  
as	   OVA-­‐challenged	   CD4	   +	   PKO	   CTL-­‐treated	   mice,	   as	   these	   groups	   showed	   significantly	  
decreased	   mean	   fluorescent	   intensity	   of	   CTV	   compared	   to	   the	   PBS-­‐challenged	   control,	  
although	  a	  statistically	  significant	  increase	  in	  proliferation	  (depicted	  as	  decreased	  MFI)	  was	  
not	   evident	   between	  WT	   CTL-­‐treated	  mice	   and	   those	   that	   received	   PKO	   CTL	   or	   no	   CTL.	  
Collectively,	   these	  data	  suggest	   that	  WT	  CTLs	  may	  be	  capable	  of	  partially	  suppressing	  the	  
proliferation	   of	   CD4+	   T	   cells	   in	   the	   adoptive	   transfer	   model	   of	   allergy,	   in	   a	   manner	  
dependent	  on	  perforin;	  however,	  as	  these	  results	  were	  not	  statistically	  significant,	  this	  was	  
not	  conclusively	  demonstrated.	  	  
	  
	  
4.3.6 The expression of activation markers on CD4+ T cells is not 
affected differentially by wild type CTLs, compared to perforin knock-
out CTLs  
	  
It	  was	   then	   investigated	  whether	  CTLs	  had	  an	  effect	  on	   the	  phenotype	  of	  CD4+	  T	  cells	   in	  
vivo.	  The	  expression	  of	  key	  activation	  markers	  CD44,	  CD69,	   ICOS	  and	  PD-­‐1	  on	  adoptively	  
transferred	  CD4+	  T	  cells	  were	  examined.	  	  
	  
As	  the	  expression	  of	  these	  markers	  is	  upregulated	  on	  CD4+	  T	  cells	  through	  the	  process	  of	  
activation	   during	   in	   vitro	   culture	   with	   DCs,	   initial	   experiments	   were	   carried	   out	   to	  
determine	   the	   time	   in	   which	   these	   markers	   are	   decreased	   in	   expression	   after	   adoptive	  
transfer	  into	  naïve	  hosts,	  without	  in	  vivo	  antigenic	  stimulation.	  A	  sample	  of	  cultured	  CD4+	  T	  
cells	  were	  analysed	  by	  flow	  cytometry	  before	  i.v.	   injection	  into	  naïve	  hosts,	  and	  then	  mice	  
were	   tail	   bled	   on	   days	   2,	   4	   and	   7	   after	   cells	   were	   injected	   (as	   depicted	   in	   Fig	   4.9	   A).	  
Adoptively	  transferred	  CD4+	  T	  cells	  were	  identified	  in	  blood	  specimens	  by	  flow	  cytometry,	  
and	   their	   expression	   of	   CD44,	   CD69,	   ICOS	   and	   PD-­‐1	  was	   compared	   to	   that	   of	   the	   pre-­‐i.v.	  
sample.	  Flow	  analysis	  showed	  that	  CD44,	  CD69	  and	  ICOS	  were	  all	  decreased	  by	  day	  2	  after	  
injection,	  while	  PD-­‐1	  remained	  elevated	  throughout	  the	  7	  day	  time-­‐course	  (Fig	  4.9	  B).	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Figure	  4.9:	  The	  expression	  of	  activation	  markers	  on	  adoptively	   transferred	  CD4+	  T	  
cells	  in	  the	  absence	  of	  intranasal	  allergen	  exposure	   	  	  
(A)	   In	   vitro	   cultured	   CD4+	   T	   cells	   were	   adoptively	   transferred	   into	   naïve	   mice	   and	  
recovered	   from	  peripheral	  blood	  2,	  4	  and	  7	  days	   later;	  cells	  were	   identified	  as	  previously	  
described	  (Fig	  4.6	  A).	  (B)	  The	  expression	  of	  CD44,	  CD69,	  ICOS	  and	  PD-­‐1	  was	  compared	  on	  
CD4+	   T	   cells	   from	   each	   time	   point	   by	   flow	   cytometric	   analysis.	   Data	   are	   from	   one	  
experiment	  of	  two	  that	  gave	  similar	  results,	  each	  with	  5	  mice	  per	  group.	  
	  
	  
These	  results	  agree	  with	  those	  published	  by	  others	  that	  show	  activated	  CD4+	  T	  cells	  quickly	  
reduce	  their	  expression	  of	  these	  markers	  after	  the	  removal	  of	  antigen	  stimulus	  (203,	  285).	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The	  effects	  of	  CTLs	  on	  the	  activation	  of	  CD4+	  T	  cells	  in	  vivo	  were	  then	  examined	  in	  a	  model	  
similar	   to	   that	   depicted	   in	   Fig	   4.5	   A;	   5	   x	   106	   CD4+	   T	   cells	   alone,	   or	  with	   5	   x	   106	  WT	   or	  
perforin	  knock	  out	  (PKO)	  CTLs	  were	  co-­‐administered	  to	  mice.	  After	  activation	  markers	  on	  
CD4+	   T	   cells	   had	   decreased,	   2	   days	   after	   i.v.	   transfer	   as	   described	   in	   Fig	   4.9	   B,	   a	   single	  
allergen	  challenge	  of	  1,	  10	  or	  100μg	  of	  OVA	  was	  delivered	  intranasally;	  a	  titration	  carried	  
out	   to	   determine	  whether	   activation	  markers	   were	   differentially	   affected	   by	   the	   dose	   of	  
allergen	   exposure.	   	   Three	   days	   after	   allergen	   challenge,	   lungs	   were	   removed	   and	   the	  
expression	   of	   CD44,	   CD69,	   ICOS	   and	   PD-­‐1	   on	   adoptively	   transferred	   CD4+	   T	   cells	   was	  
analysed.	  Results	   showed	   that	   both	  CD44	   and	  CD69	   expression	  were	   similar	   between	   all	  
treatment	   groups,	  with	  no	   statistically	   significant	   differences	  between	  mice	   that	   received	  
CD4	  only,	  CD4	  +	  WT	  CTLs	  or	  CD4	  +	  PKO	  CTLs	  (Fig	  4.10	  A).	  The	  same	  was	  true	  for	  ICOS	  and	  
PD-­‐1	   expression,	  with	   no	   significant	   difference	   in	   expression	   between	   treatment	   groups.	  
Within	  treatment	  groups,	  however,	  a	  dose-­‐dependent	  trend	  towards	  increased	  expression	  
was	   observed	   with	   increasing	   allergen	   dose.	   This	   response,	   however,	   was	   no	   different	  
between	   WT	   and	   PKO	   CTL-­‐treated	   groups,	   suggesting	   that	   it	   may	   be	   a	   result	   of	   CTL	  
cytokine	   production.	   In	   a	   similar	   experiment,	   the	   expression	   of	   CD49d	  was	   examined	   on	  
adoptively	  transferred	  CD4+	  T	  cells	  in	  the	  lung,	  as	  this	  integrin	  has	  been	  shown	  to	  mediate	  
the	  migration	  of	  T	  cells	  to	  extravascular	  spaces	  (such	  as	  the	  lung).	  This	  marker	  additionally	  
was	  found	  to	  show	  no	  difference	  in	  expression	  between	  CD4	  only,	  CD4	  +	  WT	  CTL	  and	  CD4	  +	  
PKO	   CTL	   treated	   groups	   (Fig	   4.10	   B).	   These	   results	   show	   that	   the	   expression	   of	   the	  
activation	  markers	  CD44,	  CD69,	  ICOS,	  PD-­‐1	  and	  integrin	  CD49d	  on	  disease-­‐mediating	  CD4+	  
T	  cells	  was	  not	  affected	  by	  WT	  CTL	  immunotherapy	  differentially	  from	  the	  effects	  mediated	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Figure	   4.10:	   The	   effects	   of	   CTL	   immunotherapy	   on	   the	   activation	   status	   of	   CD4+	   T	  
cells	  in	  vivo	   	  	  
Mice	  were	  exposed	  to	  the	  adoptive	  transfer	  model	  depicted	  in	  Fig	  4.5	  A.	  5	  x	  106	  CD4+	  T	  cells	  
were	   injected	   into	   naive	   mice	   with	   or	   without	   5	   x	   106	   WT	   or	   PKO	   CTLs.	   OVA	   was	  
administered	   i.n	   two	  days	   later;	   titrated	  dose	   (A)	   or	   standard	  100ug	  dose	   (B)	  was	   used.	  
Lungs	  were	  harvested	  on	  day	  3	  and	  processed	  to	  a	  single	  cell	  suspension	  and	  stained	  for	  the	  
identification	  of	  adoptively	  transferred	  CD4+	  T	  cells	  by	  flow	  cytometry.	  The	  expression	  of	  
CD44,	  CD69,	  ICOS,	  PD-­‐1	  and	  CD49d	  was	  then	  examined	  and	  compared	  between	  treatment	  
groups.	  	  Data	  are	  from	  one	  experiment	  of	  two	  that	  gave	  similar	  results,	  each	  with	  3-­‐5	  mice	  
per	  group.	  *p	  <	  0.05,	  ***p	  <	  0.001	  as	  determined	  by	  one	  way	  ANOVA	  with	  Bonferroni’s	  post	  
test.	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4.3.7 Number of total and Th2 cytokine-producing CD4+ T cells in lung 
is significantly reduced by CTL immunotherapy 
	  
As	  CTL	  treatment	  resulted	  in	  reduced	  Th2	  cytokines	  in	  BAL,	  it	  was	  investigated	  whether	  the	  
decrease	  in	  BAL	  cytokine	  levels	  was	  due	  to	  reduced	  secretion	  by	  CD4+	  T	  cells.	  To	  assess	  this,	  
4C13R-­‐OTII	   CD4+	   T	   cells	   were	   used,	   where	   the	   fluorescent	  markers	   AmCyan	   and	   dsRed	  
report	  expression	  of	  IL-­‐4	  and	  IL-­‐13,	  respectively.	  The	  bacterial	  artificial	  chromosome	  used	  
to	  generate	  4C13R	  mice	  (660)	  is	  depicted	  in	  Fig	  4.11	  A.	  	  
	  
4C13R	   CD4+	   T	   cells	   were	   adoptively	   transferred	   as	   described	   in	   figure	   4.11	   B,	   with	   or	  
without	   CTLs.	   BAL	  was	   obtained	   on	   day	   1	   and	   day	   3	   after	   airway	   allergen	   challenge,	   to	  
determine	   whether	   the	   4C13R-­‐OTII	   cells	   replicated	   the	   eosinophilia	   and	   Th2	   cytokine	  
production	  induced	  by	  non-­‐reporting	  OT-­‐II	  cells.	  It	  was	  found	  that	  eosinophils	  infiltrated	  in	  
high	  numbers	   in	  4C13R-­‐OTII	   treated	  mice;	   this	  was	  significantly	  ameliorated	   in	  mice	  also	  
treated	   with	   CTLs	   (Fig	   4.11	   C).	   Cytokine	   production	   reflected	   that	   of	   the	   OTII-­‐induced	  
inflammation	  previously	  reported	  (Fig	  4.5),	  and	  a	  trend	  towards	  a	  decrease	  was	  seen	  in	  IL-­‐
4,	   as	  well	   as	   significant	   abrogation	  of	   IL-­‐5	   and	   IL-­‐13,	   in	  CTL-­‐treated	   groups	   (Fig	  4.11	  D).	  
These	   results	   show	   that	   4C13R-­‐OTII	   cells	  may	   be	   used	   in	   an	   adoptive	   transfer	  model	   to	  
generate	  measurable	  allergic	  inflammation	  in	  the	  airway,	  which	  can	  be	  suppressed	  by	  CTLs.	  	  	  
	  
Cytokine-­‐reporting	  CD4+	  T	  cells	  in	  the	  lung	  were	  then	  enumerated	  in	  an	  adoptive	  transfer	  
experiment	   as	   described	   in	   Fig	   4.11	   B.	   The	   fluorescent	   reporting	   of	   IL-­‐4	   and	   IL-­‐13	   was	  
examined	  one	  day	  after	  intranasal	  allergen	  exposure,	  when	  peak	  cytokine	  production	  may	  
be	  measured,	   as	  well	   as	   on	   the	   day	   3	   peak	   of	   cellular	   infiltration	   in	   the	   lung.	   Adoptively	  
transferred	  4C13R	   cells	  were	   identified,	   after	   gating	   on	   live	   cells,	   as	   depicted	   in	   the	   flow	  
panels	  shown	  in	  Fig	  4.12	  –	  classified	  as	   live,	  SSC-­‐A	  low,	  FSC-­‐H	  low-­‐to-­‐intermediate,	  CD3+,	  
CD4+Vα2+	  cells.	   	  Representative	  panels	  showing	  the	  number	  of	  cells	  reporting	  IL-­‐4,	   IL-­‐13	  
and	  both	  cytokines	  are	  depicted	  for	  lung	  samples	  from	  day	  1	  (Fig	  4.12	  A,	  upper	  panel)	  and	  
day	  3	  (Fig	  4.12	  A,	  lower	  panel).	  	  
	  
On	  day	  1,	  the	  number	  of	  infiltrating	  CD4+	  T	  cells	  in	  the	  lung	  was	  not	  significantly	  different	  
between	  CD4	  +	  OVA-­‐treated,	  CD4	  +	  CTL	  +	  OVA-­‐treated,	  and	  CD4	  +	  PBS-­‐treated	  groups,	  and	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Figure	  4.11:	  CTLs	  suppress	  airway	   inflammation	   induced	  by	  adoptively	   transferred	  
4C13R	  CD4+	  T	  cells	  	  	  
(A)	  Bacterial	  artificial	  chromosome	  clone	  used	  to	  generate	  4C13R	  mice	  (William	  Paul	  Lab);	  
LCR	   -­‐	   Th2	   locus	   control	   region,	   Kif3a	   -­‐	   gene	   encoding	   kinesin-­‐related	   protein	   3.	   dsRed	  
reports	  IL-­‐13	  production	  and	  AmCyan	  reports	  IL-­‐4	  production.	  (B)	  Adoptive	  transfer	  model	  
was	   carried	   out	   with	   4C13R	   OTII	   CD4+	   T	   cells	   injected	   with	   or	   without	   WT	   CTLs.	   (C)	  
Eosinophils	  were	  enumerated	  in	  day	  3	  BAL	  samples	  by	  flow	  cytometry.	  (D)	  Cytokines	  were	  
measured	   in	   day	  1	  BAL	   samples	   by	  Bio-­‐Plex	   analysis.	  Mean	   cell	   number	   in	  BAL	  or	  mean	  
cytokine	   concentration	   in	   BAL	   	   +	   SEM	   are	   shown.	   Data	   are	   from	   one	   representative	  
experiment	  of	   two	   that	  gave	  similar	   results,	   each	  with	  5	  mice	  per	  group.	   *p	  <	  0.05,	   **p	  <	  




few	  of	  these	  cells	  were	  reporting	  cytokine	  production	  (Fig	  4.12	  B).	  Nonetheless,	  the	  number	  
of	   CD4+	   T	   cells	   that	   were	   reporting	   IL-­‐4	   and	   IL-­‐13	   was	   lower	   in	   CTL-­‐treated	   mice,	  
compared	   to	   CD4	   +	   OVA-­‐treated	   mice;	   a	   reduction	   in	   IL-­‐4+IL-­‐13-­‐,	   IL-­‐4-­‐IL-­‐13+	   and	   IL-­‐
4+IL13+	  cells	  was	  observed	  at	  this	  time	  point	  (Fig	  4.12	  B),	  although	  the	  decrease	  in	  IL-­‐4-­‐IL-­‐
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13+	   cells	   did	   not	   quite	   reach	   statistical	   significance	   (p=0.052).	   At	   3	   days	   post	   intranasal	  
challenge,	  consistent	  with	  the	  peak	  of	  lung	  cellular	  infiltration	  previously	  described,	  4C13R	  
Th2	   cells	   had	   infiltrated	   the	   lungs	   in	   higher	   numbers	   (Fig	   4.12	   C)	   in	   CD4	   +	   OVA-­‐treated	  
groups,	   compared	   to	  both	  CD4	  +	  CTL	  and	  CD4	  +	  PBS-­‐treated	  groups;	  many	  of	   those	   cells	  
were	   reporting	   IL-­‐4	   and	   IL-­‐13	   production.	   In	   mice	   where	   CTLs	   had	   been	   administered,	  
there	  was	   a	   significant	   decrease	   in	   the	  number	   of	   CD4+	  T	   cells	   reporting	   IL-­‐4,	   IL-­‐13	   and	  
those	  reporting	  production	  of	  both	  cytokines,	  compared	  to	  mice	  that	  received	  CD4+	  T	  cells	  
+	  OVA.	  These	  data	   suggest	   that,	   additional	   to	   reducing	  CD4+	  T	  cells	  numbers	   in	   the	   lung,	  
CTL	   immunotherapy	  may	   affect	   CD4+	   T	   cells	   by	   decreasing	   their	   production	   of	   key	   Th2	  
cytokines.	  
 
4.3.8 T regulatory cell numbers in the lung are not affected by CTL 
treatment at the day 3 peak of lung inflammatory cell infiltrate 
	  
Additional	   to	   the	   decreased	  Th2	   cytokines,	   an	   increase	   in	   IL-­‐10	   in	  BAL	  was	  measured	   in	  
CTL-­‐treated	  mice	  (Fig	  4.5	  B).	  	  As	  the	  production	  of	  IL-­‐10	  can	  stimulate	  CD4+CD25+FoxP3+	  
T	   regulatory	   (Treg)	   cells	   that	   may	   lead	   to	   the	   skewing	   of	   the	   allergic	   environment	   to	   a	  
tolerogenic	  environment	  (497,	  714-­‐716),	   it	  was	  investigated	  whether	  there	  was	  in	  fact	  an	  
increase	  in	  Treg	  cells	  in	  the	  lung	  infiltrates	  of	  CTL-­‐treated	  mice.	  An	  adoptive	  transfer	  model	  
(described	   in	   Fig	   4.5A)	   was	   utilised,	   and	   lungs	   were	   harvested	   3	   days	   after	   intranasal	  
allergen	  challenge.	  Lung	  cells	  were	  stained	  intracellularly	  with	  a	  FoxP3	  antibody,	  or	  isotype	  
control,	  as	  well	  as	  surface	  staining	  for	  the	  markers	  CD4	  and	  CD25.	  Flow	  cytometric	  analysis	  
revealed	  no	  difference	  in	  the	  proportion	  of	  Tregs	  in	  the	  lungs	  of	  mice	  treated	  with	  CD4	  only,	  
CD4	  +	  CTL	  or	  CD4	  +	  PKO	  CTL	  (Fig	  4.13	  B).	  Therefore,	  IL-­‐10	  production	  in	  CTL-­‐treated	  mice	  
does	  not	  appear	  to	  be	  accompanied	  by	  an	  increase	  in	  Tregs	  in	  the	  lungs	  at	  this	  time	  point;	  
the	  peak	  of	  inflammatory	  cellular	  infiltrates.	  	  
	  
The	  source	  of	  IL-­‐10	  was	  also	  investigated.	  As	  CTLs	  are	  themselves	  capable	  of	  producing	  IL-­‐
10	   depending	   on	   environmental	   stimuli	   (717,	   718),	   it	   was	   examined	   whether	   in	   vitro	  
generated	  CTLs	  in	  these	  experiments	  had	  adopted	  an	  IL-­‐10	  producing	  phenotype.	  PKO	  CTL	  
cultures	  were	  additionally	  tested	  for	  IL-­‐10	  production.	  Cells	  cultured	  for	  6	  days	  under	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Figure	  4.12:	  The	  number	  of	   total	  and	  cytokine-­‐reporting	  CD4+	  T	  cells	   in	   the	   lung	   is	  
significantly	  reduced	  by	  CTL	  immunotherapy	   	  	  
Adoptive	   transfer	   of	   4C13R	   CD4+	   T	   cells	   with	   or	   without	   WT	   CTLs	   was	   carried	   out	   as	  
described	  in	  Fig	  4.11	  B,	  with	  OVA	  or	  PBS	  administered	  intranasally	  1	  day	  later.	  Lungs	  were	  
harvested	  on	  days	  1	  and	  3	  and	  processed	  to	  a	  single	  cell	  suspension	  for	  the	  identification	  of	  
adoptively	   transferred	   cells.	   (A)	   Fluorescent	   reporting	   of	   IL-­‐4	   and	   IL-­‐13	   production	   by	  
adoptively	  transferred	  4C13R	  CD4+	  T	  cells	  was	  analysed	  by	  flow	  cytometry	  on	  days	  1	  and	  3	  
as	   depicted.	   The	   total	   number	   of	   transferred	   CD4+Vα2+	  T	   cells	   in	   lungs	   and	   the	   number	  
reporting	   IL-­‐4	   and	   IL-­‐13	   production	  were	   enumerated	   on	   day	   1	   (B)	   and	   day	   3	   (C)	   after	  
intranasal	  challenge.	  Bar	  graphs	  show	  mean	  number	  of	  CD4+	  T	  cells	  +	  SEM.	  Data	  are	  from	  
one	  of	  two	  experiments	  that	  gave	  similar	  results,	  each	  with	  5	  mice	  per	  group.	  *p,	  0.05,	  **p,	  
0.01.	  ns,	  not	  significant	  as	  determined	  by	  two-­‐tailed,	  unpaired	  t	  test.	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conditions	   previously	   described	   (Chapter	   2)	   were	   restimulated	   with	   OVA257-­‐264	   antigen	  
(CTL	  +	  Ag),	  or	  no	  antigen	   (CTL	  no	  Ag),	   for	  4	  hours	  or	  24	  hours.	  Culture	  supernatant	  was	  
then	   sampled	   and	   IL-­‐10	  measured	  by	  Bio-­‐Plex	   analysis.	   It	  was	   found	   that	   both	  CTLs	   and	  
PKO	  CTLs	  were	  driven	   to	  produce	   IL-­‐10	  after	  4	  hours	  and	  24	  hours	  of	   in	  vitro	  OVA257-­‐264	  
stimulation,	   while	   cultured	   cells	   that	   were	   not	   restimulated	   with	   antigen	   did	   not	   show	  
measureable	   IL-­‐10	   production	   (Fig	   4.13	   C).	   Therefore,	   the	   IL-­‐10	  measured	   in	   the	  BAL	   of	  
OVA-­‐challenged,	   CTL-­‐treated	  mice	   could	   be	   produced	   by	   the	   CTLs	   themselves.	   However,	  
this	   IL-­‐10	  does	  not	  result	   in	  an	   increase	   in	  Treg	  cells	   in	   lung	   inflammatory	  cell	   infiltrates,	  
and	   may	   also	   be	   produced	   in	   vivo	   by	   PKO	   CTLs	   that	   do	   not	   inhibit	   allergic	   airway	  
inflammation.	   These	   data	   suggest	   that	   IL-­‐10	   production	   by	   CTLs	   is	   unlikely	   to	   have	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Figure	  4.13:	  T	  regulatory	  cell	  numbers	  in	  the	  lung	  are	  not	  affected	  by	  CTL	  treatment	  
at	  the	  day	  3	  peak	  of	  lung	  inflammatory	  cell	  infiltrate	  	  
An	  adoptive	  transfer	  model	  (described	  in	  Fig	  4.5A)	  was	  utilised,	  and	  lungs	  were	  harvested	  3	  
days	   after	   intranasal	   allergen	   challenge.	   Lung	   cells	   were	   stained	   intracellularly	   with	   a	  
FoxP3	   antibody,	   or	   isotype	   control,	   as	   well	   as	   surface	   staining	   for	   CD4	   and	   CD25.	   (A)	  
Representative	  gating	  shown	  for	  determining	  CD25+FoxP3+	  population.	  Doublets	  and	  dead	  
cells	   removed	   prior	   to	   this	   gating,	   as	   depicted	   in	   figure	   3.1.	   	   (B)	   Bar	   graphs	   show	  mean	  
percentage	  of	  CD25+FoxP3+	  cells	  of	  CD4+	  T	  cells	  in	  the	  lung	  +	  SEM.	  (C)	  WT	  and	  PKO	  CTLs	  
cultured	   for	  6	  days	  under	  conditions	  previously	  described	  (Chapter	  2)	  were	  restimulated	  
with	  OVA257-­‐264	  antigen	  (CTL	  +	  Ag),	  or	  no	  antigen	  (CTL	  no	  Ag),	  for	  4	  hours	  or	  24	  hours.	  
Culture	  supernatant	  was	  then	  sampled	  and	  IL-­‐10	  measured	  by	  Bio-­‐Plex	  analysis.	  Bar	  graphs	  
show	   mean	   concentration	   of	   IL-­‐10	   in	   supernatant	   +	   SEM.	   Data	   are	   from	   one	   of	   two	  
experiments	   that	  gave	  similar	  results,	  each	  with	  3	  supernatant	  samples	  per	  group.	  ***p	  <	  
0.001,	   ****p	   <	   0.0001,	   ns=	   not	   significant	   as	   determined	   by	   one	   way	   ANOVA	   with	  
Bonferroni’s	  post	  test.	   




CTLs suppress inflammation in an adoptive transfer model of allergic airway 
disease  
	  
In	   this	   chapter,	   an	  experimental	  model	  of	   allergy	  was	  described	  where	  OTII	  CD4+	  T	  cells	  
were	   cultured	   under	   Th2	   conditions	   and	   injected	   into	   naïve	   hosts,	   generating	   airway	  
inflammation	  upon	  allergen	  exposure.	  This	  inflammatory	  response	  was	  characterised	  by	  a	  
robust	  eosinophilia	  in	  BAL,	  the	  production	  of	  IL-­‐4,	  IL-­‐5	  and	  IL-­‐13	  and	  lung	  histopathology	  
including	   cell	   infiltrates	   and	   increased	   mucus	   production.	   Therefore,	   similar	   to	   the	  
observations	   of	   others,	   (650,	   651)	   this	   adoptive	   transfer	   model	   replicates	   many	   of	   the	  
features	  of	  allergic	  disease	  that	  are	  generated	  by	  in	  vivo	  sensitisation	  protocols.	  	  
	  
There	   are,	   however,	   some	   differences	   in	   the	   immunology	   of	   the	   allergic	   response	   in	   the	  
adoptive	  transfer	  model	  compared	  to	  in	  vivo	  sensitisation.	  Primarily,	  this	  is	  due	  to	  the	  fact	  
that	  there	  is	  no	  systemic	  sensitisation	  in	  the	  adoptive	  transfer	  model.	  Thus,	  the	  activity	  of	  
transferred	  CD4+	  T	   cells	   is	   the	   primary	   driving	   factor	   for	   the	   pathology	   observed	   in	   this	  
model.	  As	  demonstrated	   in	  an	   in	  vivo	   sensitisation	  model	  of	   allergic	   airway	   inflammation	  
(321),	  host	  APCs,	  importantly	  DCs,	  are	  also	  required	  for	  allergen	  presentation	  to	  adoptively	  
transferred	   CD4+	   T	   cells	   to	   initiate	   the	   subsequent	   allergic	   response	   (Daniels,	   Mucosal	  
Immunology,	   2015;	   In	   press).	   The	   allergic	   disease	   induced	   in	   this	   model,	   then,	   in	   the	  
absence	  of	  host	  sensitisation,	  does	  not	  rely	  on	  IgE	  or	  the	  activation	  of	  mast	  cells.	  Indeed,	  IgE	  
was	   not	   detected	   in	   serum	   of	   OTII-­‐transferred,	   OVA-­‐exposed	   mice,	   neither	   was	  
mastocytosis	  induced	  in	  the	  lung	  tissue	  in	  the	  current	  study.	  As	  discussed	  in	  Chapter	  3,	  IgE	  
has	  an	  important	  role	  only	  where	  strong	  eosinophilia	  is	  not	  present	  (540),	  and	  mast	  cells	  do	  
not	  have	  a	  critical	  role	  in	  the	  induction	  of	  allergic	  airway	  inflammation	  (444);	  as	  such,	  the	  
absence	  of	  measurable	  IgE	  or	  mast	  cell	  activation	  in	  the	  adoptive	  transfer	  model	  should	  not	  
have	  had	  a	  significant	  impact	  during	  the	  course	  of	  the	  experiments	  described.	  	  
	  
Another	   important	   difference	   between	   the	   adoptive	   transfer	   and	   in	   vivo	   sensitisation	  
models	  is	  that	  the	  number	  of	  allergen-­‐specific	  CD4+	  T	  cells	  injected	  in	  the	  adoptive	  transfer	  
model	   may	   exceed	   that	   induced	   by	   classical	   prime/challenge	   protocols.	   The	   number	   of	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allergen-­‐specific	  cells	  used	  in	  published	  adoptive	  transfer	  models	  varies	  greatly	  depending	  
on	  the	  purpose	  of	  the	  experiments;	  as	  few	  as	  1	  x	  106	  total	  cultured	  splenocytes	  (including	  
<1%	   CD4+CD62Llo	   cells)	   have	   been	   shown	   to	   generate	   measurable	   eosinophilic	   lung	  
inflammation	   (651).	  Other	  authors	   implemented	  higher	  numbers	   (5	  x	  106)	   as	   a	  means	  of	  
comparing	  Th2	  versus	  Th1-­‐induced	  airway	   inflammation;	  experiments	   requiring	  a	   strong	  
inflammatory	   infiltrate	   to	   effectively	   tease	   apart	   these	   responses	   (719).	  While	   an	   allergic	  
response	  may	   be	   elicited	   by	   low	  numbers	   of	   CD4+	  T	   cells,	   the	   recovery	   and	  detection	   of	  
allergen-­‐specific	  cells	  from	  tissue	  may	  be	  difficult.	  As	  the	  present	  study	  aimed	  to	  track	  and	  
investigate	   changes	   in	   the	   CD4+	  T	   cell	   population	   in	   response	   to	   CTL	   immunotherapy,	   it	  
was	  important	  that	  a	  significant	  number	  of	  cells	  be	  recovered	  from	  tissue	  in	  order	  to	  derive	  
meaningful	  differences	  between	  cells	  that	  had	  been	  transferred	  with	  or	  without	  CTLs.	  The	  
titration	  performed	  in	  this	  chapter	  indicated	  the	  use	  of	  5	  x	  106	  adoptively	  transferred	  CD4+	  
T	   cells;	   the	   ensuing	   airway	   inflammation	   being	   robust,	   reproducible,	   and	   resulting	   in	   a	  
distinct	  population	  of	  allergen-­‐specific	  cells	  being	  reliably	  recovered	  from	  multiple	  tissues	  
for	  analysis.	  	  
	  
CTL	  immunotherapy	  effectively	  prevented	  the	  induction	  of	  allergic	  airway	  inflammation	  in	  
mice	  given	  CD4+	  Th2	  cells;	  there	  was	  a	  reduction	  in	  lung	  eosinophilia,	  IL-­‐4,	  IL-­‐5	  and	  IL-­‐13	  
production,	   mucus	   hypersecretion	   and	   inflammatory	   infiltrates	   in	   CTL-­‐treated	   mice.	  
Therefore,	   the	   adoptive	   transfer	   model	   recapitulates	   many	   features	   of	   allergic	   airway	  
inflammation	   induced	  by	   in	  vivo	   sensitisation	  models,	  as	  well	  as	   the	  associated	   inhibitory	  
effect	  of	  allergen-­‐specific	  CTLs.	  	  	  
	  
	  
Effects of CTLs on the number of allergy-driving CD4+ T cells in the lung and 
airway 
	  
Associated	  with	  the	  suppression	  of	  allergic	  airway	  inflammation,	  a	  reduction	  in	  the	  number	  
of	   disease-­‐mediating	   CD4+	   T	   cells	   in	   the	   lung	   was	   consistently	   induced	   by	   CTL	  
immunotherapy.	   This	   finding	   prompted	   an	   investigation	   into	   whether	   the	   migration,	  
proliferation,	  activation	  or	  cytokine	  production	  of	  CD4+	  T	  cells	  were	  being	  affected	  by	  the	  
treatment.	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As	  CD4	  +/-­‐	   CTL–treated	  mice	   that	   received	  PBS	   intranasally	   did	  not	   show	  an	   increase	   in	  
adoptively	   transferred	  T	   cells,	   this	   indicated	   that	   adoptively	   transferred	   cells	   entered	   the	  
lungs	  by	  an	  active	  process,	   induced	  by	  allergen	  exposure.	  It	   is	   interesting,	  then,	  that	  there	  
was	   a	   reduction	   in	   the	   infiltration	   of	   adoptively	   transferred	   CD4+	  T	   cells	   as	  well	   as	   host	  
CD4+	  and	  CD8+	  T	  cells	  in	  the	  lungs	  of	  CTL-­‐treated	  mice.	  	  	  
	  
Some	   studies	   have	   suggested	   that	   co-­‐stimulatory	   factors	   play	   a	   role	   in	   the	   regulation	   of	  
Th2-­‐mediated	   airway	   inflammation	   by	   controlling	   the	   migration,	   and	   subsequent	   tissue	  
numbers,	  of	  CD4+	  T	  cells	  in	  the	  lung.	  CD4+	  T	  cells	  that	  lack	  ICOS	  expression	  were	  previously	  
found	  to	  have	  increased	  lymph	  node-­‐homing	  receptors	  CCR7	  and	  CD62L	  compared	  to	  WT	  
CD4+	  T	  cells;	  these	  cells	  preferentially	  migrate	  to	  non-­‐draining	  lymph	  nodes	  rather	  than	  the	  
lung	   or	   MLN	   (720,	   721).	   In	   the	   current	   study,	   however,	   the	   decrease	   in	   the	   number	   of	  
adoptively	  transferred	  CD4+	  T	  cells	  in	  the	  lung	  and	  BAL	  of	  CTL-­‐treated	  mice	  did	  not	  appear	  
to	  be	  associated	  with	  an	  increase	  in	  these	  cells	  in	  the	  alternative	  tissues	  examined;	  spleen,	  
peripheral	  blood,	  and	  non-­‐lung-­‐draining	   lymph	  nodes	  showed	  no	  significant	  difference	   in	  
the	  number	  of	  cells	  recovered	  throughout	  the	  course	  of	  inflammation	  in	  CTL	  treated	  versus	  
untreated	  groups.	   It	  was	   interesting	  that	  despite	   the	  elevated	  CD4+	  T	  cell	  numbers	   in	   the	  
lungs	  of	  mice	  that	  did	  not	  receive	  CTL	  therapy,	  no	  additional	  increase	  in	  CD4+	  T	  cells	  in	  the	  
lung-­‐draining	  MLN	  was	  evident	  in	  these	  mice	  during	  the	  time	  course.	  While	  the	  migration	  of	  
OVA-­‐loaded	  lung	  APCs	  and	  the	  trafficking	  of	  adoptively	  transferred	  OTII	  cells	  to	  LNs	  does	  
occur	  (486,	  722)	  this	  may	  not	  be	  necessary	  for	  the	  stimulation	  of	  pre-­‐activated	  cells.	  Indeed,	  
the	   ability	   of	   these	   cells	   to	   migrate	   to	   lymph	   nodes	   depends	   on	   their	   expression	   of	   the	  
lymph	  node	  homing	  molecules	  CD62L	  and	  CCR7	  (274,	  723,	  724)	  and	  previously	  activated	  
TCM	   and	   TEM	   cells	   express	   these	   molecules	   differently,	   CCR7+CD62Lhi	   and	   CCR7-­‐CD62Llo	  
respectively	  (274).	  The	  majority	  of	   in	  vitro	  generated	  OTII	  cells	   in	  the	  present	  study	  were	  
CD62Llo	  upon	  transfer	  (Fig	  4.1),	  potentially	  explaining	  the	  absence	  of	  significant	  migration	  
to	  the	  MLN.	  Rather,	  this	  trait	  is	  in	  common	  with	  TEM	  cells,	  which	  have	  been	  demonstrated	  to	  
rapidly	   respond	   to	   antigen	   exposure	   in	   non-­‐lymphoid	   tissues	   (274,	   275).	   Harris	   and	  
colleagues	   used	   an	   adoptive	   transfer	   model	   to	   examine	   the	   fate	   of	   in	   vitro-­‐activated,	  
adoptively	   transferred	   CD4+	   T	   cells	   of	   differing	   CD62L	   expression,	   upon	   airway	   allergen	  
challenge.	   Expectedly,	   CD62Lhi	   cells	   migrated	   to	   lymph	   nodes,	   while	   CD62Lmed-­‐lo	   cells	  
   163 
 
localised	  to	  non-­‐lymphoid	  tissues	  (486).	  Indeed,	  it	  was	  demonstrated	  that	  in	  this	  model,	  the	  
CD62Lmed-­‐lo	  cells	  were	  capable	  of	  rapid	  effector	  cytokine	  production	  upon	  allergen	  exposure	  
in	  the	  lung,	  despite	  being	  unable	  to	  traffic	  to	  the	  MLN.	  	  
	  
Some	   studies	   have	   also	   shown	   that	   antigen-­‐loaded	   APCs	   may	   be	   preferentially	   retained	  
within	  the	  lung	  tissue	  and	  local	  antigen	  presentation	  to	  T	  cells	  may	  occur	  in	  situ	  (114,	  115).	  
Distinct	   differences	   have	   also	   been	   found	   between	   the	   interaction	   of	   T	   cells	   with	   lung	  
parenchymal	  DCs	  and	  alveolar	  DCs;	  while	  parenchymal	  DCs	  are	  capable	  of	  activating	  both	  
naïve	   and	   antigen-­‐primed	   T	   cells,	   alveolar	   DCs	   are	   only	   capable	   of	   activating	   antigen-­‐
primed	  (but	  not	  naïve)	  T	  cells	  (725).	  Collectively,	  these	  studies	  reveal	  the	  presence	  of	  lung	  
DCs	   specialised	   in	   the	   activation	   of	   antigen-­‐primed	   T	   cells,	   and	   the	   potential	   for	   in	   situ	  
antigen	   presentation.	   It	   is	   likely,	   then,	   that	   the	   pre-­‐activated	   allergen-­‐experienced	  
adoptively	   transferred	   CD4+	   T	   cells	   described	   in	   the	   present	   study	   may	   not	   need	   to	   be	  
licenced	  in	  the	  MLN.	  	  
	  
The	  decrease	  in	  CD4+	  T	  cells	  in	  the	  lungs	  of	  CTL-­‐treated	  mice	  was	  found	  to	  be	  dependent	  on	  
the	   CTLs	   being	   capable	   of	   perforin	   expression.	   While	   the	   direct	   targeting	   and	   killing	   of	  
CD4+	  T	  cells	  is	  a	  known	  mechanism	  for	  the	  control	  of	  virally-­‐infected	  cells,	  especially	  during	  
HIV	  infection	  (726-­‐728),	  it	  is	  unlikely	  that	  direct	  killing	  would	  occur	  in	  the	  case	  of	  allergen-­‐
reactive	   CD4+	  Th2	   cells.	   	   Unlike	  HIV	   infection	  where	   viral	   components	   are	   presented	   on	  
CD4+	  T	  cell	  MHC-­‐I	  molecules	  and	  recognised	  by	  CD8+	  T	  cells	  through	  their	  TCR,	  allergen-­‐
specific	   Th2	   cells	   have	   not	   been	   reported	   to	   display	   allergens	   on	   their	   surface,	   or	   to	   be	  
capable	  of	  cross-­‐presenting	  antigens,	  so	  cannot	  be	  recognised	  for	  CTL-­‐mediated	  killing.	  This	  
result,	   then,	   suggests	   that	   a	   cell	  upstream	  of	   the	  CD4+	  T	   cell	   response	   (ie,	   an	  APC)	   is	   the	  
more	  likely	  target	  of	  CTL-­‐mediated	  killing.	  This	  hypothesis	  is	  examined	  in	  Chapter	  5.	  	  
	  
While	   the	   requirement	   for,	   and	   contrasting	   effects	   of,	   CD4+	   and	   CD8+	   T	   cells	   in	   allergic	  
airway	  inflammation	  have	  been	  investigated	  (222,	  707,	  729),	  little	  has	  been	  reported	  on	  the	  
direct	   or	   consequential	   effects	   of	   CD8+	  T	   cells	   on	  CD4+	  T	   cells.	  One	   important	   finding	   in	  
asthmatic	   patients,	   as	  well	   as	   experimental	  models,	  was	   that	   an	   increase	   in	   CD4+	  T	   cells	  
directly	  correlates	  with	  the	  severity	  of	  AHR;	  interestingly,	  an	  inverse	  correlation	  exists	  with	  
CD8+	  T	  cells(711,	  730).	  It	  has	  also	  been	  reported,	  however,	  that	  both	  CD4+	  and	  CD8+	  T	  cell	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populations	   increase	   in	  number	   as	   chronic	  disease	  progresses	   (731).	   These	   findings	  may	  
not	   be	   conflicting,	   but	   rather	   implicate	   the	   involvement	   of	   temporal	   factors	  whereby	   the	  
balance	   of	   CD4+:CD8+	   T	   cells	   is	   crucial	   to	   preventing	   the	   progression	   of	   early	   allergic	  
responses	   to	   fully	   established	   chronic	  disease.	   Indeed,	   it	   has	  been	   reported	   that	  blocking	  
CD8+	   T	   cell	   responses	   increases	   CD4+	   T	   cell	   responsiveness	   to	   antigens,	   enhancing	  
protection	  against	  pathogens	  (732);	  however,	   increased	  responsiveness	  may	  be	  damaging	  
in	  an	  allergic	  Th2	  environment.	  Additionally,	   in	  an	  experimental	  model	  where	   robust	   IgE	  
production	  and	  a	  high	  CD4+:CD8+	  T	  cell	   ratio	  exists,	   like	   in	  an	  allergic	  asthmatic	  patient,	  




Effects of CTLs on the proliferation and activation of CD4+ T cells 
	  
While	  not	  statistically	  significant,	  it	  appeared	  that	  the	  proliferation	  of	  CD4+	  T	  cells	  may	  be,	  
in	  part,	  affected	  by	  CTLs.	  It	  has	  been	  shown	  that	  CD62Llo	  adoptively	  transferred	  T	  cells	  that	  
migrate	   to	   the	   lung,	  while	  capable	  of	  effector	  cytokine	  production,	  are	  unable	   to	  divide	   in	  
situ	   (486).	   It	   is	   possible,	   then,	   that	   the	   moderate	   effect	   on	   CD4+	   T	   cell	   proliferation	  
observed	  in	  the	  present	  study	  reflects	  the	  effects	  of	  CTLs	  on	  the	  small	  proportion	  of	  CD62Lhi	  
cells	   within	   the	   adoptively	   transferred	   population	   that	   would	   have	   been	   stimulated	   to	  
divide	  in	  the	  lymph	  nodes	  before	  trafficking	  to	  the	  lungs.	  It	  is	  known	  that	  IFN-­‐γ	  can	  mediate	  
the	  suppression	  of	  CD4+	  Th2	  cell	  proliferation	  (734),	  however	  in	  the	  present	  study,	  IFN-­‐γ-­‐
sufficient,	  perforin-­‐deficient	  CTLs	  did	  not	  induce	  a	  similar	  decrease	  in	  proliferation.	  This,	  in	  
accordance	  with	  the	  effects	  on	  CD4+	  T	  cell	  numbers,	  also	  suggests	  an	  indirect	  mechanism	  
by	  which	  CD4+	  T	  cells	  are	  affected	  by	  CTLs.	  	  
	  
Minimal	  effects	  were	  observed	  in	  the	  expression	  of	  activation	  and	  costimulatory	  receptors	  
CD44,	  CD69,	   ICOS,	  PD-­‐1	  and	  CD49d	  on	  CD4+	  T	  cells	   in	  mice	   treated	  with	  wild	   type	  CTLs,	  
compared	  to	  those	  treated	  with	  perforin	  deficient	  CTLs.	  This	  implied	  that	  the	  activation	  of	  
CD4+	  T	  cells	  was	  not	  being	  interfered	  with	  as	  a	  mechanism	  of	  CTL-­‐mediated	  suppression	  of	  
airway	   inflammation.	   It	   was	   interesting	   however	   that	   PD-­‐1,	   upregulated	   after	   in	   vitro	  
exposure	  to	  OVA,	  remained	  elevated	  on	  adoptively	  transferred	  CD4+	  T	  cells	  in	  the	  absence	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of	   in	   vivo	   allergen	   stimulation,	   throughout	   the	   7	   day	   course	   of	   testing.	   PD-­‐1	   is	   rapidly	  
upregulated	   on	   T	   cells	   after	   stimulation	   of	   the	   TCR	   (735,	   736)	   and,	   consequently,	   upon	  
ligation	  with	  PD-­‐L1	  or	  PD-­‐L2	  on	  APCs,	  T	  cell	  proliferation	  and	  effector	  cytokine	  production	  
is	  inhibited	  (737,	  738).	  This	  has	  been	  proposed	  to	  have	  an	  important	  role	  in	  modulating	  and	  
restraining	   immune	   responses	   to	   avoid	   autoimmunity	   and	   pathology	   and	   maintain	  
tolerance	   (739-­‐742).	   In	   allergy,	   PD-­‐1:PD-­‐L1/2	   ligation	   can	   either	   lead	   to	   increased	   or	  
decreased	  airway	  hyperreactivity,	  and	  effects	  on	  the	  proliferation	  and	  cytokine	  production	  
of	  CD4+	  T	  cells	  can	  be	  influenced	  by	  the	  amount	  of	  antigen	  present	  as	  well	  as	  the	  cytokine	  
environment	  (738,	  743-­‐745).	  In	  the	  presence	  of	  high	  antigen	  concentrations,	  the	  inhibitory	  
effect	  on	  proliferation	   is	  no	   longer	  significant,	  neither	   is	  cytokine	  production	  diminished–	  
especially,	   IL-­‐4	   production	   does	   not	   appear	   significantly	   restrained	   (738).	   In	   the	   present	  
study,	   it	   is	  clear	  that	  adoptively	  transferred	  CD4+	  T	  cells	  maintain	  the	  ability	   to	  carry	  out	  
strong	   effector	   function,	   despite	   their	   upregulation	   of	   PD-­‐1.	   This	   may	   suggest	   that	   the	  
amount	   of	   OVA	   administered	   intranasally	  was	   strong	   enough	   to	   overcome	   the	   inhibitory	  
effects	  elicited	  by	  PD-­‐1:PD-­‐L1/2	  ligation.	  	  
	  
While	  a	  dose-­‐dependent	  trend	  in	  all	  treatment	  groups	  was	  observed	  in	  the	  titration	  data	  for	  
PD-­‐1	   expression	  described	   in	   this	   chapter,	   a	   significant	   increase	  was	  not	  present	   in	  mice	  
that	   received	   CD4+	   T	   cells	   only.	   In	   CTL-­‐treated	   groups,	   however,	   higher	   doses	   of	   OVA	  
induced	  higher	  PD-­‐1	  expression	  on	  CD4+	  T	  cells.	  As	  this	  occurred	  in	  both	  mice	  treated	  with	  
WT	  CTLs	  and	  PKO	  CTLs,	  it	  is	  possibly	  an	  effect	  of	  higher	  allergen	  doses	  eliciting	  increased	  
production	  of	  CD8+	  T	  cell	  effector	  cytokines	  and	  molecules.	  One	  such	  cytokine,	   IFN-­‐γ,	  has	  
been	  shown	  to	  induce	  PD-­‐L1	  and	  PD-­‐L2	  expression	  on	  APCs	  (737,	  746).	  The	  similarly	  high	  
PD-­‐1	  expression	   in	   these	   two	  groups	  did	  not	   reflect	   the	   associated	  CD4+	  T	   cell-­‐mediated	  
inflammatory	  response;	  PKO	  CTL-­‐treated	  mice	  had	  robust	  Th2	  allergic	  airway	  inflammation	  
while	  WT	  CTL-­‐treated	  mice	  showed	  suppression.	  This	  suggests	  that	  effects	  on	  PD-­‐1	  are	  not	  
important	   for	   the	   amelioration	   of	   allergic	   airway	   inflammation	   by	   allergen-­‐specific	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Effects of CTLs on Th2 cytokine-producing CD4+ T cells in the lung  
	  
The	   ability	   of	   CD4+	   Th2	   cells	   to	   mediate	   allergic	   airway	   disease	   relies	   heavily	   on	   their	  
ability	   to	   produce	   key	   effector	   cytokines,	   IL-­‐4,	   IL-­‐5	   and	   IL-­‐13	   (381,	   525,	   747-­‐751);	   these	  
cytokines	  were	  found	  to	  be	  decreased	  in	  the	  BAL	  of	  CTL-­‐treated	  mice.	  In	  this	  chapter,	  the	  
effects	  of	  CTL	   immunotherapy	  on	  the	  IL-­‐4	  and	  IL-­‐13	  production	  of	  adoptively	   transferred	  
CD4+	  T	  cells	  was	  examined.	  Results	  showed	  that	  at	  the	  day	  one	  peak	  of	  cytokine	  production,	  
the	  number	  of	  total	  CD4+	  T	  cells	  in	  the	  lung	  were	  similar	  whether	  mice	  were	  treated	  with	  
CTLs	   or	   not;	   however	   the	   number	   of	   those	   cells	   that	  were	   reporting	   IL-­‐4,	   IL-­‐13	   or	   both	  
cytokines,	   was	   significantly	   lower	   in	   CTL-­‐treated	  mice	   (Fig	   4.12).	   This	   finding	   suggested	  
that	  the	  decrease	  in	  BAL	  cytokine	  production	  (Fig	  4.11)	  was	  not	  simply	  a	  consequence	  of	  a	  
reduced	  number	  of	  infiltrating	  CD4+	  T	  cells,	  but	  rather	  that	  the	  cytokine	  production	  of	  the	  
cells	  within	  the	  lung	  may	  be	  suppressed.	  The	  diminution	  of	  the	  early	  cytokine	  response	  is	  
significant	  as	  IL-­‐4	  is	  critical	  for	  the	  recruitment	  of	  Th2	  cells	  to	  the	  lung	  (650),	  while	  IL-­‐13	  
has	  an	  essential	  role	  in	  generating	  airway	  resistance	  and	  mucus	  production	  (525,	  680,	  681).	  
This	  reduction	  in	  CD4+	  T	  cell	  recruitment	  would	  prevent	  the	  amplification	  of	  Th2-­‐mediated	  
pathology,	  thus	  restraining	  the	  allergic	  response.	  Indeed,	  by	  day	  three,	  the	  number	  of	  total	  
and	  cytokine-­‐reporting	  CD4+	  T	  cells	   in	   the	   lung	  were,	  additionally,	  effectively	  reduced	  by	  
CTL	  immunotherapy.	  Together	  these	  findings	  suggest	  that	  the	  early	  stimulation	  of	  CD4+	  T	  
cells	  may	  have	  been	  insufficient	  to	  drive	  significant	  allergic	  airway	  inflammation,	  perhaps	  
implying	   inadequate	   interaction	   with	   antigen	   presenting	   cells.	   This	   hypothesis	   will	   be	  




In	  this	  chapter,	  an	  adoptive	  transfer	  model	  of	  allergic	  airway	  inflammation	  was	  established	  
and	   characterised;	   key	   features	   of	   pathology	   induced	   by	   in	   vivo	   sensitisation	   were	  
replicated	  within	  this	  model	  and	  allergy-­‐driving	  CD4+	  T	  cells	  were	  tracked.	  Investigation	  of	  
the	   effects	   of	   CTL	   immunotherapy	   on	   allergy-­‐driving	  CD4+	  T	   cells	   revealed	   that	   effective	  
abrogation	  of	  allergic	  airway	   inflammation	  was	  associated	  with	  a	  decrease	   in	  CD4+	  T	  cell	  
numbers	   in	   the	   lung.	   This	   appeared	   to	   be	   predominantly	   due	   to	   decreased	   Th2	   cytokine	  
production	   during	   the	   early	   stage	   of	   the	   response	   to	   allergen	   exposure,	   and	   in	   part	   by	   a	  
   167 
 
reduction	   in	  CD4+	  T	   cell	  proliferation.	   	  These	   results	   suggest	   that	   in	   the	  presence	  of	  CTL	  
immunotherapy,	   CD4+	   T	   cells	  may	   receive	   insufficient	   stimulation	   by	   antigen	   presenting	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The	  role	  of	  CD8+	  T	  cells	  in	  allergic	  asthma	  is	  not	  well	  understood,	  and	  has	  been	  a	  point	  of	  
some	   controversy,	   with	   studies	   reporting	   both	   exaggerative	   (227-­‐229)	   and	   suppressive	  
(220-­‐226)	  activity	  on	  airway	  inflammation,	  as	  discussed	  in	  Chapter	  1.	  Previous	  work	  in	  our	  
lab	   highlighted	   the	   critical	   requirement	   for	   perforin	   in	   successful	   amelioration	   of	   acute	  
disease	  (226).	  Further	  to	  the	  work	  of	  Enomoto	  et	  al,	  Chapter	  3	  of	  this	  thesis	  describes	  long	  
term	  preventative	   and	   therapeutic	   effects	   of	   allergen-­‐specific	   CTLs	   in	   a	  multiple	   allergen	  
exposure	   model	   of	   allergic	   airway	   inflammation;	   these	   effects	   were	   also	   dependent	   on	  
perforin.	   It	  was	   thus	   apparent	   that	  CTL-­‐mediated	  killing	   is	   critical	   for	   the	   suppression	  of	  
airway	  disease,	  however,	  further	  investigation	  was	  required	  to	  identify	  the	  cellular	  targets.	  	  
	  
The	  localisation	  of	  CD8+	  T	  cells	  in	  the	  allergy-­‐inflamed	  lung	  has	  not	  been	  reported,	  nor	  has	  
the	  interaction	  of	  CTLs	  with	  lung	  DCs	  during	  active	  disease	  been	  elucidated.	  Critical	  to	  the	  
induction	  of	  the	  allergic	  response,	  dendritic	  cells	  stimulate	  Th2	  responses	  in	  the	  lung	  that	  
culminate	   in	   airway	   inflammation	   (321).	   While	   DCs	   may	   elude	   being	   killed	   by	   CTLs	   to	  
enable	  continued	  antigen	  presentation	  (752-­‐754),	  CTL-­‐mediated	  killing	  of	  DCs	   in	  vivo	  has	  
also	   been	   demonstrated	   (755-­‐757).	   Additionally,	   a	   decrease	   in	   DC	   numbers	   in	   the	   lung-­‐
draining	  MLN	   of	   CTL-­‐treated	  mice	   has	   been	   reported	   (226),	   a	   finding	   that	   proposes	   the	  
possibility	   that	   allergen-­‐specific	   CTLs	   kill	   allergen-­‐presenting	  DCs.	   This	  may	   result	   in	   the	  
suppression	  of	  CD4+	  Th2-­‐driven	  inflammation.	  	  	  
	  
Recent	  advances	  in	  inflammatory	  and	  conventional	  DC	  subset-­‐distinguishing	  markers,	  lung	  
imaging	   technology,	   and	   the	  development	   of	   transgenic	  mice	   that	   display	   fluorescence	   in	  
DC	  populations	  have	  provided	  new	  insights	  into	  the	  localisation	  and	  functional	  activities	  of	  
DCs	   in	   the	   lung	   and	   MLN.	   Critical	   to	   the	   induction	   of	   secondary	   Th2	   responses	   to	  
aeroallergens	   (493),	   the	   depletion	   of	   CD11c+	   DC	   during	   allergen	   challenge	   of	   sensitised	  
mice	   ameliorates	   inflammation	   (321),	   revealing	   their	   necessity	   in	   the	   effector	   response.	  
CD11b+	  cDCs	  have	  recently	  been	  examined	  through	  the	  use	  of	  CD11ceYFP-­‐expressing	  mice	  
(652),	   counterstained	   with	   CD11b-­‐APC,	   to	   reveal	   their	   distribution	   within	   the	   lung.	  
Following	   allergen	   challenge	   of	   sensitised	   mice,	   CD11b+	   DCs	   increase	   in	   number	   and	  
localise	  within	   the	  vicinity	  of	  allergic	  airways	   (494).	  Conversely,	   little	   is	  known	  about	   the	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localisation	   of	   the	   CD103+	   lung	   DC	   population	   in	   allergic	   disease,	   this	   subset	   being	  
specialised	  in	  cross-­‐presentation	  to	  CD8+	  T	  cells	  (123,	  126).	  It	  has	  been	  reported	  that	  these	  
DCs	   are	   primarily	   found	   in	   the	   vicinity	   of	   the	   airway	   mucosa	   and	   arteriole	   walls	   (320),	  
however,	   further	   study	   is	   required	   to	   elucidate	   their	   redistribution,	   function	   and	  
interactions	  with	  T	   cells	  during	   the	   course	  of	   allergic	  airway	   inflammation.	  Expression	  of	  
XCR1	   identifies	   this	   CD103+	   DC	   population	   (655,	   758),	   and	   the	   recent	   generation	   of	  
XCR1venus-­‐expressing	   (653)	   and	   novel	   XCR1GFP-­‐expressing	   reporter	   mice	   (Generated	   by	  
Okada,	  Kaisho,	  et	  al;	  Daniels,	  Mucosal	  Immunology,	  2015	  In	  Press)	  provide	  invaluable	  tools	  
for	  the	  examination	  of	  these	  DC	  in	  the	  lung.	  	  
	  
Dendritic	   cell	   vaccines	   that	   elicit	   endogenous	   antigen-­‐specific	   CTL-­‐mediated	   immune	  
responses	   have	   been	   widely	   proven	   effective	   in	   anti-­‐tumour	   immunity	   (602-­‐605),	  
additionally,	   immunisation	  with	  allergen-­‐pulsed	  DCs	  has	  been	  shown	   to	  elicit	   an	   immune	  
response	   that	  mediates	   suppression	  of	   allergic	   airway	  disease	   in	   a	   similar	  manner	   to	   the	  
direct	  adoptive	  transfer	  of	  CTLs	  (226).	  The	  present	  study	  elucidated	  the	  preventative	  and	  
therapeutic	  effects	  of	  allergen-­‐specific	  CTLs	  on	  allergic	  airway	  inflammation,	  in	  accordance	  
with	   effects	   previously	   reported	   (220,	   222-­‐224,	   226),	   suggesting	   a	   CTL-­‐inducing	   vaccine	  
may	   be	   effective	   at	   mediating	   the	   suppression	   of	   allergy.	   To	   this	   end,	   a	   self-­‐adjuvanting	  
glycolipid-­‐peptide	   conjugate	   vaccine	   was	   recently	   generated	   through	   collaboration	  
between	  the	  Malaghan	  Institute	  of	  Medical	  Research	  and	  the	  Ferrier	  Research	  Institute,	  as	  
recently	   described	   (668).	   This	   vaccine	   consists	   of	   the	   OT-­‐I	   CD8+	   T	   cell-­‐specific	   peptide	  
OVA257-­‐264	   conjugated	   to	   α-­‐galactosylceramide	   (α-­‐GalCer)	   by	   a	   linker	   that	   incorporates	  
cleavage	   sites.	  Upon	   i.v.	   administration,	   the	   conjugated	  vaccine	   remains	   inactive	  until	   the	  
linker	   is	   cleaved;	   the	   specific	   defined	   enzymatic	   cleavage	   sequences	   were	   designed	   to	  
preferentially	  release	  the	  active	  components	  of	  the	  vaccine	  within	  APCs.	  Upon	  release,	  both	  
the	   OVA257-­‐264	  peptide	   and	   α-­‐GalCer	   may	   be	   processed	   for	   presentation	   by	   APCs.	   The	   α-­‐
GalCer	  binds	  CD1d	  to	  trigger	  activation	  of	  group	  1	  NKT	  cells	  (759),	  recruiting	  their	  ‘help’	  for	  
the	   activation	   of	   APCs	   such	   as	   DC.	   An	   endogenous	   CD8+	   T	   cell	   response	   may	   then	   be	  
initiated	   upon	   presentation	   of	   the	   OVA257-­‐264	   peptide.	   Therefore,	   this	   vaccine	   may	  
potentially	   have	   therapeutic	   effects	   similar	   to	   those	   mediated	   by	   adoptively	   transferred	  
CTLs.	   The	   effects	   of	   this	   vaccine	   on	   allergic	   airway	   inflammation	   are	   investigated	   in	   this	  
chapter.	  




The	   purpose	   of	   this	   chapter	   was	   to	   investigate	   the	   mechanism	   of	   action	   of	   perforin-­‐
dependent	  allergen-­‐specific	  CTL	  immunotherapy	  of	  allergic	  airway	  disease,	  with	  a	  specific	  
focus	   on	   determining	   the	   cellular	   targets	   of	   CTL-­‐mediated	   killing.	   Additionally,	   the	  
localisation	  and	  interaction	  of	  CD4+	  T	  cells	  and	  CTLs	  with	  lung	  DC	  subsets	  in	  the	  inflamed	  
lung	  was	  examined,	  to	  investigate	  killer-­‐target	  interactions.	  Furthermore,	   it	  was	  purposed	  
to	   determine	   whether	   a	   peptide	   conjugate	   vaccine-­‐	   initially	   designed	   to	   elicit	   an	  
endogenous	   CTL-­‐mediated	   anti-­‐tumour	   response-­‐	  may	   be	   effective	   in	   the	   suppression	   of	  
allergy.	  As	  the	  expression	  of	  perforin	  is	  critical	  to	  the	  effective	  suppression	  of	  disease,	  and	  
the	  depletion	  of	  lung	  CD11c+	  DC	  results	  in	  amelioration	  of	  asthma,	  the	  hypothesis	  was	  that	  
CTL-­‐mediated	  killing	  of	  allergy-­‐driving	  DC	  may	  be	  occurring.	  	  
	  
	  
The	  specific	  aims	  were:	  
• To	  determine	  the	  targets	  of	  CTL-­‐mediated	  killing	  	  
• To	  elucidate	  the	  localisation	  of	  cross-­‐presenting	  CD103+	  DCs	  in	  the	  lung	  during	  
allergic	  airway	  inflammation	  
• To	  examine	  the	  interaction	  of	  CD4+	  T	  cells	  and	  CTLs	  with	  DC	  populations	  within	  
the	  lung	  
• To	   assess	   the	   capability	   of	   an	   allergen-­‐specific	   peptide	   conjugate	   vaccine	   to	  
















5.3.1 CTL therapy increases the expression of pro-apoptotic caspases 
in DCs 
 
To	  determine	  the	  potential	  cellular	  targets	  of	  CTL-­‐mediated	  killing	  in	  OVA-­‐challenged	  mice,	  
the	  fluorogenic	  substrate	  FLIVO	  was	  used	  to	  directly	  identify	  pre-­‐apoptotic	  cells	  expressing	  
active	  caspases	   in	  vivo.	  An	   in	  vivo	  sensitisation	  model	  of	  allergic	  airway	  inflammation	  was	  
used	  (Fig	  5.1	  A)	  so	  that	  all	  induced	  cell	  populations	  may	  be	  examined.	  Lung	  and	  mediastinal	  
lymph	   nodes	   (MLN)	   were	   extracted	   and	   the	   cellular	   composition	   determined	   by	   flow	  
cytometry.	  The	  proportion	  of	  MLN	  cells	  displaying	  active	  caspases	  revealed	  that	  these	  were	  
increased	   in	   the	   CTL-­‐treated	   group	   compared	   to	   the	   OVA/Alum	   and	   PKO	   CTL-­‐treated	  
groups	   (Fig	   5.1	   B),	   indicating	   that	   the	   increase	   in	   apoptotic	   cells	   was	   dependent	   on	   the	  
administration	   of	   cytolytic	   perforin-­‐sufficient	   CTLs.	   In	   lymph	   nodes,	   cells	   undergoing	  
apoptosis	  displayed	   increased	   fluorescence	   (Fig	  5.1	  C,	   upper	  panel),	   distinguishable	   from	  
samples	  without	  FLIVO	  staining	  (Fig	  5.1	  C,	  lower	  panel),	  as	  depicted	  in	  representative	  flow	  
panels.	   Unfortunately,	   the	   presence	   of	   autofluorescent	   cells	   made	   the	   identification	   of	  
apoptotic	  cells	   in	   lung	  tissue	  difficult,	   therefore	  this	  tissue	  could	  not	  be	  further	  examined.	  
Upon	   further	  analysis	  of	   the	  FLIVO+	  cells	   in	  CTL-­‐treated	  mice,	   it	  was	  discovered	   that	   the	  
majority	   of	   these	   cells	   showed	   the	   FSC/SSC	   and	   CD11c+MHCII+	   characteristics	   typical	   of	  
dendritic	  cells	  (Fig	  5.1	  D,	  upper	  panel);	  this	  population	  was	  highly	  overrepresented	  in	  the	  
FLIVO+	  population,	  making	  up	  66.1%	  of	  the	  cells	  compared	  to	  the	  total	  lymph	  node	  cells	  in	  
which	   DCs	   only	   account	   for	   3.4%	   (Fig	   5.1	   D,	   lower	   panel).	   Additionally,	   about	   63%	   of	  
FLIVO+	  DCs	  were	  MHCIIhi,	  characteristic	  of	  migratory	  DCs,	  compared	  to	  45%	  in	  the	  total	  DC	  
population	   (Fig	   5.1	   E,	   upper	   and	   lower	   panels).	   These	   results	   suggest	   that	   targeted	   cell	  
killing	   occurs	   in	   WT	   CTL-­‐treated	   mice,	   and	   a	   migratory	   DC	   population	   in	   the	   MLN	   is	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Figure	  5.1:	  Increased	  activation	  of	  pro-­‐apoptotic	  caspases	  in	  DCs	  after	  CTL	  therapy	  
(A)	  Mice	  were	  sensitized	  by	  i.p.	  injection	  of	  2μg	  OVA	  in	  alum	  adjuvant	  and	  challenged	  with	  
OVA	  by	   intranasal	   instillation	  according	   to	   the	   indicated	  schedule.	  OVA-­‐specific	  CTL	  were	  
given	   1	   day	   before	   OVA	   challenge.	   One	   day	   after	   OVA	   challenge,	  mice	  were	   treated	  with	  
FLIVO	   to	   identify	   apoptotic	   cells,	   and	   were	   sacrificed	   3	   h	   later.	   (B)	   The	   proportion	   of	  
apoptotic	  cells	  in	  the	  mediastinal	  lymph	  node	  was	  determined	  by	  FLIVO	  staining	  as	  shown	  
in	  (C).	  The	  bar	  graph	  shows	  the	  mean	  proportion	  apoptotic	  cells	  of	  live	  cells	  in	  the	  MLN	  for	  
3-­‐5	  mice/group,	   +	   SEM.	   Data	   are	   from	   one	   of	   two	   experiments	   that	   gave	   similar	   results.	  
***p<0.001	   as	   determined	   using	   one	   way	   ANOVA	   with	   Bonferroni	   correction.	   (C)	  
Identification	   of	   apoptotic	   cells	   by	   flow	   cytometric	   analysis	   of	   mediastinal	   lymph	   nodes	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from	  FLIVO-­‐treated	  (upper	  panel)	  and	  untreated	  mice	  (lower	  panel).	  DAPI-­‐high	  cells	  were	  
gated	  out	  before	  the	  apoptotic	  cells	  were	  identified	  and	  gated.	  (D)	  Characterization	  of	  the	  
apoptotic	   population	   by	   flow	   cytometry.	   FLIVO+	   cells	   gated	   as	   in	   (C)	  were	   examined	   for	  
expression	  of	  CD11c	  and	  MHCII/3JP	  (upper	  panel).	  	  Expression	  of	  CD11c	  and	  MHCII	  in	  the	  
total	  LN	  population	  is	  shown	  as	  a	  comparison	  (lower	  panel).	  (E)	  The	  proportion	  of	  MHCII-­‐
high	   cells	   (lung-­‐derived	   DC)	   in	   the	   FLIVO+CD11c+MHCII+	   population	   was	   determined	  
(upper	   panel);	   the	   enrichment	   of	   this	   population	   was	   compared	   to	   the	   total	   MHCII-­‐high	  
cells	  in	  the	  LN	  (lower	  panel).	  Data	  are	  from	  one	  of	  two	  experiments,	  each	  with	  3-­‐5	  mice	  per	  
group,	  that	  gave	  similar	  results.	  	  
 
 
5.3.2 CTLs elicit a perforin-dependent decrease in lung DCs 
To	   determine	   whether	   CTLs	   also	   target	   DCs	   in	   the	   lung,	   an	   adoptive	   transfer	   model	   of	  
allergic	  airway	  inflammation	  was	  carried	  out	  as	  described	  in	  Fig	  5.2	  A,	  where	  mice	  received	  
5	  x	  106	  CD4+	  Th2	  cells,	  with	  or	  without	  5	  x	  106	  WT	  or	  PKO	  CTLs.	  A	  single	  cell	  suspension	  
was	  generated	  from	  lungs	  one	  day	  after	  intranasal	  challenge	  and	  the	  numbers	  of	  DCs	  were	  
examined.	   Steady	   state	   CD11b+CD64-­‐	   and	   CD103+	   DCs,	   as	   well	   as	   inflammatory	  
CD11b+CD64+	  monocyte-­‐derived	  DCs	  were	   identified	  by	   flow	  cytometry	   as	  depicted	   (Fig	  
5.2	  B).	  Mice	   treated	  with	  WT	  CTLs,	  but	  not	  PKO	  CTLs,	   showed	  a	  decrease	   in	  all	   three	  DC	  
subsets	  compared	  to	  the	  CD4	  only	  group	  (Fig	  5.2	  C).	  These	  data	  suggest	  that	  CTL	  therapy	  
causes	  a	  perforin-­‐dependent	  decrease	  in	  DC	  numbers	  in	  the	  lung.	  	  
The	   expression	   of	   CD86	   and	   ICOS-­‐L	   on	   lung	   DC	   subsets	   was	   additionally	   examined	   in	  
experiments	  utilising	  the	  adoptive	  transfer	  model	  (described	  in	  Fig	  5.2	  A),	  with	  the	  dose	  of	  
OVA	   titrated	   to	   elucidate	   changes	   occurring	   in	   the	   presence	   of	   low	   to	   high	   allergen	  
concentration.	   An	   antigen-­‐dependent	   increase	   in	   CD86	   expression	  was	   apparent	   on	   both	  
steady	  state	  populations,	   the	  CD103+	  and	  CD11b+CD64-­‐	  DCs,	   in	  all	   treatment	  groups,	  but	  
did	  not	  appear	  to	  increase	  in	  CD11b+CD64+	  DC	  (Fig	  5.3).	  In	  mice	  that	  were	  not	  treated	  with	  
T	  cells,	  but	  received	  100μg	  OVA	  intranasally,	  the	  expression	  of	  CD86	  on	  CD11b+CD64-­‐	  and	  
CD11b+CD64+	  DC	  populations	  appeared	  similar	  to	  that	  of	  T	  cell-­‐treated	  mice	  that	  received	  
100μg	   OVA.	   The	   increase	   in	   CD86	   expression	   was	   therefore	   dependent	   on	   the	  
concentration	   of	   antigen	   administered	   to	   the	   airway.	   The	   rapid	   upregulation	   of	   CD86	   in	  
response	  to	  antigen	  and	  increasing	  cytokine	  stimulation	  by	  IL-­‐4	  and	  GM-­‐CSF	  has	  been	  	  
   177 
 
	  
Figure	  5.2:	  CTLs	  elicit	  a	  perforin-­‐dependent	  decrease	  in	  lung	  DCs	   	  	  
(A)	   C57BL/6	  mice	  were	   injected	  with	   activated	   CD4+	   T	   cells	   and	   CTLs	   as	   depicted,	   and	  
challenged	  with	  OVA	  by	  i.n.	   instillation	  1d	  later.	  Lung	  DC	  were	  examined	  1d	  after	  i.n.	  OVA	  
challenge.	   (B)	   Representative	   gating	   of	   lung	   DC	   by	   CD11c	   and	   MHCII	   staining,	   and	  
identification	   of	   CD11c+CD103+,	   CD11c+CD11b+CD64-­‐	   and	   CD11c+CD11b+CD64+	   DC	  
subsets	   by	   flow	   cytometry.	   FMO,	   Fluorescence	   Minus	   One	   (Lower	   right	   panel)	   for	   APC	  
staining	   shows	   distinction	   between	   CD64+	   and	   CD64-­‐	   cells.	   (C)	   Numbers	   of	   CD103+,	  
CD11b+CD64-­‐	   and	   CD11b+CD64+	   DC	   per	   lung	   were	   determined	   as	   shown	   in	   (B).	   Bar	  
graphs	  show	  mean	  DC	  numbers	  +	  SEM	  in	  the	  indicated	  experimental	  groups.	  Data	  are	  from	  
one	  of	  two	  experiments,	  each	  with	  3-­‐5	  mice	  per	  group,	  that	  gave	  similar	  results.	  **p<0.01,	  
***p<0.001,	   ****p<0.0001,	   ns,	   not	   significant,	   as	   determined	   using	   one	  way	   ANOVA	  with	  
Bonferroni	  correction. 
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reported	  by	  others	   (760-­‐762)	   additionally,	   histamine	   can	   exert	   similar	   effects	   (763).	   The	  
expression	  of	  CD86	  on	  the	  CD103+	  DC	  population	  in	  mice	  not	  treated	  with	  T	  cells,	  however,	  
did	  not	   increase	  above	   that	  which	  was	  evident	   in	  T	  cell-­‐treated	  mice	   that	  had	  been	  given	  
1μg	  OVA.	   This	   result	  may	   suggest	   that	   CD103+	  DC,	   that	   localise	   near	   to	   the	   airway	  wall,	  
have	   increased	   antigen	   uptake	   in	   response	   to	   the	   presence	   of	   inflammatory	   cells	   in	   the	  
airway,	  more	  so	  than	  CD11b+	  DC.	  	  	  
While	   not	   statistically	   significant,	   ICOS-­‐L	   showed	   an	   opposite	   trend	   to	   the	   expression	   of	  
CD86;	   ICOS-­‐L	   decreased	   in	   expression	   with	   increasing	   allergen	   exposure	   in	   all	   three	   DC	  
subsets,	  across	  all	  treatment	  groups.	  In	  general,	  the	  MFI	  of	  ICOS-­‐L	  expression	  was	  similar	  in	  
CD103+	  and	  CD11b+CD64-­‐	  cDC	  subsets,	  while	  CD11b+CD64+	  DC	  expressed	  higher	   levels;	  
this	  was	   in	  contrast	   to	   the	  MFI	  of	  CD86	  expression,	  which	  was	  highest	  overall	   in	  CD103+	  
DCs,	  while	  CD11b+CD64-­‐	  and	  CD11b+CD64+	  populations	  displayed	  similar	  levels.	  	  
In	   terms	  of	   the	   expression	  of	   ICOS-­‐L	   and	  CD86	   in	   relation	   to	  T	   cell	   administration,	   there	  
were	  no	  significant	  differences	  detected	   in	   the	  expression	  of	   these	  molecules	  at	   this	   time	  
point	  for	  any	  of	  the	  DC	  subsets,	  when	  comparing	  mice	  treated	  with	  CD4	  only,	  CD4	  +	  CTL	  or	  
CD4	   +	   PKO	   CTL.	   	   These	   data	   suggest	   that,	   while	   some	   DC	   subpopulation	   and	   antigen	  
concentration-­‐dependent	   differences	   exist,	   co-­‐treatment	   with	   WT	   or	   PKO	   CTLs	   did	   not	  
appear	   to	  affect	   the	  expression	  of	   ICOS-­‐L	  and	  CD86,	   compared	   to	   treatment	  with	  CD4+	  T	  
cells	  only.	  	  
 
5.3.3 CTL therapy targets CD11c+CD11b+CD64- conventional lung 
dendritic cells  
As	  shown	  in	  Fig	  5.2,	  DC	  numbers	  increase	  in	  the	  lung	  during	  allergic	  airway	  inflammation,	  a	  
phenomenon	   that	  may	   be	   suppressed	   in	   response	   to	   treatment	  with	   CTLs.	   To	   determine	  
whether	  the	  decrease	  in	  DC	  numbers	  in	  CTL-­‐treated	  mice	  was	  related	  to	  an	  overall	  decrease	  
in	   lung	   inflammation,	  or	  whether	  specific	  deletion	  of	  DCs	  was	  occurring,	  an	  experimental	  
model	  was	  devised	  where	  DC	  viability	  could	  be	  compared	  among	  mice	  where	  airway	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Figure	   5.3:	   The	   effects	   of	   CTL	   immunotherapy	   on	   the	   activation	   status	   of	   DC	  
populations	  in	  vivo	   	  	  
Mice	  were	  exposed	  to	  the	  adoptive	  transfer	  model	  depicted	  in	  Fig	  5.2	  A.	  5	  x	  106	  CD4+	  T	  cells	  
were	   injected	   into	   naive	   mice	   with	   or	   without	   5	   x	   106	  WT	   CTL	   or	   PKO	   CTLs.	   OVA	   was	  
administered	  i.n	  1d	  later,	  titrated	  in	  dose.	  Lungs	  were	  harvested	  1d	  after	  i.n,	  processed	  to	  a	  
single	  cell	  suspension	  and	  stained	  for	  the	  identification	  of	  DC	  subsets	  by	  flow	  cytometry	  as	  
described	   in	   Fig	   5.2	   B.	   The	   expression	   of	   ICOS-­‐L	   and	   CD86	   were	   then	   examined	   and	  
compared	   between	   treatment	   groups.	   	   Data	   are	   from	   one	   experiment	   of	   two	   that	   gave	  
similar	  results,	  each	  with	  3-­‐5	  mice	  per	  group.	  *p	  <	  0.05,	  **p	  <	  0.01	  as	  determined	  by	  one	  
way	  ANOVA	  with	  Bonferroni’s	  post	  test.	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inflammation	   would	   be	   expected	   to	   be	   similar.	   For	   this	   purpose,	   mixed	   bone	   marrow	  
chimeras	   were	   generated	   using	   bone	   marrow	   cells	   from	   wild	   type	   H2-­‐Kb	  (WT	   CD45.1+)	  
mice	  mixed	  with	  bone	  marrow	  from	  H2-­‐Kbm1	  	  (bm-­‐1	  CD45.2+)	  mice.	  Naïve	  recipient	  B6-­‐SJ	  
mice	   were	   depleted	   of	   CD4+	   and	   CD8+	   T	   cells	   as	   well	   as	   NK	   cells	   by	   intraperitoneal	  
injection	  of	  anti-­‐GK1.5,	  anti-­‐CD8	  and	  anti-­‐NK1.1	  one	  day	  before	  bone	  marrow	  transfer,	  as	  
well	  as	  one	  day	  after	  bone	  marrow	  transfer.	  This	  was	  to	  avoid	  the	  development	  of	  T	  cell	  or	  
NK	  cell-­‐mediated	  attacks	  between	  donor	  bone	  marrow	  and	  the	  host.	  DCs	  that	  express	  the	  
mutated	  H2-­‐Kbm-­‐1	  MHCI	  molecule	  are	  unable	  to	  interact	  with	  OVA-­‐specific	  CTLs,	  but	  express	  
wild	  type	  MHCII,	  thus	  retaining	  the	  ability	  to	  present	  antigen	  to	  CD4+	  T	  cells	  (Fig	  5.4	  A).	  The	  
success	  of	  chimerism	  was	  examined	  six	  weeks	  after	  the	  bone	  marrow	  mix	  was	  transferred	  
into	  irradiated	  recipient	  mice.	  A	  peripheral	  blood	  sample	  was	  taken	  and	  examined	  by	  flow	  
cytometry	   for	   the	   presence	   of	   WT	   CD45.1+	   and	   bm-­‐1	   CD45.2+	   cells,	   as	   well	   as	   B220+,	  
CD11b+,	  CD4+,	  and	  CD8+	  subsets.	  At	   this	   time,	  both	  CD45.1+	  and	  CD45.2+	  populations	   in	  
the	  blood	  predominantly	  consisted	  of	  B220+	  cells	  (Fig	  5.4	  B),	  as	  well	  as	  CD11b+	  cells.	  CD4+	  
and	  CD8+	  cells	  were	  detected	   in	  much	   fewer	  numbers.	  As	   the	  B220+	  cells	  were	   the	  most	  
prevalent	  population	  at	  this	  time	  point,	  these	  cells	  were	  gated	  and	  examined	  to	  determine	  
the	  degree	  of	  chimerism	  in	  individual	  mice.	  In	  the	  majority	  of	  mice,	  WT	  and	  bm-­‐1	  cells	  were	  
approximately	  equal	  in	  proportion	  (Fig	  5.4	  C).	  Where	  the	  proportion	  of	  cells	  from	  one	  bone	  
marrow	  to	  the	  other	  was	  greater	  than	  60%	  to	  40%,	  those	  mice	  were	  excluded	  from	  further	  
experimentation	  due	  to	  inequivalent	  reconstitution;	  that	  is,	  mouse	  numbers	  6,	  7,	  8	  and	  14	  
in	  the	  depicted	  experiment	  (Fig	  5.4	  C).	  
To	   investigate	   the	   effects	   of	   CTLs	   on	   DC	   populations,	   chimeric	   mice	   were	   injected	   with	  
activated	   CD4+	   T	   cells	   alone	   or	   co-­‐transferred	   with	   CTLs	   as	   described	   in	   Fig	   5.5	   A	   and	  
sacrificed	   1	   day	   after	   allergen	   challenge.	   The	   ratio	   of	  WT	   to	   bm-­‐1	   DCs	   in	   the	   lungs	   and	  
mediastinal	  LN	  was	  determined	  by	   flow	  cytometry.	  To	  account	   for	  potential	  variations	   in	  
the	   degree	   of	   chimerism	   in	   individual	   mice,	   this	   ratio	   was	   normalised	   to	   the	  
CD45.1+/CD45.2+	   ratio	   of	   total	   CD11c+	   cells	   in	   the	   spleen	   of	   each	   mouse,	   where	  
inflammation	   was	   not	   expected	   to	   significantly	   alter	   cell	   proportions.	   CTL	   treatment	  
resulted	   in	   decreased	   ratios	   of	  WT	   to	   bm-­‐1	  DCs	   in	   the	   CD103+	   as	  well	   as	   CD11b+CD64-­‐	  
populations	  in	  the	  lung,	  but	  was	  only	  statistically	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Figure	   5.4:	   Evaluation	   of	   the	   degree	   of	   chimerism	  of	  mixed	  bone	  marrow	   chimeric	  
mice	  	  
Mixed	  bone	  marrow	  chimeras	  were	  generated	  by	  injecting	  a	  mixture	  of	  bone	  marrow	  cells	  
from	  wild	   type	  B6-­‐SJ	   (WT	  CD45.1+)	   and	  H2-­‐Kbm-­‐1	   (bm-­‐1	   CD45.2+)	  mice	   into	   irradiated	  
B6-­‐SJ	   hosts.	   (A)	   WT	   DCs	   interact	   with	   both	   CD4+	   T	   cells	   and	   CTLs,	   however,	   DCs	   that	  
express	   the	  mutated	   H2-­‐Kbm-­‐1	  MHCI	  molecule	   are	   unable	   to	   interact	   with	   OVA-­‐specific	  
CTLs,	  but	  express	  wild	  type	  MHCII,	  thus	  retaining	  the	  ability	  to	  present	  antigen	  to	  CD4+	  T	  
cells.	   Airway	   inflammation	   is	   thus	   maintained	   in	   chimeric	   mice.	   (B)	   The	   success	   of	  
chimerism	   was	   examined	   six	   weeks	   after	   the	   bone	   marrow	   mix	   was	   transferred	   into	  
irradiated	  recipient	  mice.	  Peripheral	  blood	  samples	  were	  examined	  by	  flow	  cytometry	  for	  
the	  presence	  of	  WT	  CD45.1+	  and	  bm-­‐1	  CD45.2+	  cells,	  delineated	  into	  B220+,	  CD11b+,	  CD4+,	  
and	  CD8+	  subsets.	  Graphs	  show	  the	  proportion	  of	  cells	  of	  each	  subset	  present	  in	  individual	  
mice.	  (C)	  The	  most	  prevalent	  cells	  at	   this	   time	  point,	  B220+,	  were	  gated	  and	  examined	  to	  
determine	   the	   proportion	   of	   each	   bone	  marrow	   type	   that	   reconstituted	   individual	   mice.	  
Mice	   numbers	   6,	   7,	   8	   and	   14	   were	   excluded	   from	   further	   experimentation	   due	   to	  
inequivalent	  reconstitution	  of	  WT	  to	  bm-­‐1	  cells.	  Data	  are	  from	  one	  experiment	  of	  two	  that	  
gave	  similar	  results	  at	  this	  time	  point,	  with	  20-­‐60	  mice	  tested	  in	  each	  experiment.	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Figure	   5.5:	   CTL	   immunotherapy	   targets	   CD11c+CD11b+CD64-­‐	   conventional	   lung	  
dendritic	  cells	   	  	  
Wild	   type	   B6-­‐SJ	   and	   bm-­‐1	  mixed	   bone	  marrow	   chimeras	  were	   generated	   and	   tested	   for	  
chimerism	  as	  described	  in	  Fig	  5.4.	  (A)	  Chimeric	  mice	  were	  injected	  with	  activated	  CD4+	  T	  
cells	  and	  CTLs	  and	  challenged	  with	  OVA	  i.n.	  as	  depicted.	  DC	  populations	   in	   lung	  and	  MLN	  
were	  examined	  by	  flow	  cytometry	  1d	  later.	  (B)	  Normalized	  ratio	  of	  WT	  (CD45.1+)	  to	  bm1	  
(CD45.2+)	  DC	  in	  the	  lung	  of	  chimeric	  mice.	  DC	  subsets	  were	  identified	  by	  flow	  cytometry	  as	  
in	  Figure	  5.2;	  ratios	  were	  normalized	  to	  the	  ratio	  of	  CD45.1/CD45.2	  DC	  in	  spleen	  to	  account	  
for	  any	  differences	  in	  the	  take	  of	  BM	  cells	  in	  individual	  mice.	  Bar	  graphs	  show	  mean	  ratio	  +	  
SEM;	  each	  symbol	  represents	  one	  mouse.	  (C)	  As	  in	  (B),	  except	  that	  normalized	  ratios	  of	  DC	  
in	  mLN	  are	  shown.	  Combined	  data	  from	  2	  experiments,	  each	  with	  4-­‐5	  mice	  per	  group,	  are	  
shown.	   *p<0.05,	   **p<0.01,	   ****p<0.0001	   as	   determined	   using	   the	   one	  way	   ANOVA	   assay	  
with	  Bonferroni’s	  correction	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significant	   in	   the	   CD11b+CD64-­‐	   DCs	   (Fig	   5.5	   B).	   No	   difference	   was	   apparent	   in	   the	  
CD11b+CD64+	  inflammatory	  DC	  population.	  Similar	  changes	  were	  observed	  for	  each	  of	  the	  
DC	  populations	  in	  the	  MLN,	  where	  significant	  decreases	  in	  both	  CD103+	  and	  CD11b+CD64-­‐	  
cDC	  were	  evident	   in	  CTL-­‐treated	  compared	  to	  CD4	  only-­‐treated	  mice;	  again	  no	  difference	  
was	  observed	   in	   the	  CD11b+CD64+	  DC	  population	   (Fig	  5.5	  C).	   These	   results	   suggest	   that	  
CD103+	  and	  CD11b+CD64-­‐	  cDCs	  are	  specifically	  targeted	  by	  CTL	  treatment.	  	  
 
5.3.4 DCs form clusters with CTLs near small airways in the lung 
during allergic airway inflammation 
Data	  in	  Figure	  5.5	  suggest	  that	  CTL	  can	  target	  both	  CD103+	  and	  CD11b+	  DC	  subsets	  in	  the	  
lung.	  To	  obtain	  further	  evidence	  of	  this,	  the	  interaction	  of	  CTL	  populations	  with	  DC	  subsets	  
in	   lung	   tissue	  was	   investigated.	   To	   elucidate	   the	   localisation	   and	   interaction	   of	   CTLs	   and	  
DCs,	   XCR1GFP	   mice	   were	   primed	   with	   OVA/Alum	   or	   Alum	   only;	   the	   XCR1GFP	   marker	  
identifying	  CD103+	  DC	  (758).	  In	  a	  modified	  in	  vivo	  sensitisation	  model,	  naive	  XCR1GFP	  mice	  
were	  intraperitoneally	  primed	  with	  a	  single	  100μg	  dose	  of	  OVA	  in	  Alum	  adjuvant,	  followed	  
7	  days	   later	  by	   airway	  allergen	   challenge	  with	  100μg	  OVA	   (depicted	  Fig	  5.6	  A).	  Tandem-­‐
dimer	   Tomato	   (TdT)	   fluorescent	   CTLs	  were	   administered	   to	   one	   group	   of	  mice,	   the	   day	  
before	  airway	  allergen	  exposure.	  One	  day	  after	   intranasal	  challenge,	   lungs	  and	  MLN	  were	  
harvested	  to	  elucidate	  the	  localisation	  of	  DC	  and	  T	  cells	  in	  tissue.	  The	  examination	  of	  fresh	  
lung	  tissue	  slices	  revealed	  that	  in	  OVA/Alum	  primed	  mice,	  18	  hours	  after	  airway	  challenge,	  
XCR1GFP+	  DC	  had	  redistributed	  to	  form	  large	  clusters;	  TdT	  CTLs	  appeared	  to	  preferentially	  
localise	  to	  the	  same	  areas	  (Fig	  5.6	  B).	  The	  migratory	  XCR1GFP+	  DCs	  were	  also	  visualised	  in	  
the	  MLN	  and	  could	  be	  seen	  interacting	  with	  CTLs	  at	  this	  site	  (Fig	  5.6	  C).	  To	  confirm	  allergic	  
airway	  inflammation	  was	  present	  in	  the	  airway	  using	  this	  experimental	  procedure,	  BAL	  was	  
performed	   3	   days	   after	   intranasal	   allergen	   exposure	   and	   inflammatory	   cell	   infiltrates	  
examined.	   The	   resulting	   inflammatory	   pattern	   was	   similar	   to	   that	   expected	   of	   the	   two-­‐
prime	   in	   vivo	   sensitisation	   model	   used	   throughout	   this	   thesis.	   Total	   cellularity	   was	  
increased	  in	  CD4+	  T	  cell	  treated	  mice,	  which	  was	  lower	  in	  CTL	  treated	  mice,	  although	  not	  
statistically	   significantly	   so,	  while	   eosinophils	   and	  CD4+	  T	   cells	   in	  BAL	  were	   significantly	  
reduced	  by	  CTL	  therapy	  (Fig	  5.6	  D).	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Figure	  5.6:	  XCR1GFP+	  DCs	  redistribute	  to	  form	  clusters	  in	  the	  allergic	  lung	  and	  MLN	   	  
(A)	  XCR1GFP	  mice	  were	  primed	  with	  OVA/Alum	  or	  Alum	  only.	  Tandem-­‐dimer	  Tomato	  (TdT)	  
fluorescent	   CTLs	  were	   then	   adoptively	   transferred	   and	   OVA	   intranasal	   challenge	   carried	  
out	   1d	   later.	   After	   18	   hours,	   lungs	   and	  MLN	  were	   harvested.	   (B)	   Fresh	   lung	   tissue	   was	  
sliced	  and	  examined	  for	   localisation	  of	  GFP+	  DCs	  and	  TdT+	  CTLs.	  (C)	  MLN	  were	  frozen	  in	  
OCT	  media,	  8μm	  cryosections	  were	  mounted	  onto	  glass	  slides	  and	  counterstained	  with	  anti-­‐
GFP	  AF488	  and	  DAPI	  for	  examination.	  Cell	  populations	  are	  identified	  by	  the	  colours	  noted	  
on	  each	   image.	   Scale	  bars	   (white)	   represent	  200μm.	   (D)	  A	   small	   separate	   cohort	  of	  mice	  
were	  used	  to	  check	   inflammatory	  cell	   infiltrates	   in	  BAL	  on	  day	  3,	  after	  being	  treated	  with	  
CD4+	  T	  cells	  with	  or	  without	  CTL	  as	  previously	  described	  (Fig	  5.2	  A).	  Mean	  cell	  number	  in	  
BAL	  +	  SEM	  are	  shown	  for	  1-­‐3	  mice	  per	  group.	  
 
To	   examine	   the	   distribution	   of	   DCs	   and	   CTLs	   within	   airways,	   frozen	   lung	   tissue	   was	  
sectioned	  and	  additionally	  stained	  with	  CD11c-­‐APC	   for	   the	   identification	  of	  CD11c+XCR1-­‐	  
DC,	  which	  primarily	  consist	  of	  CD11b+	  lung	  DC.	  Analysis	  revealed	  that	  there	  was	  little	  or	  no	  
DC	  clustering	  around	  the	  larger	  airways;	  XCR1GFP+	  DC	  preferentially	  lined	  the	  airway	  wall,	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while	  CD11c+XCR1-­‐	  DC	  were	  distributed	  more	  diffusely	  (Fig	  5.7	  A).	  CTLs	  did	  not	  frequently	  
appear	  to	  be	  in	  close	  association	  with	  DCs	  around	  the	  large	  airways.	  Higher	  magnification	  
of	  the	  small	  airways,	  however,	  showed	  that	  both	  XCR1GFP+	  and	  CD11c+XCR1-­‐	  DC	  clustered	  
at	   these	   sites;	   additionally,	   TdT	  CTLs	  were	   found	   in	   the	   same	   clusters	   (Fig	   5.7	   B).	   These	  
results	   suggest	   that	   allergic	   airway	   inflammation	   induces	   DC	   clustering	   in	   the	   vicinity	   of	  
small	  airways	  in	  the	  lung,	  and	  that	  CTLs	  preferentially	  migrate	  to	  these	  DC-­‐abundant	  sites.	  
 
5.3.5 CTLs and CD4+ T cells co-localise with both XCR1GFP+ and 
CD11c+XCR1- DCs in the lung  
CD103+	   DC	   are	   specialised	   at	   cross-­‐presentation	   to	   CTLs	   (123),	   however,	   less	   is	   known	  
about	   the	   importance	   of	   CD11b+	   DC:CTL	   interactions	   in	   the	   allergic	   lung.	   Data	   from	  
chimera	   experiments	   revealed	   that	   the	   CD11b+	   cDC	   population,	   critical	   mediators	   of	  
allergic	   airway	   disease	   (323),	   are	   in	   fact	   decreased	   in	   CTL-­‐treated	   mice	   (Fig	   5.5).	   To	  
determine	  whether	  CTLs	  were	  directly	   interacting	  with	  CD11b+	  DC,	  CD103+	  DC,	  or	  both,	  
mice	  were	  primed	  and	  challenged	  with	  OVA/Alum	  as	  previously	  described	  (Fig	  5.6	  A)	  and	  
lung	  sections	  were	  analysed	  for	  co-­‐localisation.	  Throughout	  the	  lung	  tissue,	  TdT	  CTLs	  were	  
found	  in	  direct	  association	  either	  XCR1GFP+	  DC	  (Fig	  5.8	  A),	  or	  CD11c+XCR1-­‐	  DC	  (Fig	  5.8	  B),	  
suggesting	  that	  in	  fact	  both	  DC	  subsets	  were	  interacting	  with	  CTLs.	  
To	  investigate	  the	  location	  of	  disease-­‐mediating	  CD4+	  Th2	  cells	  in	  the	  lung,	  non-­‐fluorescent	  
CD4+	  T	   cells	  were	   injected	  either	  alone,	  or	   co-­‐transferred	  with	  TdT-­‐expressing	  CTLs	   into	  
XCR1GFP	  x	  CD11cYFP	  mice	  as	  depicted	  in	  Fig	  5.9	  A.	  These	  double-­‐positive	  XCR1GFP	  x	  CD11cYFP	  
mice	   dually	   reveal	   both	   XCR1+	   (CD103+)	   and	   other	   CD11c+	   (CD11b+)	   DC	   populations.	  
Intranasal	  OVA	  was	  administered	  and,	  18hours	   later,	   fresh	  lung	  tissue	  slices	  were	  stained	  
with	   anti-­‐CD45.1	   and	   examined	   by	   confocal	   microscopy;	   the	   CD45.1	   staining	   identifies	  
adoptively	  transferred	  non-­‐fluorescent	  CD4+	  T	  cells,	  and	  partially	  stains	  TdT	  CTLs.	   It	  was	  
discovered	  that	  CD4+	  T	  cells	  also	  localised	  to	  the	  areas	  of	  DC	  clustering	  (Fig	  5.9	  B,	  CD4	  only	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Figure	   5.7:	   CTLs	   are	   located	   sparsely	   around	   large	   airways	   in	   the	   lung;	   more	  
predominantly	  clustering	  with	  XCR1GFP+	  and	  CD11c+XCR1-­‐	  DC	  around	  small	  airways	  	  
In	   vivo	   sensitisation	   and	   challenge	   of	   XCR1GFP	   mice	   as	   well	   as	   administration	   of	   Tdt-­‐
expressing	  CTLs	  was	  carried	  out	  as	  described	  in	  Fig	  5.6	  A.	  Lungs	  were	  frozen	  in	  OCT	  media,	  
8μm	  cryosections	  were	  mounted	  onto	  glass	  slides	  and	  stained	  with	  anti-­‐GFP	  AF488,	  CD11c-­‐
APC	  and	  DAPI	   for	   examination.	   (A)	   Tissue	   sections	   from	  OVA-­‐challenged	  mice	   show	   that	  
XCR1GFP+	  DC	  localize	  around	  the	  epithelia	  of	   large	  airways,	  whereas	  CD11c+XCR1-­‐	  DC	  are	  
spread	  throughout	  the	  lung	  parenchyma.	  (B)	  High	  magnification	  images	  of	  tissue	  sections	  
from	  OVA-­‐challenged	  mice	  show	  the	  clustering	  of	  XCR1GFP+	  DC,	  CD11c+XCR1-­‐	  DC	  and	  CTL	  
to	   the	   inflamed	   areas	   around	   the	   small	   airways.	   	   Cell	   populations	   are	   identified	   by	   the	  
colours	  noted	  on	  each	  image.	  Scale	  bars	  (white)	  represent	  200μm	  (A)	  and	  100μm	  (B).	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panel),	   similar	   to	   CTLs	   (Fig	   5.9	   B,	   CD4	   +	   CTL	   panel,	   and	   Figs	   5.6	   and	   5.7).	   Upon	   higher	  
magnification	  of	   the	  DC	   clusters	   in	  mice	   treated	  with	  both	  CD4+	  T	   cells	   and	  CTLs,	   it	  was	  
apparent	   that	   both	   CTLs	   and	   CD4+	   T	   cells	   co-­‐localised	   with	   XCR1GFP+	   DCs	   as	   well	   as	  
CD11c+XCR1-­‐	  DCs	  (Fig	  5.9	  C);	  panels	  in	  Fig	  5.9	  C	  show	  Tandem	  tomato	  CTLs	  (left),	  CD45.1+	  
CD4+	   T	   cells	   and	   some	   staining	   of	   CTLs	   (middle),	   and	   the	  merged	   image	   (right)	   reveals	  
CD4+	  T	  cells	  as	  solely	  yellow	  stained,	  while	  CTLs	  appear	  red-­‐yellow.	  BAL	  was	  performed	  on	  
a	  small	  number	  of	  separate	  mice,	  1-­‐3	  from	  each	  group,	  on	  day	  3	  after	  intranasal	  challenge,	  
to	   check	   whether	   robust	   airway	   inflammatory	   infiltrates	   were	   induced	   in	   these	  
experiments.	   Unfortunately,	   and	   potentially	   due	   to	   differing	   lab	   and	   experimental	  
conditions	  (as	  discussed	  in	  Chapter	  5.4	  Discussion),	  BAL	  inflammation	  was	  not	  established	  
comparable	   to	   that	   previously	   seen	  using	   the	   adoptive	   transfer	  model.	  Mice	   treated	  with	  
CD4+	  T	  cells	  only	  had	  very	  low	  BAL	  cellularity,	  with	  few	  eosinophils	  or	  CD4+	  T	  cells	  (Fig	  5.9	  
D),	   while	   mice	   treated	   with	   CD4+	   T	   cells	   and	   CTLs	   did	   experience	   some	   inflammation	  
including	  an	  increase	  in	  total	  cells,	  eosinophils	  and	  CD4+	  T	  cells	  in	  BAL,	  although	  this	  was	  
still	  much	  lower	  than	  expected.	  While	  the	  BAL	  data	  appears	  to	  suggest	  that	  the	  adoptively	  
transferred	  CD4+	  T	  cells	  were	  not	  effective	  at	  establishing	  allergic	  airway	  inflammation,	  it	  is	  
evident	   from	  the	  airway	  histology	   that	   the	  CD4+	  T	  cells	  were	  capable	  of	  migrating	   to	   the	  
lung	  and	  interacting	  with	  DCs.	  
Together,	  these	  results	  support	  the	  findings	  reported	  in	  Figures	  5.2	  and	  5.5:	  CTLs	  can	  target	  
both	  CD103+	  and	  CD11b+	  lung	  DC	  subsets.	  This	  occurs	  in	  zones	  of	  abundant	  DC	  gatherings,	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Figure	  5.8:	  CTLs	  interact	  with	  both	  XCR1GFP+	  DC	  and	  CD11c+XCR1-­‐	  DC	   	  	  	  
In	   vivo	   sensitisation	   and	   challenge	   of	   XCR1GFP	   mice	   as	   well	   as	   administration	   of	   Tdt-­‐
expressing	  CTLs	  was	  carried	  out	  as	  described	  in	  Fig	  5.6	  A.	  Lungs	  were	  frozen	  in	  OCT	  media,	  
8μm	   cryosections	  were	  mounted	   onto	   glass	   slides	   and	   stained	  with	   anti-­‐GFP	   AF488	   and	  
CD11c-­‐APC	  for	  examination.	  (A)	  Tissue	  section	  showing	  Tdt-­‐CTL	  mainly	  co-­‐localizing	  with	  
XCR1GFP+	  DC.	  (B)	  Tissue	  section	  showing	  Tdt-­‐CTL	  mainly	  co-­‐localizing	  with	  CD11c+XCR1-­‐	  
DC.	  Cell	  populations	  are	   identified	  by	  the	  colours	  noted	  on	  each	  image.	  Scale	  bars	  (white)	  
represent	  100μm	  (left	  panels)	  and	  50μm	  (right	  enlarged	  panel).	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Figure	  5.9:	  CD4+	  T	  cells	  also	  localise	  within	  DC/CTL	  clusters	   	  	  
(A)	   Non-­‐fluorescent	   CD4+	   T	   cells	   were	   injected	   either	   alone,	   or	   co-­‐transferred	   with	  
Tandem-­‐Tomato	  expressing	  CTLs	  into	  XCR1GFP	  x	  CD11cYFP	  mice	  as	  depicted.	  Intranasal	  OVA	  
was	   administered	   and	   lungs	   harvested	   18h	   later.	   Fresh	   lung	   sections	   were	   stained	   with	  
anti-­‐CD45.1	   Cy5	   and	   examined	   by	   confocal	   microscopy.	   The	   CD45.1	   staining	   identifies	  
adoptively	   transferred	  non-­‐fluorescent	  CD4+	  T	   cells,	   and	  partially	   stains	  Tandem	  Tomato	  
CTLs.	  (B)	  Three	  separate	  lung	  sections	  are	  depicted,	  one	  from	  each	  group	  as	  noted.	  CD45.1+	  
CD4+	  T	  cells	  cluster	  with	  DCs	  (CD4	  only	  panel)	  similarly	  to	  CTLs	  clustering	  with	  DCs	  (CD4	  +	  
CTL	  panel).	  (C)	  A	  single	  lung	  section	  is	  depicted,	  from	  a	  CD4	  +	  CTL	  treated	  mouse.	  Panels	  
show	   the	   presence	   of	   Tdt-­‐expressing	   CTLs	   (left,	   red),	   and	   CD45.1-­‐stained	   CD4+	   T	   cells	  
(centre,	   yellow)	   interacting	   with	   XCR1GFP+CD11cYFP+	   DCs	   (turquoise)	   and	   XCR1GFP-­‐
CD11cYFP+	  DCs	  (dark	  blue).	  The	  image	  on	  the	  right	  shows	  an	  overlay	  of	  the	  CTL	  and	  CD45.1	  
images.	   CTLs	   show	   dual	   red	   (centre)	   and	   yellow	   (surface)	   staining,	   while	   CD4+	   T	   cells	  
appear	   yellow	   only.	   Scale	   bars	   (white)	   represent	   100μm	   (B)	   and	   25μm	   (C).	   (D)	   A	   small	  
separate	  cohort	  of	  mice	  were	  used	  to	  check	   inflammatory	  cell	   infiltrates	   in	  BAL	  on	  day	  3.	  
Mean	  cell	  number	  in	  BAL	  +	  SEM	  are	  shown	  for	  1-­‐3	  mice	  per	  group.	  
 
 
5.3.6 OVA-specific CTLs abrogate allergic airway inflammation in 
OVA/HDM dually sensitised mice 
 
Many	   individuals,	   both	   children	   and	   adults,	   who	   suffer	   from	   allergy	   are	   sensitised	   to	  
multiple	  allergens	  (22,	  578,	  579).	  As	  CTLs	  target	  allergen-­‐presenting	  DCs,	  this	  may	  diminish	  
the	  response	  to	  other	  allergens,	  particularly	  as	  the	  DC	  population	  critical	  to	  driving	  allergic	  
responses,	  CD11b+	  cDC,	  are	  affected.	  To	  investigate	  this,	  the	  effect	  of	  OVA-­‐specific	  CTLs	  in	  
mice	  sensitised	  to	  both	  OVA	  and	  house	  dust	  mite	  (HDM)	  was	  examined.	  	  
	  
A	   common	   cause	   of	   allergic	   airway	   inflammation	   in	   humans,	   HDM	   may	   be	   used	   in	  
experimental	  models	   of	   allergic	   disease	   and	   causes	   sensitisation	   directly	   through	   airway	  
exposure	  without	  the	  requirement	  for	  exogenous	  adjuvants	  or	  systemic	  priming	  (373,	  619).	  
Therefore,	   this	   model	   allergen	   was	   chosen	   as	   a	   contributory	   agent	   for	   allergic	   airway	  
inflammation,	  which	  might	   be	   expected	   to	  present	   as	   a	   cause	   of	   allergy	   in	  polysensitised	  
individuals.	  As	  C57BL/6	  mice	  are	  not	  often	  used	  in	  HDM	  models	  of	  airway	  allergy,	  due	  to	  
their	   reduced	  propensity	   for	   the	  development	  of	   allergic	  disease	   as	   compared	   to	  BALB/c	  
hosts	   (628),	   it	  was	  necessary	   to	  establish	  an	  HDM	  model	  of	  allergy	   in	  C57BL/6	  mice	   that	  
generates	  sufficient	  airway	  inflammation	  in	  which	  to	  test	  the	  effects	  of	  OVA-­‐specific	  CTLs.	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To	  this	  end,	  mice	  were	  sensitised	  by	  intranasal	   instillation	  of	  100μg	  HDM	  in	  50μL	  PBS	  on	  
day	   0,	   followed	   by	   intranasal	   challenges	   with	   25μg	   HDM	   in	   50μL	   PBS	   that	   were	  
administered	   either	   once,	   on	  day	  14,	   or	   three	   times,	   on	  days	  14,	   15	   and	  16	   (Fig	   5.10	  A).	  
Control	  mice	  received	  PBS	  alone.	  Mice	  were	  sacrificed	  24	  hours	  after	  the	  last	  challenge,	  on	  
day	  15	  or	  17,	  and	  BAL	  was	  performed.	  The	  total	  cellularity	  in	  BAL	  was	  higher	  in	  mice	  that	  
had	   three	  HDM	  challenges	   than	   those	   that	  received	  one	  HDM	  challenge,	  although	  this	  did	  
not	   reach	   statistical	   significance,	   while	   PBS	   treated	   groups	   showed	   no	   difference	   in	  
cellularity	  when	  administered	  either	  one	  or	  three	  PBS	  challenges	  (Fig	  5.10	  B).	  Importantly,	  
eosinophilia	  was	   increased	  10-­‐fold	   in	  mice	  given	   three	  HDM	  challenges,	   compared	   to	   the	  
PBS	   control,	   while	   those	   that	   received	   a	   single	   HDM	   challenge	   had	   a	   3-­‐fold	   increase	   in	  
eosinophilia,	  which	  was	  not	  statistically	  significant.	  This	  finding	  suggests	  that	  carrying	  out	  
three	  intranasal	  exposures	  to	  HDM,	  rather	  than	  one,	  results	  in	  allergic	  inflammation	  that	  is	  
more	  distinguishable	  from	  PBS	  controls.	  	  
	  
Interestingly,	   additional	   HDM	   challenges	   did	   not	   appear	   to	   have	   a	   cumulative	   effect	   on	  
neutrophil	   infiltration;	   a	   robust	  neutrophilia	  was	   induced	  by	  a	   single	  HDM	  challenge	  and	  
was	  not	  significantly	  different	  between	  HDM-­‐challenged	  groups.	  As	  neutrophil	   infiltration	  
in	  this	  model	  is	  likely	  due,	  at	  least	  in	  part,	  to	  the	  endotoxin	  content	  of	  the	  HDM	  preparation,	  
it	  is	  possible	  that	  the	  infiltrating	  neutrophils	  are	  an	  acute	  phase	  response	  to	  the	  endotoxin	  
challenge,	   which	   does	   not	   result	   in	   active	   accumulation	   of	   additional	   neutrophils	   as	   the	  
HDM-­‐induced	   allergic	   response	   progresses.	   DC	   numbers,	   while	   low	   overall,	   were	  
significantly	   higher	   in	   mice	   exposed	   to	   three	   HDM	   challenges	   compared	   to	   those	   that	  
received	  one	  HDM	  challenge,	  and	  a	  strong	  increase	  in	  B	  cells	  was	  observed	  in	  the	  3	  x	  HDM	  
group	  alone.	  The	  numbers	  of	  alveolar	  macrophages	  and	  T	  cells	  were	  similar	  between	  HDM-­‐
challenged	  groups.	  These	  results	  suggest	  that	  the	  three-­‐challenge	  model	  is	  better	  for	  testing	  
the	   effects	   of	   CTL	   immunotherapy	   as	   this	   protocol	   generated	   the	   greatest	   disparity	   in	  
eosinophilia	   between	  HDM	   and	   PBS	   treated	   groups,	  with	   increases	   also	   observed	   in	  DCs	  
and	  B	  cells.	  	  
	  
To	   investigate	   the	   effects	   of	   OVA-­‐specific	   CTLs	   on	   allergic	   airway	   inflammation	   in	   dually	  
sensitised	  mice,	  mice	  were	  primed	  with	  HDM	  alone	  or	  both	  OVA	  and	  HDM;	  all	  mice	  were	  
given	  three	  HDM	  challenges	  as	  well	  as	  a	  single	  OVA	  intranasal	  challenge	  (Fig	  5.11	  A).	  One	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Figure	  5.10:	  HDM-­‐induced	  allergic	  airway	  inflammation	  in	  C57BL/6	  mice	   	  
(A)	  Mice	  were	  sensitised	  with	  HDM	  i.n.	  on	  day	  0	  and	  challenged	  i.n.	  on	  day	  14	  alone,	  or	  on	  
days	  14,	  15	  and	  16;	  control	  mice	  were	  given	  PBS.	  Black	  arrows	  refer	  to	  the	  single	  PBS/HDM	  
challenge	  and	  end	  point,	  while	  blue	  arrows	  refer	  to	  the	  triple	  PBS/HDM	  challenges	  and	  end	  
point.	   Bar	   graphs	   are	   correspondingly	   coloured.	   (B)	   Total	   cells,	   eosinophils,	   neutrophils,	  
DCs,	  B	  cells,	  alveolar	  macrophages	  and	  T	  cells	  were	  enumerated	  in	  BAL	  on	  day	  15	  for	  mice	  
challenged	   once,	   and	   day	   17	   for	   mice	   challenged	   thrice,	   by	   flow	   cytometry.	   Mean	   cell	  
number	  in	  BAL	  +	  SEM	  are	  shown.	  ns	  =	  not	  significant,	  *p	  <	  0.05,	  **p	  <	  0.01,	  ****p	  <0.0001	  as	  
assessed	  by	  one	  way	  ANOVA	  with	  Bonferroni’s	  post	  test.	  Data	  are	  from	  one	  representative	  
experiment	  of	  two	  that	  gave	  similar	  results,	  each	  with	  5	  mice	  per	  group.	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Figure	  5.11:	  OVA-­‐specific	   CTLs	   abrogate	   allergic	   airway	   inflammation	   in	  OVA/HDM	  
dually	  sensitised	  mice	   	  	  
(A)	   Mice	   were	   primed	   with	   HDM	   alone	   or	   both	   OVA	   and	   HDM.	   One	   group	   were	  
administered	  5	  x	  106	  CTLs	  intravenously	  before	  the	  first	  challenge,	  on	  day	  13.	  All	  mice	  were	  
then	   challenged	   three	   times	  with	   HDM	   as	  well	   as	   a	   single	   OVA	   intranasal	   challenge.	   (B)	  
Inflammatory	  cell	  populations	  measured	  in	  BAL	  on	  day	  17.	  Mean	  cell	  number	  in	  BAL	  +	  SEM	  
are	  shown.	  Data	  are	   from	  one	  representative	  experiment	  of	   two	  that	  gave	  similar	  results,	  
each	  with	  3-­‐5	  mice	  per	  group.	   *p	  <	  0.05,	   **p	  <	  0.01	  as	  assessed	  by	  one	  way	  ANOVA	  with	  
Bonferroni’s	  post	  test.	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group	  were	  administered	  5	  x	  106	  CTLs	  intravenously	  before	  the	  first	  challenge,	  on	  day	  13.	  It	  
was	  found	  that	  the	  total	  cell	  number	  and	  eosinophilia	  in	  BAL	  were	  increased	  in	  challenged	  
mice	  that	  were	  sensitised	  to	  both	  OVA	  and	  HDM,	  compared	  to	  those	  sensitised	  with	  HDM	  
only	   (Fig	   5.11	   B).	   Dually	   sensitised	  mice	   that	  were	   treated	  with	   CTLs	   showed	   a	  marked	  
suppression	  of	  BAL	  cellularity	  and	  eosinophils.	  A	  similar	  trend	  of	  CTL-­‐induced	  suppression	  
of	   increasing	  cell	  numbers	   in	  OVA/HDM-­‐primed	  mice	  was	  seen	   in	  other	  BAL	  populations:	  
neutrophils,	  B	  cells,	  macrophages	  and	  T	  cells,	  although	  these	  results	  were	  not	  statistically	  
significant.	  DCs	  were	  detected	  in	  fewer	  number	  than	  previous	  experiments	  (i.e.,	  compared	  
to	   Fig	   5.10),	   and	   could	   not	   be	   differentiated	   between	   treatment	   groups,	   possibly	   due	   to	  
their	   low	   numbers	   in	   these	   BAL	   samples.	   These	   data	   show	   that	   the	   allergic	   response	   is	  
exaggerated	   when	   dually	   sensitised	   mice	   are	   exposed	   to	   both	   HDM	   and	   OVA	   allergen	  
challenge,	  compared	  to	  HDM-­‐induced	   inflammation	  alone,	  and	  that	  OVA-­‐specific	  CTLs	  can	  
ameliorate	   the	   lung	   cellular	   inflammatory	   infiltrate.	   Therefore,	   it	   is	   possible	   that	   CTL-­‐
mediated	  targeting	  of	  allergy-­‐driving	  DCs	  (as	  reported	  in	  Figs	  5.2,	  5.5,	  5.8,	  5.9)	  may	  in	  fact	  
lead	   to	   suppression	   of	   allergic	   airway	   inflammation	   even	   in	   polysensitised	   individuals	  
where	  inflammation	  may	  be	  generated	  to	  multiple	  allergens.	  	  	  	  
	  
 
5.3.7 A novel peptide conjugate vaccine elicits an allergen-specific 
CTL response that inhibits allergic airway inflammation 
To	   investigate	   the	   potential	   for	   inducing	   allergen-­‐specific	   CTL-­‐mediated	   suppression	   of	  
allergic	   airway	   inflammation	  by	  means	  of	   immunisation,	   a	  novel	   self-­‐adjuvanting	  peptide	  
conjugate	   vaccine	   (668)	   was	   tested	   in	   an	   in	   vivo	   sensitisation	   model.	   The	   OVA257-­‐264–
conjugated	   vaccine	   (chemical	   and	   functional	   structure	   depicted	   in	   Fig	   5.12	   A)	   was	  
administered	   intravenously	   to	   OVA/Alum	   primed	   mice	   7	   days	   before	   intranasal	   OVA	  
challenge	   (Fig	   5.12	   B),	   as	   cytotoxic	   activity	   peaks	   after	   7	   days	   (668).	   Treatment	  with	   an	  
LCMVgp33-­‐conjugate	   and	   unconjugated	   αGalCer	   +	   OVA257-­‐264	   were	   included	   to	   ascertain	  
allergen	   specificity	   of	   the	   response	   and	   benefit	   of	   the	   vaccine	   conjugate	   structure,	  
respectively.	  Additionally,	  allergen-­‐specific	  CTLs	  were	  administered	  to	  compare	  the	  effects	  
of	  the	  vaccine	  with	  CTL	  therapy.	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It	   was	   found	   that	   the	   OVA257-­‐264–conjugate	   (CN-­‐OVA257-­‐264)	   vaccine	   suppressed	   allergic	  
airway	   inflammation	   as	   effectively	   as	   treatment	   with	   CTLs;	   total	   infiltrating	   cells	   and	  
eosinophils	   in	   the	   BAL	   were	   significantly	   reduced	   compared	   to	   untreated	   OVA/Alum	  
groups	   (Fig	   5.12	   C).	   Conversely,	   the	   irrelevant	   peptide	   conjugate	   (CN-­‐gp33)	   and	  
unconjugated	  αGalCer	  +	  OVA257-­‐264	  did	  not	  mediate	  effective	  suppression	  of	  cell	   infiltrates	  
or	   eosinophils	   compared	   to	   CN-­‐OVA257-­‐264-­‐treated	   mice,	   though	   some	   reduction	   in	  
eosinophilia	   was	   observed	   in	   the	   CN-­‐gp33	   treated	   mice.	   All	   OVA/Alum	   primed	   mice	  
generated	   similar	   levels	   of	   total	   and	   OVA-­‐specific	   IgE,	   and	   this	   was	   not	   affected	   by	  
administration	  of	  any	  of	  the	  vaccines,	  nor	  CTL	  immunotherapy	  (Fig	  5.12	  D).	  These	  results	  
suggest	   that	   CN-­‐OVA257-­‐264	  suppresses	   airway	   inflammation	   in	   a	   predominantly	   allergen-­‐
specific	  manner,	  and	  that	  the	  efficacy	  relied	  on	  the	  conjugate	  design	  of	  the	  vaccine.	  	  
Under	  the	  same	  experimental	  conditions,	  histological	  examination	  of	  the	   lung	  was	  carried	  
out,	  revealing	  infiltration	  of	  immune	  cells	  in	  OVA/Alum	  treated	  mice	  that	  was	  not	  present	  in	  
PBS-­‐challenged	  mice,	  and	  clearly	   reduced	   in	  CTL-­‐treated	  mice	   (Fig	  5.13	  A,	  upper	  panels).	  
Treatment	  with	  CN-­‐OVA257-­‐264	  similarly	  protected	  mice	  from	  lung	  infiltrates,	  while	  CN-­‐gp33	  
and	  unconjugated	  αGalCer	  +	  OVA257-­‐264	  did	  not	   (Fig	  5.13	  A,	   lower	  panels).	  This	   trend	  was	  
paralleled	  in	  the	  effect	  on	  mucus	  production	  induced	  by	  the	  various	  treatments;	  untreated	  
OVA/Alum	  mice	  as	  well	  as	  those	  treated	  with	  CN-­‐gp33	  and	  unconjugated	  αGalCer	  +	  OVA257-­‐
264	  displayed	  extensive	  mucus	  production	  in	  the	  lung,	  and	  this	  was	  distinctly	  diminished	  in	  
mice	  treated	  with	  CTLs	  or	  CN-­‐OVA257-­‐264	  (Fig	  5.13	  B).	  Collectively,	  these	  data	  reveal	  that	  the	  
peptide	   conjugate	   vaccine	   CN-­‐OVA257-­‐264	   is	   capable	   of	   mediating	   suppression	   of	   allergic	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Figure	  5.12 
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Figure	  5.12:	  A	  novel	  peptide	  conjugate	  vaccine	  inhibits	  allergic	  airway	  inflammation	  
(A)	   Chemical	   structure	   of	   OVA257-­‐264–conjugated	   vaccine,	   annotated	   with	   simplified	  
functional	   structure.	   (B)	   Mice	   were	   sensitised	   and	   challenged	   with	   OVA	   as	   depicted.	  
Vaccines	  were	  administered	  7	  days	  before	   intranasal	  challenge:	  either	  vaccine	  conjugated	  
to	  OVA257-­‐264	  or	  unrelated	  peptide	  gp33,	  or	  unconjugated	  αGal	  +	  OVA257-­‐264.	  A	  CTL-­‐treated	  
group	  was	   also	   included	   for	   comparison.	   (C)	   Day	   3	   BAL	   samples	  were	   analysed	   by	   flow	  
cytometry	  to	  enumerate	  total	  cell	  number	  and	  eosinophils.	  (D)	  Serum	  IgE	  was	  measured	  by	  
ELISA.	   Total	   serum	   IgE	   is	   presented	   in	   ng/mL	   and	   OVA-­‐specific	   IgE	   from	   a	   1:2	   serum	  
dilution	  is	  reported	  as	  the	  OD	  at	  450nm.	  Bar	  graphs	  show	  mean	  cell	  number,	  concentration,	  
or	  OD	  +	   SEM,	   individual	   symbols	   represent	   each	  mouse.	   *p	  <	  0.05,	   ***p	  <	  0.001,	   ns=	  not	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Figure	  5.13:	  A	  novel	  peptide	  conjugate	  vaccine	  prevents	  airway	  histopathology	   	  	  
Mice	  were	  sensitised	  and	  challenged	  with	  OVA/PBS,	  and	  treated	  with	  vaccines	  or	  CTLs	  	  as	  
described	   in	  Fig	  5.12.	  Day	  3	   lung	  histology	  shows	  cellular	   infiltrate	  by	  H&E	  stain	  (A)	   and	  
mucus	  producing	  goblet	  cells	  by	  ABPAS	  staining	  (B).	  Scale	  bars	  represent	  200μm	  (A)	  and	  
100μm	   (B).	   Stained	   sections	   are	   from	   one	   experiment	   that	   shows	   representative	  
histopathology	  of	  two	  experiments,	  each	  with	  5	  mice	  per	  group.	  	  




The	   inhibitory	   effects	   of	   allergen-­‐specific	   CTLs	   on	   allergic	   airway	   inflammation	   are	  
dependent	  on	  the	  expression	  of	  perforin,	  suggesting	  CTL-­‐mediated	  killing	  of	  critical	  allergy-­‐
driving	   cells	   as	   a	   mechanism	   of	   suppressing	   airway	   disease.	   This	   chapter	   aimed	   to	  
determine	   the	   identity	   and	   localisation	   of	   the	   targets	   of	   CTL-­‐mediated	   killing,	   and	  
investigate	  the	  efficacy	  of	  eliciting	  an	  endogenous	  CTL	  response	  by	  use	  of	  a	  novel	  vaccine.	  	  
	  
	  
Allergen-specific CTLs target dendritic cell populations 
	  
Successful	   CTL-­‐mediated	   suppression	   of	   allergic	   airway	   inflammation	   has	   been	  
demonstrated,	  in	  this	  chapter,	  to	  result	  in	  a	  decrease	  in	  the	  number	  of	  DCs	  in	  the	  lung	  and	  
MLN	  of	  treated	  mice.	  This	  suggested	  that	  it	  was	  possible	  that	  allergen-­‐specific	  CTLs	  may	  be	  
targeting	  allergen-­‐presenting	  DCs	  as	  a	  mechanism	  of	  suppression.	  Indeed,	  the	  phenomenon	  
of	   direct	   CTL-­‐mediated	   killing	   of	   DCs	   in	   vivo	   has	   been	   demonstrated	   in	   different	  
experimental	  contexts	  (755,	  756).	  This	  occurrence	  would	  require	  the	  direct	  engagement	  of	  
allergen-­‐MHC-­‐I	   complexes	   on	   target	   DC	   with	   the	   CTL	   TCR,	   implying	   the	   affected	   DC	  
population	  must	  be	  able	  to	  either	  cross-­‐present	  allergen	  to	  CTLs,	  or	  acquire	  allergen-­‐MHC	  
complexes	  from	  other	  DCs.	  Of	  the	  migratory	  lung	  DC	  populations,	  CD103+	  cDCs	  have	  been	  
clearly	  demonstrated	  to	  be	  the	  most	  efficient	  at	  cross-­‐presenting	  lung-­‐acquired	  antigens	  in	  
the	  lymph	  nodes	  (73,	  123,	  126).	  Conversely,	  the	  cross-­‐presenting	  function	  of	  CD11b+	  cDCs	  
is	  not	  well	  established	  (764).	  Intriguingly,	  in	  the	  present	  study,	  it	  was	  not	  only	  CD103+	  DC	  
that	   were	   affected	   by	   CTL	   therapy;	   a	   decrease	   in	   the	   CD11b+	   cDC	   population	   was	   also	  
evident	  in	  the	  lungs	  and	  MLN	  of	  normal	  and	  chimeric	  CTL-­‐treated	  mice.	  The	  interaction	  of	  
CTLs	  with	  CD11b+	  cDC,	  as	   implicated	  in	  these	  experiments,	  had	  not	  been	  reported	  in	  this	  
context	   and	   was	   rather	   unexpected.	   Additionally,	   as	   CD11b+	   cDCs	   are	   the	   primary	   DC	  
subset	   involved	   in	   priming	   airway	   allergy	   (306,	   323),	   this	   finding	   could	   elucidate	   the	  
mechanism	  by	  which	  CTL	  therapy	  suppresses	  allergic	  airway	  inflammation.	  	  
	  
To	  investigate	  the	  contacts	  of	  CTLs	  in	  vivo,	  examination	  of	  lung	  tissue	  was	  carried	  out	  using	  
the	  newly	  developed	  XCR1GFP	  mice	  and	  previously	  described	  CD11cYFP	  mice	  (652),	  allowing	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for	  the	  visualisation	  of	  interactions	  between	  adoptively	  transferred	  CTLs	  with	  endogenous	  
DC	  populations.	  Fascinatingly,	  both	  CD103+	  DC	  and	  CD11b+	  DC	  (CD11cYFP+)	  redistributed	  
after	   airway	   allergen	   challenge	   to	   form	   clusters	   around	   small	   airways.	   CTLs	   were	   also	  
preferentially	  located	  in	  these	  areas	  and,	  within	  clusters,	  both	  DC	  subsets	  could	  be	  observed	  
interacting	  with	   CTLs.	   CD4+	   T	   cells	  were	   also	   clustered	  with	   DCs	   and	   CTLs,	   however,	   in	  
terms	   of	   the	   interaction	   of	   these	   cells	  with	   CD4+	   T	   cells,	   the	   experiments	   carried	   out	   as	  
presented	  in	  Fig	  5.9	  did	  not	  show	  the	  expected	  BAL	  inflammation.	  These	  experiments	  were	  
carried	  out	  in	  a	  different	  research	  institute	  under	  conditions	  not	  entirely	  similar	  to	  that	  of	  
the	   adoptive	   transfer	   experiments	   reported	   in	   the	   rest	   of	   this	   thesis.	   The	   results	   showed	  
that,	  while	  the	  clustering	  phenomenon	  in	  the	  histology	  appeared	  to	  be	  similar	  to	  that	  of	  in	  
vivo	   sensitised	  mice	   (Figs	   5.6,	   5.7,	   5.8),	   the	   BAL	   of	   CD4	   only-­‐treated	  mice	   did	   not	   reveal	  
significant	  inflammatory	  cell	  infiltrates,	  whereas	  the	  CD4	  +	  CTL-­‐treated	  mice	  did	  experience	  
some	  BAL	  cellularity.	  There	  were	  numerous	  potentially	  confounding	  factors	  involved	  such	  
that	  it	  was	  difficult	  to	  conclude	  why	  effective	  airway	  inflammation	  was	  not	  established	  by	  
CD4	   T	   cells,	   and	   why	   the	   co-­‐injection	   of	   CTLs	   did,	   in	   fact,	   result	   in	   some	   inflammatory	  
infiltrates.	   Nevertheless,	   the	   clustering	   of	   CD11b+	   DC	   with	   CD4+	   T	   cells	   was	   recently	  
reported	   in	   the	   lungs	   (494)	   and,	   despite	   the	   low	   airway	   inflammation	   in	   the	   Fig	   5.9	  
experiments	   described	   herein,	   the	   clustering	   phenomenon	   in	   the	   lung	   appeared	   to	   be	  
occurring	   in	   a	   similar	   manner.	   Therefore,	   this	   may	   be	   a	   true	   representation	   of	   the	  
interaction	  of	  CD4+	  T	  cells	  with	  lung	  DC	  and	  as	  such	  the	  previously	  unreported	  interaction	  
of	   CD4+	   T	   cells	   with	   CD103+	   DC,	   and	   in	   association	   with	   CTLs,	   may	   also	   be	   valid	  
observations.	   Thornton	  et	  al	   proposed	  DC:T	   cell	   clustering	   to	   be	   a	   function	  of	   facilitating	  
antigen	   presentation,	   however	   the	   critical	   elements	   involved	   in	   the	   formation	   and	  
biologically	  significant	   functions	  of	   these	  clusters	  remains	   to	  be	  elucidated.	  Other	  authors	  
have	   described	   DC	   clustering	   in	   dermal	   perivascular	   areas	   of	   the	   skin,	   during	   contact	  
hypersensitivity	  reactions,	  that	  enabled	  the	  activation	  of	  T	  cells	  (765).	  This	  similar	  pattern	  
of	  cluster	  formation	  could	  suggest	  the	  importance	  of	  this	  phenomenon	  in	  the	  generation	  of	  
local	  immune	  responses	  across	  multiple	  tissue	  sites.	  	  
	  
The	  association	  of	  XCR1GFP-­‐	  CD11cYFP+	  DCs	  with	  CTLs	  provided	  interesting	  insight	  into	  the	  
mechanism	   of	   action	   of	   CTL-­‐mediated	   immunotherapy.	   Both	   conventional	  
CD11c+CD11b+C64-­‐	  DCs	  and	  monocyte-­‐derived	  CD11b+CD64+	  DCs,	  upon	  upregulation	  of	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CD11c,	  contribute	  to	  the	  total	  CD11cYFP+	  cell	  population	  during	  airway	  inflammation.	   It	   is	  
worth	  noting	   the	  possibility	   that	  alveolar	  macrophages,	  due	   to	   their	  expression	  of	  CD11c,	  
may	  additionally	  be	   revealed	  by	  CD11cYFP+	   fluorescence	   in	   the	   lung	  sections	  examined	   in	  
this	  study,	  however,	  the	  majority	  of	  these	  cells	  would	  have	  been	  removed	  from	  the	  airway	  
by	   BAL	   prior	   to	   imaging.	   Additionally,	   the	   CD11cYFP+	   cells	   visualised	   appeared	  
morphologically	  more	  similar	  to	  DCs	  than	  alveolar	  macrophages;	  although	  dendrites	  were	  
not	   easily	   distinguished	   in	   some	   CD11c-­‐stained	   sections,	   close-­‐up	   visualization	   of	   lungs	  
from	  the	  inherently	  fluorescent	  CD11cYFP	  mice	  by	  confocal	  microscopy	  revealed	  the	  distinct	  
DC-­‐like	  morphology	  of	  these	  cells	  (Fig	  5.9).	  Further	  analysis	  of	  tissue	  sections	  could	  include	  
counter-­‐staining	   with	   CD11b	   antibodies	   to	   conclusively	   identify	   this	   subset	   as	   the	  
predominant	   constituent	   of	   the	   CD11cYFP+	   cell	   population,	   however,	   other	   authors	   have	  
reported	   success	   in	   distinguishing	   alveolar	   macrophages	   from	   DCs	   in	   a	   similar	   manner;	  
based	   on	   their	   morphological	   roundness,	   rather	   than	   dendritic	   appearance	   (494).	   The	  
identification	  of	  CD11b+	  cDC	  versus	  moDC	  is	  not	  as	  straight	  forward,	  however,	  their	  spatial	  
characteristics	  in	  lung	  tissue	  may	  allow	  for	  discrimination	  of	  these	  DCs.	  	  
	  
While	  monocyte-­‐derived	  DCs	  have	  been	  demonstrated	  to	  effectively	  stimulate	  CD8+	  T	  cell	  
responses	   through	   cross-­‐presentation	   (766-­‐769),	   imaging	   of	   moDC	   infiltrating	   the	   lung	  
tissue	  upon	  allergen	  challenge	  revealed	   they	  were	  primarily	  confined	   to	   the	  parenchymal	  
tissue	   rather	   than	   the	   airway	   mucosa	   (770).	   Therefore,	   moDCs	   may	   not	   make	   up	   a	  
significant	  proportion	  of	   the	  CD11cYFP+	  DCs	  observed	   clustering	   in	   association	  with	  CTLs	  
around	  small	  airways	   in	   the	  present	  study,	  and	  may	  preclude	   them	  from	  being	   the	  major	  
targets	   of	   CTL-­‐mediated	   killing.	   This	   postulation	   is	   in	   accordance	   with	   the	   finding	   that	  
chimeric	   CTL-­‐treated	   mice	   did	   not	   display	   a	   significant	   decrease	   in	   the	   CD11b+CD64+	  
moDC	  population.	  	  
	  
Conversely,	  the	  localisation	  of	  CD11b+	  cDC	  around	  allergic	  airways	  has	  been	  demonstrated	  
(494).	   The	   co-­‐localisation	   of	   CTLs	   with	   CD11b+	   cDC	   does	   not	   conclusively	   imply	   that	  
effective	  cross-­‐presentation	  is	  occurring,	  a	  function	  that	  has	  not	  been	  widely	  recognised	  for	  
this	  DC	  subset,	  however,	  it	  appears	  that	  interactions	  between	  these	  populations	  exist	  in	  the	  
allergic	   lung	   that	  may	  not	  have	  been	   realised.	   If	   direct	   cross-­‐presentation	  of	   allergens	  by	  
CD11b+	   cDCs	  was	  occurring,	   and	   resulted	   in	  CTL-­‐mediated	  killing	  of	   those	  DCs,	   this	  may	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effectively	   prevent	   allergic	   airway	   inflammation	   as	   evidenced	   in	   this	   thesis,	   and	   in	  
accordance	   with	   the	   proposed	   physiological	   role	   of	   CTL-­‐mediated	   killing:	   to	   reduce	   the	  
magnitude	   of	   antigen	   presentation	   and	   prevent	   undesirable	   immune	   responses	   from	  
proceeding	  (756,	  771-­‐773).	  
	  
Alternatively	  to	  the	  direct	  processing	  and	  cross-­‐presentation	  of	  allergens	  by	  CD11b+	  cDC,	  
the	   formation	  of	  DC	  clusters	  during	  allergic	  airway	   inflammation	  may	   facilitate	   the	  cross-­‐
dressing	   of	   CD11b+	   cDCs,	   potentially	   acquiring	   allergen-­‐MHC-­‐I	   complexes	   from	   nearby	  
specialised	   cross-­‐presenting	   CD103+	   DC.	   This	   phenomenon	   has	   not	   been	   investigated	   in	  
migratory	   CD11b+	   lung	   cDC	   specifically,	   however,	   cross-­‐dressing	   has	   been	   implicated	   as	  
the	   major	   mechanism	   by	   which	   poor	   cross-­‐presenting	   APCs	   are	   enabled	   to	   stimulate	  
effective	  naïve	  and	  memory	  CD8+	  T	  cell	   responses	   (76,	  128-­‐132).	  Additionally,	  bm-­‐1	  DCs	  
that	  lack	  the	  ability	  to	  cross-­‐present	  OVA	  peptides	  have	  also	  been	  demonstrated	  as	  capable	  
of	  stimulating	  OT-­‐I	  CD8+	  T	  cells	  through	  their	  acquisition	  of	  peptide-­‐MHC	  complexes	  from	  
other	  cross-­‐presenting	  DCs	  (131).	  Cross-­‐dressing	  has	  been	  described	  to	  occur	  through	  the	  
acquisition	  of	  peptide-­‐MHC	  complexes	  by	  at	  least	  two	  distinct	  mechanisms:	  either	  through	  
the	   transfer	  of	   exosomes	   from	  surrounding	   cells	   (76,	  129,	  774-­‐776),	   or	  by	  direct	   cell:cell	  
interaction	   during	   which	   intact	   peptide-­‐MHC	   complexes	   may	   be	   obtained	   (131).	   The	  
method	   of	   exosome	   uptake,	   however,	   will	   result	   in	   successful	   presentation	   of	   acquired	  
peptides	  only	  in	  cells	  capable	  of	  reloading	  these	  peptides	  onto	  their	  own	  MHC-­‐I	  molecules	  
for	  cross-­‐presentation.	  APCs	  that	  can	  not	  carry	  out	  cross-­‐presentation	  on	  their	  own,	  such	  as	  
bm-­‐1	  DCs,	  may	  only	  present	  intact	  peptide-­‐MHC	  complexes	  obtained	  through	  direct	  cell:cell	  
contact	  with	   cross-­‐presenting	   APCs	   (131).	   In	   the	  microscopic	   examination	   of	   lung	   tissue	  
sections,	   there	  were	  numerous	   fields	  of	  view,	  exemplified	   in	  Figure	  5.8,	  where	  CTLs	  were	  
associated	  with	  XCR1GFP-­‐	  CD11c+	  DC	  in	  apparent	  isolation	  from	  close	  contact	  with	  other	  DC	  
subsets.	  This	  could	  rather	  support	  the	  proposal	  that	  direct	  cross-­‐presentation	  is	  occurring,	  
however,	  potentially,	   these	  DC	  acquired	  allergen-­‐MHC	  complexes	  elsewhere	   in	   tissue	  and	  
subsequently	  migrated	  to	  the	  vicinity	  of	  CTLs.	  The	  results	  of	  mixed	  bone	  marrow	  chimera	  
experiments	  provided	  insight	  into	  these	  queries.	  As	  mixed	  bone	  marrow	  chimeras	  showed	  
a	  specific	  decrease	  in	  the	  ratio	  of	  WT	  DCs	  to	  bm-­‐1	  DCs	  in	  CTL-­‐treated	  mice	  (Figure	  5.5),	  this	  
suggests	  the	  dependence	  of	  DC-­‐targeting	  on	  the	  DC’s	  ability	  to	  cross-­‐present	  the	  allergen	  of	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interest;	   an	   equivalent	   decrease	   in	   both	   populations	   may	   be	   expected	   if	   bm-­‐1	   DC	   were	  
effectively	  acquiring	  and	  presenting	  peptide-­‐MHC-­‐I	  complexes.	  	  
	  
While	  CD103+	  and,	  presumably	  CD11b+,	  CD11c+	  DCs	  were	  identified	  interacting	  with	  CTLs	  
in	  the	  present	  study,	  it	  is	  possible	  that	  there	  may	  be	  other	  targets	  of	  CTL-­‐mediated	  killing.	  
Mast	   cells	   and	   basophils	   have	   been	   demonstrated	   to	   carry	   out	   cross-­‐presentation	   of	  
antigens	  (777,	  778),	  potentially	  rendering	  them	  targets	  to	  the	  same	  fate	  as	  cross-­‐presenting	  
DCs.	  However,	   these	  cell	  populations	  are	  not	  critical	   to	   the	  priming	  and	  differentiation	  of	  
Th2	  cells	  (435,	  444,	  685,	  779),	  as	  discussed	  in	  Chapter	  3,	  implying	  they	  are	  less	  significant	  
targets	  than	  CD11c+	  DCs,	  the	  depletion	  of	  which	  effectively	  abrogates	  airway	  inflammation	  
(321).	   Additionally,	   the	   CTL-­‐mediated	   killing	   of	   these	   populations	   in	   vivo	   has	   not	   been	  
reported.	  It	  was	  also	  shown	  in	  Chapter	  4	  that	  CTLs	  successfully	  mediated	  the	  suppression	  
of	  allergic	  airway	  inflammation	  in	  the	  adoptive	  transfer	  model,	  where	  the	  elicitation	  of	  mast	  
cells	  and	  basophils	  was	  not	  significantly	  involved.	  Collectively,	  these	  evidences	  suggest	  that	  
mast	   cells	   and	   basophils	   may	   not	   be	   critical	   targets	   of	   CTL-­‐mediated	   killing	   in	   the	  
suppression	  of	  allergic	  airway	  inflammation.	  	  
	  
The	   CTL-­‐mediated	   killing	   of	   DCs	   could	   occur	   upon	   cross-­‐presentation	   of	   allergens	   in	   the	  
lung,	  or	  after	  the	  migration	  of	  DCs	  to	  the	  MLN.	  Experiments	  with	  the	  fluorogenic	  substrate	  
FLIVO	   revealed	   an	   increase	   in	   pre-­‐apoptotic	   cells	   in	   the	   MLN	   of	   CTL-­‐treated	   mice	   that	  
predominantly	   phenotypically	   resembled	  migratory	  DCs;	   thus	   suggesting	   that	   killing	  was	  
occurring	  in	  the	  lungs,	  though	  perhaps	  not	  exclusively	  so.	  Antigen	  presentation	  in	  the	  lungs	  
has	   been	   shown	   to	   be	   important	   for	   facilitating	   local	   immune	   responses,	   and	   significant	  
numbers	   of	   antigen-­‐loaded	   APCs	   are	   retained	   within	   the	   lung	   (114,	   115).	   As	   such,	   the	  
targeting	   of	   allergen-­‐presenting	   DCs	   in	   the	   lung	   may	   halt	   the	   induction	   of	   an	   allergic	  
response	   at	   the	   local	   site;	   this	  would	   reduce	   the	  migration	   of	   DCs	   to	   draining	   LN	  where	  
many	  T	  cell	  contacts,	  as	  well	  as	  inter-­‐DC	  antigen	  transfer,	  may	  subsequently	  amplify	  the	  T	  
cell	  response	  (74).	  Indeed,	  the	  finding	  that	  DCs	  are	  reduced	  in	  number	  in	  the	  lungs	  of	  both	  
normal	  and	  mixed	  bone	  marrow	  chimeric	  mice	  in	  the	  experiments	  described	  in	  this	  thesis,	  
supports	   the	  notion	  of	   local	   targeting.	  Therefore,	   it	  has	   recurrently	  been	   indicated	   in	   this	  
study	  that	  CTLs	  target	  allergen-­‐presenting	  DCs	  in	  the	  lung.	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Effects of CTLs in airway inflammation driven by an alternative allergen 
specificity 
	  
The	   targeted	   killing	   of	   DCs	   revealed	   a	   means	   by	   which	   allergy-­‐driving	   APCs	   may	   be	  
depleted	   in	   the	   lung;	   the	  effect	  of	   this	  phenomenon	  on	   the	   initiation	  of	  unrelated	  allergic	  
responses	   was	   thus	   investigated.	   In	   a	   model	   of	   dual	   sensitisation,	   OVA-­‐specific	   CTLs	  
appeared	   to	   be	   capable	   of	   effectively	   preventing	   HDM-­‐and-­‐OVA-­‐induced	   airway	  
inflammation,	  the	  mechanism	  of	  which	  was	  not	  fully	  elucidated.	  	  
	  
It	   is	  possible	   that	   the	  auto-­‐adjuvanting	  properties	  of	  HDM	  may	   contribute	   to	  CD8+	  T	   cell	  
activation	   in	   the	   lungs.	   The	  major	  HDM	  allergen,	  Der	   p	   2,	   displays	   similar	   structural	   and	  
functional	  homology	  to	  MD-­‐2:	  the	  protein	  associated	  with	  TLR4	  for	  the	  recognition	  of	  LPS	  
(596-­‐598).	   Therefore,	   the	   combination	   of	   HDM	   endotoxin	   and	   Der	   p	   2	  mimicry	   of	  MD-­‐2	  
could	  initiate	  TLR4	  signalling	  and	  lead	  to	  subsequent	  activation	  of	  CTLs.	  This	  bystander	  CTL	  
effect	   has	   been	   reported	   in	   the	   context	   of	   viral	   infections,	   the	   biological	   importance	   of	  
which	  has	  been	  questioned;	  some	  evidence	  suggests	  that	  effective	  immune	  responses	  may	  
be	   carried	   out	   by	   CTLs	   of	   alternative	   antigen	   specificities	   where	   the	   total	   induced	   and	  
activated	  cell	  number	  reaches	  a	  relatively	  high	  threshold	  level	  (224,	  599-­‐601).	  Additionally,	  
it	   has	   been	   reported	   that	   bystander	   effector/memory	   CD8+	   T	   cells	   in	   the	   airway	   can	  
mediate	  suppression	  of	  allergic	  responses	  in	  the	  lung,	  in	  an	  IFN-­‐γ	  dependent	  manner	  (221).	  
However,	   these	   experiments	   were	   carried	   out	   in	   the	   presence	   of	   endotoxin,	   unlike	   the	  
systems	   generated	   in	   this	   thesis,	   and	   reported	   by	   others	   (226),	   where	   low	   endotoxin	  
conditions	   resulted	   in	   the	   suppression	   of	   allergic	   airway	   inflammation	   that	  was	   critically	  
dependent	  on	  the	  expression	  of	  perforin,	  while	  no	  requirement	  for	  IFN-­‐γ	  was	  determined.	  
Additionally,	  while	  TLR	  signalling	  may	  lead	  to	  the	  activation	  of	  bystander	  CTLs,	  the	  lack	  of	  
TCR	  engagement	  would	  preclude	  CTL-­‐mediated	  killing.	  	  
	  
An	   alternative	   mechanism	   may	   be	   proposed,	   then,	   whereby	   both	   OVA	   and	   HDM	   are	  
presented	  predominantly	  on	  the	  same	  APCs	  concurrently,	  either	  via	  cross-­‐presentation	  or	  
cross-­‐dressing.	  As	  such,	  the	  effective	  killing	  of	  OVA-­‐and-­‐HDM-­‐cross-­‐presenting	  DCs	  by	  OVA-­‐
specific	  CTLs	  may	  reduce	  the	  presentation	  of	  both	  OVA	  and	  HDM	  to	  CD4+	  T	  cells,	  leading	  to	  
the	  suppression	  of	  inflammation	  associated	  with	  either	  allergen	  (as	  depicted	  in	  Fig	  5.14).	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Figure	  5.14:	  Proposed	  mechanism	  of	  OVA-­‐specific	  CTL-­‐mediated	  suppression	  of	  OVA-­‐
and-­‐HDM-­‐induced	  airway	  inflammation	   	  
Suppression	  of	  allergic	  airway	  inflammation	  induced	  by	  both	  OVA	  and	  HDM	  was	  mediated	  
by	  OVA-­‐specific	  CTLs	  alone.	  As	  OVA-­‐specific	  CTL	  may	   target	  OVA-­‐presenting	   (A),	   but	  not	  
HDM-­‐presenting	  (B)	  DC,	  this	  finding	  suggested	  DCs	  may	  be	  predominantly	  presenting	  both	  
OVA	  and	  HDM	  simultaneously	  (C);	  these	  DC	  may	  be	  targeted	  by	  OVA-­‐specific	  CTL,	  resulting	  
in	   a	   decrease	   in	   both	   OVA	   and	   HDM	   presentation	   to	   CD4+	   T	   cells,	   and	   subsequent	  
suppression	  of	  allergic	  airway	  inflammation.	  
	  
	  
Kedl	  and	  colleagues	  describe	  a	  phenomenon	  whereby	  the	  simultaneous	  presentation	  of	  two	  
different	   antigens	  on	   the	   same	  DC	   led	   to	   competitive	   exclusion	  of	  T	   cell	   responses	  of	   the	  
sub-­‐dominant	  antigen	  specificity,	  due	  in	  part	  to	  spatial	  interference	  (780).	  It	  could	  thus	  be	  
argued	   that	   in	   the	   dual-­‐sensitisation	   system,	   the	   high-­‐affinity	   of	   OVA-­‐specific	   T	   cells	   for	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OVA-­‐and-­‐HDM-­‐presenting	  DCs	  could	  allow	  the	  physical	  exclusion	  of	  some	  HDM-­‐specific	  T	  
cells,	  reducing	  HDM-­‐induced	  airway	  inflammation.	  However,	  in	  the	  experiments	  described	  
in	  this	  thesis,	  competition	  between	  T	  cells,	  that	  is,	  CD4+	  T	  cells	  and	  CTLs,	  is	  not	  implicated	  
as	   a	   key	   mechanism	   for	   the	   suppression	   of	   allergic	   disease,	   as	   WT	   OT-­‐I	   CTLs	   abrogate	  
inflammation	  while	  PKO	  OT-­‐I	  CTLs	  are	  unable	  to	  do	  so;	  spatial	  exclusion	  by	  higher-­‐affinity	  
cells,	   as	   a	   primary	   mechanism,	   would	   result	   in	   equivalent	   suppression	   by	   either	   CTL	  
population,	  as	  both	  populations	  interact	  with	  APCs.	  	  In	  fact,	  it	  has	  been	  demonstrated	  that	  
PKO	   cytotoxic	   lymphocytes	   have	   extended	   interaction	   time	  with	   target	   cells	   due	   to	   their	  
inability	   to	  effectively	  kill	   the	  cells	  and	  subsequently	  disengage	  (781).	  This	   finding	  rather	  
implicates,	  yet	  again,	  the	  CTL-­‐mediated	  killing	  of	  allergen	  presenting	  DCs.	  	  
	  
For	  the	  killing	  of	  OVA-­‐and-­‐HDM	  presenting	  DCs	  to	  be	  so	  effective	  in	  the	  suppression	  of	  the	  
HDM-­‐induced	  component	  of	  airway	  inflammation,	  as	  reported	  in	  Figure	  5.11,	  the	  majority	  
of	   HDM-­‐presenting	   DCs	   would	   also	   need	   to	   be	   presenting	   OVA.	   It	   is	   possible	   that	   this	  
phenomenon	   could	   have	   occurred	   due	   to	   the	   surplus	   concentration	   of	   OVA	   allergen	  
compared	   to	  HDM	  used	   in	   these	   experiments,	   such	   that	   the	  majority	   of	   allergen-­‐exposed	  
DCs	   in	  the	   lung	  had	  picked	  up	  OVA	  with	  or	  without	  HDM.	  Alternatively,	   it	   is	  possible	  that	  
specific	  DCs	  are	  more	  likely	  to	  acquire	  and	  present	  these	  allergens,	  and	  as	  such,	  the	  same	  
population(s)	   of	   DCs	   are	   more	   frequently	   presenting	   both	   allergens.	   Thornton	   and	  
colleagues	  describe	  CD11b+	  DC	  as	  being	  better	  at	   soluble	  antigen	  uptake	   than	  other	   lung	  
DCs,	  however	  it	  was	  postulated	  that	  this	  may	  be	  due	  to	  their	  localisation	  within	  tissue	  and	  
the	  higher	  frequency	  of	  these	  DC	  (494);	  the	  uptake	  of	  multiple	  antigens	  was	  not	  assessed.	  It	  
would	   be	   interesting	   to	   carry	   out	   subsequent	   OVA/HDM	   experiments	   where	   the	  
concentrations	   of	   OVA	   and	   HDM	   were	   limiting	   and	   more	   equivalent,	   such	   that	   the	   co-­‐
presentation	  of	  OVA	  or	  HDM	  on	  DCs	  would	  be	  expected	  to	  occur	   less	   frequently,	  unless	  a	  
bias	  towards	  specific	  DCs	  was	  indeed	  a	  factor.	  
	  
As	  the	  majority	  of	  individuals	  affected	  by	  allergy	  are	  polysensitised	  (22,	  578,	  579),	  potential	  
benefits	   exist	   for	   therapeutic	   interventions	   that	   may	   confer	   cross-­‐protection	   to	   multiple	  
allergens,	  while	  targeting	  specific	  allergen-­‐presenting	  DCs.	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Immunotherapy of allergic airway inflammation by a novel peptide conjugate 
vaccine that elicits an allergen-specific CTL response  
	  
The	  efficacy	  of	  utilising	  tumour-­‐derived	  (782,	  783)	  or	  genetically	  engineered	  T	  cells	  (784)	  
for	   the	   purpose	   of	   anti-­‐tumour	   immunotherapy	   has	   been	   demonstrated.	   While	   the	  
identification	  of	  antigen-­‐specific	  CD8+	  T	  cells	   from	  peripheral	  blood	  samples	   is	  extremely	  
difficult,	  due	  to	  their	  low	  proportion	  of	  total	  circulating	  lymphocytes	  (785),	  analogous	  T	  cell	  
engineering	   could	   in	   theory	   provide	   a	   CD8+	   T	   cell-­‐based	   vaccine	   for	   allergic	   asthma.	  
Similarly,	   treatment	   with	   autologous	   tumour-­‐antigen-­‐presenting	   DCs	   has	   also	   proven	  
beneficial	   in	   the	   induction	   of	   CTL-­‐mediated	   anti-­‐tumour	   responses	   (786-­‐788).	   The	  
generation	   of	   cell-­‐based	   vaccines,	   however,	   can	   be	   arduous;	   leukapheresis	   to	   obtain	  
patient-­‐specific	  haematopoietic	  precursor	  cells	  is	  a	  somewhat	  invasive	  and	  time-­‐consuming	  
procedure	   that	   may	   have	   variable	   success	   in	   the	   recovery	   of	   adequate	   numbers	   of	  
precursor	  cells.	  Additionally,	  the	  processing	  involved	  in	  the	  subsequent	  antigen-­‐pulsing	  and	  
enrichment	   procedures,	   or	   engineering	   of	   cells	  may	   affect	   cell	   viability,	   the	   final	   cellular	  
preparation	   for	   immunisation	   thus	   being	   potentially	   variable	   in	   efficacy.	   Furthermore,	  
these	  processes	   render	   the	   generation	  of	   cell-­‐based	  vaccines	   an	   expensive	   endeavour	   for	  
individualised	  medicine.	  
	  
For	  the	  clinical	  treatment	  of	  allergic	  asthma,	  a	  cell-­‐free	  vaccine	  that	  induces	  an	  endogenous	  
response	   may	   be	   preferable	   and	   more	   feasible	   than	   the	   use	   of	   cellular	   immunisation.	   A	  
novel	   conjugate	   vaccine	   has	   herein	   shown	   similar	   efficacy	   in	   the	   suppression	   of	   allergic	  
airway	  inflammation	  to	  that	  reported	  using	  the	  adoptive	  transfer	  of	  allergen-­‐specific	  CTLs;	  
its	   effects	   generated	   by	   the	   elicitation	   of	   an	   endogenous	   CTL-­‐mediated	   response	   (Figure	  
5.12	   and	   5.13,	   and	   (668)).	   This	   vaccine	   may	   have	   several	   benefits	   over	   cellular	  
immunotherapy	   as	   well	   as	   conventional	   CTL-­‐eliciting	   vaccines.	   Firstly,	   there	   is	   no	  
requirement	   for	   the	   recovery	   of	   cells	   from	   patients,	   additionally,	   the	   vaccine	   may	   be	  
designed	   to	   conjugate	   common	   allergens	   that	   affect	   numerous	   individuals	   so	   that	  
personalised	   treatment	   is	   not	   required	   in	   every	   case.	   Finally,	   many	   existing	   cell-­‐free	  
vaccines	  are	  designed	  to	  recruit	  CD4+	  T	  cells	  as	  their	  helper	  functions	  have	  been	  shown	  to	  
play	  an	  essential	  role	  in	  the	  propagation	  of	  successful	  anti-­‐tumour	  immune	  responses	  (789-­‐
792),	   however,	   in	   the	   context	   of	   allergy	   the	   stimulation	   of	   CD4+	   T	   cells	  may	   potentially	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exacerbate	   disease,	   rendering	   this	   approach	   undesirable	   for	   the	   treatment	   of	   allergic	  
airway	  inflammation.	  For	  this	  purpose,	  the	  conjugate	  vaccine	  rather	  employs	  the	  assistance	  
of	  NKT	  cells	  by	  presentation	  of	  αGalCer	  on	  DC	  CD1d	  molecules.	  	  
	  
The	   therapeutic	   potential	   for	   the	   conjugate	   vaccine	   in	   the	   context	   of	   established	   airway	  
inflammation	  was	  not	  examined	  in	  this	  chapter,	  neither	  was	  long-­‐term	  efficacy	  determined.	  
The	  vaccine,	  however,	   induces	  CTLs	  of	  a	  similar	  phenotype	  to	  those	  generated	   in	  vitro	   for	  
adoptive	  transfer;	  IFN-­‐y	  producing,	  and	  no	  detectable	  production	  of	  the	  Tc2-­‐type	  cytokine	  
IL-­‐4	   (668).	   Additionally,	   vaccine	   treatment	   suppresses	   disease	   similarly	   to	   the	   adoptive	  
transfer	   of	   CTLs.	   Therefore,	   it	   could	   be	   hypothesised	   that	   the	   vaccine	  may	   also	   abrogate	  





In	  this	  chapter,	  allergen-­‐specific	  CTLs	  were	  demonstrated	  to	  abrogate	  airway	  inflammation	  
by	  targeting	  allergen-­‐loaded	  DCs	  within	  the	  lungs,	  importantly,	  by	  inducing	  apoptosis	  of	  the	  
critical	   CD11b+	   cDC	   population.	   This	   required	   the	   expression	   of	   perforin	   and	   the	  
recognition	   of	   cross-­‐presented	   allergen	   on	   DC	   MHC-­‐I.	   Additionally,	   novel	   insights	   were	  
gained	  into	  the	  localisation	  of	  DC	  subsets	  in	  the	  allergic	  lung;	  visualisation	  of	  lungs	  revealed	  
a	   redistribution	   of	   DCs,	   after	   allergen	   challenge,	   to	   form	   clusters	   around	   small	   airways	  
within	  which	  CTLs	  were	  interacting	  with	  both	  CD103+	  DC	  and,	  unexpectedly,	  CD11b+	  DCs.	  
This	  targeting	  of	  allergy-­‐driving	  DCs	  appeared	  to	  have	  cross-­‐protective	  effects	  that	  may	  be	  
beneficial	   to	   individuals	   suffering	   from	   reactions	   to	   multiple	   allergens.	   Finally,	   a	   novel	  
peptide	   conjugate	   vaccine	  was	  described	   that	   is	   capable	   of	   eliciting	   effective	   endogenous	  
CTL-­‐mediated	   suppression	   of	   airway	   inflammation.	   Collectively,	   these	   findings	   reveal	   the	  
exciting	  potential	  for	  effective	  immunotherapy	  of	  allergies	  through	  the	  targeting	  of	  allergy-­‐
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6.1 The main findings of this thesis 
This	   thesis	   aimed	   to	  determine	   the	   therapeutic	  potential	   for	   allergen-­‐specific	  CTLs	   in	   the	  
treatment	  of	  established	  allergic	  airway	  inflammation,	  and	  to	  elucidate	  the	  mechanism	  by	  
which	   CTLs	  mediated	   suppression	   of	   disease.	   It	   was	   hypothesised	   that	   CTLs	  may	   target	  
allergy-­‐driving	  APCs,	  reducing	  the	  presentation	  of	  allergen	  to	  CD4+	  T	  cells	  and	  subsequent	  
Th2-­‐polarised	   inflammation.	   Key	   findings	   are	   highlighted	   in	   this	   chapter,	   and	   some	  
limitations	  are	  also	  discussed	  herein.	  	  
	  
The	  main	  findings	  of	  this	  thesis	  may	  be	  summarised	  as	  follows:	  
	  
• Immunotherapy	  with	  allergen-­‐specific	  CTL	  has	  long-­‐term	  preventative	  and	  
therapeutic	  effects	  on	  established	  airway	  inflammation,	  in	  a	  manner	  dependent	  on	  
perforin; 
• CTL-­‐mediated	   suppression	   of	   allergic	   inflammation	   is	   associated	   with	   reduced	  
number	  and	  cytokine	  production	  of	  disease-­‐mediating	  CD4+	  Th2	  cells	  in	  the	  airway;	  	  
• Lung	   CD11b+	   and	   CD103+	   DC	   form	   clusters	   with	   CTL	   and	   CD4+	   T	   cells	   during	  
allergic	  inflammation,	  where	  killing	  may	  be	  facilitated;	  
• Allergen-­‐specific	  CTLs	  target	  and	  kill	  lung	  CD11b+	  and	  CD103+	  dendritic	  cell	  
populations	  in	  a	  manner	  that	  is	  dependent	  on	  MHC-­‐I	  engagement; 
• Both	   the	   classical	   cross-­‐presenting	   CD103+	   DC	   as	   well	   as	   critical	   allergy-­‐driving	  
CD11b+	  DC	  present	  allergens	  to	  CTLs;	  
• Allergic	  airway	  inflammation	  can	  be	  suppressed	  using	  a	  CTL	  vaccine	  	  
	  
	  
6.1.1 CTL-mediated suppression of allergic disease is associated with 
effects on disease-mediating CD4+ Th2 cells 
	  
Despite	  being	  critical	  to	  the	  development	  of	  allergic	  asthma,	  the	  role	  and	  activity	  of	  CD4+	  T	  
cells	  is	  not	  fully	  resolved;	  indeed,	  the	  role	  of	  CD4+	  T	  cells	  is	  being	  revised	  due	  to	  the	  recent	  
discovery	   of	   ILCs	   and	   innate	   mediators	   that	   may	   posses	   overlapping	   or	   complementary	  
roles	   in	   the	  development	  of	  Th2	   immunity.	  The	  direct	  or	   consequential	   effects	  of	  CD8+	  T	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cells	  on	  CD4+	  T	  cells	  in	  allergic	  airway	  inflammation	  also	  remains	  to	  be	  fully	  elucidated.	  In	  
this	   study,	   an	   adoptive	   transfer	   model	   was	   developed	   that	   replicated	   the	   characteristic	  
features	   of	   allergic	   airway	   inflammation	   and	   allowed	   for	   the	   identification	   of	   allergen-­‐
specific	   CD4+	   T	   cells.	   This	   model	   provides	   a	   platform	   for	   others	   to	   carry	   out	   additional	  
investigations.	  Within	  this	  model,	  CTLs	  suppressed	  allergic	  disease	  and	  it	  became	  apparent	  
that	  lower	  numbers	  of	  CD4+	  T	  cells	  in	  the	  lung	  tissue	  and	  reduced	  Th2	  cytokine	  production	  
were	  associated	  with	  CTL-­‐mediated	  amelioration	  of	  disease,	  thus	  suggesting	  that	  CTLs	  were	  
affecting	  the	  stimulation	  of	  pathogenic	  CD4+	  T	  cells.	  	  
	  
The	   absence	   of	   host	   sensitisation	   in	   this	   model,	   however,	   subverts	   the	   elicitation	   of	   a	  
number	   of	   cell	   populations	   that	   would	   normally	   participate	   in	   the	   induction	   of	   a	   Th2	  
response.	   Additionally,	   allergen-­‐specific	   IgE	   is	   not	   generated.	   Importantly,	   epithelial	   cells	  
and	  ILCs	  would	  not	  have	  been	  activated	  prior	  to	  allergen	  challenge.	  It	  could	  be	  argued	  that	  
the	  main	  crucial	  outcome	  of	   the	  co-­‐operation	  of	   these	  cells	   in	   the	  development	  of	  allergic	  
disease	  is	  the	  stimulation	  of	  CD4+	  Th2	  cells,	  long	  recognised	  as	  critical	  mediators	  of	  allergy	  
(707-­‐709,	  793,	  794).	  In	  this	  regard,	  adoptively	  transferred	  CD4+	  Th2	  cells	  are	  sufficient	  to	  
orchestrate	   the	   late	  phase	  asthmatic	  reactions	   that	  replicate	   the	  characteristic	   features	  of	  
allergic	   disease	   (650,	   651,	   795,	   796).	   Indeed,	   it	   was	   found	   in	   this	   study	   that	   significant	  
eosinophilia,	  mucus	  production	  and	  histological	  pathology	  were	  induced	  by	  the	  transferred	  
cells,	  without	  the	  requirement	  for	  host	  sensitisation.	  	  
	  
It	   is	   additionally	   true,	   however,	   that	   the	   in	  vivo	   sensitisation	  model	   utilised	   in	   this	   study	  
may	  not	  elicit	  the	  recruitment	  of	  innate	  cells	  for	  the	  initiation	  of	  the	  Th2	  response,	  either.	  
Indeed,	  a	  criticism	  of	   the	   i.p.	   sensitisation	  protocol	   is	   the	   failure	   to	  stimulate	   local	  airway	  
cells,	   including	   ILCs	   and	   epithelial	   cells,	   that	   would	   naturally	   be	   induced	   during	   the	  
sensitisation	   phase	   of	  models	   employing	   the	   intranasal	   administration	   of	   allergens	   (274,	  
611,	  612).	  Consequently,	  it	  has	  been	  demonstrated	  that	  while	  ILC2	  play	  a	  crucial	  role	  in	  the	  
initiation	  of	  Th2	  responses	  that	  are	  generated	  through	   local	  sensitisation,	   like	   that	  driven	  
by	   the	   repeated	   inhalation	  of	   allergens	   such	  as	  HDM,	  an	   important	   initiating	   role	  has	  not	  
been	   described	   for	   ILC2	  where	   sensitisation	   is	   carried	   out	   by	   allergens	   administered	   i.p.	  
(467,	   797,	   798).	   Therefore,	   although	   the	   characteristic	   features	   of	   allergic	   airway	  
inflammation	  were	  generated	  using	  both	  the	  adoptive	  transfer	  and	  i.p.	  sensitisation	  models	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in	   this	   study,	   these	   models	   may	   not	   involve	   the	   recruitment	   and	   involvement	   of	   a	   co-­‐
ordinated	  response	  between	  CD4+	  T	  cells	  and	  Th2-­‐driving	  innate	  cells.	  
	  
The	   importance	   of	   innate	   cells	   such	   as	   epithelial	   cells	   and	   ILCs,	   and	   their	   associated	  
cytokines,	  has	   recently	  become	   increasingly	  apparent,	   as	  multiple	   roles	   in	  allergic	  airway	  
inflammation	   have	   been	   described.	   A	   recent	   report	   by	   Christianson	   and	   colleagues	  
described	   multiple	   feedback	   loops	   involving	   these	   cells	   that	   are	   important	   for	   the	  
persistence	  of	  chronic	  asthmatic	  disease.	  The	  stimulation	  of	  epithelial	  cells	  resulted	  in	  IL-­‐33	  
production	   that	   led	   to	   the	   recruitment	   of	   ILC2s;	   subsequent	   ILC2	   production	   of	   IL-­‐13	  
prompted	   the	   upregulation	   of	   IL-­‐33	   receptors	   and	   facilitated	   the	   autoinduction	   of	   IL-­‐33	  
(674,	  799,	  800).	  Chronic	  asthma	  was	  resolved	  upon	  elimination	  of	  any	  of	  these	  components.	  
These	  findings	  therefore	  reveal	  a	  previously	  unappreciated	  role	  for	  epithelial	  cells	  and	  ILC2	  
in	  the	  maintenance	  of	  chronicity	  through	  multiple	  feedback	  loops.	  This	  study	  also	  reported	  
that	  while	   T	   cells	   contributed	   to	   the	   severity	   of	   chronic	   asthma,	   they	  were	   not	   critically	  
required	  for	  persisting	  AHR	  and	  airway	  remodelling;	  this	  result	  was	  in	  accordance	  with	  that	  
previously	  published	  by	  another	  group	  in	  a	  study	  of	  chronic	  disease	  (799,	  801),	  adding	  to	  
the	   argument	   that	   CD4+	   T	   cells	   are	   not	   solely	   responsible	   for	   co-­‐ordinating	   airway	  
pathology.	  Previous	  studies	  have,	  however,	  demonstrated	  an	  essential	  role	  for	  CD4+	  T	  cells	  
in	   the	   initial	   development	   of	   AHR;	  when	   CD4+	  T	   cells	   are	   depleted	   from	   sensitised	  mice	  
before	   allergen	   challenge,	   AHR	   does	   not	   develop	   (475,	   476,	   709,	   747,	   802,	   803).	  
Nevertheless,	  significant	  interplay	  still	  exists	  between	  innate	  cells	  and	  Th2	  cells	  in	  chronic	  
asthma	  (675,	  804-­‐806).	  Together,	   these	   findings	  reveal	  some	  important	  differences	   in	  the	  
role	  and	  requirement	  for	  effector	  CD4+	  T	  cells	  in	  different	  stages	  of	  disease,	  and	  implicate	  
the	   importance	  of	   ILCs	  and	  epithelial	  cells	   in	  established	  chronic	  disease.	  Therefore	  while	  
Th2	  priming	  and	  airway	  disease	  may	  develop	  without	  the	  requirement	  for	  these	  cells,	  there	  
may	  be	  aspects	  of	  pathology	  that	  are	  not	  replicated	  without	  their	  recruitment.	  
	  
The	   recruitment	   of	   ILCs,	   in	   collaboration	  with	   innate	   cytokines	   IL-­‐33	   and	   TSLP,	   has	   also	  
been	  deemed	  of	  clinical	  importance,	  as	  these	  factors	  are	  involved	  in	  driving	  corticosteroid	  
resistance	   in	   asthma	   (807-­‐811).	   These	   studies	   recently	   showed	   that,	  while	   Th2	   cells	   and	  
eosinophils	  may	  be	  predominantly	  sensitive	  to	  corticosteroid	  therapy,	  ILC2s	  may	  evade	  cell	  
death	   in	   response	   to	   innate	   cytokines.	   The	   induction	   of	   TSLP	   in	   an	   IL-­‐33/OVA	  model	   of	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allergic	   airway	   inflammation	   was	   shown	   to	   cause	   ILC2	   to	   become	   resistant	   to	   steroid-­‐
mediated	   cell	   death	   through	   a	   STAT5-­‐dependent	   pathway	   (807,	   808),	   thus	   enabling	   on-­‐
going	   inflammation.	   IL-­‐33	   has	   also	   been	   implicated	   in	   patients	   with	   severe	   therapy-­‐
resistant	  asthma,	  found	  in	  high	  concentration	  in	  the	  inflamed	  airway	  (811,	  812).	  Strikingly,	  
it	   was	   demonstrated	   experimentally	   that	   corticosteroid	   sensitivity	   could	   be	   restored	  
through	  blockade	  of	  the	  TSLP/STAT5	  signalling	  pathway	  (808,	  813).	  Therefore,	   IL-­‐33	  and	  
TSLP	  represent	  potential	  therapeutic	  targets	  in	  ILC2-­‐driven	  corticosteroid-­‐resistant	  asthma,	  
and	  it	  would	  be	  useful	  for	  studies	  further	  to	  the	  work	  described	  in	  this	  thesis	  to	  address	  the	  
effects	  of	  CTL	  immunotherapy	  on	  ILC2s.	  	  	  
	  	  
The	   involvement	   of	   epithelial	   cells	   in	   allergic	   disease,	   interestingly,	   differs	   between	   the	  
commonly	  used	  strains	  of	  mice.	  While	  a	  critical	  role	  has	  been	  demonstrated	   for	  epithelial	  
cells	   in	  OVA-­‐induced	  allergic	  airway	   inflammation	   in	  BALB/c	  mice,	   this	  requirement	  does	  
not	  apply	  in	  C57BL/6	  models	  (635,	  814).	  As	  experiments	  in	  this	  study	  were	  carried	  out	  in	  
C57BL/6	   mice,	   it	   stands	   to	   reason	   that	   epithelial	   cell	   involvement	   may	   not	   have	   been	  
critical	  in	  these	  models,	  regardless	  of	  whether	  adoptive	  transfer	  or	  in	  vivo	  sensitisation	  was	  
performed;	   although,	   they	   would	   have	   of	   course	   contributed	   to	   pathology.	   As	   more	  
extensive	   genetic	   heterogeneity	   exists	   in	   humans,	   it	   is	   possible	   that	   these	   cells	   also	  
contribute	  differently	  in	  the	  perpetuation	  of	  human	  asthmatic	  disease,	  between	  individuals.	  	  
	  
In	  summary,	  it	  is	  evident	  that	  while	  the	  generation	  of	  allergic	  airway	  inflammation	  is	  reliant	  
on	  a	  robust	  Th2	  response,	  like	  that	  induced	  in	  the	  adoptive	  transfer	  and	  in	  vivo	  sensitisation	  
models,	   it	   is	   possible	   that	   the	   absence	  of	   local	   airway	   cell	   sensitisation	   results	   in	   allergic	  
pathology	   that	   may	   differ	   in	   some	   aspects	   to	   naturally	   acquired	   allergic	   airway	  
inflammation.	  Specifically,	  the	  late-­‐phase	  asthmatic	  response	  is	  generated,	  but	  early-­‐phase	  
response	   is	   not.	   Nevertheless,	   it	   was	   found	   that	   CTL	   immunotherapy	   inhibited	   airway	  
inflammation	   both	   in	   the	   adoptive	   transfer	   and	   in	   vivo	   models,	   suggesting	   that	   the	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6.1.2 Allergen-specific CTLs counteract Th2 immune responses to 
suppress allergic airway inflammation 
	  
This	   thesis	  shows	   that	  allergen-­‐specific	  CTLs	   target	   lung	  DCs,	   resulting	   in	  amelioration	  of	  
airway	   inflammation.	   Effective	   targeting	   was	   dependent	   on	   perforin	   expression	   and	  
apoptosis	  was	  likely	  initiated	  in	  the	  lung.	  The	  interaction	  of	  CTLs	  with	  DC	  MHC-­‐I	  was	  crucial	  
to	  the	  killing	  response,	  suggesting	  that	  cross-­‐presenting	  DCs	  were	  targeted.	  While	  CD103+	  
cDC,	  classically	  recognised	  as	  the	  most	  efficient	  cross-­‐presenting	  migratory	  DC	  population	  
in	   the	   lung,	   were	   targeted,	   critical	   allergy-­‐driving	   CD11b+	   cDC	   were	   also	   found	   to	   be	  
affected.	   Indeed,	   fluorescent	   imaging	   of	   the	   lung	   showed	  both	   subsets	   closely	   interacting	  
with	  CTLs;	  allergen	  challenged	  mice	  fascinatingly	  revealed	  the	  formation	  of	  DC-­‐CTL-­‐CD4+	  T	  
cell	   clusters	   within	  which	   each	   of	   these	   cell	   types	   appeared	   to	   interact	   with	   each	   other.	  
Together,	   these	   findings	   describe	   the	   mechanism	   by	   which	   CTLs	   mediate	   effective	  
suppression	   of	   allergic	   disease.	   A	   novel	   conjugate	   vaccine	  was	   also	   described	   that	   elicits	  
endogenous	  CTLs	  to	  suppress	  airway	  inflammation,	  providing	  the	  potential	  for	  translation	  
of	  these	  findings	  into	  the	  treatment	  of	  human	  disease.	  	  
	  
The	  potent	  efficacy	  of	  CTL-­‐mediated	  DC	  killing	  as	  a	  central	  mechanism	  in	  the	  suppression	  of	  
allergic	   airway	   disease	   begs	   the	   question	   of	   how	   this	   may	   relate	   to	   physiological	  
interactions	  normally	  occurring	  between	  DCs	  and	  CTLs	  in	  human	  health	  and	  disease.	  It	  has	  
been	  proposed	  that	  CTL-­‐mediated	  killing,	  in	  addition	  to	  the	  clearance	  of	  virally-­‐infected	  or	  
tumorous	   cells,	   functions	   to	   reduce	   excessive	   presentation	   of	   antigens	   which	   may	   drive	  
superfluous	  or	  inappropriate	  immune	  responses	  (73,	  123,	  126,	  322,	  324,	  755,	  756,	  771-­‐773,	  
815).	  Indeed,	  Ma	  and	  colleagues	  report	  that	  under	  particular	  experimental	  conditions,	  CTL-­‐
mediated	  killing	  of	  DCs	  may	  result	  in	  reduced	  proliferation	  of	  naïve	  CD4+	  T	  cells	  in	  lymph	  
nodes	   (764,	   816).	   For	   the	   purpose	   of	   ensuring	   that	   effective	   immunity	   is	   developed,	  
however,	  dendritic	  cells	  may	  possess	  mechanisms	  by	  which	  they	  can	  avoid	  being	  killed	  by	  
CTLs	  during	  antigen	  presentation.	  Numerous	  mechanisms	  have	  been	  examined	   in	   in	  vitro	  
studies;	   DCs	   may	   express	   anti-­‐apoptotic	   molecules	   to	   protect	   themselves	   from	   FasL-­‐
mediated	  killing	  (817-­‐824)	  and	  in	  the	  defence	  of	  perforin/granzyme-­‐mediated	  killing,	  DCs	  
may	  express	  serine	  protease	  inhibitors	  (serpins)	  that	  neutralise	  granzyme	  B:	  serpin	  B9	  in	  
humans	  (formerly	  known	  as	  PI-­‐9),	  or	  the	  murine	  homologue,	  SPI-­‐6	  (226,	  752).	  Interaction	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with	  memory	  CD8+	  T	  cells	  was	  also	  reported	  to	  protect	  DCs	  from	  being	  killed	  (320,	  754).	  In	  
vivo,	  however,	  these	  factors	  were	  not	  shown	  to	  protect	  DCs	  from	  CTL-­‐mediated	  killing	  (494,	  
757,	   825,	   826).	  While	   a	   universally	   protective	  mechanism	  does	   not	   appear	   to	   have	   been	  
clearly	  demonstrated	  in	  vivo,	  it	  may	  be	  that	  DCs	  possess	  these	  features	  for	  the	  avoidance	  of	  
CTL-­‐mediated	  killing.	  Alternatively,	  DCs	  may	  remain	  susceptible	  to	  CTL-­‐mediated	  killing	  as	  
an	  immune	  regulatory	  function.	  	  
	  
In	  the	  current	  study,	  allergen-­‐presenting	  DC	  did	  appear	  to	  be	  susceptible	  to	  CTL-­‐mediated	  
killing.	   It	   would	   be	   interesting	   to	   investigate	   whether	   allergen-­‐presenting	   lung	   DCs	   in	  
humans	  that	  suffer	  from	  allergic	  asthma	  differ	  in	  their	  susceptibility	  to	  CTL-­‐mediated	  killing	  
to	   those	   from	   non-­‐allergic	   individuals.	   This	   could	   occur	   through	   defective	   CTL-­‐mediated	  
killing	   or	   enhanced	   DC	   protection	  mechanisms,	   which	  may	   lead	   to	   a	   failure	   to	   suppress	  
allergic	   responses.	   However,	   in	   the	   case	   of	   defective	   CTLs,	   this	   would	   of	   course	   lead	   to	  
additional	  serious	  pathologies.	  Indeed,	  in	  patients	  suffering	  from	  perforinopathies,	  such	  as	  
Familial	  Haemophagocytic	  Lymphohistiocytosis,	  CTLs	  cannot	  kill	  effectively	  which	  leads	  to	  
an	   increase	   in	   activated	   immune	   cells	   and	   excessive	   cytokine	   production	   causing	  
widespread,	   often	   fatal,	   pathology	   (255,	   258,	   765).	   To	   the	  best	   of	  my	  knowledge,	   studies	  
have	  not	  yet	  been	  performed	  to	  investigate	  the	  relative	  presence	  or	  absence	  of	  CTL-­‐killing	  
avoidance	  mechanisms	   between	   DCs	   of	   allergic	   and	   non-­‐allergic	   individuals.	   It	   has	   been	  
shown	   however,	   that	   atopic	   asthmatic	   patients	   have	   increased	   numbers	   of	   DCs	   in	   the	  
airway	  mucosa	  and	  peripheral	  blood	  (765,	  827-­‐829),	  and	  while	  this	  may	  be	  a	  consequence	  
of	  airway	  inflammation,	  it	  has	  also	  been	  shown	  that	  excess	  DC	  proliferation	  is	  promoted	  in	  
the	   airways	   by	   aeroallergen	   challenge	   (755,	   757,	   770,	   825,	   826).	   Interestingly,	   increased	  
CD8+	   T	   cells	   in	   asthmatics	   has	   been	   shown	   to	   correlate	  with	   decreased	   severity	   of	   AHR	  
(711,	  773,	  816).	  However,	   large	  numbers	  of	   activated	  CD8+	  Tc2	  CTLs	  exacerbate	  disease	  
and	   express	  decreased	   cytotoxic	   function	   (830-­‐836).	   In	   a	  murine	  model,	   the	  depletion	  of	  
CD8+	   T	   cells	   prior	   to	   the	   induction	   of	   allergen	   sensitisation	   and	   challenge	   resulted	   in	  
increased	  Th2	  responses	  and	  worsened	  allergic	  airway	  disease	  (222,	  733,	  837).	  The	  work	  
of	   Laprise	   and	   colleagues	   (711,	   838,	   839)	   shed	   light	   on	   some	   particularly	   interesting	  
evidence	  of	  a	  potential	  role	  for	  CD8+	  T	  cells	  in	  preventing	  the	  progression	  of	  asymptomatic	  
AHR	  to	  symptomatic	  asthmatic	  disease.	  It	  is	  known	  that	  individuals	  who	  suffer	  from	  atopy	  –	  
the	  genetic	  predisposition	  to	  mount	  mucosal	  IgE	  responses	  –	  often	  develop	  asymptomatic	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AHR,	  which	   later	   develops	   into	   allergic	   asthma,	   although	   it	   is	   not	   clear	   how	   or	  why	   this	  
progression	   of	   disease	   occurs	   (6,	   840).	   Laprise	   and	   colleagues	   followed	   a	   number	   of	  
individuals	  presenting	  with	  asymptomatic	  AHR,	  and	  over	  a	  2	  year	  period	  a	  number	  of	  those	  
subjects	   had	   developed	   asthma	   symptoms.	   It	   was	   discovered	   that	   the	   progression	   to	  
asthma	   was	   associated	   with	   a	   decrease	   in	   bronchial	   CD8+	   T	   cells,	   with	   a	   concomitant	  
increase	   in	   CD4+	   T	   cells	   and	   subepithelial	   fibrosis	   (542,	   711).	   This	   finding	   reveals	   a	  
potential	  protective	  role	  for	  CD8+	  T	  cells	  in	  the	  progression	  of	  asthmatic	  disease.	  	  
	  
In	  this	  thesis,	  significant	  numbers	  of	  adoptively	  transferred	  CTLs	  were	  recovered	  from	  the	  
lung	  tissue,	  and	  where	  enumerated,	  these	  represented	  a	  larger	  infiltrating	  population	  than	  
the	   co-­‐transferred	   CD4+	   T	   cells.	   This	   correlates	   with	   the	   findings	   of	   others	   that	   have	  
described	  a	  greater	  CD8:CD4	  T	  cell	  ratio	  being	  associated	  with	  decreased	  severity	  of	  disease	  
(711,	  730,	  733,	  841-­‐843).	   It	   is	  possible,	  however,	   that	   the	   severity	  of	  disease	  may	  not	  be	  
fully	  predicted	   through	   the	   enumeration	  of	   these	   cell	   populations	  by	   the	  method	  used	   in	  
this	  study.	  Recent	  studies	  have	  utilised	  an	  intravascular	  staining	  technique	  (831,	  833,	  835,	  
836,	   844)	   to	   investigate	   the	   localisation	   of	   CD8+	   T	   cells	   in	   the	   lung	   during	   an	   antiviral	  
response.	   Strikingly,	   it	   was	   discovered	   that	   a	   large	   majority	   of	   the	   cells	   thought	   to	   be	  
located	  within	  the	   lung	  tissue-­‐	  which	  had	  been	  perfused	  and	  digested-­‐	  were	   in	   fact	   in	   the	  
pulmonary	  vasculature	  (845-­‐847).	  It	  may	  therefore	  not	  be	  possible	  to	  use	  this	  measure	  as	  
an	   indicator	   of	   protective	   immunity,	   or	   in	   the	   case	   of	   experimental	   allergic	   airway	  
inflammation,	   that	  higher	  numbers	  of	  CD8+	  T	  cells	   in	  digested	  whole	   lung	  tissue	  may	  not	  
represent	   an	   established	   lung-­‐resident	   population.	   It	   has	   not	   yet	   been	   thoroughly	  
investigated,	  however,	  whether	  this	  massive	  population	  of	  cells	  in	  the	  lung	  vasculature	  are	  
in	   fact	   significant	   participants	   in	   local	   immune	   responses	   in	   the	   lung.	   Indeed,	   their	  
proximity	  to	  the	  airway	  may	  enable	  rapid	  activation	  and	  migration	  into	  the	  lung	  tissue	  upon	  
sensing	  of	  chemotactic	  signals.	  The	  work	  of	  others	  also	  revealed	  that	  lymphocyte	  isolation	  
carried	  out	  by	  flow	  cytometric	  analysis	  of	  nonlymphoid	  tissues	  may	  fail	  to	  recover	  a	  large	  
proportion	   of	   the	   cells	   actually	   present	   in	   tissue,	   and	   particular	   subsets	   may	   be	   more	  
frequently	   recovered	   (848).	   These	   revelations	   suggest	   the	   re-­‐evaluation	   of	   how	   cell	  
populations	   are	   isolated,	   identified,	   and	   enumerated	   from	   tissue	   samples	   and	   what	  
conclusions	   may	   therefore	   be	   drawn.	   While	   these	   factors	   were	   not	   investigated	   in	   the	  
current	  study,	  it	  was	  recurrently	  demonstrated	  herein	  that	  the	  enumeration	  of	  CD4+	  T	  cells	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in	   whole	   digested	   lung	   tissue	   accurately	   correlated	   with	   therapeutic	   success	   of	   CTL	  
immunotherapy.	  	  
	  
Together,	   the	   evidence	   from	   this	   study	   and	   the	   related	  work	   of	   other	   authors	   discussed	  
herein	   suggest	   that	   CD8+	   T	   cells	   regulate	   immune	   responses	   and	   may	   be	   beneficial	   to	  
counteracting	   Th2	   immunity.	   Additionally,	   that	   CTLs	   are	   capable	   of	   suppressing	   airway	  
inflammation	   in	   a	   perforin-­‐dependent	   manner,	   and	   eliminating	   DCs	   in	   vivo-­‐	   which	   are	  





6.1.3 Allergen-specific CTLs have therapeutic effects on established 
airway inflammation 
	  
In	   a	  multiple	   allergen	   challenge	  model,	   allergen-­‐specific	  CTLs	  were	   shown	   to	  be	   effective	  
long	  term	  in	  the	  prevention	  of	  allergic	  airway	   inflammation	  throughout	  repeated	  allergen	  
exposure.	   Additionally,	   the	   characteristic	   features	   of	   disease	   were	   abrogated	  when	   CTLs	  
were	   administered	   during	   established	   airway	   inflammation.	   These	   findings	   revealed	   the	  
exciting	   prospect	   that	   CTL	   immunotherapy	   may	   be	   developed	   for	   the	   treatment	   of	  
persistent	  airway	  inflammation,	  presenting	  in	  the	  clinic	  as	  established	  disease.	  	  	  
	  
It	   was	   not	   investigated	   in	   this	   study,	   however,	   how	   CTLs	   may	   affect	   immunological	  
allergen-­‐specific	   memory.	   Through	   allergen	   sensitisation,	   central	   and	   effector	   memory	  
populations	  of	  CD4+	  T	  cells	  are	  generated,	  residing	  in	  lymph	  nodes	  and	  peripheral	  tissues	  
such	   as	   the	   lungs	   (274-­‐276).	   In	   the	  mechanism	   of	   suppression	   elucidated	   by	   this	   study,	  
CTLs	  target	  allergen-­‐presenting	  DCs	  to	  reduce	  the	  stimulation	  of	  CD4+	  Th2	  cell	  responses.	  
This	   was	   not	   only	   found	   to	   be	   effective	   during	   acute	   primary	   challenge,	   but	   also	   in	   a	  
multiple	  challenge	  model	  where	  established	  memory	  T	  cell	  populations	  would	  be	  expected	  
to	   predominate	   the	   rapid	   response	   to	   allergen	   exposure	   (669).	   Indeed,	   as	   both	   models	  
involved	   the	   treatment	   of	  mice	   that	  were	   already	   sensitised	   to	   allergen,	  memory	   T	   cells	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were	  presumably	  present	  before	  CTLs	  were	  administered	  in	  all	  of	  these	  in	  vivo	  sensitisation	  
experiments.	  The	  numbers	  of	  CD4+	  T	  cells	  infiltrating	  the	  airway	  as	  measured	  by	  BAL	  and	  
lung	  harvesting,	  or	   those	  present	   in	  the	   lung-­‐draining	   lymph	  node,	  were	  examined	   in	  this	  
study	  after	  allergen	  challenge.	  It	  was	  consistently	  found	  that	  CD4+	  T	  cells	  were	  fewer	  in	  the	  
lungs	   and	   BAL	   fluid	   of	   CTL-­‐treated	  mice.	   It	   was	   not	   determined,	   however,	   the	   extent	   to	  
which	   memory	   CD4+	   T	   cell	   populations	   remained	   after	   the	   contraction	   of	   the	   allergen-­‐
induced	   responses,	   neither	   were	   memory	   CD8+	   T	   cell	   populations	   directly	   examined	   in	  
tissue.	   Elucidation	   of	   these	   factors	  may	   be	   important	   for	   the	   development	   of	   therapeutic	  
interventions,	   as	   this	   will	   give	   some	   indication	   of	   the	   longevity	   of	   vaccine	   efficacy.	  
Nevertheless,	   it	  was	   apparent	   from	   this	   study	   that	   a	   single	   dose	   of	   CTLs	  was	   effective	   at	  
suppressing	   allergic	   inflammation	   over	   multiple	   allergen	   challenges,	   suggesting	   that	   the	  
effect	  of	  CTLs	  was	  long-­‐lived.	  	  
	  
It	  would	  be	  interesting	  to	  discover	  whether	  the	  long-­‐term	  efficacy	  of	  CTL	  therapy	  was	  due	  
to	  the	  persistence	  of	  memory	  CTLs	  throughout	  these	  experiments,	  or	  whether	  their	  initial	  
effector	  function	  was	  sufficient	  to	  prevent	  further	  allergic	  episodes.	  It	  is	  feasible	  that	  CTLs	  
generated	   in	   response	   to	   allergic	   stimuli	   may	   reside	   in	   the	   tissue	   long-­‐term	   and	   upon	  
exposure	   to	   allergen	   at	   some	   later	   time,	   become	   reactivated	   and	  mediate	   suppression	   of	  
allergy.	  It	  is	  known	  that,	  following	  the	  resolution	  of	  viral	  infection,	  antigen-­‐specific	  memory	  
CTL	   persist	   in	   the	   lung	   tissue,	   the	   memory	   pool	   being	   maintained	   by	   two	   distinct	  
populations:	   a	   large	   minimally-­‐dividing	   population	   deposited	   in	   the	   airways	   during	   the	  
acute	   anti-­‐viral	   response,	   and	   a	   second	   smaller	   population	  maintained	   in	   the	   airways	   by	  
homeostatic	  proliferation	  (846,	  849,	  850).	  This	  second	  population	  was	  initially	  thought	  to	  
derive	   from	   lymphoid	   tissue	   (850),	   however	   it	   was	   recently	   reported	   that	   specialised	  
niches	   exist	   in	   the	   lung	  where	  memory	   cells	   are	   generated	   and	  maintained	   (851).	   In	   the	  
absence	  of	  on-­‐going	  antigenic	  stimulation,	  these	  lung-­‐resident	  memory	  CTL	  down-­‐regulate	  
cytolytic	   molecule	   transcription,	   despite	  maintaining	   an	   activated	   phenotype	   (849,	   852),	  
and	  upon	  exposure	  to	  their	  cognate	  antigen,	  clonal	  expansion	  is	  triggered	  (853).	  In	  contrast,	  
CD4+	  T	  cell	  memory	  was	  initially	  reported	  to	  wane	  in	  the	  absence	  of	  antigenic	  stimulation	  
(289),	   although	   other	   authors	   have	   since	   shown	   that	   mice	   exposed	   to	   an	   allergen	  
sensitisation	   and	   challenge	   protocol,	   and	   subsequently	   rested,	   are	   capable	   of	   mounting	  
allergic	   responses	   upon	   re-­‐exposure	   to	   allergen	   some	   time	   later	   (669).	   It	   is	   not	   known,	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however,	  whether	  this	  is	  in	  fact	  due	  to	  the	  persistence	  of	  memory	  CD4+	  T	  cells,	  as	  of	  course	  
long-­‐lived	  memory	  B	  cells	  and	  plasma	  cells	  producing	  allergen-­‐specific	  IgE	  contribute	  to	  on-­‐
going	  allergy.	   In	   the	  clinical	  context,	   the	  persistence	  of	  allergy	   is	  somewhat	  dependent	  on	  
the	  allergen,	  and	  severity	  of	  allergic	  responses;	  up	  to	  85%	  of	  infants	  with	  milk	  or	  egg	  allergy	  
have	  been	   reported	   to	   tolerate	   these	  allergens	  by	  age	  3	  or	  5,	   respectively	   (707-­‐709,	  793,	  
794,	  848),	  whereas	  only	  10-­‐20%	  of	  peanut	  allergic	  children	  lose	  their	  sensitivity	  over	  time	  
(274-­‐276,	  650,	  651,	  795,	  796).	   Individuals	  with	  severe	  allergy,	  especially	   those	  who	  have	  
experienced	   anaphylaxis,	   may	   rigorously	   avoid	   exposure	   to	   the	   allergen	   for	   many	   years	  
before	  suffering	  another	  episode	  some	  time	  later.	  Human	  CD4+	  memory	  T	  cells,	   including	  
CD45RO+CCD7+CD62L+	   central	   memory	   and	   CD45RO+CCR7-­‐CD62L+/-­‐	   effector	   memory	  
subsets	  have	  been	  identified	  (274,	  611,	  612,	  669),	  and	  Th2	  memory	  cells	  have	  additionally	  
been	  described;	  expressing	  the	  prostaglandin	  D2	  receptor	  (CRTH2),	  and	  of	  a	  characteristic	  
phenotype,	   gene	   expression	  profile,	   cytokine	  production,	   and	   response	   to	   allergens	   (467,	  
797,	   798,	   846,	   849,	   850).	   Interestingly,	   the	   central	   memory	   Th2	   subset	   were	   found	   to	  
undergo	  substantial	  expansion	  only	  in	  response	  to	  TSLP-­‐activated	  DCs,	  and	  are	  thought	  to	  
be	  maintained	   through	   their	   association	  with	   these	  DCs	   (674,	   799,	   800,	   850).	  While	   this	  
evidence	  exists	  to	  suggest	  that	  Th2	  memory	  may	  persist	  in	  humans,	  it	  is	  difficult	  to	  isolate	  
and	  identify	  allergen-­‐specific	  T	  cells	  from	  patients,	  and	  it	  is	  therefore	  not	  known	  how	  long	  
these	   populations	   may	   survive	   and	   whether	   their	   depletion	   would	   resolve	   allergy.	   If	  
allergy-­‐driving	  memory	   CD4+	  T	   cells	   do	   in	   fact	   decline	   in	   number	   due	   to	   lack	   of	   antigen	  
presentation,	   and	   this	   is	   sufficient	   to	   diminish	   the	   effects	   of	   long-­‐lived	   IgE-­‐producing	  
plasma	   cells,	   this	   could	   potentially	   mean	   that	   the	   continued	   suppressive	   function	   of	  
allergen-­‐specific	   memory	   CTLs	   may	   effectively	   out-­‐live	   CD4+	   T	   cell	   memory,	   as	   well	   as	  
prevent	  the	  expansion	  of	  CD4+	  T	  cells	  in	  response	  to	  allergens.	  Alternatively,	  as	  it	  appears	  
that	  specific	  DCs	  are	  required	  for	  the	  maintenance	  of	  memory	  Th2	  cells	  (799,	  801,	  851),	  it	  is	  
possible	  that	  the	  CTL-­‐mediated	  targeting	  of	  allergen-­‐presenting	  DC	  may	  therefore	  diminish	  
the	  stimuli	  required	  for	  the	  persistence	  of	  the	  memory	  Th2	  population.	  	  	  
	  
In	   the	  experiments	  described	   in	  Chapters	  3	  and	  5	  of	   this	   thesis,	   allergen-­‐specific	   IgE	  was	  
generated	  in	  response	  to	  i.p.	  sensitisation	  alone,	  and	  was	  detected	  in	  both	  CTL-­‐treated	  and	  
–untreated	   mice	   at	   the	   experimental	   end	   point,	   despite	   resolution	   of	   the	   characteristic	  
features	   of	   allergic	   airway	   inflammation	   in	  mice	   that	   received	  CTLs	   or	   peptide	   conjugate	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drugs.	   During	   the	   sensitisation	   process,	   IgE-­‐producing	   allergen-­‐specific	   B	   cells	   are	  
generated,	  through	  CD40/CD40L	  interactions	  with	  CD4+	  T	  cells	  and	  in	  the	  presence	  of	  IL-­‐4	  
(475,	   476,	   709,	   747,	   802,	   803,	   849,	   852).	   It	   has	   also	   been	   reported	   that	   the	  majority	   of	  
secondary	  IgE	  responses	  require	  IL-­‐4	  stimulation,	  although	  this	  is	  not	  always	  the	  case	  (675,	  
804-­‐806,	  853).	  After	  CTL	  treatment,	  these	  stimuli	  for	  IgE	  production	  are	  diminished,	  as	  DC-­‐
targeting	  leads	  to	  a	  reduction	  in	  CD4+	  Th2	  cell	  numbers	  and	  cytokine	  production.	  As	  such,	  it	  
is	  unclear	  why	  IgE	  persisted	  throughout	  experiments.	  	  
	  
Some	   recent	   papers	   have	   focussed	   on	   determining	   the	   factors	   that	   drive	   IgE+	   B	   cell	  
generation,	   and	  how	   these	   cells	  may	  derive	   from	  both	  T	   cell-­‐dependent	  and	   independent	  
pathways	   (289,	   807-­‐811).	   Indeed,	   human	   patients	   that	   are	   deficient	   in	   CD40L	   do	   in	   fact	  
produce	   IgE+	   B	   cells	   (669,	   807,	   808),	   although	   it	   is	   not	   known	  whether	   the	   pathway	   by	  
which	   these	   cells	   are	   generated	   may	   be	   normally	   activated	   in	   immunocompetent	  
individuals.	  Other	  authors	  have	  found	  that	  the	  blocking	  of	  inducible	  T	  cell	   tyrosine	  kinase	  
(ITK),	   a	   critical	   regulator	   of	   Th2	   cytokine	   production,	   was	   sufficient	   to	   suppress	   allergic	  
airway	   inflammation	  without	  affecting	   the	  generation	  of	   IgE	  (811,	  812).	  Further	  evidence	  
has	   revealed	   that	   ILC2	  are	  able	   to	  enhance	   IgE	  production	   from	  B	  cells	  despite	  not	  being	  
able	   to	   produce	   IL-­‐4	   (808,	   813).	   The	   mechanism	   of	   this	   is	   unclear,	   although	   Magri	   and	  
colleagues	   determined	   that	   this	  may	   involve	   the	   promotion	   of	   CD40/CD40L	   interactions	  
between	  lymph	  node	  marginal	  reticular	  cells	  and	  B	  cells	  (635,	  814).	  While	  it	  is	  evident	  that,	  
in	  the	  experiments	  in	  this	  thesis,	  the	  inflammatory	  manifestations	  of	  disease	  in	  the	  allergic	  
airway	   are	   diminished	   by	   CTL	   immunotherapy	   regardless	   of	   the	   presence	   of	   allergen-­‐
specific	   IgE,	   it	   would	   be	   important	   to	   determine	   whether	   the	   generation	   of	   IgE	   was	  
persistent	  despite	  CTL	  treatment,	  which	  may	  have	  implications	  for	  on-­‐going	  success	  of	  the	  
clinical	   treatment	   of	   allergic	   disease.	   This	   question	   could	   be	   addressed	  by	   carrying	   out	   a	  
long-­‐term	   experiment	   where	   sensitised/challenged	   mice	   are	   rested	   before	   the	   re-­‐
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6.2 Importance of findings in the understanding of allergy  
 
CD11b+ DC present allergens to CD8+ T cells 
An	   interesting	  discovery	   in	   the	   study	   conducted	  herein	  was	   that	  of	   the	   interaction	  of	   the	  
major	   lung	  DC	   populations	  with	   CD4+	   and	   CD8+	  T	   cells.	   There	   is	  widespread	   agreement	  
that	   CD11b+	   DC	   are	   specialised	   in	   the	   presentation	   of	   antigen	   to	   CD4+	   T	   cells,	   while	  
CD103+	  DC	  specialise	   in	  cross-­‐presentation,	  effectively	  stimulating	  CD8+	  T	  cell	   responses	  
(73,	  123,	  126,	  322,	  324,	  755,	  756,	  771-­‐773,	  815).	  While	   this	   is	  not	  untrue,	   the	   findings	  of	  
this	  thesis	  gave	  weight	  to	  the	  importance	  of	  CD11b+	  DC	  cross-­‐presentation	  in	  the	  lung;	  an	  
interaction	   that	   can	   result	   in	   these	   critical	   allergy-­‐driving	  DCs	   being	   eliminated	   by	   CTLs.	  
Desch	  and	  colleagues	  have	  very	  recently	  shown	  that	  antigen-­‐specific	  CTLs	  may	  be	  induced	  
by	   CD11b+	   DC	   upon	   TLR7	   ligation	   (764,	   816);	   the	   natural	   ligands	   of	   which	   are	   single-­‐
stranded	   RNAs,	   from	   viruses	   such	   as	   influenza,	   Sendai	   and	   Coxsackie	   virus	   (817-­‐824).	  
Together	   these	   findings	   have	   expanded	   our	   understanding	   of	   the	   ability	   of	   specific	   DC	  
subsets	   to	   stimulate	   T	   cell	   responses.	   It	   would	   be	   interesting,	   however,	   to	   investigate	  
whether	   there	   is	  any	  effect	  of	   the	  concentration	  or	  nature	  of	   the	  antigen	  administered	  on	  
the	  occurrence	  of	  CD11b+	  DC	  cross-­‐presentation,	  as	  these	  factors	  were	  not	  determined	  in	  
the	  present	  study.	  	  
	  
	  
The same DCs present allergen to both CD4+ and CD8+ T cells 
If	  DC	  specialisation	  translates	  to	  strict	  antigen	  presentation	  patterns	  this	  logically	  extends	  
to	   the	   assumption	   that	   different	  DC	   are	   likely	   to	   be	   presenting	   allergens	   to	   CD4+	  T	   cells	  
from	  those	  cross-­‐presenting	  to	  CD8+	  T	  cells.	  However,	  the	  implication	  of	  the	  findings	  in	  the	  
present	   study	   is	   rather	   that	   the	   same	  DCs	  must	   predominantly	   be	   presenting	   antigen	   to	  
both	   CD4+	   and	   CD8+	   T	   cells,	   as	   the	   CTL-­‐mediated	   targeting	   of	   DCs	   resulted	   in	   apparent	  
reduced	   antigen	   presentation	   to	   CD4+	   T	   cells.	   This	   also	   appeared	   to	   be	   confirmed	   by	  
fluorescent	  visualisation	  of	  DC-­‐T	  cell	  interactions	  in	  the	  lung.	  These	  findings	  agree	  with	  the	  
postulations	  of	  Enomoto	  and	  colleagues	  (226,	  752).	  	  
	  
	  




CD103+ DC form clusters with DCs and T cells during allergic inflammation 
Recognised	  for	  their	  role	   in	  the	  cross-­‐presentation	  of	  antigens	  and	  migratory	  transport	  of	  
antigens	  from	  the	  lung	  to	  the	  draining	  lymph	  nodes,	  surprisingly	  little	  is	  known	  about	  the	  
localisation	  of	  CD103+	  DCs	  in	  the	  lung.	  One	  group	  reported	  that	  these	  DCs	  predominantly	  
reside	  within	   the	   airway	  mucosa	   and	   arteriole	  walls	   in	   the	   steady	   state	   (320,	   754).	   The	  
finding	  in	  this	  thesis	  that	  during	  allergy,	  CD103+	  DCs	  re-­‐localise	  into	  cluster	  formation	  with	  
other	  DCs	  as	  well	  as	  CD4+	  and	  CD8+	  T	  cells,	  implies	  a	  more	  complex	  role	  for	  these	  DC	  than	  
was	   previously	   recognised.	   A	   similar	   clustering	   phenomenon	   was	   recently	   described	  
between	  CD11b+	  DC	  and	  CD4+	  T	  cells	  in	  the	  lung	  (494,	  757,	  825,	  826)	  and	  between	  CD11c+	  
DC	  and	  T	  cells	  (CD3+,	  not	  subtyped)	  in	  the	  skin	  (255,	  258,	  765)	  suggesting	  the	  importance	  
of	   this	   clustering	   phenomenon	   in	   local	   immunity	   may	   be	   conserved	   across	   tissues.	   The	  
significance	  of	  DC:T	  cell	  clustering	  is	  yet	  to	  be	  fully	  determined,	  however,	  this	  environment	  
may	   facilitate	  more	   efficient	   antigen	   transfer	   between	   APCs	   and	   antigen	   presentation	   to	  
numerous	  T	  cell	  populations	  within	   the	   local	   tissue.	   It	  would	  be	   interesting	   to	   investigate	  
the	   requirements	   for	   cluster	   formation,	   and	  whether	   the	  disruption	  of	   clusters	   leads	   to	   a	  
reduction	   in	   T	   cell	   stimulation,	   which	   may	   be	   beneficial	   in	   particular	   contexts.	   	   Indeed,	  
Natsuaki	   and	   colleagues	   report	   that	   cluster	   formation	  was	   essential	   for	   driving	   acquired	  
cutaneous	  immunity	  (765,	  827-­‐829).	  	  	  
	  
CTLs target allergen-presenting DCs to suppress allergic airway inflammation 
The	  mechanisms	  by	  which	  CTLs	  may	  suppress	  allergic	  disease	  are	  not	  fully	  resolved	  in	  the	  
published	   literature.	   It	   has	   been	   reported	   that	   CTLs	   are	   capable	   of	   killing	   antigen-­‐
presenting	  DCs	  in	  vivo	  (755,	  757,	  770,	  825,	  826),	  and	  that	  this	  may	  affect	  the	  proliferation	  of	  
CD4+	  and	  CD8+	  T	  cells	  (711,	  773,	  816).	  The	  effect	  this	  may	  have	  in	  the	  context	  of	  CD4+	  T	  
cell-­‐mediated	  diseases	  was	  not	  ascertained,	  nevertheless,	  these	  findings	  show	  that	  CTLs	  are	  
capable	  of	  directly	  targeting	  DCs.	  Investigations	  in	  this	  thesis	  provided	  evidence	  that	  CTLs	  
do	   in	   fact	   target	  and	  kill	  critical	  allergen-­‐presenting	  DC	  populations	   in	  a	  model	  of	  allergic	  
airway	   inflammation,	  and	  that	   this	   leads	  to	   the	  suppression	  of	  disease.	  The	  consequential	  
effects	   on	   CD4+	   T	   cells	   were	   also	   characterised	   as	   previously	   discussed,	   especially	  
concerning	  the	  reduced	  frequency	  and	  cytokine	  production	  of	  Th2	  cells.	  Collectively,	  these	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data	  reveal	  a	  potential	  role	  for	  CD8+	  T	  cells	  in	  limiting	  allergic	  disease	  and	  further	  elucidate	  
the	  way	  in	  which	  DC/CD4+	  T	  cell	  interactions	  may	  be	  modified.	  	  	  
	  
6.3 Implications for clinical immunotherapy 
	  
The	  findings	  in	  this	  study	  have	  shown	  the	  efficacy	  of	  allergen-­‐specific	  CTLs	  in	  the	  treatment	  
of	  established	  allergic	  airway	   inflammation	   in	  the	  mouse.	  This	  highlights	  the	  potential	   for	  
development	   of	   a	   therapeutic	   vaccine	   to	   translate	   these	   results	   into	   the	   clinic.	   Indeed,	   a	  
collaboration	   between	   the	   Malaghan	   Institute	   of	   Medical	   Research	   and	   Callaghan	  
Innovation	  has	  begun	  developing	  such	  a	  vaccine,	  as	  described	  in	  Chapter	  5	  of	  this	  thesis,	  to	  
elicit	  an	  endogenous	  CTL-­‐mediated	  response.	  	  
	  
The	   CTL-­‐mediated	   immunotherapy	   described	   in	   this	   thesis	   involves	   the	   targeting	   and	  
killing	  of	  allergen-­‐presenting	  DCs.	  An	  important	   issue	  to	  consider	  for	  clinical	  treatment	  of	  
disease,	  then,	  is	  whether	  the	  depletion	  of	  these	  DCs	  results	  in	  a	  reduction	  of	  necessary	  DC-­‐
driven	   immune	   responses;	   that	   is,	   would	   vaccine-­‐treated	   individuals	   become	   more	  
susceptible	  to	  respiratory	  infections?	  This	  question	  has	  been	  considered	  through	  the	  course	  
of	  these	  studies,	  although	  not	  yet	  fully	  addressed.	  A	  colleague	  in	  our	  lab	  group	  has,	  however,	  
carried	   out	   preliminary	  work	   to	   compare	  CTL	   immunotherapy	  with	   a	   currently	   available	  
treatment	  for	  allergic	  exacerbations	  of	  disease,	  dexamethasone,	  in	  terms	  of	  effects	  on	  DCs.	  
It	   was	   found	   that	   dexamethasone	   severely	   ablated	   DC	   populations	   in	   the	   lung-­‐draining	  
lymph	  node,	  while	  CTL	   immunotherapy	  was	  significantly	   less	   immune	  suppressive	   in	   this	  
regard	   (E	  Hyde,	  manuscript	   in	  preparation	  by	  Daniels	  et	  al.).	   Therefore,	   the	   specificity	  of	  
CTL	   immunotherapy	   could	   lead	   to	   significantly	   improved	   outcomes	   for	   individuals	   who	  
suffer	  from	  allergic	  asthma,	  compared	  to	  corticosteroid	  regimes.	  	  
	  
As	  memory	  responses	  were	  not	  examined	  in	  this	  thesis,	  it	  is	  not	  known	  what	  the	  long-­‐term	  
efficacy	  of	  CTL	  immunotherapy	  may	  be	  in	  terms	  of	  treating	  human	  disease.	  Specifically,	  it	  is	  
not	   know	   if	   allergen-­‐specific	   CTLs	   need	   to	   persist	   in	   the	   tissue	   to	   facilitate	   continued	  
suppression	  of	  allergic	  responses	  in	  the	  airway,	  or	  whether	  allergy	  may	  be	  overcome.	  The	  
persistent	   antigenic	   stimulation	  of	  CD8+	  T	   cells,	   such	  as	   that	   encountered	  during	   chronic	  
viral	   infection,	   has	   been	   shown	   to	   result	   in	   the	  progressive	   loss	   of	   effector	   function	   over	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time	   (830-­‐836),	   so	   it	   is	   possible	   that	   frequent	   assault	   by	   commonly	   encountered	  
environmental	  allergens	  may	  cause	  waning	  of	  the	  efficacy	  of	  CTL	  responsiveness	  over	  time.	  
As	  such,	  treatment	  to	  counteract	  T	  cell	  exhaustion	  may	  be	  required	  to	  maintain	  a	  protective	  
response.	  	  
	  
For	  established	  chronic	  disease	  such	  as	  asthma,	  extensive	  airway	  remodelling	  and	  fibrosis	  
permanently	   scar	   the	   lung	   tissue	   and	   there	   has	   yet	   to	   be	   an	   agent	   developed	   that	   can	  
stimulate	   the	   repair	   of	   this	   damage.	   CTL	   immunotherapy	   does	   not	   appear	   to	   reverse	  
extensive	  lung	  fibrosis	  either,	  however,	  the	  suppression	  of	  allergic	  responses	  in	  the	  airway	  
was	   shown	   to	   prevent	   the	   worsening	   of	   histopathology.	   As	   such,	   treatment	   would	   be	  
expected	   to	   benefit	   individuals	  with	  well	   established	   asthma	   through	   the	   suppression	   of	  
allergic	  exacerbations	  of	  disease,	  “asthma	  attacks”,	  and	  may	  be	  able	  to	  halt	  the	  progression	  
of	   lung	  injury,	  resulting	  in	  an	  improved	  quality	  of	   life.	  In	  patients	  with	  recently	  diagnosed	  
allergic	   asthma,	   lung	  pathology	  may	  not	  be	  well	   established,	   and	  as	   such,	   treatment	  with	  
CTL	   immunotherapy	   to	   prevent	   further	   allergic	   exacerbations	   may	   result	   in	   the	  
maintenance	  of	  healthy	  airways.	  The	  beneficial	  effect	  of	  earlier	  treatment	  of	  disease	  is	  thus	  
implicated.	  	  
	  
As	  CTL	  immunotherapy	  essentially	  targets	  the	  allergic	  response	  elicited	  in	  the	  airway	  that	  
drives	   atopic	   asthma,	   it	   is	   not	   likely	   to	   be	   of	   benefit	   to	   individuals	  who	   suffer	   from	  non-­‐
atopic	   (intrinsic)	   asthma.	   However,	   there	   may	   be	   therapeutic	   potential	   for	   CTLs	   in	   the	  
treatment	   of	   allergy	   at	   sites	   other	   than	   the	   lung,	   such	   as	   atopic	   diseases	   of	   the	   skin	   and	  
gastrointestinal	   tract.	   Therefore,	   CTL	   immunotherapy	   may	   in	   theory	   be	   more	   widely	  
applicable	   in	   the	   treatment	  of	   allergy.	   Investigation	  of	   the	   effects	   of	   allergen-­‐specific	  CTL	  
immunotherapy	  in	  experimental	  models	  of	  food	  allergy	  and	  atopic	  dermatitis	  may	  address	  
this.	  	  
	  
A	  final	  consideration	  for	  the	  application	  of	  these	  results	  to	  human	  disease	  is	  the	  disparity	  
between	  the	  characteristics	  of	  allergic	  asthma,	  or	  in	  fact	  any	  disease,	  in	  humans	  from	  that	  
which	  may	  be	  modelled	   in	  mice.	   Importantly,	  mice	  do	  not	  spontaneously	  develop	  asthma,	  
and	   while	   repeated	   stimulation	   may	   mimic	   the	   pathology	   of	   chronic	   inflammation,	   the	  
chronic	  disease	  in	  mice	  may	  still	  lack	  some	  key	  features	  of	  that	  in	  humans,	  outlined	  herein.	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An	  intrinsic	  predisposition	  to	  AHR	  in	  response	  to	  spasmogens,	  such	  as	  methacholine,	  may	  
be	  present	  in	  some	  human	  individuals,	  and	  could	  be	  inherited	  (222,	  733,	  837).	  In	  contrast,	  
this	  has	  not	  been	  demonstrated	   in	   the	  majority	  of	   commonly	  used	  mice	  strains;	  A/J	  mice	  
being	  the	  only	  exception	  (711,	  838,	  839).	  Also	  unique	  to	  humans	  is	  the	  presence	  of	  smooth	  
muscle	   in	   both	   large	   and	   smaller	   airways	   (versus	   large	   airways	   only	   in	   mice)	   (6,	   840),	  
which	  results	  in	  more	  extensive	  AHR.	  The	  involvement	  of	  smooth	  muscle-­‐infiltrating	  mast	  
cells	  in	  exacerbations	  of	  disease	  has	  also	  only	  been	  demonstrated	  in	  humans	  (542,	  711).	  It	  
is	   also	   becoming	   evident	   that	   the	   interplay	   between	   the	   recently	   discovered	   lung	  
microbiome	   and	   the	   immune	   system	   may	   affect	   the	   development	   and	   progression	   of	  
allergic	  asthma	  (711,	  730,	  733,	  841-­‐843);	  variation	  in	  human	  and	  murine	  lung	  colonisation,	  
and	  between	  mouse	  strains,	  may	  thus	  reflect	  differences	  in	  susceptibility	  to	  disease.	  It	  has	  
also	   been	   discovered	   that	   in	   asthmatic	   patients	   allergen-­‐specific	   CD8+	   T	   cells	   are	  
predominantly	   of	   a	   Tc2	   phenotype,	   producing	   Th2	   cytokines,	   and	   additionally	   having	  
defective	   cytotoxic	   activity;	   due	   to	   the	   Tc2	   bias,	   clinical	   studies	   have	   often	   reported	   that	  
higher	   numbers	   of	   activated	   CD8+	   T	   cells	   in	   asthma	   patients	   correlates	   with	   disease	  
severity	   (831,	  833,	  835,	  836,	  844).	  The	   implication	   for	   treatment	   in	  humans,	   then,	  would	  
require	  a	  focus	  on	  the	  repolarisation	  of	  Tc2-­‐skewed	  CTLs	  to	  functionally	  effective	  allergy-­‐
suppressing	   cells.	   Collectively,	   these	   differences	   between	   human	   asthma	   and	   the	   allergic	  
airway	   inflammation	   that	   is	   modelled	   in	   mice	   suggest	   limitations	   when	   considering	  
whether	  therapies	  that	  are	  effective	  in	  mice	  may	  translate	  to	  clinical	  success.	  Nevertheless,	  
investigations	  carried	  out	  in	  mouse	  models	  have	  led	  to	  many	  significant	  discoveries	  in	  the	  
biology	   of	   allergy	   and	   asthma	   and	   remain	   an	   effective,	   and	   indeed	   necessary,	   tool	   for	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6.4 Summary and conclusions 
	  
The	  therapeutic	  effects	  of	  CTLs	  in	  this	  thesis	  were	  found	  to	  be	  mediated	  through	  the	  direct	  
targeting	  and	  killing	  of	  critical	  DC	  populations,	  as	  evidenced	  in	  a	  number	  of	  ways.	  CD103+	  
and	   CD11b+	   DCs	   were	   identified	   in	   the	   allergic	   lung,	   arranging	   into	   clusters	   where	  
interaction	   with	   CTLs	   and	   CD4+	   T	   cells	   was	   likely	   to	   occur.	   After	   allergen	   challenge,	   a	  
decrease	   in	  DC	  numbers	  was	  evident	   in	   the	   lungs	  of	  mice	   treated	  with	  perforin-­‐sufficient	  
but	  not	  perforin	  knock-­‐out	  CTLs,	  suggesting	  cell	  killing	  was	  involved.	  A	  subsequent	  increase	  
in	  pre-­‐apoptotic	  DCs	  expressing	  active	  caspases	  appeared	  in	  the	  lung-­‐draining	  lymph	  nodes.	  
The	  targeting	  of	  DCs	  was	  dependent	  on	  their	  ability	   to	  directly	   interact	  with	  CTL	  through	  
the	  presentation	  of	  antigen	  on	  MHC-­‐I,	  which	  was	  evident	  not	  only	  in	  the	  CD103+	  classical	  
cross-­‐presenting	  DCs,	  but	  also	  in	  the	  critical	  allergy-­‐driving	  CD11b+	  DCs.	  Subsequently,	  the	  
activation	  of	  CD4+	  Th2	  cells	  was	  reduced,	  resulting	   in	  decreased	  CD4+	  T	  cells	   in	   the	   lung	  
and	  a	  reduction	   in	  Th2	  cytokine	  production.	  This	   led	   to	  amelioration	  of	   the	  characteristic	  
features	  of	  allergic	  asthma	  in	  both	  preventative	  and	  therapeutic	  contexts.	  A	  novel	  vaccine	  
that	  elicits	  endogenous	  CTL-­‐mediated	  responses	  also	  achieved	  suppression	  of	  disease;	  this	  
may	  be	  developed	   for	   translation	   in	   the	  clinic.	  The	  CTL	   immunotherapy	  described	   in	   this	  
study	   was	   less	   immune	   suppressive	   than	   corticosteroid	   treatment,	   the	   current	   clinical	  
option	   for	   patients	   with	   allergic	   asthma.	   Finally,	   it	   appeared	   that	   some	   cross-­‐protection	  
may	   be	   conferred	   for	   individuals	   who	   are	   polysensitised,	   without	   the	   requirement	   for	  
treatment	  with	  CTLs	  of	  multiple	  allergen	  specificities,	  although	  this	  was	  not	  fully	  resolved.	  
Therefore,	  allergen-­‐specific	  CTL-­‐mediated	  immunotherapy	  represents	  a	  targeted	  treatment	  
for	   allergic	   asthma	   that	  may	   provide	   new	   hope	   in	   the	   fight	   against	   this	   highly	   prevalent	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6.5 Future directions 
	  
Further	   investigation	   is	   required	   to	   resolve	   some	  outstanding	  questions	   on	   the	   effects	   of	  
CTL	   immunotherapy	  on	   treated	   individuals,	   as	  well	   as	   the	  potential	   for	   translation	   to	   the	  
clinic.	  Several	  experiments	  to	  address	  these	  questions	  are	  briefly	  outlined	  below.	  
	  
How	  does	  CTL	  immunotherapy	  affect	  T	  cell	  memory?	  
In	  this	  study,	  the	  number,	  phenotype	  and	  effector	  function	  of	  T	  cells	  were	  examined	  in	  CTL-­‐
treated	  mice	  at	  the	  peak	  of	  the	  cellular	  response,	  3	  days	  after	  airway	  allergen	  challenge.	  To	  
assess	  memory	   responses,	   mice	   that	   have	   experienced	   allergic	   airway	   inflammation	   and	  
subsequent	  treatment	  with	  CTLs	  could	  be	  experimentally	  ‘rested’	  until	  airway	  inflammation	  
has	  fully	  resolved.	  At	  that	  time,	  a	  further	  airway	  challenge	  could	  be	  carried	  out	  to	  determine	  
whether	  CTLs	  were	  still	  capable	  of	  suppressing	  allergic	   inflammation,	  and	  lungs	  and	  MLN	  
harvested	  to	  identify	  and	  phenotype	  persisting	  allergen-­‐specific	  CD4+	  and	  CD8+	  T	  cells.	  	  	  
	  
Can	  CTL-­‐mediated	  killing	  of	  DCs	  be	  directly	  visualised	  in	  the	  lung?	  
The	  present	  study	  showed	  that	  DC-­‐CTL	  interactions	  in	  the	  lung	  were	  likely	  to	  result	  in	  the	  
initiation	   of	   apoptosis	   at	   this	   site;	   this	   was	   revealed	   in	   pre-­‐apoptotic	   migratory	   DCs	  
subsequently	   trafficking	   to	   the	   MLN.	   Unfortunately,	   due	   to	   the	   presence	   of	   highly	  
autofluorescent	  cells,	  it	  was	  difficult	  to	  conclusively	  identify	  fluorescently	  marked	  apoptotic	  
cells	   in	   the	   lung,	   as	   the	   autofluorescent	   cells	   could	   not	   be	   excluded	   as	   potential	   targets	  
themselves.	  The	  most	  direct	  way	   to	  address	   this	   could	  be	   through	   the	  use	  of	   two	  photon	  
microscopy;	   techniques	  have	   recently	  been	  developed	   for	   the	   live	   imaging	  of	   lungs	   (845-­‐
847),	  which	  may	  be	  useful	  to	  track	  CTL	  contacts	  in	  real-­‐time	  and	  observe	  those	  which	  result	  
in	   killing,	   again	   through	   the	   use	   of	   apoptosis-­‐induced	   fluorogenic	   substrates.	   Transfer	   of	  
fluorescent	  CTLs	  into	  mice	  with	  identifiable	  lung	  APC	  populations	  would	  be	  necessary.	  	  
	  
What	  are	  the	  effects	  of	  CTLs	  on	  innate	  lymphoid	  cells	  and	  the	  airway	  epithelium?	  	  
It	  would	  be	  interesting	  to	  investigate	  whether	  cytokines	  and	  chemokines	  produced	  by	  lung	  
epithelial	   cells	   and	   ILC2	   are	   diminished	   or	   altered	   as	   a	   result	   of	   effective	   CTL	  
immunotherapy.	   It	  would	  not	   be	   a	   straightforward	   task,	   however,	   to	   identify	   the	   specific	  
cellular	  source	  of	  important	  epithelial-­‐derived	  chemokines	  and	  cytokines	  such	  as	  IL-­‐25,	  IL-­‐
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33	   and	   TSLP	   which	   may	   also	   be	   produced	   by	   mast	   cells,	   basophils,	   eosinophils,	  
macrophages	  and	  DCs	   (as	  discussed	   in	  Chapter	  1	  –	  General	   Introduction).	   Similarly,	   ILC2	  
production	  of	  IL-­‐5	  and	  IL-­‐13	  are	  in	  common	  with	  Th2	  cytokines.	  As	  such,	  using	  fluorescent	  
reporter	  mice	  could	   reveal	   the	  cellular	   source	  of	   these	  mediators.	   Immunohistochemistry	  
or	  fluorescent	  labelling	  of	   lung	  sections	  could	  also	  be	  used	  to	  characterise	  surface	  marker	  
expression	   while	   flow	   cytometry	   or	   cell	   sorting	   may	   enable	   identification	   of	   cytokine-­‐
producing	  cells	  by	  intracellular	  staining.	  	  	  
	  
Is	  the	  ability	  to	  mount	  antiviral	  and	  antibacterial	  immune	  responses	  diminished	  in	  the	  
lungs	  after	  CTL	  treatment?	  
This	  question	  may	  be	  addressed	  by	  administering	  a	  viral	  or	  bacterial	  intranasal	  challenge	  to	  
mice	  after	   the	   treatment	  of	  established	  airway	   inflammation	  by	  CTL	   immunotherapy.	  The	  
infectivity	   and	   severity	   of	   disease	   resulting	   from	   exposure	   to	   an	   influenza	   virus	   or	  
pneumonia-­‐causing	  bacteria	  such	  as	  Streptococcus	  pneumoniae	  may	  be	  compared	  between	  
CTL-­‐treated	  allergic	  mice	  and	  non-­‐CTL-­‐treated	  allergic	  mice,	  as	  well	  as	  non-­‐allergic	  controls.	  
This	   may	   determine	   whether	   the	   depletion	   of	   DCs	   by	   CTL	   immunotherapy	   results	   in	  
reduced	  immunity	  to	  viral	  or	  bacterial	  infection.	  	  
	  
Is	  CTL	  immunotherapy	  effective	  in	  allergic	  disease	  of	  the	  gut	  and	  skin?	  
The	   anatomy	   and	   physiology	   of	   the	   gut,	   skin	   and	   lung	   are	   functionally	   specialised	   and	  
diverse	  resident	  and	  migratory	  immune	  cell	  populations	  are	  present	  within	  each	  tissue.	  As	  
such,	   it	   cannot	   be	   assumed	   that	   the	   allergy-­‐suppressing	   effect	   of	   CTLs	   on	   airway	  
inflammation	  may	   be	   directly	   replicated	   in	   the	   gut	   and	   skin.	   Appropriate	  models	   of	   food	  
allergy	  and	  atopic	  dermatitis	  may	  be	  used	  to	   test	   the	  efficacy	  of	  allergen-­‐specific	  CTLs	  on	  
allergic	  disease.	  	  
	  
Is	   clinical	   translation	   of	   CTL	   immunotherapy	   effective	   in	   patients	   suffering	   from	  
allergic	  asthma?	  
Asthma	  is	  a	  complex,	  chronic	  disease.	  As	  discussed	  earlier,	  the	  allergic	  airway	  inflammation	  
generated	  in	  mice	  through	  multiple	  allergen	  exposures	  does	  not	  fully	  replicate	  the	  human	  
asthmatic	  condition,	  and	  therefore	  it	  is	  unclear	  how	  effective	  targeting	  allergy	  in	  the	  airway	  
would	   be	   in	   the	   treatment	   of	   asthma.	   Upon	   resolution	   of	   outstanding	   immunological	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queries	  proposed	  herein,	  a	  therapy	  may	  be	  developed	  for	  testing	  in	  clinical	  trials.	  It	  would	  
need	   to	   be	   established	   whether	   an	   endogenous	   allergen-­‐specific	   CTL-­‐mediated	   response	  
may	  be	  elicited	   in	  patients	   in	  response	   to	   treatment,	  and	  whether	   this	   leads	   to	  successful	  
amelioration	   of	   asthmatic	   disease	   in	   terms	   of	   fewer	   episodes	   of	   exacerbations	   and	  
improved	  lung	  function.	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A   Distribution of cell frequencies in tissue samples 
 
 




Figure	   A.1:	   Cell	   frequencies	   and	   cytokine	   concentration	   in	   BAL	   and	   lung	   are	  
consistent	  with	  Gaussian	  distribution	   	  	  
The	   D’Agostino-­‐Pearson	   omnibus	   K2	   test	   for	   normality	   was	   performed,	   with	   p	   values	  
reported	  at	   the	  top	  of	  each	  dataset.	  p	  >	  0.05	   is	  considered	  to	  be	  consistent	  with	  Gaussian	  
distribution.	   Graphs	   show	  mean	   +	   SD	   of	   cell	   number	   or	   cytokine	   concentration	   and	   are	  
pooled	  from	  2-­‐3	  experiments	  with	  3-­‐5	  mice	  per	  group.	  (A,B,C)	  Mice	  were	  treated	  as	  in	  Fig	  
3.5:	  sensitised	  by	  i.p.	  injection	  of	  OVA	  in	  alum	  adjuvant	  (OVA/Alum),	  or	  alum	  alone	  (Alum),	  
followed	  by	  three	  intranasal	  allergen	  exposures.	  CTLs	  were	  administered	  i.v.	  one	  day	  before	  
intranasal	   challenge	   (OVA/Alum	  +	  CTL).	   Total	   cells,	   eosinophils,	   alveolar	  macrophages,	   T	  
cells,	  neutrophils,	  B	  cells	  and	  DCs	  were	  enumerated	  by	  flow	  cytometry	  three	  days	  after	  the	  
final	  allergen	  challenge.	  (C)	  Mice	  were	  treated	  with	  OVA/Alum	  +/-­‐	  CTLs	  as	  in	  A	  and	  B,	  and	  
lungs	  were	  harvested	   three	  days	  after	   the	   final	  allergen	  challenge.	  Sections	  of	   lung	   tissue	  
were	  stained	  with	  CAE	  to	  identify	  mast	  cells,	  which	  were	  counted	  manually.	  (D)	  Mice	  were	  
treated	  as	  in	  Fig	  4.5:	  5	  x	  106	  CD4+	  T	  cells	  were	  injected	  into	  naive	  mice	  with	  or	  without	  5	  x	  
106	  WT	  CTLs.	  OVA	  was	  administered	  i.n	  one	  day	  later	  and	  cytokines	  were	  assessed	  one	  day	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